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           Summary of Thesis: 
Mycoplasmas represent some of the smallest and simplest free-living organisms known.  
Mycoplasma hominis and Mycoplasma pneumoniae are two human pathogens that colonise 
the urogenital and respiratory tracts, respectively, causing a diverse range of disease.  
Detection of Mycoplasma hominis is hampered by the fastidious nature and genetic 
heterogeneity of this organism.  Characterisation of mycoplasmas is becoming more important 
due to increasing antibiotic resistance, particularly in M. pneumoniae, and the need for more 
discriminatory methods to enhance epidemiology and examine transmission chains. 
Firstly, this thesis develops a quantitative, multiplex, real-time PCR assay to simultaneously 
detect M. hominis and Ureaplasma species in neonatal clinical specimens, where infection is 
associated with chronic lung disease, bacteremia and other clinical signs.  Results showed that 
the PCR method was clinically more sensitive than culture and has applications for monitoring 
bacterial load in clinical specimens and characterising bacterial response to antibiotics. 
Secondly, genetic characterisation of M. hominis was undertaken by the examination of the 
variable adherence-associated antigen and the development of sequence based typing.  Due to 
the genetic heterogeneity of M. hominis, bioinformatics analysis of genomic sequence was 
used as a novel method to develop a minimum multi-locus sequence typing (MLST) scheme 
that accurately represented genomic phylogeny of this species. 
Finally, an MLST scheme was developed for M. pneumoniae, to aid the analysis of epidemic 
periods and clusters of infection.  A successful scheme was developed based on eight 
housekeeping genes which had increased discrimination of M. pneumoniae compared to 
established typing methods for this organism.  Furthermore, the MLST scheme was found to 
be representative of genomic sequence-derived phylogeny, with two distinct genetic clades 
identified.  Application of this MLST to UK epidemics revealed that no predominant sequence 
type was responsible for the epidemic periods studied, indicating a polyclonal population, 
supporting the hypothesis that epidemics are driven by population immunity. 
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1 
Chapter 1 - Introduction 
1.1 Mycoplasma hominis and Mycoplasma pneumoniae 
Mycoplasmas represent some of the smallest self-replicating organisms that are 
capable of cell-free existence.  The first report of a mycoplasma to be recovered 
directly from a human in association with a pathological condition occurred in 1937, 
when Mycoplasma hominis was isolated from a Bartholin’s gland abscess [1].  Shortly 
after this, Mycoplasma pneumoniae was isolated in the sputum from a patient with 
primary atypical pneumonia [2].   
1.1.1 Classification of Mycoplasma hominis and Mycoplasma pneumoniae 
Mycoplasma species are taxonomically placed in the phylum Firmicutes, class 
Mollicutes, order Mycoplasmatales, family Mycoplasmataceae and genus 
Mycoplasma.  The taxonomic description of species within the Mollicutes class has 
been complicated and was first established in the 1960s.  This class now contains four 
orders, five families, eight genera and more than 200 known species that have been 
detected in humans, vertebrate animals, arthropods, fish/shellfish, and plants [3].  In 
1989, phylogenetic analysis based on 16S ribosomal ribonucleic acid (rRNA) 
sequences was reported for the Mollicutes [4] where 47 species were included; 
revealing five distinct phylogenetic clades of descent namely: anaeroplasmas, 
asteroleplasmas, hominis, pneumoniae and siproplasmas.  Subsequently these groups 
were further divided into several subgroups or clusters with M. hominis positioning in 
the hominis cluster and M. pneumoniae positioning in the pneumoniae cluster [5, 6]. 
1.1.2 Characteristics of Mycoplasma hominis and Mycoplasma pneumoniae 
Mycoplasmas are smaller than conventional bacteria and lack a cell wall, a 
characteristic that is used to distinguish these microorganisms from ordinary bacteria.  
The lack of a cell wall prevents mycoplasmas from staining by Gram stain, conferring 
pleomorphism of their cells, and makes them very susceptible to osmotic pressure.  
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They have small genomes and limited biosynthetic capabilities, restricting them to a 
parasitic existence in association with eukaryotic cells of their host [3, 7].  A majority 
of mycoplasmas exhibit strict host and tissue specificities, where, once they have 
entered the host, they can multiply and survive for long periods of time.  To facilitate 
this, mycoplasmas have evolved molecular mechanisms to evade the host immune 
system and to allow transmission and colonisation of a new host.  Mechanisms 
include: mimicry of host antigens, survival within phagocytic and non-phagocytic 
cells, and generation of phenotype plasticity [8].  Nineteen Mycoplasma species (listed 
in Table 1.1) have been isolated from humans and at least six of these species are 
considered to be of pathological significance specifically: Mycoplasma genitalium, 
M. pneumoniae and M. hominis [7].  
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Table 1.1.  Human Mycoplasma species and their colonisation site. 
Human species Colonisation site 
Mycoplasma salivarium Oral cavity 
Mycoplasma orale Oral cavity and oropharynx 
Mycoplasma pneumoniae Respiratory tract 
Mycoplasma amphoriforme Respiratory tract 
Mycoplasma fermentans Urogenital tract 
Mycoplasma hominis Urogenital tract 
Mycoplasma penetrans Urogenital tract 
Ureaplasma urealyticum Urogenital tract 
Ureaplasma parvum Urogenital tract 
Mycoplasma genitalium Urogenital tract 
Mycoplasma buccale Oropharynx 
Mycoplasma faucium Oropharynx 
Mycoplasma lipophilum Oral cavity 
Mycoplasma pirum  
Mycoplasma primatum Oral cavity and urogenital tract 
Mycoplasma spermatophilum Genital tract 
Acholeplasma laidlawii Oropharynx 
Hemoplasma  
Candidatus Mycoplasma girerdii Urogenital tract 
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Individual mycoplasmas and their morphological features cannot be visualised by 
light microscopy therefore observation under an electron microscope is required.  
Additionally, mycoplasmas do not produce visible turbidity in liquid growth media 
and the small cellular mass of these organisms means that they can pass through 
0.45µm-pore-size filters that are commonly used to filter-sterilise media [9]. 
M. hominis forms characteristic “fried egg” colonies when grown on agar which 
results from the bacteria burrowing into the agar and both bacteria and colonies are 
pleomorphic in size and shape (Figure 1.1A+B).  M. hominis cells are filamentous- or 
rod-shaped and are typically 0.25 µm wide [10].  Individual M. pneumoniae cells are 
spindle-shaped and 1 µm -2 µm in length and 0.1 µm-0.2 µm wide, resulting in a cell 
volume that is approximately 5% of that of a typical bacillus [9].     
Another characteristic of the genus of Mycoplasma is the need for sterols in the 
growth media, usually provided by serum.  Sterols are critical components of the 
mycoplasma cell membrane that provide stability and structural support to the 
organisms in the absence of a cell wall [9, 11]. 
The metabolic activities of mycoplasmas appear to be primarily associated with 
the generation of energy rather than the provision of substrates for synthetic pathways.  
All Mollicutes so far examined have truncated respiratory systems, lacking a complete 
tricarboxylic acid cycle and have no quinones and cytochromes preventing the 
generation of adenosine triphosphate (ATP) by oxidative phosphorylation.  Therefore, 
it is assumed that mycoplasmas produce low ATP yields and relatively large quantities 
of metabolic end products [5, 12, 13]. 
Mycoplasmas can be divided into fermentative and non-fermentative organisms 
depending on their ability to metabolise carbohydrates.  In addition, some 
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Mycoplasma species contain genes encoding proteins pertaining to both pathways and 
therefore potentially have the ability to be both fermentative and non-fermentative.  
Fermentative Mycoplasmas, such as M. pneumoniae, produce acids from 
carbohydrates.  M. pneumoniae metabolises glucose to lactic acid and acetic acid by 
substrate phosphorylation.  This process is mediated by phosphoglyceric acid kinase, 
pyruvate kinase, and acetate kinase activities, and generates ATP.  M. pneumoniae can 
also utilise glycerol and other small carbohydrates to generate ATP [5, 9].  In 
comparison, non-fermentative organisms, such as M. hominis, metabolise arginine via 
the arginine dihydrolase pathway.  The hydrolysis of arginine by this pathway results 
in the production of ornithine, carbon dioxide and ammonia, and generates ATP.  This 
pathway utilises three enzymes: arginine deiminase, ornithine carbamoyl transferase, 
and carbamate kinase [5, 14].  However, it is interesting to note that annotation of the 
genomes of both M. pneumoniae and M. hominis have shown genomic evidence for 
enzymes required for other metabolic pathways.  The utilisation of these enzymes for 
metabolism has not been directly observed [12, 14]. 
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Figure 1.1.  Micrographs of Mycoplasma hominis and Mycoplasma pneumoniae. 
(A) Electron micrograph of a cross-section of a M. hominis colony grown on 
Mycoplasma agar showing growth into the medium (scale bar = 10 µm).  (B) Electron 
micrograph of M. hominis showing small size and pleomorphic cells within a colony 
grown on Mycoplasma agar (scale bar = 100 nm). 
 
1.1.3 Genome and coding capacity 
Mollicutes have small genomes, consisting of a single circular chromosome and 
low guanine (G) + cytosine (C) content.  The small genome is now believed to be the 
result of a gradual reduction in genome size from a common ancestor in a process 
known as devolution but the selective pressure for this is unknown.  Mycoplasmas are 
most closely related to the gram-positive bacterial group that includes Streptococci, 
Bacilli and Lactobacilli [15]. 
The genome of M. pneumoniae was completely sequenced in 1996 and has a size 
of 816394 base pairs (bp) encoding 687 genes with a G + C content of 40 mol% [16].  
A. 
B. 
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In comparison, M. hominis has a genome size of 665445 bp with a G+C content of 
27.1 mol% [14].  Currently, 19 M. pneumoniae and four M. hominis complete 
chromosomes are available on the National Center for Biotechnology Information 
(NCBI) website.  Of the M. pneumoniae chromosomes, 14 were sequenced in August 
2015 [17] including the re-sequencing of the type strain FH.  Additionally, the 
M. pneumoniae M129-B chromosome is a chimera sequence generated by combining 
the re-sequenced M129 genome (by next generation sequencing) and the first Sanger-
based M129 genome.  The UGA codon in all other organisms’ functions as a terminal 
stop codon (opal), but in Mycoplasma this codon encodes the amino acid tryptophan 
[18].  
The reduced genome size and streamlined metabolism of M. pneumoniae provides 
an ideal model for system-wide studies.  The M. pneumoniae type strain M129 has 
been extensively characterised including full analysis of its transcriptome, 
metabolome, and proteome [19-22].  Since the small genome size results from loss of 
major anabolic pathways and a reduction in the complexity of gene expression 
regulation, mycoplasmas can still serve as models for other kinds of complex cellular 
processes such as: genesis of cell polarity, assembly of macromolecular structures, cell 
division, adherence, and motility [23]. 
The small genome of mycoplasmas confers their limited biosynthetic capabilities 
and is responsible for many biological characteristics of the organisms, including the 
requirement for complex growth medium for cultivation in vitro [9].  Mycoplasmas 
have no ability to synthesise a peptidoglycan cell wall due to many of the genes 
responsible for this process being absent from the genome.  A consequence of such 
genome reduction is the loss of non-essential genes which can be found in other 
bacteria, sometimes limiting the organism to an obligate dependence upon a host.  One 
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illustration of the limitations of gene loss is the complete reliance of mycoplasmas, as 
well as other Mollicutes, on the thymidine kinase (TK) enzyme salvage pathway for 
de novo synthesis of deoxyribonucleic acid (DNA) precursors [24-26].   
1.2 Virulence factors 
Virulence factors are molecules produced by pathogens, such as mycoplasmas, 
that contribute to the pathogenicity of the organism and enable them to colonise a 
niche in the host, evade and/or suppress the host’s immune response, allow entry into 
and exit out of cells, and obtain nutrition from the host.   
1.2.1 Mycoplasma pneumoniae virulence factors 
Pathogenic effects of M. pneumoniae infections are assumed to be caused directly 
(by active interaction with the host), indirectly (by infection-induced immune 
mechanisms), or by both mechanisms.  M. pneumoniae is known to cause direct injury 
to the host through the generation of activated oxygen and the production of a pertussis 
toxin-like protein, the community-acquired respiratory distress syndrome (CARDS) 
toxin.  In addition to direct damage, M. pneumoniae can modulate the immune 
response of the host, generating inflammatory reactions causing the pulmonary and 
extra-pulmonary symptoms associated with infection.  M. pneumoniae expresses a 
variety of adhesion proteins and glycolipids that share structural homology to host 
cells which may induce host immune responses that lead to cross-reactive antibodies 
and autoimmune damage [27]. 
1.2.1.1 Hydrogen peroxide release  
In M. pneumoniae, as well as other Mollicutes, pathogenicity is closely linked 
to carbon metabolism [28].  The utilisation of glycerol and phospholipids plays an 
important role in the virulence of Mycoplasma species because the hydrogen peroxide 
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generated as a product of glycerol metabolism is the major cytotoxic substance 
produced by these bacteria.  In addition to the induction of autoimmune responses, the 
formation of hydrogen peroxide is the only established mechanism by which 
Mycoplasmas cause damage to their hosts [9, 29].  The role of glycerol metabolism as 
a mechanism conferring pathogenicity in Mycoplasma was first described for 
Mycoplasma mycoides, [30] where the efficient formation of hydrogen peroxide by 
M. mycoides is the major virulence factor of the highly pathogenic strains of this 
species.  Like M. mycoides, M. pneumoniae possesses the complete set of genes for 
glycerol utilisation (Figure 1.2) [31, 32]. 
In addition to glycerol, the metabolism of phospholipids plays an important 
role in the generation of hydrogen peroxide by M. pneumoniae.  Glycerophospholipids 
are the major building blocks of the cell membrane in bacteria and eukaryotes and are 
degraded in several steps (Figure 1.2), resulting in the formation of glycerol-3-
phosphate and the subsequent production of hydrogen peroxide [29, 33].   
The formation of glpD and glpQ mutant strains of M. pneumoniae revealed 
that the utilisation of glycerol and phospholipids and subsequence hydrogen peroxide 
production plays a particularly important role in the virulence of M. pneumoniae as 
the mutant strains have severely affected pathogenicity [32, 33]. 
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Figure 1.2.  Schematic illustration of the uptake and conversion of carbohydrates 
leading to the formation of glycerol-3-phosphate and hydrogen peroxide in 
M. pneumoniae. 
 
1.2.1.2 Adhesion complex 
Following transmission to a new host, M. pneumoniae colonises the bronchial 
passages and is found localised to the base of the cilia where it interacts directly with 
the host cell surface [5].  M. pneumoniae colonisation results from the interaction 
between adhesin proteins on the mycoplasma surface and sulphated glycolipid or 
sialoglycoprotein molecules on the host respiratory epithelium [34-37].  Electron 
micrographs of M. pneumoniae colonisation of infected bronchial epithelia revealed a 
differentiated terminal organelle orientated towards, and directly associated with, the 
host cell surface, commonly designated the ‘attachment organelle’.  This organelle is 
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a membrane-bound extension of the bacterial cell and is characterised by an electron-
dense core (part of the cytoskeleton) orientated lengthwise and enlarging to form a 
button which interfaces with the inner surface of the Mycoplasma membrane at the tip 
of the cell [38-40].  The attachment organelle is thought to be multi-functional [23] 
and is involved in gliding motility [16, 41], cell division [42] and adhesion [43].   
There are many proteins associated with cytoadherence of M. pneumoniae, 
including: P1, P30, HMW1-5, A, B, and C, of which the membrane protein P1 is 
thought to have a major receptor-binding role [5, 34, 38].  Antibodies to P1 inhibit 
M. pneumoniae adherence to tracheal epithelium [44].  P1 is primarily localised to the 
attachment organelle but it is also found distributed over the entire surface of 
M. pneumoniae [45, 46].  Humans mount an aggressive immune response to P1 during 
infection.  Interestingly, that response fails to yield antibodies directed against 
epitopes responsible for receptor binding and therefore capable of blocking 
cytoadherence [35].  Biological mimicry and immunological tolerance may account 
for this, therefore contributing to host specificity. 
1.2.1.3 CARDS toxin 
The CARDS toxin of M. pneumoniae is an adenosine diphosphate (ADP)-
ribosylating and vacuolating cytotoxin that provides a mechanism which explains the 
observed epithelial damage that occurs with infection [47].  This cytotoxin exhibits 
similarities to pertussis toxin [48].  CARDS toxin binds alveolar surfactant protein A 
[48, 49] and is likely to contribute to additional colonisation and pathogenic pathways.  
The CARDS toxin has an enzymatic action on both similar and distinct human cell 
proteins when compared with the S1 catalytic subunit of pertussis toxin.  This leads to 
a cascade of events such as tissue disorganisation, inflammation and airway 
dysfunction along with cell vacuolisation [48, 50].  The expression and function of 
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pathogenic toxins is often mediated by other microbial components and it is postulated 
that the CARDS toxin relies on other mycoplasma components to fully potentiate its 
expression, delivery and impact on the host.  Other possible microbial components 
include gene and protein regulatory systems, adherence factors for colonisation and 
invasion and possible secretion systems for delivery of specific pathogenic products 
[51, 52].  
1.2.1.4 Biofilm formation 
Many bacterial species aggregate to form biofilms which are immobile 
communities of micro-organisms encased within a matrix of polysaccharide, protein 
and lipid that protects the micro-organisms from harsh interactions with the 
environment, including the host immune response and antimicrobials [53-55].  It has 
previously been shown that biofilms are formed by Mollicutes [56, 57].  Of the 
mycoplasmas, biofilms were first described for Mycoplasma pulmonis, where the 
formation of biofilms was shown to protect this organism from the lytic effects of 
complement and the small antimicrobial peptide gramicidin [57].  Biofilms have been 
observed for M. pneumoniae where, when grown on an abiotic surface in the presence 
of a serum-containing medium, M. pneumoniae adhered to the surface and formed 
highly differentiated volcano-like biofilm structures [58].  Additionally, the biofilms 
formed by P1 type 1 and P1 type 2 strains of M. pneumoniae differ both qualitatively 
and quantitatively [59].  The P1 type 1 strain was found to secrete 
N-acetylglucosamine-containing polysaccharide into the culture medium whereas the 
polysaccharide was found in tight association with the cell surface of P1 type 2 strains 
[59].  N-acetylglucosamine-containing polysaccharides contribute to virulence and to 
the structure of biofilms produced by a wide range of microbial species [60-63] and 
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may provide a mechanism behind the difference in biofilms formed by the two major 
P1 type strains of M. pneumoniae. 
1.2.1.5 Interaction of surface-displayed enzymes with host factors 
The ability of pathogenic micro-organisms to adhere to and colonise host 
targets involves complex interactions and molecular cross-talk between microbial 
adhesins and host cell receptors [64, 65].  M. pneumoniae utilises glycolysis as the 
major pathway to produce ATP as it lacks the enzymes for the citric acid cycle.  The 
process takes place in the cytoplasm of the cells; however, glycolytic enzymes can be 
transported to the surface of the microorganisms by an unknown mechanism [66], 
where they can interact with host factors [67].  This phenomenon was first reported 
for Streptococci but it appears to be a common feature of micro-organisms as it has 
been described in phylogenetically different organisms including Gram-negative and 
Gram-positive bacteria, fungi and parasites [68-70].  An increasing number of 
microbial glycolytic enzymes have been characterised as involved in interaction with 
the human extracellular matrix (ECM); glyceraldehyde-3-phsophate and enolase 
enzymes are typical examples of surface-expressed glycolytic enzymes that interact 
with proteins of the human ECM [70-72].   
Elongation factor Tu, pyruvate dehydrogenase subunit B and glyceraldehyde-
3-phosphate dehydrogenase of M. pneumoniae have been reported as being surface-
localised and function as binding proteins to human fibronectin [73-75].  In addition, 
pyruvate dehydrogenase subunit B of M. pneumoniae has been shown to bind and 
activate human plasminogen, a key protein of the human fibrinolysis system which 
interacts with components of ECM after conversion to plasmin [67, 76]. 
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Analysis of the Triton X-100 insoluble proteins of total cells of M. pneumoniae 
indicated the presence of further membrane-associated glycolytic enzymes [77].  It is 
therefore expected that further interactions of glycolytic enzymes of M. pneumoniae 
with host components can occur.   
1.2.2 Mycoplasma hominis virulence factors 
The mechanisms behind the pathogenic effects of M. hominis and the patho-
physiological mechanisms that enable commensal M. hominis to become pathogenic 
are mostly unresolved.  The ability of mycoplasmas to adhere to host epithelial cells 
on mucosal surfaces, in the case of M. hominis the urogenital tract, is an essential stage 
to establish successful colonisation and infection.  Several mycoplasmas, such as 
M. pneumoniae and M. genitalium, have adhesin proteins associated with adhesion 
concentrated at specific tip structures [43].  In comparison, M. hominis, along with 
other Mycoplasma species, lack this attachment organelle.  Many surface antigens 
have been identified in M. hominis and some of these play a role in cytoadherence as 
shown by monoclonal antibody inhibition assays [78, 79].  Adhesion of M. hominis is 
facilitated by cytoadhesive membrane proteins and lipoproteins such as P80 secretin 
and variable adherence-associated (Vaa) protein, P60 and OppA, respectively [79-81].  
Additionally, in bacterial vaginosis, shifts to a higher pH in vaginal flora are often 
accompanied by higher titres of M. hominis.  However, whether higher colonisation 
rates are the consequence or the reason for such changes in the milieu is still unknown. 
1.2.2.1 Cytoadhesive membrane proteins 
Cytoadhesins of M. hominis have been shown to bind to sulphated structures 
on human cells and ECM molecules [79, 82].  Upregulation of laminin, 
thrombospondin and collagen as ligands and integrins as receptors for M. hominis 
cytoadherence and internalisation has been shown on the host cell membrane as a 
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response to infection with M. hominis [83].  The method by which M. hominis is 
internalised into host cells is however unknown.  Nevertheless, it has been shown by 
confocal microscopy that M. hominis invades HeLa cells and can result in the re-
arrangement of the actin cytoskeleton [83]. 
A surface-expressed, membrane protein of M. hominis, P80, was found to 
function as a cytoadhesin, facilitating attachment of M. hominis to host cells in 
combination with another membrane protein, P60.  The masking of P80 or P60 using 
monoclonal antibodies resulted in a reduction of M. hominis adherence to HeLa cells 
[79].  P80 is also released into the extra-cellular environment [80].  Release of proteins 
into the surroundings of a Mycoplasma cell is thought to lead to an immediate 
alternation of the cell surface architecture and, as most membrane proteins are targets 
for the host immune response [79, 84], it may help evade the host’s immune system.   
The exact role of P80 as a virulence factor is unknown but the release of type 
II secreted proteins is typically associated with non-invasive organisms that colonise 
mucosal surfaces, like M. hominis, and are considered to be required for the 
establishment of infection at these sites.  A type II protein secretion system has been 
characterised for Legionella pneumophila as a virulence factor linked to intracellular 
infection [85]. 
1.2.2.2 Membrane bound lipoproteins 
Mycoplasmas are heterogeneous organisms and many display antigenic 
variation and pronounced variation of surface proteins.  This is thought to be an 
important way of evading the host immune response, particularly the humoral immune 
response, resulting in the chronic infection characteristic of many Mycoplasma 
infections [5].  Previous studies have indicated that the surface antigenic profiles of 
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M. hominis strains are highly heterogeneous, expressing both size and phase variants 
of surface exposed membrane proteins [78, 86-88].  Several M. hominis surface 
proteins have been characterised, including P120, P135 and Vaa; however, the 
molecular basis of variation in M. hominis has only been elucidated in some cases.  
The mechanisms involved in the diversification of mycoplasma surface proteins are 
highly complex and include: size variation caused by gain or loss of intragenic 
repetitive sequences; phase switching by deletion/insertion mutations or DNA 
inversion affecting promoter activity; and presence of multigene families or multiple 
copies of partial genes in the mycoplasmal chromosome [89].   
Mycoplasma hominis Variable adherence-associated antigen (Vaa) 
The presence of a Vaa surface protein of M. hominis was initially identified 
over 20 years ago as a potential adhesin of M. hominis by using specific monoclonal 
antibodies to inhibit mycoplasma adherence to cultured cells [78, 79].  This protein 
was first identified as; a 49 kDa surface protein in M. hominis strain PG21 [90]; an 
adherence-associated, multiple-banding membrane lipoprotein in strain 1620 [78]; and 
as a 50 kDa adhesin in strain FBG, known as P50 [79].  While these groups used 
different nomenclature (Vaa versus P50), the surface lipoprotein in question is the 
same protein.  The original terminology, Vaa antigen will be used, as this lipoprotein 
often has varying molecular masses with conserved regions and therefore P50 is a less 
accurate descriptor.  Variation in the composition and size of the Vaa proteins results 
from allelic variant forms of the single copy vaa gene in M. hominis [91, 92].  The 
importance of Vaa in the pathogenesis and immune evasion of M. hominis infections 
is still not fully understood.  But, Vaa was identified as a potential adhesion of 
M. hominis using monoclonal antibody inhibition, with the masking of Vaa showing 
prominent difference in the ability of M. hominis to adhere to HeLa cells [78, 79]. 
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Differences in the expression of Vaa between strains of M. hominis have been 
observed and Vaa has been shown to undergo high-frequency phase variation resulting 
in ON/OFF expression [78, 91, 92].  Phase variation of Vaa is controlled at translation, 
not as a consequence of transcriptional events due to alterations to the promoter 
sequence seen in other bacteria such as Neisseria gonorrhoeae and Ureaplasma 
species [91, 93-95].   
Size variation has been observed in Vaa [78], and was initially examined in 
clonal lineages generated from M. hominis strain 1620, wherein three size variants of 
the Vaa antigen were identified and designated Vaa-2, Vaa-3, and Vaa-4.  Sequence 
analysis showed that this vaa gene length variation corresponded to the number of 363 
bp intragenic tandem-repeat (TR) elements.  The number of repeats was then used in 
the nomenclature of the different clonal lineages: Vaa-2 (two repeats), Vaa-3 (three 
repeats), and Vaa-4 (four repeats) [92].  These repeats form the basis of “modules” 
which provide a platform for further separation of Vaa types into categories (Figure 
1.3).  This 363 bp repeat became the prototype for what is now referred to as module 
III. 
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Figure 1.3.  Schematic representation of the deduced amino acid sequences of the 
six vaa gene types.   
The proteins show a modular composition with homologous modules showing more 
than 82% amino acid identity.  Modules I, II and I’/II’’ form the conserved N-terminal 
of the protein and Module VI represents the 10 amino acids conserved at the C-
terminal Modules III, IV, V, VII and VIII form the interchangeable cassettes.  
Prototype M. hominis strains for each Vaa category are stated along with 
corresponding strains from Henrich et al.  (1998) [96].  Figure modified from Boesen 
et al.  (1998) [97].    
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All vaa genes described thus far all start with highly homologous modules I 
and II, followed by either module II’ or II’’.  All reported combinations of identified 
module types analysed in over 100 clinical isolates [96, 97] has resulted in six possible 
categories (Figure 1.3); however, the number of module III in category 4 have been 
found to vary between two and four repeats.  Sequence homology for each module 
type was initially restricted to 82% between strains [92, 97].   
Modules III, IV, V, VII and VIII form an interchangeable cassette of sequences 
that provide the size variation observed in Vaa variants.  Inter-module homology 
(38-78%) suggests a common ancestral sequence [97].  A stable, repeated motif of 
four amino acids (SFKE) was observed in module II, a constant part of the gene.  This 
motif was extended to ELESFKE in almost all of the interchangeable cassettes.  Three 
highly conserved tryptophan residues were also identified in distinct positions in a 16 
amino acid region situated in the C-terminal part of the cassette sequence [97].   
The presence of these highly homologous interchangeable cassettes in the vaa 
gene suggests a mechanism of variation in which homologous recombination provides 
insertions or deletions of whole cassettes.  Homologous recombination can bring 
mutations arising in different genomes together and has a strong impact on pathogenic 
adaptation [98].  The absence of sequences homologous to the vaa gene in other 
members of the mycoplasma family, or other bacterial species, suggests that intra-
species genetic transfer is responsible for the current array of Vaa categories. 
Sequence analysis and modelling of the Vaa protein indicates that Vaa belongs 
to the group of monomeric microbial surface-exposed coiled-coil proteins similar to 
Protein A of Staphylococci [99-101].  Figure 1.4 shows a hypothetical model of the 
topology of Vaa.  The Figure shows a bacterial membrane lipid anchor that is typical 
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of prokaryotic lipoproteins attached to the N-terminal cysteine residue of the mature 
Vaa, with the conserved N-terminal in a triple-helix bundle, extending into an 
elongated helix.  Two β sheets then form a loop region and a C-terminal helix folds 
back on the elongated helix.  This model indicates that Vaa is composed of an N-
terminal base domain in close proximity to the membrane and a C-terminal spike 
cassette domain projecting out from the surface of M. hominis [99].     
 
Figure 1.4.  Model of the predicted protein structure for Vaa category 5.   
(A) Schematic representation of Vaa category 5 modified from Boesen et al. [99].  The 
modules are numbered as outlined in Figure 1.3.  (B) Protein homology model of Vaa 
category 5 strain 2867B.  Model was created using www.swissmodel.expasy.org and 
uses NheA protein as a template.  (C) Alignment of Vaa category 5 strain 2867B amino 
acid sequence with the NheA protein template.  Secondary structure is indicated in the 
template.
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OppA 
An Opp transport system has also been identified in M. hominis [102] which 
shares little sequence similarity with the respective domains of other species but shares 
the typical features of these transport systems.  It is composed of four domains 
OppBCDF and the cytoadherence-associated lipoprotein P110 as the substrate binding 
domain OppA [102].  OppA displays ecto-ATPase activity, which hydrolyses ATP at 
the external surface of the cell membrane.  Extracellular ATP has profound effects on 
cellular functions and can cause plasma membrane depolarisation and cell death [103, 
104].  OppA is proposed to be the main ecto-ATPase of M. hominis with 80% of the 
surface-localised ATPase activity of M. hominis derived from OppA [105].   
Evidence indicates that M. hominis OppA is involved in processes that induce 
ATP release from and damage to host cells.  OppA induces ATP release from HeLa 
cells and ATP hydrolysis by OppA results in apoptosis of the host cell which is 
proposed to guarantee the nutrition uptake and survival of M. hominis [106].  
Additionally, this supports the hypothesis that extracellular colonising pathogens 
enhance apoptotic cell death.  The enzymatic function of OppA as the main ecto-
ATPase of M. hominis is essential for OppA-mediated adhesion [107].  It is 
hypothesised that this unique feature of M. hominis has an impact on patho-
physiological important processes involved in host-pathogen interactions [107].   
1.2.2.3 Modulation of host immune response by Mycoplasma hominis 
M. hominis infection of HeLa cells is initiated by cytoadherence followed by a 
prominent induction of pro- and anti-apoptotic cytokines and the repression of heat 
shock protein (HSP) 70 [83].  Heat shock proteins are expressed by cells in response 
to stress and act as molecular chaperones.  They have been documented to modulate 
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innate and adaptive immune responses after exposure to microbial pathogens.  The 
down-regulation of HSP70 by micro-organisms has been proposed to be a mechanism 
of immune evasion and to promote chronic infection [108].  The repression of HSP70 
by M. hominis is in accordance with this observation, as M. hominis infection is rarely 
acute and the M. hominis induced cytokine profile in human dendritic cells 
corresponds to that of a pathogen associated with chronic infections [109].   
1.3 Detection, quantification and typing of Mycoplasma hominis and 
Mycoplasma pneumoniae 
Laboratory based detection of M. pneumoniae and M. hominis in clinical 
specimens is gaining greater attention largely due to the availability of improved 
methods for detection.  Traditionally M. pneumoniae infections has been detected by 
serological methods, detecting specific immunoglobulin (Ig) M, IgG, IgA antibodies 
and cold agglutinins.  For M. hominis, culture is the most economical and practical 
means of detection.  However, the use of molecular techniques for detection of both 
M. pneumoniae and M. hominis is increasing. 
1.3.1 Culture and quantification 
Mollicutes require an enriched growth medium supplemented with nucleic acid 
precursors, fatty acids, and amino acids for growth, due to their limited genome 
capabilities.  Detection of M. pneumoniae by culture is rarely undertaken due to the 
length of time necessary for growth to be observed, ranging from days up to three 
weeks or more.  This limiting factor makes culture diagnosis of M. pneumoniae 
impractical for patient management and is therefore rarely offered as a means to 
diagnose infection by clinical laboratories [110].  However, M. pneumoniae can be 
grown in specialised media containing glucose and colonies can be observed when 
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grown on agar.  Colonies grown on agar must undergo additional testing, usually 
polymerase chain reaction (PCR), to confirm their identity because several commensal 
mycoplasma species often inhabit the human oropharynx and they are 
indistinguishable when grown on agar. 
In comparison to M. pneumoniae, M. hominis grows well in specialised media and 
on agar, with colonies usually visible under a stereomicroscope within two to three 
days.  There are no phenotypic tests that can distinguish M. hominis from other 
mycoplasma species growing on the agar therefore additional testing is usually 
performed to confirm diagnosis, such as PCR.  Culture is preferred over PCR in 
laboratories with low to moderate test volumes as cultures can be set up one at a time.  
For efficient and cost-effective use of PCR, laboratories need to run the assay in 
batches of several specimens.  Culture also has an advantage over PCR as it provides 
an isolate on which further testing can be performed, e.g. antimicrobial susceptibility, 
and culture confirms  the presence of live bacteria and therefore active infection.   
1.3.2 Serological detection  
Serological testing was the first method developed for the detection of infection 
with M. pneumoniae.  M. pneumoniae has both lipid and protein antigens, which elicit 
an antibody response that can be detected after about one week of illness, with a peak 
at 3-6 weeks followed by a gradual decline.  Initially IgM antibodies occur 6-10 days 
after infection; however, only about 80% of patients younger than 20 years develop 
IgM antibodies and this reduces to about 40% in patients that are older than 20 years.  
This means that a specific IgM response can be absent, especially in older patients.  It 
has also been shown that IgM antibodies can still be detected at least one year after 
the beginning of symptoms [111].  Specific IgG antibodies appear 9-14 days after 
infection and may persist for up to four years.  Specific IgA antibodies appear one 
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week after the start of infection and decrease after about five weeks.  Due to this 
antibody response, acute and convalescent patient sera, taken 2-3 weeks apart, are 
required for confirmation of infection.  This is a significant limitation for prompt 
point-of-care diagnosis, particularly in adults over 40 years of age who may not mount 
an IgM response.   
Complement fixation was the original serological test used for the detection of 
M. pneumoniae infection by clinical laboratories; however, this has now been replaced 
by newer methods.  Complement fixation measures mainly the early IgM response and 
does not differentiate between antibody classes, which can be used to determine the 
stage of the infection.  This method also suffers from low sensitivity because the 
glycolipid antigen mixture used may be found in other microorganisms, as well as 
human tissues; in particular cross-reactions with M. genitalium are well recognised.   
Immunofluorescent antibody assays, direct and indirect haemagglutination using 
IgM capture, and other particle agglutination antibody assays have been developed to 
detected specific anti-M. pneumoniae antibodies.  However, enzyme immunoassays 
(EIAs) have become the most widely used commercial methods for detection of 
M. pneumoniae.  Enzyme immunoassays allow the class of the antibody to be 
measured and the sensitivity can be comparable that of the PCR assay, providing 
sufficient time has elapsed since infection for antibodies to develop and for the patient 
to have a functioning immune system.  These assays may be qualitative or quantitative 
and can be performed with very small volumes of patient serum.   
Comparative studies between commercially available EIAs show variability in 
diagnosis results, highlighting the need for standardisation and improved sensitivities 
and specificities among serological reagents used for detecting acute M. pneumoniae 
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infection [112-114].  Other limitations of serological diagnosis of acute 
M. pneumoniae infection include the possibilities that antibody production can be 
delayed in some infections, or even absent if the patient has an impaired humoral 
immune response.  False-negative tests can also occur if serum is collected after 
antibiotics have been administered [110]. 
Serological test methods for M. hominis include micro-immunofluoresence, 
metabolism inhibition and EIA, but the presence of M. hominis in healthy people 
makes interpretation of antibody titres difficult.  Serological tests for M. hominis are 
not easily developed due to the significant heterogeneity and antigenic variation 
among different isolates.  However, the measurement of an IgG antibody response to 
M. hominis infection has been performed by enzyme-linked immunosorbent assay 
(ELISA) using a mixture of membrane proteins from two different M. hominis isolates 
as a preferred antigen [115].  No serological assays for M. hominis have been 
standardised for diagnostic use.   
1.3.3 Molecular detection 
PCR has been used increasingly for M. pneumoniae detection due to the 
significant reduction in time to obtain a result compared to culture and the removal of 
the requirement for acute and convalescent sera for serology testing.  It can also 
confirm M. hominis infection.  The first reports of the use of PCR for the detection of 
M. pneumoniae in clinical samples dates back to 1989 and since then there have been 
more than 200 publications describing the technique for this use [116, 117].   
The sensitivity of PCR is very high, corresponding to the detection of the presence 
of a single organism when purified DNA is used.  Other advantages of using this 
technique for diagnosis of infection include; the ability to complete the assay in one 
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day; the possibility of obtaining a positive result more quickly after the onset of illness 
than when using serology; the need for one specimen containing organisms that do not 
have to be viable and the ability to detect nucleic acid in preserved tissue [9].  PCR is 
also a valuable tool for identifying mycoplasma aetiology in people with a variety of 
extra-pulmonary syndromes, due to the ability to detect the organism in blood and 
cerebrospinal fluid which has rarely been successful by culture.   
Several M. pneumoniae gene targets have been used for PCR assays, including 
the 16s rRNA gene, the elongation factor tuf, the P1 cytadhesin gene and repetitive 
elements located within the latter [118-122].  Comparison of PCR with culture and/or 
serology has yielded varied results that are not always in agreement.  Positive PCR 
results in culture-negative persons, without evidence of respiratory disease, suggest 
inadequate assay specificity, persistence of the organism after infection, or 
asymptomatic carriage of the organism.  Positive PCR results in serology negative 
persons may be due to an inadequate immune response, early successful antibiotic 
treatment, or to the collection of specimens before the specific antibody response 
occurs.  Negative PCR results in culture or serology proven infections increase the 
possibility of inhibitors or other technical problems with the assay and its gene target 
and emphasises the increased sensitivity of culture methods [11].   
Conventional PCR assays for M. hominis have mainly used 16s rRNA as a gene 
target.  However, due to minor heterogeneity in this gene, other targets including gap, 
fstY, and yidC have been developed [123-126].  M. hominis is a common commensal 
in the female cervix and vagina and the male urethra.  A positive PCR result on 
specimens from these sites may therefore not be meaningful in the absence of clinical 
manifestations known to be associated with this organism unless the M. hominis load 
reaches ≥ 104 colony forming units (CFU)/mL, which is considered a crucial criterion 
27 
Chapter 1 - Introduction 
for urogenital infections in women [127].  In the case of extra-genital specimens in 
adults or neonates, a positive M. hominis PCR assay or culture result should be 
considered clinically significant. 
Real-time PCR assays have significant advantages over traditional PCR, 
including a more rapid turnaround time, less handling of PCR products by 
electrophoresis analysis and increased sensitivity [110]. 
1.3.4 Molecular typing 
The typing of clinical isolates allows investigation into the epidemiology of 
M. pneumoniae and M. hominis infections and analysis of endemic outbreaks.   
Molecular typing of M. pneumoniae is hindered by the fact that M. pneumoniae 
is a genetically homogenous species.  Previous investigations have shown that clinical 
isolates differ in the sequence of the gene encoding the P1 cytoadhesin and this has 
been the most common genotyping method used in the past 30 years.  PCR-restriction 
fragment length polymorphism (RFLP) analysis of the P1 gene enabled the separation 
of M. pneumoniae isolates into two types, types 1 and 2 [128, 129].  However, more 
recent studies use repetitive elements within the P1 gene for molecular typing which, 
as well as identifying type 1 and 2, identify variants of these sub-types [130]. 
In addition to these molecular typing methods that target only one gene, other 
methods based on the whole genome have been adapted to M. pneumoniae, such as 
pulsed-field gel electrophoresis (PFGE), and multiple-locus variable-number tandem-
repeat (VNTR) analysis (MLVA) [128, 131, 132].  PFGE, like P1 gene analysis, can 
separate M. pneumoniae strains into two groups (groups 1 and 2) and can subdivide 
group 2 into two subgroups, 2a and 2b [128].  However, due to the homogenous nature 
of the M. pneumoniae genome, very little polymorphism had previously been found 
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in M. pneumoniae housekeeping genes leading previous investigators to conclude that 
multi-locus sequence typing (MLST) was not useful as a molecular typing method for 
M. pneumoniae [131]. 
MLVA has successfully been used for typing an increasing number of microbial 
species, including M. pneumoniae and, more recently, M. hominis [132, 133].  MLVA 
is a molecular typing method based on the variation in the copy number of tandemly 
repeated sequences, called VNTRs, found at different loci on the genome.  The 
variation of the copy number of these repeat units varies between isolates.  More than 
26 differing types have been described for M. pneumoniae [130, 132, 134].  However, 
in comparison to M. pneumoniae, M. hominis displays high genetic heterogeneity 
among isolates and 40 MLVA types have been described for 210 isolates tested [133]. 
Other molecular typing methods have been developed for M. hominis, including 
methods based on sequence analysis of the p75, p120’ and vaa genes [135-137].  
Isolate groupings based on the sequence analysis of these genes are not comparable, 
indicating that the three genes vary by different mechanisms. 
1.4 Mycoplasma hominis, Mycoplasma pneumoniae and disease 
1.4.1 Mycoplasma pneumoniae infections 
M. pneumoniae infections affect both the upper and lower respiratory tracts and 
occur both endemically and epidemically worldwide in children and adults.  
M. pneumoniae is a leading cause of community-acquired pneumonia (CAP) and is 
responsible for 15-20 % of CAP cases in adults and up to 40% of cases in children 
[112, 138, 139].   
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M. pneumoniae infections are normally mild and in adults cases may be 
asymptomatic; however, infections are often more serious in children and 
immunocompromised individuals.  Respiratory infections caused by M. pneumoniae 
are often slow to develop, presenting with pharyngitis, sinus congestion, and 
eventually prolonged lower respiratory involvement up to and including primary 
atypical pneumonia with fever and bibasilar pulmonary infiltrates.  The clinical 
symptoms that manifest due to infection can be diverse with the most severe infections 
resulting in CAP and occasionally abscesses persisting for weeks to months [140].  
The most common manifestations include a sore throat, fever, a cough which is 
initially non-productive, headache, and general malaise [9].    
Children with hypogammaglobulinemia are known to be at greater risk for 
development of respiratory and joint infections due to M. pneumoniae, demonstrating 
the importance of functional humoral immunity in protection against infection due to 
this organism [9]. 
1.4.1.1 Role of Mycoplasma pneumoniae in persistent cough in children 
Most coughs in children are caused by acute respiratory tract infections and 
usually resolve within two weeks [141]; however, a persistent cough following a 
respiratory tract infection is common in children.  A multi-centre parent questionnaire 
survey undertaken in Europe reported that 12.7% of children aged 7-11 years had 
experienced a persistent cough lasting three months or longer during the previous 
autumn/winter season.  Of these, 7.6% had a persistent cough in the absence of a cold 
and 11.5% had a persistent cough at night [142].  Most acute respiratory tract 
infections are caused by respiratory viruses [143].  M. pneumoniae is one of the most 
common bacterial causes of respiratory tract infections in children with the highest 
incidence in children aged five to nine years (4/1000 children per year) [144].   
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A retrospective study was undertaken in England in 2011 to examine the 
incidence of M. pneumoniae in children with a persistent cough and the duration of 
cough in children infected with M. pneumoniae [143].  The patient cohort examined 
were children aged 5-16 who presented to their General Practitioner (GP) with a cough 
lasting 14 days or longer that was unexplained or triggered by an acute respiratory 
tract infection.  Samples were obtained from patients from 18 GP surgeries in 
Oxfordshire, England.  M. pneumoniae was detected, based on PCR of nasopharyngeal 
aspirates, in 7.1% (11/155) of children with a persistent cough which was considerably 
higher than previous estimates reported in children with acute cough and fever (2.6%) 
[145] and asymptomatic household contacts of M. pneumoniae cases (0.25%) [146].  
The duration of a persistent cough in M. pneumoniae cases was found to be one-third 
of that in children infected with pertussis [143].  Incidence of M. pneumoniae in 
school-aged children with a persistent cough was found to be increase during periods 
of high M. pneumoniae activity, i.e. during an epidemic [143].      
1.4.1.2 Role of Mycoplasma pneumoniae in asthma and chronic lung disease 
M. pneumoniae has been implicated in both the pathogenesis and the 
exacerbation of acute attacks of asthma [147].  Asthma is a chronic inflammatory 
disease of the airways, characterised by hyper-responsiveness to multiple stimuli, 
reversible airway limitation and chronic eosinophilic infiltration of the airways.  
Current literature indicates that M. pneumoniae infection can be an important trigger 
for the acute exacerbation of asthma, accounting for between 3.3% and 50% of cases 
of exacerbations.  It is also thought that M. pneumoniae can initiate asthma in 
previously asymptomatic patients [148].   
M. pneumoniae can be recovered from the respiratory tract up to several 
months after recovery from pneumonia, and pulmonary structural abnormalities, 
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indicating small airway obstruction, have been observed 1-2 years after disease [148].  
M. pneumoniae can be isolated in higher prevalence from asthmatics than from healthy 
individuals and follow-up studies in children have demonstrated prolonged airway 
dysfunction consistent with a persistent infection. 
M. pneumoniae induces a number of inflammatory mediators such as IgE, 
substance P and neurokinin 1, and interleukin (IL)-5, which have been implicated in 
the pathogenesis of asthma resulting in exacerbations.  Children with wheezing and 
acute M. pneumoniae infection have a specific cytokine profile that is characterised 
by a marked increase in IL-5 [149].  Patients also have increased airway expression of 
transcription factor (TNF)-α and IL-4, both pro-inflammatory cytokines.  Models of 
chronic respiratory infection in mice have demonstrated that M. pneumoniae can 
produce pneumonia, and stimulate cytokine production, airway hyper-responsiveness 
resembling chronic asthma and a Th2-dominant airway inflammatory process that 
enhances organism survival in the lungs [110, 150]. 
1.4.1.3 Extra-pulmonary manifestations of Mycoplasma pneumoniae infection 
It is estimated that 25% of people infected with M. pneumoniae may 
experience extra-pulmonary complications at various times after the onset of or even 
in the absence of respiratory illness [151].  Complications that can arise involve the 
skin and the nervous, cardiovascular, renal, gastrointestinal, musculoskeletal, and 
haematologic systems.  It is thought that the host immune response that develops after 
M. pneumoniae infection contributes to these complications as well as contributing to 
autoimmunity [9].  The presence of M. pneumoniae in these extra-pulmonary sites has 
been confirmed by PCR as well as culture [152-156].   
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Complications that occur within the central nervous system (CNS) are 
recognised as the most common extra-pulmonary manifestations of M. pneumoniae 
infections.  A recent study of 1,988 children with encephalitis showed M. pneumoniae 
as the most common causative agent [157].  M. pneumoniae infection is established in 
5% to 10% of paediatric encephalitis patients [158, 159] and up to 60% of them show 
neurologic sequelae [159, 160].  Clusters of encephalitis are occasionally observed in 
epidemics of M. pneumoniae infections.  Other CNS complications include: cerebellar 
syndrome and polyradiculitis, cranial nerve palsy, aseptic meningitis or 
meningoencephalitis, and acute disseminated encephalomyelitis among others [9].  
The mechanisms that result in these neurological manifestations of M. pneumoniae 
infection are not completely understood.  However, immune-mediated mechanisms 
are suspected due to the development of cross-reactive antibodies to the brain and 
other neurological structures [110].  Anti-GM 1 and galactocerebroside antibodies 
have been the main autoantibodies associated with M. pneumoniae induced 
encephalitis, and pro-inflammatory cytokines such as IL-6 and IL-8 can be detected in 
the cerebrospinal fluid at elevated levels in such patients [158, 161, 162].  These pro-
inflammatory cytokines are important mediators of inflammation.  M. pneumoniae 
RNA has been detected in brain tissue by nucleic acid hybridisation.  The presence of 
the organisms in the cerebrospinal fluid has been confirmed by PCR and culture 
techniques, indicating that M. pneumoniae may disseminate and directly invade the 
CNS [163].  Most neurological manifestations of M. pneumoniae infections resolve 
completely; however, some incidences can result in chronic debilitating deficits in 
motor or mental function [9]. 
Complications involving the CNS are considered to be the most severe 
extra-pulmonary manifestations of M. pneumoniae infections.  However, 
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dermatological disorders are common, clinically significant complications, occurring 
in approximately 25% of patients.  Disorders that occur include; erythematous 
maculopapular and vesicular rashes which are usually self-limiting.  In contrast to this, 
severe forms of Stevens-Johnson syndrome, conjunctivitis, ulcerative stomatitis, and 
bullous exanthems have been reported and directly linked to the presence of 
M. pneumoniae at infection sites [140, 164-167]. 
M. pneumoniae, like other Mycoplasmas, can cause chronic infection of the 
joints.  Acute and septic arthritis has occasionally been identified in patients with 
detection of M. pneumoniae in the synovial fluid.  This manifestation occurs most 
commonly in patients with hypogammaglobulinemia [168] but can also occur in 
patients with normal immunity [169].  Other instances of M. pneumoniae infection-
associated arthritis may be due to the presence of autoantibodies, resulting in synovial 
inflammation rather than direct infection of the synovial fluid by M. pneumoniae [170, 
171]. 
Haemolytic anaemia is a rare but serious complication of M. pneumoniae 
infection and is more common in children than in adults [172, 173].  This complication 
is attributed to cross-reactive cold agglutinins, which are primarily IgM antibodies to 
the Ii blood group.  This antigen is found on surface glycoproteins or glycolipids of 
erythrocytes and other cells but is not present on the M. pneumoniae membrane.  
Instead it acts as a surface receptor for M. pneumoniae and is therefore immunogenic 
[110].   
1.4.2 Mycoplasma hominis infections 
M. hominis can be found on the mucosal surfaces of the cervix or vagina of 21 to 
53% of sexually mature, asymptomatic women; this prevalence is somewhat lower in 
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the urethra of males.  Colonisation of M. hominis is linked to younger age, lower 
socioeconomic status, sexual activity with multiple partners, African-American 
ethnicity, and oral contraceptive use [3, 174].   
1.4.2.1 Contribution of Mycoplasma hominis infection to bacterial vaginosis and 
pelvic inflammatory disease 
Bacterial vaginosis is the most common cause of abnormal vaginal discharge 
in women of child-bearing age.  The cause of bacterial vaginosis is unknown, but it is 
characterised by the depletion of the normal Lactobacillus population in the 
commensal flora of the vagina and an overgrowth of vaginal anaerobes, accompanied 
by the loss of the usual vaginal acidity.  Approximately 50% of bacterial vaginosis 
cases appear to be asymptomatic or women experience only mild symptoms.  Women 
with bacterial vaginosis consistently have up to one thousand fold increase in the 
concentration of several organisms, namely Gardnerella vaginalis, Bacteroides 
(Prevotella) species, Mobiluncus species and M. hominis [3, 175]. 
Not one of these organisms is the sole cause of bacterial vaginosis in women 
and M. hominis is found in the vagina of approximately 60% of women with the 
condition.  Additionally, higher titres of serum IgG antibody to M. hominis are found 
in women with bacterial vaginosis than in healthy women, indicating that M. hominis 
is strongly associated with the condition.  However, the mechanism of how M. hominis 
contributes to the pathology of bacterial vaginosis is unknown, if indeed it does at all 
[175]. 
A symbiotic relationship between M. hominis and Trichomonas vaginalis, 
another micro-organism associated with bacterial vaginosis, has been proposed.  It has 
been demonstrated that T. vaginalis is able to pass M. hominis infection to 
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mycoplasma-free trichomonad isolates and human cervical cells in vitro [176].  
Additionally, M. hominins is able to reside and replicate within trichomonad cells 
[177].  Both M. hominis and T. vaginalis metabolise arginine, M. hominis as its main 
source of energy and T. vaginalis in anaerobic conditions [178].  Co-cultures of 
M. hominis and T. vaginalis show increased arginine metabolism by T. vaginalis 
[179], suggesting a possible mechanism that might be important for the establishment 
of the association between the two micro-organisms.  This metabolic interaction might 
be important in the evasion from the host innate defences.  It has been documented 
that the presence of M. hominis in a T. vaginalis in vitro infection model upregulated 
the pro-inflammatory response of macrophages to T. vaginalis and that M. hominis 
may be protected from the environmental conditions of the vagina and from antibiotic 
treatments by T. vaginalis [180, 181]. 
Bacterial vaginosis can be associated with miscarriage in the second-trimester 
and preterm birth, potentially via increasing the risk of chorioamnionitis which can 
stimulate preterm birth through the release of pro-inflammatory cytokines.  Bacterial 
vaginosis has also been associated with vaginal cuff cellulitis, wound infection and 
abscess formation after hysterectomy. 
M. hominis has been isolated form the endometrium and fallopian tubes of 
approximately 10% of women with pelvic inflammatory disease (diagnosed by 
laparoscopy), and its role in this disorder has been supported by the occurrence of 
specific antibody responses; up to one quarter of women with pelvic inflammatory 
disease develop a significant antibody response to M. hominis [174].   
In men, M. hominis is recovered from the lower genital tract, more often in 
uncircumcised than circumcised men.  Bacterial vaginosis has been proposed as one 
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cause of non-gonococcal urethritis in men, and M. hominis, as an important component 
of the bacterial vaginosis flora, could have a role in non-gonococcal urethritis.  
However, infection with M. hominis alone does not result in disease and appears to 
behave as a commensal in the majority of patients [174, 182]. 
1.4.2.2 Mycoplasma hominis, pregnancy and postpartum fever 
In contrast to M. pneumoniae, M. hominis may invade the blood stream.  
M. hominis has been isolated from the blood from women diagnosed with febrile 
abortion and postpartum fevers, indicating that M. hominis may be responsible for 
some of these fevers.  These fevers are often transient and self-limiting, but in some 
cases in which M. hominis is involved, trauma or infection in compromised hosts, may 
result in dissemination of M. hominis [3, 174, 183]. 
M. hominis has been isolated from placentae following pre-term birth, although 
less frequently than Ureaplasma species.  A casual relation between different species 
of genital mycoplasmas and preterm labour has been difficult to prove.  However, 
M. hominis has been proven to be the sole pathogen responsible for the induction of 
preterm birth in pregnant macaque monkeys [184].  Following intra-amniotic 
injection, there was a short delay in recoverable infectious M. hominis, but levels of 
M. hominis then continued to climb without peaking until intra-uterine contractions 
were stimulated. 
1.4.2.3 Extra-genital Mycoplasma hominis infection in adults 
Mycoplasma hominis is usually associated with infections localised to the 
urogenital tract.  However; it may be pathogenic in non-genitourinary infections such 
as septicaemia, wound infections, central nervous system infections, joint infections 
and lower respiratory tract infections particularly in immunocompromised patients 
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[185, 186].  It is also a rare cause of septic arthritis with predisposing risk factors 
including underlying joint abnormality and immunocompromised states [187]. 
Most cases of M. hominis septic arthritis have been documented to occur in 
patients who were post-partum, had recently undergone urogenital surgery or 
manipulation, or were immunocompromised due to an underlying condition such as 
hypogammaglobulinemia, solid organ transplant, collagen vascular disease or 
haematologic malignancy [188].  However, cases of M. hominis bone infections, 
including septic arthritis, have been reported in immune-competent hosts following 
closed trauma [189].  The knee and hip were found to be the most common joints 
affected but incidences of M. hominis septic arthritis in the shoulder, wrist, ankle and 
spine have also been reported [190]. 
M. hominis infections have been documented in organ transplant recipients.  
M. hominis infections following renal transplant have been associated with peritonitis, 
wound infections, urinary tract infections, septic arthritis and organ rejection [191-
194].  Additionally M. hominis infections have been reported in recipients of lung 
[191, 195], heart and lung [196, 197] and liver [198, 199] transplants and after vascular 
allografts [200].  Post-operative M. hominis infections, in addition to transplants, have 
also been documented [201-203]. 
1.4.2.4 Mycoplasma hominis infections in neonates 
M. hominis from the maternal urogenital tract can colonise neonates and has 
been implicated in cases of meningitis [204, 205], ventriculitis [3], brain abscesses 
[206], pneumonia, pericarditis, scalp-wound infection complicating foetal monitoring 
[3, 185], eye infection [207, 208], and supramandibular adenitis in neonates [209]. 
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M. hominis can be transmitted from an infected female to the foetus or neonate 
by several mechanisms.  Firstly, there can be an ascending intrauterine infection in 
which organisms gain access to the amniotic sac, where they multiply and are then 
passed into the foetal lung.  There have also been numerous reports of M. hominis 
being isolated from cord blood and of M. hominis isolation from the bloodstream of 
neonates and young infants.  Secondly and more commonly, acquisition of M. hominis 
by the neonate can occur through passage of an infected maternal birth canal with 
resultant colonisation of the skin, mucosal membranes and respiratory tract [3, 210]. 
Isolation of M. hominis in the bloodstream of neonates and young infants is 
sometimes associated with pneumonia and/or meningitis in the infant.  Reports of 
meningitis caused by M. hominis have been published since the 1950s with incidences 
reported in both preterm and full-term newborns with or without neurological defects 
(e.g.  myelomeningocele) [3, 205, 211, 212]. 
1.5 Epidemiology of Mycoplasma pneumoniae infections 
As previously described in section 1.4.1, M. pneumoniae is a major cause of 
CAP, with infections occurring globally.  M. pneumoniae infection is endemic with 
epidemic peaks occurring every 4 to 7 years [134, 213, 214]. 
Typical outbreaks of M. pneumoniae infection occur in areas of close personal 
contact for example, schools and military barracks.  Individuals with an active 
M. pneumoniae infection carry the organism in their nose, throat, trachea and sputum, 
and it is transmitted from person to person via aerosols.  The spread of M. pneumoniae 
is greatly facilitated by the ubiquitous cough that is associated with the infection [9, 
215].  Current opinion suggests that asymptomatic carriage of M. pneumoniae occurs, 
facilitating the spread of infection [27].  Epidemics of M. pneumoniae infections can 
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be prolonged; this could be due to the long incubation period of 1 to 3 weeks of 
M. pneumoniae as well as the relatively low transmission rate of infection.  Long-term 
morbidity due to M. pneumoniae infection is uncommon however, the acute illness is 
often disruptive and can consume significant resources [9].   
1.5.1 Epidemiology in the United Kingdom 
Epidemics of M. pneumoniae infections historically occur every four years in the 
United Kingdom (UK), with epidemic periods lasting on average 18 months (Figure 
1.5) [216, 217].  Sporadic infection occurs at low levels with seasonal peaks from 
December to February [146].  The most recent epidemic in the UK started in 2014 and 
continued into 2015, with an increased number of confirmed infections over the 
winter.  Previously, the last documented epidemic was seen in the UK in 2010 and 
2011 [134, 218].   
In the UK, M. pneumoniae is not a notifiable infection and so analysis of infection 
numbers and epidemics relies on cooperation between the National Health Service 
(NHS) and the national public health body (Public Health England (PHE); Health 
Protection Scotland (HPS)).  In England and Wales, data is submitted voluntarily from 
regional laboratories and hospitals and collated by PHE, according to age and region 
to give an indication of the number of patients testing positive for M. pneumoniae by 
serological, molecular or culture tests each week.  Additionally, since 2005, a 
community surveillance scheme for M. pneumoniae using quantitative PCR (qPCR) 
analysis has been used to monitor infection.  Until 2010, this scheme was used for 
monitoring patients of all ages and from 2010, for children aged under 16 years [134].  
In Scotland, reports from NHS laboratories are collated by HPS via a non-mandatory 
reporting system.  Some diagnostic laboratories in Scotland carry out PCR testing for 
M. pneumoniae as part of screening for respiratory viruses [219].  Therefore, young 
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children presenting with presumed respiratory viral infection to hospitals served by 
these laboratories also receive concomitant testing for M. pneumoniae.  Due to the 
voluntary reporting scheme for information on cases M. pneumoniae infection, the 
number of positive cases is likely to be higher than those documented. 
From January 1989 to June 2015, seven epidemics of M. pneumoniae were noted 
in England and Wales of declining amplitude with a recent peak in 2015 (Figure 1.5) 
[220].  For some epidemic periods, clear annual fluctuations can also be seen, apparent 
as a double peak over two winter seasons.  The clarity of epidemic periods have, in 
recent years, declined with fewer reported cases overall.  From 1975 to 2009, 
incidence was found to be similar by gender, both during epidemic and inter-epidemic 
periods.  The annual notification rate in 2010-2014 was consistently highest in those 
aged 15-44 years.  the use of culture has declined in recent years and despite serology 
being the most commonly used methodology, the implementation and increased use 
of molecular methods has resulted in a proportional increase in reports based on 
molecular tests from 0.32% in 2010 to 28.5% in the first 6 months of 2015 (Figure 
1.6) [220].   
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Figure 1.5. Laboratory reports of M. pneumoniae infection detection by genomic and serological methods in England and Wales 
from January 1989 to June 2015.   
The line at 20 cases per 3 weekly average rolling period defines seven epidemic periods of declining magnitude and clarity, lasting up to 
two years (1991-1992, 1994-1995, 1998-1999, 2001-2003, 2005-2006, 2011,2015).  National reporting categories include antibody 
detection and antibody detection – rising titre.  A rising titre is defined as a four-fold increase in detectable anti-M. pneumoniae antibody 
level 
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Figure 1.6. Number of laboratory reports per year from January 1995 to June 2015 separated by detection methodology.   
National reporting categories included are: antibody detection and antibody detection-rising titre.  A rising titre is defined as a four-fold 
increase in detectable anti-M. penumoniae antibody level.  Other indicates specimens for which M. pneumoniae infection was determined 
using antigen detection, microscopy and unknown categories.  Culture indicates cases from which specimens yielded isolates of M. 
pneumoniae and genomic detection those for which DNA of M. pneumoniae was detected by PCR. 
.
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Analysis of the epidemic that occurred between 2010 and 2011 in England and 
Wales showed that M. pneumoniae infection was found in all age groups; however, no 
significant difference between age group affected by M. pneumoniae infection was 
found over this time period.  The mean age of positive cases was identified as 8.7 years 
(standard deviation; SD ± 2.6) with the majority of patients being over five years old 
[134, 214].  In comparison, in the epidemic that occurred between 2005 and 2006, 
M. pneumoniae infections were mainly reported in children aged 5-14 years in 
England and Wales.  However, in Scotland, M. pneumoniae infection had the highest 
incidence in the age group 0-4 years old in the 2010-2011 epidemics [218]. 
Molecular typing is used to characterise epidemic outbreaks of M. pneumoniae, 
typically using P1 typing and MLVA.  During the outbreak in 2010/2011, a total of 11 
distinct MLVA types were identified, with MLVA-M being the most prevalent [134].  
However, when new international guidelines for MLVA typing [221] are applied to 
this study, the number of distinct MLVA types detected reduced to 5 types.  At the 
time of the study, strain type MLVA-M had been found previously in France, Germany 
and Japan [132].  A study of MLVA types found in children in England and Wales 
during this epidemic period identified that clonal strains were not detected in the 
cohort of patients studied [214].  Currently it is unknown whether increases in 
incidence of M. pneumoniae infections are due to an increased incidence of an 
individual strain or a concurrent increased incidence of several strains.  Speculation 
that a shift in P1 adhesin type may be the cause of epidemics has been disputed [132, 
222].  Evidence from studies performed in the UK does not support this hypothesis 
that a single strain type of M. pneumoniae was responsible for the observed increase 
of infection in England and Wales, specifically in the 2010/2011 epidemic.  Instead, it 
was hypothesised that the outbreak was caused by a decline in immunity or an increase 
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of the immunologically naïve population that may have triggered the four-year cycle 
of epidemic periods [134].   
From January 2005 to June 2015 eleven cases were referred to the Bacterial 
Reference Department, PHE that were identified as positive for M. pneumoniae that 
were of particular note [220].  Two cases of Stevens-Johnson syndrome were noted in 
2009 and 2010 in male children aged 8 and 6.  Two cases were noted in respiratory 
specimens in immunocompromised patients following extra-pulmonary organ 
transplantation (2013 and 2015).  Infection in donor transplant patient respiratory 
secretions was also noted in 2015.  M. pneumoniae was detected by qPCR in the 
nasopharyngeal aspirate but not the cerebrospinal fluid (CSF) of a child with 
pneumonia and reactive transverse myelitis in 2005, and in the brochoalveolar lavage 
of a child with encephalitis and seizures in 2011.  In 2011, a young adult patient 
presented with post respiratory tract infection with encephalitis and transverse myelitis 
that progressed to tetraplegia with ventilator dependency.  In this case, M. pneumoniae 
was confirmed by qPCR on throat swab specimens taken 19 and 21 days post onset 
but was not detected in concurrent CSF specimens [223].  Detection of M. pneumoniae 
in CSF is unusual and it is postulated that neurological manifestation of 
M. pneumoniae infection is antibody mediated rather than by direct presence of the 
bacteria itself [9].  Of 68 CSF specimens referred, only one positive case was detected 
in 2010, in a child with a ventriculoperitoneal shunt, in which contamination of the 
CSF during sampling could not be excluded.  In 2012, M. penumoniae was detected 
by qPCR in the lung of two co-habiting adults that both suffered sudden fatal collapse.  
This was presumed to be a secondary infection, as one of the two patients also have 
confirmed Staphylococcus aureus infection [220]. 
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1.5.2 Global epidemiology 
The global epidemiology and incidence of M. pneumoniae infection as a causative 
agent of CAP has been extensively studied.  M. pneumoniae was believed to be 
responsible for 15-20% of all cases of CAP between 1962 and 1975 in Seattle, 
Washington [138].  A Finnish study [139] reported M. pneumoniae detection in 30% 
of paediatric CAP, and detection in over 50% among children aged five years or older, 
making it the single most common pathogen detected.  A study performed in the USA 
during the 1990s detected M. pneumoniae in 23% of CAP in children 3-4 years of age 
[224].  In France a study [225] documented occurrence in children under four years of 
age as having similar infection rates to other children or adults.  It was considered that 
these results may reflect the fact that young children who attend nurseries or child care 
on a regular basis easily share respiratory secretions with older household members or 
contacts.  Marston et al.  [226] reported that M. pneumoniae was definitely responsible 
for 5.4% and possibly responsible for 32.5% of 2776 cases of CAP in hospitalised 
adults in Ohio.  An additional finding was their observation that the incidence of 
mycoplasmal pneumonias in hospitalised adults increased with age and it was second 
only to S. pneumoniae in elderly persons.   
Globally, epidemics of M. pneumoniae are considered to occur every 3-7 years; 
however, recent epidemiological studies have documented varying trends in epidemic 
patterns.  Serological studies performed in Denmark showed a pattern of 
M. pneumoniae infections over a 50 year period from 1946 through 1995 with endemic 
disease transmission punctuated with cyclic epidemics every 3-5 years [227].  As 
described in section 1.5.1, epidemics occur at approximately four-yearly intervals in 
the UK.  In comparison, recent studies from China have indicated a peak constant level 
of M. pneumoniae infections following the last epidemic in 2012 [228].  In Jerusalem, 
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historically, epidemics were observed every 3-5 years with seasonal peaks in October 
and early spring; however, since autumn 2014 a constant rate of infection has been 
observed, diverging from the historical pattern [229].   
1.6 Antimicrobial therapy against Mycoplasma hominis and Mycoplasma 
pneumoniae 
Antimicrobial therapy is used to treat infections with either M. pneumoniae or 
M. hominis.  However, because of intrinsic resistance within these species, therapy is 
restricted to a small number of agents including the tetracyclines, macrolides and 
fluoroquinolones [27].  Further complications for therapy arise in neonates and 
children who are colonised with Mycoplasma.  Tetracycline use in neonates and 
children younger than 8 years of age is restricted due to effects on bone toxicity and 
deposition within calcifying tissue, but its use has been reported in a limited number 
of CSF infections [206, 230].  The usage of quinolones is also restricted in neonates 
due to effects on cartilage development and should not be administered before 
adolescence [231].  The susceptibilities of M. pneumoniae and M. hominis to a 
selection of antibiotics are listed in Table 1.2.  All three classes of antibiotics have the 
advantage of being active against additional bacteria that may be associated with 
mycoplasmas in respiratory and genital tract infections. 
The first-line antibiotics for treatment of M. pneumoniae infections in children are 
protein synthesis inhibitors of the macrolide class [231].  The 2011 British Thoracic 
Society guidelines for the management of CAP in children suggest empiric macrolide 
treatment at any age if there is no response to first-line β-lactam antibiotics, or in the 
case of very severe disease [232].  In adults, the first-line antibiotics for treatment of 
hospitalised cases of CAP, recommended by the British Thoracic Society, is empirical 
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treatment with penicillin/β-lactam antibiotics; however, depending on severity of 
disease, a macrolide may be added to treatment.  If there is no response to first-line 
penicillin/β-lactam treatment then it is recommended that a macrolide is added or 
substituted to the treatment.  Additionally, in cases of more severe disease that are 
already being treated with a macrolide, doxycycline or a fluoroquinolone can be added 
to the treatment when initial empirical treatment has failed [233].   
Table 1.2. Minimum inhibitory concentration ranges (µg/mL) by antibiotic 
class for selected M. pneumoniae and M. hominis [234-236]. 
Antibiotic M. pneumoniae M. hominis 
Tetracyclines   
Doxycycline 0.03-0.5 0.1-2 
Minocycline 0.06-0.25 0.03-1 
MLS group   
Erythromycin ≤0.004-0.06 32->1000 
Roxithromycin ≤0.01-0.03 >16 
Clarithromycin ≤0.004-0.125 16->256 
Azithromycin ≤0.004-0.01 4->64 
Josamycin ≤0.01-0.03 0.05-2 
Clindamycin ≤0.008-2 ≤0.008-2 
Pristinamycin 0.02-0.5 0.1-0.5 
Quinupristin/Dalfopristin 0.008-0.25 0.03-2 
Ketolides   
Telithromycin ≤0.001-0.06 2-32 
Solithromycin ≤0.000000063-0.000125 0.002-0.008 
Fluoroquinolones   
Ciprofloxacin 0.5-2 0.1-4 
Ofloxacin 0.05-2 0.1-4 
Levofloxacin 0.5-1 0.1-2 
Moxifloxacin 0.06-0.3 0.06-0.125 
Other agents   
Chloramphenicol 2-10 4225 
Gentamicin 4 2-16 
 
1.6.1 Intrinsic antibiotic resistance in Mycoplasma hominis and 
Mycoplasma pneumoniae and therapeutic considerations 
Two types of intrinsic resistance to antibiotics are found in mycoplasmas; the first 
is common to all species in the class Mollicutes and the other is specific to certain 
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species.  These properties have been used to isolate mycoplasmas from specimens 
contaminated by other bacteria, and to differentiate Mycoplasma species within a 
specimen [236, 237].  The class Mollicutes lack a cell wall and therefore all organisms 
within the class are resistant to cell wall synthesis inhibitors, such as β-lactams, 
glycopeptides and fosfomycin.  Additionally they are also resistant to polymyxins, 
sulphonamides, trimethoprim, nalidixic acid and rifampin [238, 239].  M. pneumoniae 
and M. hominis, like other human mycoplasmas, are resistant to linezolid.  The second 
type of intrinsic resistance is species-specific and concerns mainly the MLSK 
antibiotics [238, 239].  Among human pathogenic Mycoplasmas, M. pneumoniae and 
M. genitalium are sensitive to all MLSK antibiotics with the exception of lincomycin 
which shows modest activity against these two species.  The same is true for 
Ureaplasma species.  However, M. hominis is resistant to 14- and 15-membered ring 
macrolides and to telithromycin, but it is susceptible to the 16-membered ring 
macrolides, josamycin, and to lincosamides [240-243] (Table 1.2).  The genetic basis 
underlying the intrinsic resistance of M. hominis to erythromycin has been studied by 
comparing the genome of M. hominis with that of M. pneumoniae, resulting in the 
identification of a single nucleotide difference in the peptidyltransferase loop of the 
domain V region of 23S rRNA, G (M. pneumoniae) to A (M. hominis) transition at 
position 2057 (E. coli numbering) [242].  This mutation is associated with macrolide 
resistance in other bacteria. 
Various mechanisms of acquired antibiotic resistance have been elucidated, 
however, the only methods described in vivo for mycoplasmas are antimicrobial target 
modification or protection [236].  An active efflux mechanism has also been 
demonstrated in vitro [244].  Resistance in M. pneumoniae and M. hominis is mediated 
either by chromosomal mutations or acquisition of a transposon and no extra-
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chromosomal element has been described in either species.  In M. pneumoniae, only 
target alterations by acquired mutations have been associated with antibiotic resistance 
[245].   
Mycoplasmas are characterised by high mutation rates and sequencing studies 
have revealed only a small amount of genetic information is dedicated to DNA repair 
[246].  It is hypothesised that there is an association between high mutation rates and 
antibiotic resistance in mycoplasmas, as has been found for Pseudomonas aeruginosa 
[247].  Resistance through mutation concerns all classes of antibiotics used to treat 
M. pneumoniae and M. hominis infections [238].   
1.6.2 Macrolide-lincosamide-streptogramin group and the ketolides 
The MLSK group of antibiotics are of great clinical significance in many patient 
groups but their use is becoming compromised due to increasing numbers of antibiotic 
resistant organisms [248]. 
Macrolides, lincosamides and streptogramins are classified in the same group 
of antibiotics although they are chemically distinct (Figure 1.7).  Antibiotics 
constituting the MLSK group inhibit protein synthesis at the ribosomal level, by 
binding to the 50S ribosomal subunit and blocking peptide bind formation and/or 
translation.  They bind to specific nucleotides in domains II and V or 23S rRNA [236, 
249-252].  All MLSK antibiotics are bacteriostatic except the streptogramin 
combinations and ketolides, which are bactericidal.    
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Figure 1.7.  Macrolide classification and example antibiotics. 
Macrolide resistance in mycoplasmas, which have a small number of 
ribosomal operons, is conferred by mutations in the ribosomal target (23S rRNA and 
ribosomal proteins L4 and L22) [253].  Resistance has been described mainly in 
M. pneumoniae [236] but resistant strains of M. hominis, Ureaplasma species [238, 
239] and, more recently, M. genitalium [254, 255], have been reported.   
Most resistant strains of M. pneumoniae that have been reported harbour an A 
to G mutation at position 2058 in the peptidyltransferase loop of 23S rRNA (E. coli 
numbering) [245] although, mutations have also been observed in clinical isolates at 
positions 2059 and 2611 [256, 257].  These mutation positions have also been 
identified as macrolide resistant hot spots in other bacteria.  To date, no mutations 
have been described for M. pneumoniae in domain II or in the ribosomal proteins L4 
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and L22 in clinical isolates.  Macrolide-resistant strains of M. pneumoniae do not show 
cross-resistance to other classes of antibiotics [236]. 
Resistant mutant strains of M. pneumoniae have been obtained in vitro against 
different macrolides, streptogramins and a ketolide.  Resistance has been shown to be 
due to mutations at positions 2058 and 2059 of the 23S rRNA, as seen in vivo [257, 
258]; positions 2611 and 2062 of the 23S rRNA; and in the genes encoding ribosomal 
proteins L4 and L22 [259]. 
M. hominis is intrinsically resistant to 14- and 15-membered ring macrolides 
through inherent sequence determination within its 23S rRNA as described in Section 
1.6.1 [242]. 
Prior to the year 2000, very few macrolide-resistant clinical isolates of 
M. pneumoniae were identified [239, 260-263].  By contrast, since 2000 a significant 
increase in macrolide-resistant strains has been reported.  The global increase in 
macrolide resistance observed in cases of M. pneumoniae infection is of increasing 
concern and importance to the international community [264].  In China resistance has 
been documented in over 90% of clinical isolates of M. pneumoniae studied [228]; 
however, resistance is lower in European counties including France, Germany, 
Switzerland and Sweden [265-268] and North America [269].  This increase in 
resistance has paralleled a similar rise in macrolide resistance in other respiratory 
pathogens as a result of antibiotic selective pressure in children during a period of 
extensive macrolide use in many parts of the world, especially in Asia [270-272]. 
Prior to 2014, seven cases of macrolide-resistant M. pneumoniae strains were 
reported in the UK, one case in England and Wales and six cases in Scotland [273, 
274].  Between 1st September 2014 and 1st September 2015, M. pneumoniae was 
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detected by PCR in 61 clinical specimens submitted to PHE.  These were screened for 
point mutations that are known to confer macrolide resistance in domain V of the 23S 
rRNA by a modified version of the method described by Li et al., 2009 [275, 276].  Of 
the 61 specimens, 18 (29.5%, 95% CI: 19.5-42.0) contained insufficient DNA to 
determine macrolide resistance-conferring mutations.  Of the remaining 43 specimens, 
mutations in the 23S rRNA known to confer macrolide-resistance were found in 9.3% 
(95% CI: 3.1-22.2; 4/43) [276]. 
Macrolide-resistance in M. pneumoniae has been reported in Scotland at 19% 
(6/32) [274], higher than the 9.3% documented in the 2014-2015 England and Wales 
study [276] but this is not statistically significant.  This may reflect sampling 
differences and it is important to note that the specimen cohort examined for macrolide 
resistance in Scotland were from patients in whom macrolide resistance was 
considered most likely based on their clinical presentation.   
It is important to note that in the 2014-2015 England and Wales study [276] 
M. pneumoniae was not isolated from those specimens where M. pneumoniae was 
detected by PCR, and therefore it was not possible to confirm macrolide resistance in 
vitro.  However, point mutations within the 23SrRNA gene in clinical specimens and 
isolates from specimens have previously been shown to confer resistance [245].  
Acquisition of resistance has been documented in patients receiving macrolides and 
resistance may develop as a consequence of antibiotic selective pressure [277].  This 
is supported by the highest macrolide-resistance rates being reported in countries with 
extensive macrolide usage [236].   
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1.6.3 The tetracyclines 
Tetracyclines have a broad spectrum of activity against most gram-positive and 
gram-negative bacteria.  Tetracyclines and the related glycylcylines inhibit bacterial 
protein synthesis.  They act as bacteriostatic antibiotics and exert their activity by 
binding to the ribosomal 20S subunit which is composed of 16S rRNA and several 
ribosomal proteins.  The major tetracycline binding site is located in a pocket formed 
by some residues of helix 34 and 31 in 16S rRNA [278].  Binding of tetracyclines to 
this site prevents the attachment of charged transcription RNA (tRNA) to the A site, 
therefore preventing protein synthesis. 
Resistance to tetracyclines has been well documented for both M. hominis and 
Ureaplasma species but not for M. pneumoniae.  One mechanism by which bacteria 
mediate tetracycline resistance is due to the acquisition of a tetracycline resistance 
gene such as tetM or tetO, which have been found in both gram-positive and gram-
negative bacteria, or tetA-tetF which are confined to gram-negative bacteria [279].  
High-level resistance to tetracyclines in M. hominis and Ureaplasma species has been 
associated with the presence of tetM [280, 281], the sole tetracycline resistance 
mechanism so far documented in clinical isolates of human mycoplasmas [239].   
1.6.4 The fluoroquinolones 
The quinolones are a group of synthetic, broad-spectrum antibiotics used to treat 
both gram-positive and gram-negative bacterial infections.  Fluoroquinolones play an 
important role in the treatment of serious bacterial infections, especially hospital-
acquired infections and infections in which resistance to other classes of antibiotics is 
suspected.  Minimal usage of fluoroquinolones is recommended for the treatment of 
CAP to discourage the spread and development of multi-drug resistant bacterial strains 
due to the broad-spectrum activity of fluoroquinolones [232, 282-284].  Newer 
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fluoroquinolones show enhanced activity against all human mycoplasmas studied, 
including M. pneumoniae and M. hominis, compared with the older ones [236].   
Fluoroquinolones are bactericidal antibiotics which disrupt DNA replication 
by binding to enzyme-DNA complexes during replication leading to the death of the 
cell.  The intracellular targets of fluoroquinolones in bacteria are considered to be the 
type II topoisomerases, DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and 
parE), which are essential for bacterial DNA replication [285].  Although the two 
enzymes are structurally homologous they have differences in activity and preferential 
sites of action; DNA gyrase proteins in gram-negative bacteria and topoisomerase IV 
in gram-positive bacteria [286].   
Resistance mechanisms to fluoroquinolones have been described and fall into 
three categories: mutations in the four target genes, gyrA, gyrB, parC and parE; 
reduction in the level of quinolone accumulation inside the cells either by efflux of 
lack of penetration; and target protection [287].  However, mutations in the target 
genes are the main mechanism conferring fluoroquinolone resistance in mycoplasmas.  
Mutations in the gene targets for each gene cluster within a conserved region referred 
to as the quinolone resistance-determining region (QRDR).  QRDRs were first 
described for GyrA and GyrB and homologous regions were later identified in ParC 
and ParE [287, 288].  Resistance in vivo has only been described in genital 
mycoplasmas including M. hominis, M. genitalium and Ureaplasma species [238, 
239], but mutant strains of M. pneumoniae have been selected in vitro [289].   
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1.7 Hypothesis 
Detection of M. hominis and Ureaplasma species in clinical samples is 
hampered by the fastidious nature of these organisms.  The development of a sensitive 
and specific PCR assay will increase detection of these organisms in clinical samples 
and can be utilised for further examination of clinical data sets.  Molecular typing 
schemes can be used to differentiate between strains of a bacterial species, allowing 
the characterisation of isolates into distinct groups and can be representative of the 
entire genome. 
1.8 Aims 
• To develop a quantitative, real-time PCR assay to simultaneously detect 
M. hominis, Ureaplasma parvum and Ureaplasma urealyticum for clinical 
diagnosis of infection and determination of MIC 
• To characterise M. hominis isolates based on their major surface antigen, Vaa, 
develop a molecular typing scheme to differentiate between M. hominis strains, 
and examine the genetic diversity of M. hominis isolates using whole genome 
sequence analysis 
• To develop a molecular typing scheme to differentiate between M. pneumoniae 
strains, and compare with whole genome sequence analysis and other 
established molecular typing methods for M. pneumoniae 
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2.1 Mycoplasma pneumoniae and Mycoplasma hominis isolate details 
Clinical samples were submitted to PHE for diagnosis of M. pneumoniae or 
M. hominis infection.  Clinical samples originate from a range of anatomical sites, 
vary in the type of sample and differ in clinical background.  M. pneumoniae and 
M. hominis were isolated from positive clinical samples and stored at -80°C.  Clinical 
samples from Wales were also submitted to the University Hospital Wales (UHW) for 
diagnosis of Ureaplasma species infection.  Endo-tracheal secretions were submitted 
to UHW as part of the UREAtrack study from a South West England hospital, for 
Ureaplasma species diagnosis.  Mixed infections with M. hominis were identified and 
M. hominis cultures were stored at -80°C.  All Mycoplasma isolates were isolated 
between 1967 and 2014.  Full details of M. pneumoniae and M. hominis isolates can 
be found in Table 2.1 and Table 2.2, respectively. 
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Table 2.1.  Mycoplasma pneumoniae clinical isolate details.   
All M. pneumoniae isolates were submitted to PHE.  Isolates from the same patient 
are indicated by coloured shading. 
Isolate Year of Isolation Isolation site Further clinical information 
M129 
(ATCC 
29342) 
1969  
FH 
(ATCC 
15531) 
1944  
MPN003 1983 Sputum Chest infection 
MPN004 1981 Sputum Bronchopneumonia 
MPN005 1983 Sputum Pneumonia 
MPN006 1982 Sputum Persistent productive cough 
MPN007 1978 Throat swab Pneumonia 
MPN008 1981 Sputum Pneumonia 
MPN010 1983 Sputum Abnormal chest X-rays; night sweats; lung 
function loss 
MPN011 1983 Sputum Two month cough 
MPN012 1981 Brain cystic cavity Probable congenital disease; meningitis 
MPN013 2009 Nose and throat swabs Stevens-Johnson syndrome; cough 
MPN014 2009 Nose and throat swabs Stevens-Johnson syndrome; cough 
MPN015 2009 Nose and throat swabs Stevens-Johnson syndrome; cough 
MPN016 2009 Nose and throat swabs Stevens-Johnson syndrome; cough 
MPN017 2009 Nose and throat swabs Stevens-Johnson syndrome; cough 
MPN018 1981 Sputum Pneumonia 
MPN019 1983 Sputum Pneumonia 
MPN020 1982 Sputum Bronchopneumonia 
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Isolate Year of Isolation Isolation site Further clinical information 
MPN021 1983 Unknown Unknown 
MPN022 2010 Sputum Atypical pneumonia; serology positive 
MPN023 1983 Sputum Pneumonia 
MPN101 1978 Throat swab Lobar pneumonia 
MPN102 1981 Brain frontal lobe Unknown 
MPN103 1982 Sputum Persistent, productive cough 
MPN104 1981 Sputum Bronchopneumonia (2nd sample, 4 days 
later) 
MPN105 1983 Sputum Unknown 
MPN106 1981 Sputum Bronchopneumonia (1st sample) 
MPN107 1983 Sputum Symptoms look like tuberculosis; night 
sweats 
MPN108 1983 Sputum Unknown 
MPN109 1982 Sputum Bronchopneumonia 
MPN110 1981 Sputum Recurring chest infection 
MPN111 1968 Unknown Unknown 
MPN112 1983 Sputum Cough 
MPN113 1967 Unknown Pneumonia 
MPN114 1983 Sputum Unknown 
MPN116 1982 Sputum Pneumonia 
MPN117 1982 Sputum Unknown 
MPN118 1996 Sputum Unknown 
MPN119 1982 Sputum Pneumonia 
MPN120 1982 Sputum Cough 
MPN121 1983 Sputum Unknown 
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Isolate Year of Isolation Isolation site Further clinical information 
MPN122 1982 Sputum Unknown 
MPN123 1983 Sputum Unknown 
MPN124 1981 Sputum Bronchopneumonia 
MPN125 1983 Sputum Chest infection 
MPN126 1979 Unknown Chest infections 
MPN127 1982 Sputum Persistent wet chest 
MPN128 1976 Unknown Unknown 
MPN129 1983 Sputum Productive cough; flu for 5 days 
MPN130 1983 Sputum Unknown 
MPN131 1981 Sputum Un-resolving pneumonia 
MPN132 1982 Sputum Chest infection 
MPN133 1982 Sputum Pneumonia 
MPN134 1982 Sputum Pneumonia 
MPN135 1986 Unknown M. pneumoniae strain M1 from Dr McKoy. 
MPN136 1982 Sputum Unknown 
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Table 2.2.  Mycoplasma hominis clinical isolate details.   
All M. hominis isolates were submitted to PHE unless otherwise stated.  Isolates from the same patient are indicated by coloured shading 
and linked patients are indicated by grey shading.   
Isolate Year of 
Isolation 
Isolation site Further clinical information 
PG21 
(NCTCC 
10111; ATCC 
23114) 
   
MH002 1989 Cerebral spinal fluid Neonate; haemorrhagic 
MH008 2012 Genital isolate Isolate from outside C-section wound 
MH009 2012 Genital isolate Isolate from outside C-section wound 
MH010 2012 Genital isolate Isolate from outside C-section wound 
MH011 2012 Peritoneal fluid Renal transplant 
MH012 2012 Peritoneal fluid Renal transplant 
MH013 2012 Peritoneal fluid Renal transplant 
MH015 2004 Blood culture Post-termination operation 
MH016 2004 Neck swab Unknown 
MH017 2004 Unknown Unknown 
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Isolate Year of 
Isolation 
Isolation site Further clinical information 
MH018 1993 Genital Hepatitis C Virus infection 
MH020 1990 Cervical swab Unknown 
MH021 1986 Knee aspirate Unknown 
MH022 1990 Breast abscess Unknown 
MH023 2005 Endo-tracheal secretions Neonate; 25 weeks gestation 
MH025 2006 Ear swab Neonate; respiratory distress syndrome; twin 
MH026 2008 Cerebral abscess Unknown 
MH027 2008 Abdominal pus Renal transplant 
MH028 2004 Pelvic aspirate Pelvic haematoma after hysterectomy 
MH029 1989 Pleural fluid Cardiac failure 
MH041 2012 Endo-tracheal secretions Neonate 
MH043 2013 Spinal tissue Post-operative; deep tissue infection & superficial irritation; spinal abscess; spinal curdle C5; 
scoliosis instrumentation 
MH044 2013 Spinal tissue Post-operative; deep tissue infection & superficial irritation; spinal abscess; spinal curdle C5; 
scoliosis instrumentation 
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Isolate Year of 
Isolation 
Isolation site Further clinical information 
MH045 2013 Spinal tissue Post-operative; deep tissue infection & superficial irritation; spinal abscess; spinal curdle C5; 
scoliosis instrumentation 
MH101 2013 Genital isolate Post-natal pyrexia 
MH102 2013 Pelvic collection fluid Post lower segment C-section; laparoscopy and drainage 
MH103 2013 Endo-tracheal secretions Neonate 
MH104 2013 Cerebral spinal fluid Neonate; query meningitis 
MH105 2013 Renal isolate End-stage renal failure; haemodialysis; anti-phospholipid syndrome; query sepsis 
MH106 2013 Sputum Neonate 
MH107 2013 Vaginal pus Gynaecology emergency 
MH108 2013 Uterine tissue Eight days post-natal bleeding 
MH109 2013 Pleural fluid Abdominal/chest stab wound 
MH110 2013 Endo-tracheal secretions Neonate 
MH111 2013 Tracheoscopy swab Sepsis 
MH112 2013 Spinal isolate Operation three weeks prior; posterior spine instrumentation; deep infection & superficial 
irritation; spinal abscess; superficial curdle; scoliosis 
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Isolate Year of 
Isolation 
Isolation site Further clinical information 
MH113 2013 Spinal isolatea Operation three weeks prior; posterior spine instrumentation; deep infection & superficial 
irritation; spinal abscess; superficial curdle; scoliosis 
MH114 2013 Respiratory isolate Neonate; severe lung disease 
MH115 2013 Spinal isolatea Post extensive spinal surgery; spinal abscess 
MH116 2013 Endo-tracheal secretions Neonate; severe lung disease 
MH117 2013 Pelvic collection fluid Puerperal sepsis; query endometriosis 
MH118 2012 Knee fluid Painful knee 
MH119 2012 Peritoneal fluid Unknown 
MH120 2012 Pelvic pus 13 days post emergency C-section 
MH121 2013 Mid-line drain fluid Unknown 
MH122 2014 Higher vaginal swab Unknown 
MH123 2014 Pelvic fluid Unknown 
MH124 2014 Abdominal fluid Unknown 
MH125 2014 Pelvic abscess fluid Acute myeloid leukaemia; diagnosed post-partum 
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Isolate Year of 
Isolation 
Isolation site Further clinical information 
MH126 2014 Isolate Sample triggered bactalert; no staining in gram stain; negative for EBV/HSV/Candida/ASP; 
sever acute respiratory distress syndrome; post influenza A (H3 not H1V1); patient had Tamiflu; 
multiple haemorrhagic skin lesions. 
MH127 1998 Pleural fluid Unknown 
MH128 2004 Uterine swab Unknown 
MH129 2004 Placental isolate Miscarriage 
MH130 2003 Wound swab Post-laparotomy 
MH131 1992 Unknown U.  urealyticum FD culture interim batches prior to accession 
MH132 1993 High vaginal swab Unknown 
MH133 1986 Blood culture Renal transplant; pyrexia; inflamed wound 
MH134 1990 Isolate Mycoplasma isolate for identification 
MH135 2004 High vaginal swab Post-natal; post evacuation of retained products of conception; late miscarriage; increased 
temperature; patient on β-lactam 
MH136 2003 Endo-tracheal tube isolate Neonate 
MH137 1990 Unknown Unknown 
MH138 1993 Genital isolate Spontaneous miscarriage at 21 weeks; high temperature 
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Isolate Year of 
Isolation 
Isolation site Further clinical information 
MH139 1989 Cerebral spinal fluid Premature neonate; spontaneous haemorrhagic hydrocephalus 
MH140 1990 Genital isolate Post-abortive sepsis 
MH141  2013 Endo-tracheal secretions P162E; neonate 
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2.2 Culturing Mycoplasma pneumoniae and Mycoplasma hominis 
Mycoplasmas were cultured in Mycoplasma-specific Medium (MM; 
Mycoplasma Experience Ltd; Blenchingly, UK) or on Mycoplasma Agar 
(Mycoplasma Experience Ltd; Blenchingly, UK).  Mycoplasma cultures were 
incubated aerobically at 37°C.  All Mycoplasma strains analysed in this thesis that 
were isolated from clinical specimens were triple cloned on Mycoplasma Agar to 
ensure a pure culture. 
2.2.1 Storage and recovery of Mycoplasma isolates 
Mycoplasmas were stored at -80°C in MM.  Usually the lowest dilution giving 
colour change or a triple cloned pure strain was stored by placing in a sealed tube.  
Aliquots of 20 µL were stored to prevent repeated freeze-thawing along with a larger 
volume stock.  Mycoplasmas grown on agar were stored at -80°C by placing blocks 
of agar containing colonies in MM. 
Isolates frozen in MM were recovered by thawing followed by inoculation and 
microbroth dilution in fresh MM.  Alternatively, the isolate was inoculated directly 
onto Mycoplasma agar.  Isolates frozen on agar blocks were inoculated on 
Mycoplasma agar using the push block technique and a small volume of the MM was 
also inoculated onto the plate.  Cultures were incubated at 37°C until either colour 
change in MM or colonies were observed.   
2.3 Detection of Mycoplasma hominis and Ureaplasma species in clinical 
samples 
2.3.1 DNA Extraction from clinical samples 
Prior to DNA extraction, all samples were heat-inactivated by incubating at 
95°C for 30 minutes. 
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2.3.1.1 QIAsymphony® 
The QIAsymphony® (Qiagen; Manchester, UK) was used to extract DNA from 
a large number of samples at one time (up 96 samples per extraction run).  The 
QIAsymphony® was set up according to manufacturer’s instructions.  Briefly, 240 µL 
of sample was added per well of a 96 well S-Block (Qiagen; Manchester, UK) and the 
S-Block was loaded onto the QIAsymphony®.  DNA was extracted by a four-step 
process: lysis, binding to magnetic particles, washing and elution, using the automated 
bacteria DNA protocol.  DNA was extracted in a final volume of 100 µL in buffer 
ATE (Qiagen; Manchester, UK; low-ethylene diaminetetraacetic acid (EDTA) elution 
buffer containing sodium azide). 
2.3.1.2 MagNA Pure Compact 
The MagNa Pure Compact System (Roche; Welwyn Garden City, UK) was used to 
extract DNA from up to eight clinical samples at one time.  The MagNa Pure Compact 
was set up according to manufacturer’s instructions.  Briefly, 180 µL of MagNa Pure 
Bacterial Lysis Buffer (Roche; Welwyn Garden City, UK) and 20 µL of Proteinase K 
recombinant PCR grade (Roche; Welwyn Garden City, UK) were added to 200 µL of 
clinical sample and thoroughly mixed.  The sample was incubated at 65°C for 
10 minutes to lyse.  DNA was extracted using the MagNa Pure Compact Nucleic acid 
Isolation Kit I (Roche; Welwyn Garden City, UK) with automated protocol 
DNA_Bacteria in a four-step process: sample lysis, immobilisation of nucleic acids 
on magnetic glass particles, removal by washing of unbound substances, and elution 
of purified nucleic acids from the magnetic particles.  DNA was extracted in a final 
volume of 100 µL in MagNa Pure Compact Elution Buffer (Roche; Welwyn Garden 
City, UK). 
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2.3.2 Detection of Mycoplasma hominis, Ureaplasma parvum and Ureaplasma 
urealyticum by qPCR – MUP PCR 
This assay simultaneously detected and identified Ureaplasma species and 
M. hominis in DNA extracts.  It was based on Yi et al., 2005 [290] and targets the 
urease gene of Ureaplasma species  and on Baczynska et al., 2004 [124] with a 
modified in-house probe design to the gap gene of M. hominis.   
2.3.2.1 Clinical sample preparation 
Clinical DNA extracts were diluted 1:10 in nuclease free water.  In addition, 
unusual and highly cellular samples such as lung tissue were diluted 1:10 and 1:100. 
2.3.2.2 Preparation of PCR Internal Processing Control (IPC) 
An IPC was previously constructed in the plasmid TOPO TA by amplification 
of a selected sequence (13825-13844, NC_001416) from bacteriophage lambda DNA 
(Genbank J02459) with extension at their 5’ ends consisting of primer sequences to be 
used to amplify the Ureaplasma template.  The plasmid pU-IPC-TOPO (clone 1, 2 
and 3) were stored on E. coli at -80°C.  The plasmid was diluted in TE to 0.01 ng/µL, 
for use in this assay. 
2.3.2.3 Preparation of positive controls 
Positive control DNA for M. hominis and U. urealyticum was obtained from 
Minerva Biolabs (Berlin, Germany) at a concentration of 10 ng/µL.  Positive control 
DNA for U. parvum was obtained by inoculating a 5 mL liquid broth culture and 
incubating at 37°C until a colour change was observed in the media.  The broth culture 
was then centrifuged at 10,000 x g for 15 minutes and the pellet was re-suspended in 
200 µL of nuclease free water.  DNA was extracted using the MagNa Pure compact 
as described in section 2.3.1 and then diluted to 10 pg/µL.   
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A standard curve of the positive control DNA for each M. hominis, U. parvum 
and U. urealyticum was used in each qPCR run: 1 pg/µL, 0.1 pg/µL and 0.01 pg/µL. 
2.3.2.4 MUP qPCR 
Amplification was performed in a Rotor-Gene® Q series thermocycler 
(Qiagen; Manchester, UK) in 25 µL reactions containing: 1 x Rotor-Gene® multiplex 
Mastermix (Qiagen; Manchester, UK), 0.5 pmol/µL of each primer, 0.2 pmol/µL of 
each probe, 0.01 ng/mL IPC DNA and 5 µL of sample DNA.  Primers and probes are 
detailed in Table 2.3.  A water blank was included in every PCR run.   
Table 2.3.  Primers and probes 
Name Sequence (5’-3’) 
Primer UUPF  AAGGTCAAGGTATGGAAGATCCAA 
Primer UUPR TTCCTGTTGCCCCTCAGTCT 
Probe UP FAM-TCCACAAGCTCCAGCAGCAATTTG-BHQ1 
Probe UU ROX-ACCACAAGCACCTGCTACGATTTGTTC-BHQ2 
Primer MHF GGAAGA-TATGTAACAAAAGAAGGTGCTG 
Primer MHR TTTATCTTCTGGCGTAATGATATCTTCG 
Probe MH Cy5-CTGCTCCAGCTAAAAGCGAAGGTGTT-BHQ3 
Probe UIPC Yakima Yellow-AGCCGCTGGCGCATTGAGCA-BHQ1 
 
The Rotor-Gene® was set up to measure in the channels: FAM, Yakima 
Yellow, ROX and CY5.  Cycling conditions were as follows: initial Taq activation 
step of 5 minutes at 95°C, followed by quantification of 45 cycles of 15 seconds at 
95°C and 15 seconds at 60°C.   
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Thresholds were set to 0.15 (Table 2.4) and the resulting standard curve was 
used to interpret the results.  If positive and negative controls were satisfactory, the Ct 
values of the clinical samples were examined and were determined to be positive if 
they fell in the ranges indicated in Table 2.5. 
Table 2.4.  Thresholds for analysis of each target. 
Channel and dye Target Threshold for analysis 
1 – Green – FAM U. parvum 0.15 
2 – Yellow – Yakima Yellow UIPC 0.15 
3 – Orange – ROX U. urealyticum 0.15 
4 – Red – Cy5 M. hominis 0.15 
  
Table 2.5.  Positive control Ct value ranges to determine positive clinical results 
 U. parvum Ct U. urealyticum Ct M. hominis Ct UIPC Ct 
pg/µL min max min max min max min max 
1000 19.8 21.2 18.0 26.9   33.5 41.6 
100 23.4 24.7 24.6 25.7 24.8 26.7   
10 26.7 28.5 27.2 30.7 28.2 30.2   
1 30.4 34.1 30.5 34.6 29.5 35.9   
0.1 33.0 37.4 31.9 34.8 31.4 40.7   
0.01 34.5 40.0 32.3 44.1 31.8 39.4   
0.001 35.5 39.6 35.3 38.6     
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2.3.3 Multiplex real-time PCR 
This assay was developed to simultaneously detect and identify Ureaplasma 
species and M. hominis in clinical DNA extracts.  It was based on Yi et al., 2005 [290] 
which targets the urease gene of Ureaplasma and on Ferandon et al., 2010 [125] which 
targets the yidC gene of M. hominis.  This multiplex assay included an internal 
processing control modified from Murphy et al., 2007 [291] and utilised a plasmid 
containing a single copy of each gene target as a positive control. 
2.3.3.1 GFP amplification control 
An IPC was constructed by inserting the gfp gene into the chromosome of a 
non-pathogenic strain of E. coli as described by Murphy et al., (2007) [291] (Section 
2.3.2.2).  The control primers outlined by Murphy et al., did not work with the 
Ureaplasma species primers used in this assay, therefore new primers were designed 
(Table 2.6). 
2.3.3.2 Preparation of standard DNA 
A plasmid (vector pUC57; cloning sites BamHI-HindIII; 
RSBS_control_plasmid_01; Genscript, Piscataway, USA) containing one copy of the 
gene targets for the three species was used as a positive control.  The plasmid was 
supplied lyophilized therefore it required reconstitution by the addition of 20 µL of 
nuclease free water resulting in a plasmid concentration of 200 ng/µL 
(4x1010 copies/µL).  The plasmid was serially diluted to 1x104, 1x103, 1x102, and 
10 copies/µL respectively using nuclease free water. 
2.3.3.3 qPCR 
Amplification was performed in a Rotor-Gene® Q series thermocycler 
(Qiagen; Manchester, UK) in 25 µL reactions containing: 1 x Rotor-Gene multiplex 
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Mastermix (Qiagen; Manchester, UK), 0.25 pmol/µL of Ureaplasma and M. hominis 
primers, 0.05 pmol/µL of gfp primers, 0.1 pmol/µL of each probe, 0.1 pg/µL gfp DNA 
and 5 µL of sample DNA.  Primers and probes are detailed in Table 2.6.  A water 
blank was included in every PCR run.  
Table 2.6.  Details of primers and probes used in the multiplex real-time PCR 
Name Sequence (5’-3’) Length 
(bp) 
G+C 
(%)a 
Tm 
(°C)a 
Amplicon 
size (bp) 
UUP_FP AAGGTCAAGGTATGGAAGATCCAA 24 41.7 59.3 90 
UUP_RP TTCCTGTTGCCCCTCAGTCT 20 55.0 59.4 
UP_HP FAM-TCCACAAGCTCCAGCAGCAATTTG-BHQ1 24 50.0 62.7 
UU_HP HEX-ACCACAAGCACCTGCTACGATTTGTTC-BHQ1 27 48.1 65 90 
gfp_FP CCTGTCCTTTTACCAGACAACCA 23 47.8 60.6 125 
gfp_RP2 ATGCCATGTGTAATCCCAGCAG 22 50.0 60.3 
gfp_HP Cy5-TACCTGTCCACACAATCTGCCCTTTCG-BHQ3 27 51.9 66.5 
MH_FP TCACTAAACCGGGTATTTTCTAACAA 26 34.6 58.5 94 
MH_RP TTGGCATATATTGCGATAGTGCTT 24 37.5 57.6 
MH_HP ATTO680-CTACCAATAATTTTAATATCTGTCGGTATG-
BHQ3 
30 30.0 59.9 
 
Rotor-Gene® cycling conditions were as follows: initial activation step of five 
minutes at 95°C, followed by quantification of 45 cycles of 15 seconds at 95°C and 
15 seconds at 60°C with acquisition in channels Green, Yellow, red and Crimson.  
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Data was analysed using Rotor-Gene® Q series Software version 2.3.1 (Qiagen; 
Manchester, UK). 
2.4 Molecular typing methods 
2.4.1 DNA Extraction from purified isolates 
DNA was extracted from approximately 500 µL of growing Mycoplasma 
culture.  Briefly, the Mycoplasma culture was centrifuged at 17,000 x g for 10 minutes, 
supernatant discarded and the pellet was re-suspended in 50 µL of molecular grade 
water (Sigma, Dorset, UK).  DNA was released by boiling lysis by incubating at 95 °C 
for 10 minutes.  The sample was then vortexed and stored at -20°C until required. 
2.4.2 PCR 
PCR amplifications were performed in a DNA Thermal Cycler (Techne Prime; 
Stone, UK) in 50 µL reactions containing: 1 x GoTaq Flexi Buffer (Promega; 
Southampton, UK), 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 
0.5 pmol/µL each primer, 1.56 units GoTaq DNA Polymerase (Promega; 
Southampton, UK), and 2.5 µL template DNA.  PCR reactions (unless otherwise 
stated) consisted of an initial denaturation step of 3 minutes at 94°C, followed by 
35 cycles of 60 seconds at 94°C, 60 seconds at the corresponding Tm and 60 seconds 
72°C.  A final extension step was maintained for 10 minutes at 72°C. 
2.4.2.1 Agarose gel electrophoresis 
PCR products were analysed on 1.5% agarose gels with ethidium bromide 
visualisation. 
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2.4.2.2 Purification of PCR products 
PCR products were purified using the QIAprep® Spin Miniprep kit (Qiagen; 
Manchester, UK).  The PCR sample was diluted by adding 5 volumes of Buffer PB to 
1 volume of the PCR sample and mixed.  The QIAquick spin columns were placed in 
the provided 2 mL collection tubes.  The DNA was bound to the column by adding 
the diluted PCR sample to the column and was centrifuged at 17,000 x g for 
60 seconds.  The flow-through was discarded and the column placed back in the same 
collection tube.  The column was then washed by adding 0.75 mL of Buffer PE to the 
column.  The column was then centrifuged at 17,000 x g for 60 seconds.  The 
flow-through was discarded and the column centrifuged again at 17,000 x g for 
60 seconds to remove any residual ethanol from Buffer PE.  The column was then 
placed in a clean 1.5 mL microcentrifuge tube.  The DNA was eluted from the column 
by adding 40 µL of PCR dH2O to the centre of the column, ensuring the water was 
dispensed directly onto the QIAquick membrane for complete elution of bound DNA.  
The column was centrifuged at 17,000 x g for 60 seconds.   
2.4.3 Sequencing 
PCR products were sequenced by Eurofins MWG Operon (Ebersberg, 
Germany) using forward and reverse primers as for PCR reactions unless otherwise 
stated.  Open-reading frame amino acid sequences were identified using Expasy 
translation tool (Mycoplasma setting; web.expasy.org/translate/). 
2.4.4  Mycoplasma pneumoniae P1-typing 
 Mycoplasma pneumoniae P1 typing was performed by PCR followed by 
sequencing as detailed in sections 2.4.2 and 2.4.3.  P1-typing included a nested step, 
where the PCR product from the first amplification round was used as the template 
DNA in the second round.  Primers used are detailed in Table 2.7. 
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2.4.4.1 P1 sequence analysis 
The sequences obtained from each corresponding forward and reverse primer 
were assembled and trimmed for double-stranded, high quality sequence.  Sequence 
was compared to published P1 sequences and variation regions to determine P1-type.  
For determination of types 1, 2, V1, V2a and V2b, sequences were converted to amino 
acid sequences.  Open-reading frame amino acid sequences were identified using 
Table 2.7.  Primers used for P1-typing of Mycoplasma pneumoniae. 
P1-subtype Purpose Name Sequence (5’-3’) Tm 
(°C) 
Product 
size (bp) 
1, 2, V1, V2a, 
V2b [292] 
First amplification Mp5f TTGACAAGACCGTCCAATCC 58 2465 
 Mp16r TTGGTTGGGTATCTTGATCAGG   
 Nested PCR Mp11f CCTCGTTGTCAGTGGCACC 61 724 
 Mp19r GTTTCCGTCACTCGTGCTTG   
3 [262] Nested PCRa Mp16f GGGAATGGGTACAGGTATGG 60 743 
 Mp20r CCAAAATAGGTTTCCACCAAC   
V2c [293] First amplification Mp111f AAGCAAGCGCGACATAATTC 60 1739 
 Mp17r ACCCGTCAGTTTGTTTGTTG   
 Nested PCR MpV2cf CTGTACGATGCGCCTTATGC 61 453 
 MpV2cr CACCCTAAAGACACCTATACTCAAAC   
a First amplification primers are Mp5f and Mp16r 
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Expasy translation tool (Mycoplasma setting; web.expasy.org/translate/) and deduced 
amino acid sequences were compared to the published sequences [292]. 
2.4.5 Multi-locus Sequence Typing (MLST) 
Ten genes were included for M. hominis: adenylate kinase (adk), carbamate 
kinase (arcC), ATP synthase subunit α (atpA), cell division protein FtsZ (ftsZ), serine 
hydroxymethyltransferase (glyA), lysyl-tRNA synthetase (lysS), methionine-tRNA 
ligase (metG), inorganic pyrophosphatase (ppa), nitrogen fixation protein (nifS) and 
recA protein (recA). 
Eight genes were included for M. pneumoniae: guanylate kinase (gmk), serine 
hydroxymethytransferase (glyA), phosphoglyceromutase (pgm), adenylate kinase 
(adk), DNA gyrase subunit B (gyrB), ATP synthase subunit α (atpA), inorganic 
pyrophosphatase (ppa) and carbamate kinase (arcC).   
Both M. hominis and M. pneumoniae MLST was performed by PCR and 
sequencing as detailed in sections 2.4.2 and 2.4.3.  PCR reactions were performed in 
duplicate and then pooled prior to gel electrophoresis and purification.  The primers 
used are detailed in Table 2.8.
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Table 2.8.  Primer pairs developed for both M. hominis and M. pneumoniae MLST 
schemes. 
 Name  Primer sequence (5’-3’) Amplicon 
(bp) 
Location of MLST 
locus in CDS 
Tm (°C) 
M
yc
op
la
sm
a 
ho
m
in
is 
adk  F GAAGTGTACAACGAACACGC 676 234-639 56 
 R ATGACCATTTTAAAGCCTCTTCT    
arcC F AGTTATTGTCGGACACGGAA 735 384-766 57 
 R CCGCCTTCTTCAACGAATTT    
atpA F ATTGCCGAAGAATGAATGGC 712 978-1304 57 
 R CATTTGCTTCAGAAACGGCT      
glyA F CATGGCAATGGTTGATCCTG 785 450-860 57 
 R TTGCCGCAGATCCTATTCTT    
recA F ACGCTATTGCCGAAATACAA 648 457-765 56 
 R TGAAACTATATCACGAGCCCT    
ftsZ F GCAAAACTGCTGCTGAATCT 714 492-705 57 
 R TGGCGATTACCGAGACAAAT    
lysS F TTCGTGGCCCATTTATTGTT 656 307-649 56 
 R ATGTTTGAAAACGCCTTCAGT    
metG F CCAAGTGGTAATCTTCACATAGG 646 304-649 56 
 R TGTGTTGCTTTTCAGCATCTT    
M
yc
op
la
sm
a 
pn
eu
m
on
ia
e 
ppa F CGCTGACCAAGCCTTTCTAC 249 192-440 60 
 R CACTCCAAACTTTGCACTCCC    
pgm F AGCACCTTGCACGATGAAGA 1197 456-1652 60 
 R CCTGCGCCTTCGTTAATTGG    
gyrB F TTGTCCCGGACTTTACCGTG 429 524-952 60 
 R TGTTTTCGACAGCAAAGCGG    
gmk F GAGCGGTGTTGGCAAAAGTA 394 189-582 60 
 R TGCATCCTCGTCATTACGCTT    
glyA F CAGAGAACTATGTGAGTAGGGACA 676 74-749 60 
 R TGACAACCCGGAAAGACACC    
atpA F GTCGCTGATGGCATTGCTAAG 796 100-895 60 
 R CCAGTAAACGCGAGTGCAAG    
arcC F CCCCATCAAGCCGTGTACTT 570 304-873 60 
 R TTGGGCAATAATGGCCGTCT    
adk F GTAGCCAACACCACCGGATT 473 70-542 60 
 R ACGGTGTCTTCGTAAAGCGT    
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2.4.5.1 MLST Sequence analysis 
The sequences obtained from each corresponding forward and reverse primer 
were assembled using BioNumerics (version 6.1; Applied Maths, Belgium) and 
trimmed for double stranded high quality sequence.  All the sequences obtained for 
each locus were aligned using ClustalW (Vector NTI; Paisley, U.K.) and the sequences 
were trimmed to the same size to allow direct comparison (Table 6.3).  Different allelic 
types (AT; sequences with at least a one-nucleotide difference) were assigned arbitrary 
numbers.  The combination of the eight alleles determined a strain’s allelic profile, 
and each unique allelic profile was designated a unique sequence type (ST).  Open-
reading frame amino acid sequences were identified using Expasy translation tool 
(Mycoplasma setting; web.expasy.org/translate/) for each AT.  Deduced amino acid 
sequences were aligned using ClustalW (Vector NTI; Paisley, U.K.) for each locus 
and synonymous changes were identified.   
2.4.6 Mycoplasma hominis variable adhesion-associated (Vaa) protein 
classification 
Mycoplasma hominis vaa gene was amplified by PCR followed by sequencing 
(sections 2.4.2 and 2.4.3) to determine module composition and therefore Vaa 
category.  Primers used for amplification and sequencing are detailed in Table 2.9. 
Table 2.9.  Details of primers used for the amplification of M. hominis vaa open-
reading frame. 
Primer 
name 
Sequence Tm (°C) Target Reference 
VaaF1 5’-CCCCGGAGATTATTAAGTCT-3’ 38 Flank the entire open-
reading frame encoded 
by the vaa gene 
Zhang and 
Wise [92] 
VaaR1 5’-GTGCCCATTAGTAGCACTAT-3’  
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2.4.6.1 Mycoplasma hominis vaa sequence analysis 
Open-reading frame amino acid sequence was identified using Expasy 
translation tool (mycoplasma setting; web.expasy.org/translate/).  Sequences were 
aligned with CLUSTAL omega (www.ebi.ac.uk/tools/msa/clustalo/) and deduced 
amino acid sequences were compared to published Vaa amino acid sequences.  
Module composition was based on published sequence data by Boesen et al. [97]. 
2.4.7 Mycoplasma pneumoniae multi-locus variable-number tandem-repeat 
analysis (MLVA) 
Multi-locus variable-number tandem-repeat analysis was performed for all 
M. pneumoniae isolates using the previously described method by Dégrange et al., 
[132] with interpretation and nomenclature clarification from Chalker et al., [221].  
Briefly, the four loci selected for MLVA were MPN14, MPN16, MPN13 and MPN15.  
Each amplification reaction was performed in a final volume of 20 µL containing 
1 x HotStarTaq® Master Mix (Qiagen), 0.5 pmol/µL of each primer, 2 mM MgCl2 and 
2 µL template DNA.  For loci MPN13 and MPN15, 3mM MgCl2 was included in each 
amplification reaction.  Primer sequences, repeat sequence and repeat size are detailed 
in Table 2.10.  Amplifications were performed in a PCR thermocycler under the 
following cycling conditions: initial denaturation step of 15 minutes at 95°C followed 
by 35 cycles of 30 seconds at 95°C, 30 seconds at 60°C and 60 seconds at 72°C, and 
a final elongation step of 10 minutes at 75°C.  PCR products were analysed to examine 
expected size by loading 5 µL onto a 2% pre-cast agarose E-gel (Oxoid; Basingstoke, 
UK).  The remaining PCR product was submitted for in house (PHE) fragment 
analysis.  The four MLVA loci were multiplexed in two solutions, M1 and M2, for 
fragment analysis consisting of MPN14 and MPN16, and MPN13 and MPN15, 
respectively.  A final volume of 15 µL was submitted for analysis containing 5 µL of 
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each PCR product and 5 µL of nuclease-free water.  Fragment size was calculated 
using a Peak Scanner and repeat number was determined based on fragment size as 
shown in Table 2.10.  Alternatively, tandem repeat finder software 
(http://tandem.bu.edu/trf/trf.htmL) was used to determine repeat numbers using the 
settings: match, mismatch, indel (2,3,5).  The naming system, MLVA 1,2,3,4, where 
each digit corresponds to repeat numbers at each locus MPN13, MPN14, MPN15 and 
MPN16, respectively, was used. 
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Table 2.10.  Primer sequences, target sequences, repeat size and fragment size (bp) of M. pneumoniae MLVA loci MPN13, MPN14, MPN15 
and MPN16 according to number of repeats. 
 MPN13 MPN14 MPN15 MPN16 
Forward primer sequence (5’-3’) GACCAGCATTAGATTGCTATG CTCAGGGCGAAACCTTAAAG HEX-CAACAGCACCACATCTTTAG NED-GACGCGTTCGCTAAAAGAG 
Reverse primer sequence (5’-3’) NED-AACAAATTAAGCAGCTCACG 6-FAM-GCAATGGCTTTCAGCACAAC GCTAATCTTGCAAACGCTGC CAGGCTCAACCAAATAATGG 
Repeat sequence based on 
M129 TRF (2,3,5)a 
 TATTAATAACTATTCT TGGACAAAATGGAAGT 
AAAAA 
TTGTCCATTTTTTCTT 
CCATC 
ATTTTTTAAAAGTTTT 
TATTTATCCGTTTTGA 
CAACTGCTTTTTGTT 
Repeat size (bp)  16 21 21 47 
Repeat number 0 364 294 108 259 
 1 380 315 129 306 
 2 396 336 150 353 
 3 412 357 171 400 
 4 428 378 192 447 
 5 444 399 213 494 
 6 460 420 234 541 
 7 476 441 255 588 
 8 492 462 276 635 
 9 508 483 297 682 
M129 fragment size  415 399 241 353 
M129 repeat number  4 5 7 2 
a Tandem repeat finder software.  The settings used were 2,3,5 (match, mismatch, indel). 
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2.4.8 Phylogenetic analysis for Molecular Typing Methods 
2.4.8.1 Phylogenetic analysis of multi-locus sequence typing data 
The locus sequences corresponding to each strain were concatenated head-to-
tail for diversity analysis and loci were assessed for stability after 10 passages.  
Sequence analyses and tree construction were performed using MEGA 6.0.  
Neighbour-joining trees were constructed for each individual locus and concatenated 
sequences using Kimura’s two-parameter model [294, 295].  Maximum-likelihood 
trees were constructed for each individual locus using the Jukes-Cantor model of 
sequence evolution [296].  Maximum-likelihood trees were constructed from 
concatenated sequences of the eight MLST loci using the generalised time-reversible 
(GTR) model of sequence evolution with uniform rates of variation [297].  Bootstrap 
analyses with 1000 replicates were performed for all phylogenetic analyses.  [298] 
2.4.8.2 Phylogenetic analysis of vaa sequences 
Phylogenetic trees were constructed based on the nucleotide sequence of the 
vaa gene using maximum-likelihood, Jukes-Cantor model of sequence evolution, and 
neighbour-joining, Kimura’s two-parameter model, methods.  Bootstrap analyses with 
1000 replicates were performed. 
2.4.8.3 Relatedness between sequence types 
Relatedness between MLST STs and MLVA types were analysed based on allelic 
profiles/MLVA profiles for M. pneumoniae using eBURST version 3.   
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2.5 Antibiotic resistance of Mycoplasma hominis 
2.5.1 Minimum inhibitory concentration calculation by microbroth dilution 
Minimum inhibitory concentration was determined based on Beeton et al., 
[299], where determination of bacterial load in a sample can be performed 
simultaneously with the determination of antibiotic resistance without prior 
knowledge of bacterial load.  Briefly, in a 96-well plate, wells A1-H1 received 360 µL 
of 128 µg/mL gentamicin or tetracycline in MM, and 180 µL sterile MM was added 
to the remaining wells (A2-H12) of the plate.  Using a multichannel pipette, rows of 
doubling dilutions were made by transferring 180 µL from row A1-H11 (an excess of 
180 µL was discarded from row A11 to H11).  Rows A12-H12 remained free of 
antibiotic for unrestricted growth comparison.  Thus, an antibiotic gradient was 
created from 128 µg/mL to 0.125 µg/mL.  Twenty microliters of Mycoplasma from a 
48 hour culture (M. hominis) of unknown CCU was added to each well in the columns 
A1-A12 (1:10 dilution).  A 10-fold dilution curve of bacteria was then titrated at 90 
degrees across the antibiotic gradient.  Plates were sealed and incubated at 37°C for 
72 hours (M. hominis, at which time colour change within the growth control had 
ceased.  The MIC was defined as the lowest concentration of antibiotic that prevented 
colour change when read at 104 CCU (relative to growth in the antibiotic-free 
medium).  MM (with and without antibiotics) was also incubated in the absence of 
added Mycoplasma isolates to serve as a negative colour-changing control. 
2.5.2 Minimum inhibitory concentration calculation by agar dilution 
Minimum inhibitory concentration was determined as described by Waites et 
al., [235].  Doubling-dilutions of tetracycline or gentamicin were incorporated into 
molten mycoplasma agar plates (Mycoplasma Experience; Blenchingly, UK), with 
each plate containing a different concentration.  Concentrations of antibiotics used 
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were the same as described for the microbroth dilution technique (Section 2.5.1).  
After the agar plates had solidified, they were inoculated with 10 µL of a Mycoplasma.  
Plates were then incubated at 37°C under anaerobic conditions for 48 hours.  Growth 
of M. hominis was assessed by counting colonies and converting to CFU/mL.  MIC 
was defined as the lowest concentration that prevented growth of bacteria. 
2.5.3 Monitoring minimum inhibitory concentration with qPCR 
Serial dilutions of antibiotic (gentamicin/tetracycline) in MM were made in a 
total volume of 900 µL.  Concentrations included for gentamicin were: 0.5 µg/mL, 
1 µg/mL, 2 µg/mL, 4 µg/mL, 8 µg/mL, 16 µg/mL and 32 µg/mL; and concentrations 
for tetracycline were: 0.125 µg/mL, 0.5 µg/mL, 1 µg/mL, 2 µg/mL, 4 µg/mL, 8 µg/mL 
and 16 µg/mL.  Antibiotic-containing MM was inoculated with 100 µL of growing 
Mycoplasma.  An unrestricted growth control was included by inoculating 900 µL of 
sterile MM with 100 µL of the same mycoplasma culture.  Cultures were incubated in 
sealed tubes at 37°C for 72 hours or until colour change was observed in the 
unrestricted growth culture.   
Cultures were then heat-inactivated by incubating for 30 minutes at 95°C; and 
DNA extracted from 240 µL using the Qiasymphony (Qiagen; section 2.3.1).  
Mycoplasma was then detected and quantified in the sample using the multiplex real-
time PCR assay described in section 2.3.3.   
2.5.4 PCR for the tetM transferable element associated with tetracycline 
resistance 
The presence of the tetM transferable element in M. hominis isolates was determined 
by PCR using the primers described by Blanchard et al., [279] (Table 2.11), which 
amplified the 397 bp product.  PCR was performed as described in Section 2.4.2. 
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Table 2.11. Primers used to detect the presence of the transferable element tetM in 
Mycoplasma hominis isolates. 
Primer Name Sequence Tm (°C) Size (bp) Reference 
TetMF 5’-TTATCAACGGTTTATCAGG-3’ 48 397 Blanchard et al., 
[279] 
TetMR 5’-CGTATATATGCAAGACG-3’ 
 
2.6 Whole Genome Sequencing 
Whole Genome Sequencing was performed by PHE (London, UK).  Sequencing 
data analysis was performed using Galaxy (PHE) and Geneious® version 8.   
2.6.1 Extraction of genomic DNA for whole genome sequencing 
Genomic DNA was extracted from Mycoplasma using the GenEluteTM 
Bacterial Genomic DNA Kit (Sigma; Dorset, UK). 
2.6.1.1 Sample preparation 
In order to obtain sufficient DNA for whole genome sequencing, 100 mL of 
MM was inoculated with a specific Mycoplasma isolate.  Cultures were incubated at 
37°C until colour change was observed in the media.  Cultures were then centrifuged 
at 17,000 x g for 45 minutes, supernatant removed and pellets stored at -20°C until 
required. 
2.6.1.2 GenEluteTM Bacterial Genomic DNA Kit 
Genomic DNA extraction was performed as described by the manufacturer.  
Briefly, the Mycoplasma pellet was re-suspended thoroughly in 180 µL of Lysis 
Solution T.  RNA-free genomic DNA was required, therefore 20 µL of RNase A 
Solution was added to the sample, mixed thoroughly and incubated at room 
temperature for two minutes.  The sample was then incubated with 20 µL of Proteinase 
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K Solution for 30 minutes at 55°C.  The sample was then incubated for 10 minutes at 
55°C with 200 µL of Lysis Solution C, following thorough vortexing as a homogenous 
mixture was essential for efficient cell lysis.   
GenElute Miniprep Binding Columns were then prepared by adding 500 µL of 
Column Preparation Solution followed by centrifugation at 12,000 x g for one minute.  
The eluate was discarded. 
To the lysate, 200 µL of 100% ethanol was then added to the lysate and mixed 
thoroughly by vortexing.  This was then added to the binding column using a wide 
bore pipette tip to reduce shearing of the DNA, followed by centrifugation at 6,500 x g 
for one minute.  The eluate was discarded.  The column was then washed by first 
adding 500 µL of Wash Solution 1 to the column, centrifugation for one minute at 
6,500 x g and second by adding 500 µL of Wash Solution to the column followed by 
centrifugation for three minutes at maximum speed (16,000 x g) to dry the column.  
To remove all ethanol from the column, the column was centrifuged for an additional 
one minute at 16,000 x g.  The collection tube was discarded and the column placed 
in a new 2 mL collection tube. 
Genomic DNA was eluted from the column by adding 200 µL of the Elution 
Solution directly onto the centre of the column.  This was then incubated for five 
minutes at room temperature to increase the elution efficiency.  The column was then 
centrifuged for one minute at 6,500 x g to elute the DNA.  The elution step was then 
repeated twice more to increase the yield of DNA.   
2.6.1.3 Ethanol precipitation of genomic DNA 
To increase the concentration of genomic DNA, ethanol precipitation was 
performed.  The sample was diluted in sodium acetate (pH 5.2; final concentration of 
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0.3 M) and mixed well, followed by the addition of 2.5 volumes of cold 100% ethanol.  
The sample was then incubated on ice or at -20°C for > 20 minutes and then 
centrifuged at maximum speed (16,000 x g) for 15 minutes.  The supernatant was 
carefully decanted and the genomic DNA pellet was then washed by adding 1 mL of 
70% ethanol.  It was then centrifuged for 5 minutes at maximum speed and the 
supernatant carefully decanted.  The pellet was then air-dried.  The resulting pellet was 
then re-suspended in the appropriate volume of Tris-EDTA (TE) buffer, typically 
70 µL, and stored at -20°C until required. 
DNA was quantified prior to sequencing using the GloMax fluorometer 
(Promega; Southampton, UK). 
2.6.2 Sequencing methodology 
Genomic sequence was obtained using the Illumina Nextera XT sample prep 
kit (Illumina, Cambridge, UK) and sequenced on an Illumina HiSeq 2500 platform 
with TruSeq rapid SBS kits (200 cycles; Illumina) and cBOT for cluster generation 
(Illumina).  Fastq reads were trimmed using Trimmomatic 0.32, with the following 
parameters: leading, 30; trailing, 30; slidingwindow, 10:30; and minlen, 50 [300]. 
2.6.3 Read quality assessment 
Read quality was assessed using FASTQC, an internal tool on the PHE Galaxy 
platform and reads of poor quality were discarded.  It was important to note that most 
reads failed G+C content assessment due to low levels; this was to be expected due to 
the known low G+C content of mycoplasma genomes.  Sequence was confirmed as 
M. hominis or M. pneumoniae using KmerID (internal tool on PHE Galaxy), by 
computing the similarity between reads in Next Generation Sequencing (NGS) sample 
and a predefined set of reference genomes from NCBI. 
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2.6.4 de novo assembly 
de novo assembly was performed using SPAdes version 2.5.0, which was 
specifically designed for small genomes [301, 302].  This software was available as a 
pipeline provided by PHE Galaxy.  The settings used were: 
Careful correction No 
Use rectangle correction for repeat resolution No 
Number of threads to use 16 
Number of iterations for read error correction 1 
K-mers to use, separated by commas 21,33,55 
Style type of reads Paired-end, separate inputs 
 
Two sequence files (.fasta) were produced by spades; a contig file and a 
scaffold file of assembled contigs.  This last file was used for mapping to reference 
genomes.   
2.6.5 Mapping of sequence data to a reference strain and annotation 
Scaffolds produced by de novo assembly were mapped to a reference genome; 
M. pneumoniae M129 (NC_000912) or M. hominis ATCC 23114 (NCTC 
10111/PG21; NC_013511), using Geneious® (version 8.0.4).   
2.6.6 Mycoplasma hominis genome assembly and pan-genome analysis 
Whole genome assembly of M. hominis was performed using SPAdes version 
3.6.1, without error correction, and kmers: 21, 33, 45, 53, 65, 77, 83, 93 [301, 302].  
For pan-genome analysis, four reference sequences (NZ_CP009652.1, NC_013511.1, 
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NZ_CP011538.1 and NZ_CP009677.1) were first clustered together using ggPRO 
(PHE internal tool).  Briefly, coding gene sequences were extracted from the annotated 
GenBank files for the strains listed above and each gene was checked against the 
database of hidden Markov models (HMMs) using HMMER version 3.2 [303].  A hit 
was considered significant if the ratio of score over HMM length was greater or equal 
to 0.85.  Alleles were clustered into the same gene family; new alleles were added to 
a gene family if they introduced a gap of less than 10% into the gene family alignment.  
The HMM database is only updated when a new gene or allele is identified.  After 
clustering the four reference sequences, the pan-genome contained 777 genes 
occurring in at least one of the reference genomes.  Each clinical M. hominis strain 
was individually scanned against the pan-genome HMM database using HMMER 
version 3.2 and significant hits (score/HMM length ration >0.85) were recorded in the 
database. 
2.6.7 Basic Local Alignment Tool (blast) 
Genes of interest were identified in scaffolds using NCBI Blast 
(http://blast.ncbi.nlm.nih.gov/) with the setting: align two sequences.  The gene 
sequence from the reference genome was used to identify the same/similar sequence 
in the scaffolds.   
2.6.8 Phylogenetic analysis of whole genome sequences 
2.6.8.1 Single nucleotide polymorphism tree 
Phylogenetic trees based on single nucleotide polymorphism (SNP) variants in 
whole genome sequences were constructed using a workflow provided by PHE Galaxy 
(Figure 2.1).  Briefly, after mapping, variants were parsed to retain high quality SNPs 
based on the following conditions: positions having a depth of greater than 5 reads, a 
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consensus base call confirmed by at least 90% of the reads, an overall mapping quality 
score of greater than 40 and a distance to nearest SNP of greater than 5.  Software used 
was: Unified Genotyper from GATK2 (version 0.0.7) [304], Annotate VCF 
(version 1.0), Combine VCF (version 1.0) VCF to VCF compendium file (version 1.0) 
VCF to FASTA (version 1.0).  A phylogenetic tree was produced from the SNP 
alignment using RaxML version 8.1.17 with the GTPGAMMA model, seed 12345 
and –f d option.   
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Figure 2.1 Workflow used to generate multiple alignments of SNP variants for the generation of a SNP phylogenetic tree 
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2.6.8.2 Whole genome alignment 
Neighbour-joining trees were constructed from whole genome sequence 
alignments using MEGA (version 6).   
2.6.9 Minimal MLST gene selection 
Mycoplasma hominis genomic sequences were used to develop a minimal 
MLST scheme.  Following pan-genome assembly, alleles of 427 genes were extracted 
into individual multi-Fasta files and aligned using Muscle software [305, 306].  Leave-
one-out analysis was performed to identify genes required to maintain whole genome 
sequence SNP phylogeny, whereby one gene was removed at a time and the remaining 
genes were concatenated into a single multi-fasta file, with one entry per sample.  The 
topology of the leave-one-out tree was compared to the whole genome tree using the 
following formula: 
𝐷𝐷 =  𝑆𝑆𝑡𝑡 𝑆𝑆𝑟𝑟𝑟𝑟𝑟𝑟�  
Where D is the similarity score between the reference and target trees; Sref and 
St are the number of sets of leafs under each internal node in reference and target trees, 
respectively.  Distance, D, has a strict range (0-1) and represents overall similarity of 
a target tree to the reference tree.  This value can be calculated for each internal node 
for more refined similarity measure.  The results were analysed and plotted using 
custom scripts written for R statistical package. 
2.6.10 Recombination analysis 
Illumina reads for all isolates were mapped against the reference chromosome 
M129 or ATCC 27545 (NZ_CP009652) for M. pneumoniae and M. hominis, 
respectively, using SMALT (http://www.sanger.ac.uk/resources/software/smalt/) to 
identify SNPs, as previously described [307].  Regions of recombination in the whole 
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chromosomes of the isolates were analysed using Genealogies Unbiased by 
recomBinations In Nucleotide Sequences (GUBBINS) [308]. 
2.7 Statistical methods 
The limit of detection (LOD) for quantitative real-timer PCR assays were 
determined using either probit or logistic regression models with 95% confidence 
intervals.  Confidence intervals were calculated based on either robust or conventional 
standard errors. 
Comparison between culture and real-time PCR results was performed using 
Fisher’s exact test.  Confidence intervals (95%) were calculated for data presented as 
a proportion using the modified Wald method [309] (GraphPad Quick Clacs; 
http://graphpad.com/quickcalcs/ConfInterval1.cfm).  Diagnostic tests were evaluated 
be examining specificity, sensitivity and positive and negative predictive values 
calculated using MedCalc (https://www.medcalc.org/calc/diagnostic_test.php). 
Diversity of MLST STs, loci, P1 types and MLVA profiles was assessed by 
using Hunter-Gaston Diversity Index.  This was performed using VNTR Diversity and 
Confidence Extractor (V-DICE; http://www.hpa-bioinformatics.org.uk/cgi-
bin/DICI/DICI.pl).  A diversity index (DI) of zero indicated no diversity compared to 
a DI of one indicating complete diversity.  The Hunter-Gaston estimate of diversity 
incorporated a finite sample adjustment.  Results included 95% Confidence Intervals 
(CI) for each locus, giving precision to the DI by providing the upper and lower 
boundaries 
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3.1 Introduction 
Mycoplasma hominis, U. parvum and U. urealyticum are considered urogenital 
commensals or opportunistic pathogens in adults and can be isolated from the 
urogenital tract of 21% to 53% and up to 80% of asymptomatic women for M. hominis 
and Ureaplasma species, respectively [3, 310].  Additionally, in adults, M. hominis 
has been associated with clinically diverse diseases including; urogenital diseases 
[311, 312], postpartum fever [313], pneumonia [191], meningitis [186, 205] and septic 
arthritis [187, 189].   
Culture methods to establish infection/colonisation with M. hominis and 
Ureaplasma species require specialised media due to the fastidious nature of 
Mollicutes, which are notoriously difficult to isolate.  This capability is not available 
in most clinical laboratories, although definitive detection and identification of active 
infection with either of these bacteria requires culture.  Conventional PCR assays for 
M. hominis and Ureaplasma species have mainly used 16S rRNA as a gene target 
[314]; however, other targets including gap, fstY, and yidC have been also developed 
[123-126].  Variation in the gap gene of M. hominis has been described and the extent 
of variation was found to be larger than that observed in the 16S rRNA gene [124, 
315].  Other gene targets in use for the detection of Ureaplasma species include the 
multiple-banded antigen (MBA) and the urease gene [290, 316].   
The objective of the work described in this chapter was to establish a reliable, 
specific, sensitive and quantitative real-time PCR to simultaneously detect M. hominis, 
U. urealyticum and U. parvum in clinical specimens, specifically neonate specimens. 
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3.2 Results 
3.2.1 Assay development and validation 
The aim of the work was to improve the current diagnostic assay used by the 
PHE National Reference Laboratory through the development of a multiplex assay to 
detect M. hominis and Ureaplasma species in clinical specimens.  PHE receives 
respiratory and CSF samples from neonates and occasionally samples from 
respiratory, invasive and systemic infections in adults for testing for the presence of 
M. hominis, Ureaplasma species, or both.  At the time of this study specimens were 
routinely tested using an in-house multiplex real-time PCR (MUP PCR) targeting the 
gap gene of M. hominis and the urease gene of Ureaplasma species (described in 
section 2.3.2), in addition to simple culture using the commercial kit, M-duo, for 
screening of all clinical specimens.  Following a positive MUP PCR result, culture 
using Mycoplasma-selective Medium (MM; Mycoplasma Experience Ltd.; 
Bletchingly, UK) was performed on the clinical specimen to enable isolation of either 
M hominis or Ureaplasma species or both (described in section 2.2).  A publication 
detailing failings in the use of the gap gene for the amplification of all M. hominis 
strains [125] and PHE data indicating that culture positive, gap PCR negative 
specimens were occurring (data not shown) resulted in an urgent need to redesign and 
validate a multiplex neonate qPCR test for use at the National Reference Laboratory 
(PHE) that could simultaneously detect M. hominis and Ureaplasma species.  
Furthermore, reference laboratory tests are required to be different and bespoke to 
those available commercially to enable independent confirmation of infection.  This 
chapter presents an improved multiplex qPCR assay developed for use on neonate 
specimens to simultaneously detect M. hominis, U. parvum and U. urealyticum.  The 
assay by Yi et al., [290] has been supplemented by the addition of an M. hominis 
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specific target identified by Ferandon et al., [125] (yidC), and a GFP amplification 
control to identify PCR inhibitors [291].  
3.2.2 Primer and probe design 
Each oligonucleotide in the qPCR was assessed using blastn (NCBI; section 
2.6.7) to examine specificity.  Analysis of the yidC target oligonucleotides and probe 
gave maximum similarity (100%) over the entire length against the available, 
complete putative inner membrane protein translocase component yidC gene sequence 
of M. hominis (ATCC 23114; PG21).  To check for intra-species heterogeneity at the 
nucleotide level, sequence analysis of the entire yidC gene from 19 M. hominis clinical 
isolates and the reference strain PG21 was undertaken.  Only 70 of 1,995 nucleotides 
varied among the 20 strains studied, and were found to be outside the sequences of 
primers and probe used for amplification in this assay.  This is in concordance with 
results for strains from other countries as published by Ferandon et al., [125].  The 
urease target oligonucleotides gave maximum similarity (100%) over the entire length 
against available complete urease complex component gene sequences of U. parvum 
(serovar 1, serovar 3 [ATCC 700970, ATCC 27815, SV3F4], serovar 6, serovar 14) 
and U. urealyticum (serovar 2 serovar 4, serovar 10).  The probes gave maximum 
similarity (100%) to U. parum and U. urealyticum, respectively.   
3.2.3 Rotor-Gene® PCR 
The multiplex real-time PCR was performed as described in section 2.3.3.  A 
standard dilution series of the plasmid control was amplified in each Rotor-Gene® 
PCR run for validation and DNA quantification.  For detection in clinical samples, 
standards of 104, 103, 102 and 101 copies/µL were included, and a run was deemed 
successful if the positive controls fell within the thresholds outline in Table 3.1.  
Fluorescence curves down to 1 copy/μL could be detected.  The slope of the standard 
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curve for each target was -3.375, -3.018 and -3.195 for M. hominis, U. parvum and 
U. urealyticum, respectively, with calculated R2 values of 0.975, 0.957, and 0.983 
(Figure 3.1).  The concentration of M. hominis, U. urealyticum and U. parvum in 
patient samples was calculated from the standard curves.   
Table 3.1.  Interpretation of positive controls.  
 Ct value ranges (average Ct ± standard deviation) for positive control plasmid 
for each U. parvum, U. urealyticum, M. hominis and IPC. 
 Ct values 
 U. parvum U. urealyticum M. hominis IPC 
Copies/µl min Max Min max min max min max 
10000 22.0 26.0 23.3 26.7 23.1 29.0 29.3 32.7 
1000 26.0 28.0 27.2 30.8 27.2 30.8   
100 28.0 34.0 29.6 35.4 29.5 35.7   
10 29.2 40.2 30.5 42.5 30.3 42.3   
aUIPC Ct average and standard deviation calculated from 502 samples 
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Figure 3.1.  Fluorescence and standard curves of serially diluted control DNA.   
Fluorescence and standard curves of serially diluted standard DNA for M. hominis 
(A), U. parvum (B), U. urealyticum (C), and fluorescence curve for the GFP 
amplification control (D).  The equation of the standard curve and calculated R2 values 
are shown for the multiplex real-time PCR. 
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3.2.4 Reproducibility and LOD 
To determine the reproducibility of the multiplex real-time PCR, the intra- and 
inter-assay variations were measured with respect to cycling threshold and 
concentration.  To determine the intra-assay variation, triplicate standard dilution 
series of 104, 103, 102 and 101 copies/µL were tested in one run.  The coefficients of 
variation (CV) of the cycling threshold (Ct) were in the range of 0.6% to 2.1% for 
M. hominis, 0.4% to 1.3% for U. parvum and 0.5% to 1.6% for U. urealyticum.  The 
CVs of the concentrations were in the range of 12.5% to 54.9% for M. hominis, 8.9% 
to 34.0% for U. parvum, and 10.6% to 42.1% for U. urealyticum, with the highest 
values in the lower concentrations.   
Twenty-two standard curves were evaluated for the determination of the inter-
assay variation.  The standard curves were chosen from runs performed on different 
days on four different Rotor-Gene® Q thermocyclers.  The CV of the Ct varied from 
3.0% to 7.0% for M. hominis, 4.0% to 7.0% for U. parvum and 3.2% to 8.3% for 
U. urealyticum, and the CV of concentration varied from 24.5% to 106.0% for 
M. hominis, 24.3% to 148.6% for U. parvum and 23.8% to 92.0% for U. urealyticum, 
with the highest values for the lowest concentration in the standard curve 
(101 copies/µl; Table 3.2).  Concentrations of 104 and 103 copies/µL were detected in 
all of the 22 runs of the standard dilution series; however, 21 out of 22 runs (95.5%) 
detected 102 copies/µL of M. hominis and this concentration was detected in 22 out of 
22 runs for both U. parvum and U. urealyticum.  Additionally, 101 copies/µL was 
detected in 19 out of 22 runs (86.4%) for M. hominis and 20 out of 22 runs (90.9%) 
for both U. parvum and U. urealyticum (Table 3.2).   
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Table 3.2.  Inter-assay reproducibility of the multiplex U. urealyticum, U. parvum and M. hominis PCR assay. 
 Ureaplasma urealyticum Ureaplasma parvum Mycoplasma hominis 
Genome 
copy no./µl 
Observed 
no. 
Mean 
Cta 
CV b Ct 
(%) 
Mean 
concn. 
CV concn. 
(%) 
Observed 
no. 
Mean 
Cta 
CV b Ct 
(%) 
Mean 
concn. 
CV concn.  
(%) 
Observed 
no. 
Mean 
Cta 
CV b Ct 
(%) 
Mean 
concn. 
CV concn.  
(%) 
104 22/22 25.0 3.4 1.01 x 
104 
25.3 22/22 25.0 4.0 1.04 x 
104 
26.6 22/22 26.0 5.0 1.07 x 
104 
24.5 
103 22/22 29.0 3.2 1.04 x 
103 
23.8 22/22 28.0 4.0 1.02 x 
103 
24.3 22/22 30.0 3.0 1.00 x 
103 
28.2 
102 22/22 32.5 4.5 1.19 x 
102 
55.9 22/22 31.4 5.0 1.15 x 
102 
55.2 21/22 33.1 5.0 1.08 x 
102 
48.1 
101 20/22 36.5 8.3 1.40 x 
101 
92.0 20/22 34.9 7.0 1.03 x 
101 
148.6 19/22 36.5 7.0 1.52 x 
101 
106.0 
a Ct, cycling threshold 
b CV, coefficient of variation 
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The LOD was approached by including additional concentrations of 8, 6, 4, 2 
and 1 copies/µL into the standard dilution series.  LOD was calculated both 
statistically and empirically as recommended by Burd [317] and Saunders et al. [318] 
(described in section 2.7) using six runs, with triplicate reactions in each run, resulting 
in a total of 18 replicates.  Details of positive replicate results for M. hominis, 
U. parvum and U. urealyticum can be found in Table 3.3  Empirical LOD 
determination resulted in 40 copies/reaction, 20 copies/reaction and 
30 copies/reaction for M. hominis, U. parvum and U. urealyticum, respectively, where 
all replicates above at or above these values were detected excluding a single outlier.  
Statistically, the LOD 95, the number of copies of each target that the assay has a 95% 
chance of detecting, was estimated as 45 copies/reaction (95% CI: 25%-63%) for 
M. hominis, 22 copies/reaction (95% CI: 18%-36%) for U. parvum, and 
25 copies/reaction (95% CI: 14%-32%) for U. urealyticum.   
Table 3.3. Percentage of replicate PCR results of the standard dilution series for 
Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum. 
 Percentage of replicates detected (%) 
Concentration of control plasmid 
(copies/µL) 
M. hominis U. parvum U. urealyticum 
104 100 100 100 
103 100 100 100 
102 100 100 100 
101 95 100 100 
8 100 100 100 
6 83 94 95 
4 83 94 89 
2 55 67 67 
1 28 22 28 
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3.2.5 Specificity 
The sequence of the yidC gene of M. hominis was examined in 20 M. hominis 
strains to examine the variability in the amplicon region.  All the sequences were 
identical except for one strain which has a single nucleotide polymorphism within the 
amplicon; however, this was not within the primer and probe binding sites (Figure 
3.2).  All 20 M. hominis strains were also tested in the assay.  In agreement with the 
results from sequencing, all the 20 M. hominis strains were detected, and the 
fluorescence curves were comparable to the 104 copies/µL standard.  Additionally, 20 
Ureaplasma species (ten U. parvum and ten U. urealyticum) isolates were tested using 
the multiplex real-time PCR assay.  All isolates were detected and the fluorescence 
curves were comparable to the 104 and 103 copies/µL standards. 
The assay proved to be specific for M. hominis, U. parvum and U. urealyticum, 
as no cross-reactions of the assay were detected against DNA from other human 
mycoplasmas and 58 other respiratory bacteria and viruses (listed in Appendices Table 
A.1) that are commonly found in respiratory specimens. 
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Figure 3.2. Alignment of the amplified region of the yidC gene of Mycoplasma 
hominis including primer and probe binding sites.   
The yidC sequence of M. hominis PG21 was compared to the yidC sequence of 19 
additional M. hominis strains and aligned using clustalW.  * (asterix) indicate 
completely conserved residues.  Single nucleotide polymorphisms within the PCR 
amplicon are indicated by grey shading.  The selected primers and probe in the yidC 
sequence are underlined. 
 
3.2.6 Evaluation with patient samples and comparison to culture and MUP 
PCR 
The multiplex real-time PCR assay was evaluated with retrospective testing of 
216 clinical specimens submitted to PHE in 2014 for Ureaplasma species and 
M. hominis testing and compared to M-duo culture and MUP PCR results.  The M-duo 
culture test cannot distinguish Ureaplasma species therefore U. parvum and 
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U. urealyticum detection totals were combined for specificity and sensitivity analysis.  
Additionally, MUP PCR positive specimens were subsequently cultured using MM 
and ureaplasma-specific (USM) media. 
This multiplex real-time PCR assay was not validated against conventional 
culture using Mycoplasma/Ureaplasma-specific media due to the retrospective nature 
of this study.  Conventional culture was not routinely performed on all clinical 
specimens sent to PHE for Mycoplasma/Ureaplasma testing and only DNA extracts 
were stored for further analysis.  M-duo culture however, was used to screen all 
specimens, therefore this data was used for evaluation. 
3.2.6.1 Comparison to M-duo culture 
The multiplex real-time PCR assay detected a higher number of positive 
samples than the M-duo screening.  The PCR assay detected 22/216 (10.2%; 95% CI: 
0.07-0.15) positive M. hominis and 63/216 (29.2%; 95% CI: 0.24-0.36) positive 
Ureaplasma species (40/216 [18.5%; 95% CI: 0.14-0.24] positive U. parvum and 
23/216 [10.7%; 95% CI: 0.07-0.16] positive U. urealyticum) clinical samples.  M-duo 
screening detected 5/216 (2.3%; 95% CI: 0.01-0.05) positive M. hominis, 29/216 
(13.4%; 95% CI: 0.10-0.19) positive Ureaplasma species clinical samples.  The results 
for the multiplex real-time PCR assay and M-duo screening are shown in Table 3.4 
and Table 3.5, respectively.  It is important to note that three clinical samples were 
positive for Ureaplasma species and two samples were positive for M. hominis by M-
duo screening but were negative in the multiplex real-time PCR assay, three of which 
could not be confirmed by subsequent culture.  The two samples that were culture 
positive but negative in this PCR were originally found to be positive using the MUP 
PCR assay at the time of DNA extraction but on re-testing with the MUP PCR assay 
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negative results were obtained.  The discrepancy is attributed to degradation, as has 
been documented for detection of other Mollicutes [319].   
The multiplex real-time PCR had a statistically higher clinical sensitivity than 
the culture technique for all targets (M. hominis, p=0.0081; Ureaplasma species, 
p=0.0001).  When M-duo culture was considered as the reference method, the 
multiplex real-time PCR has sensitivities of 60.0% (95% CI: 14.7-94.7) and 89.3% 
(95% CI: 71.8-97.7) for M. hominis and Ureaplasma species, respectively, and 
specificities of 91.0% (95% CI: 86.3-94.5) and 80.3% (95% CI: 73.9-85.8).  Mixed 
infections were detected in patient clinical specimens with the multiplex real-time 
PCR assay, however this was uncommon with 4/216 (1.9%; 95% CI: 0.006-0.05) 
M. hominis and U. urealyticum infections, 5/216 (2.3%; 95% CI: 0.008-0.06) 
M. hominis and U. parvum infections, and 1/216 (0.46%; 95% CI: 0.0001-0.03) 
U. parvum and U. urealyticum infection. 
Table 3.4. Comparison of PCR and M-duo culture results for 
M. hominis from 216 clinical specimens. 
  M-duo culture MUP PCR 
  Positive Negative Positive Negative 
M
ul
tip
le
x 
re
al
-
tim
e 
PC
R 
Positive 3 19 10 12 
Negative 2 192 1 193 
M
U
P 
PC
R 
Positive 2 9   
Negative 3 202   
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Table 3.5. Comparison of PCR and M-duo culture results for 
Ureaplasma species from 216 clinical specimens. 
  M-duo culture MUP PCR 
  Positive Negative Positive Negative 
M
ul
tip
le
x 
re
al
-
tim
e 
PC
R 
Positive 26 37 49 14 
Negative 2 151 3 150 
M
U
P 
PC
R 
Positive 28 24   
Negative 0 164   
 
3.2.6.2 Comparison to MUP PCR 
The multiplex real-time PCR assay detected a higher number of positive 
samples than the MUP PCR (Table 3.4-Table 3.5; method described in section 2.3.2). 
Using the MUP PCR, 11/216 (5.1%; 95% CI: 2.8-9.0) specimens were positive for 
M. hominis and 52/216 (24.1%; 95% CI: 18.8-30.2) specimens were positive for 
Ureaplasma species (34/216 [15.7%; 95% CI: 11.5-21.2] specimens were positive for 
U. parvum and 18/216 [8.3%; 95% CI: 5.3-12.9] specimens were positive for 
U. urealyticum).  It is important to note that 26/216 (12.0%; 95% CI: 8.3-17.1) clinical 
specimens were found to be positive for either M. hominis or Ureaplasma species by 
the multiplex real-time PCR but were reported as negative using the MUP PCR.  Of 
these, the 11/216 (5.1%; 95% CI: 2.8-9.0) U. parvum and 5/216 (2.3%; 95% CI: 0.8-
5.5) U. urealyticum positive samples had very low copy numbers (6.5 to 
25.6 copies/µl) but the 12/216 (5.6%; 95% CI: 3.1-9.6) M. hominis positive samples 
had copy numbers of 9.0 to 7.6 x 103 copies/µl.  The multiplex real-time PCR was 
repeated with the positive samples and all samples remained positive with consistent 
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copy numbers. Additionally, three samples that were positive for M. hominis with the 
real-time multiplex PCR were confirmed as positive by 16S rRNA sequencing.  
The multiplex real-time PCR had a statistically higher clinical specificity than 
the MUP PCR for all targets (M. hominis, p=0.0001; U. parvum, p=0.0001; 
U. urealyticum, p=0.0001).  When MUP PCR was considered as the reference method, 
the multiplex real-time PCR had sensitivities of 90.9% (95% CI: 58.7-99.8), 72.5% 
(95% CI: 56.1-85.4), and 78.3% (95% CI: 56.3-92.5) for M. hominis, U. parvum and 
U. urealyticum, respectively and specificities of 94.2% (95% CI: 90.0-96.9), 98.3% 
(95% CI: 95.1-99.7), and 100% (95% CI: 98.1-100). 
Sixty-one clinical specimens were subjected to culture using MM or USM 
media, following a positive detection result from the MUP PCR, as per standard 
diagnostic procedure performed by PHE.  A total of 63 positive results were recorded 
due to the detection of both M. hominis and Ureaplasma species two clinical 
specimens.  Of the 63 MUP PCR positive results, 26/63 (41.3%; 95% CI: 30.0-53.6) 
were confirmed by MM/USM culture.  Of these, 10/63 (15.9%; 95% CI: 8.7-27.0) 
were positive for M. hominis and 16/63 (25.4%; 95% CI: 16.2-37.4) were positive for 
Ureaplasma species (Table 3.6).  These 61 clinical specimens were also subjected to 
the multiplex real-time assay and comparison was made between results from the 
assay and MM/USM culture.  Of the 63 MUP PCR positive results, 23/63 (36.5%; 
95% CI: 25.7-48.9) were positive by both the multiplex real-time PCR and MM/USM 
culture; 8/63 (12.7%; 95% CI: 6.3-23.4) were found to be positive for M. hominis and 
15/63 (23.8%; 95% CI: 14.9-35.7) were positive for Ureaplasma species (Table 3.6).  
Three clinical specimens were found to be positive for M. hominis (1/63; 1.6%; 95% 
CI: 0.01-9.3) and Ureaplasma species (2/63; 3.2%; 95% CI: 0.23-11.5) by MUP PCR 
but this was not confirmed by MM culture or the multiplex real-time PCR (Table 3.6). 
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The two clinical specimens identified as having mixed infections by: MUP 
PCR, multiplex real-time PCR and M-duo screening were not confirmed by MM 
culture.  MM culture returned one positive M. hominis result in a single clinical 
specimen. 
The GFP control included in the assay allowed assessment of inhibition within 
the clinical specimens. No inhibitory specimens were identified out of the 216 clinical 
specimens tested. 
Table 3.6. Comparison of PCR and Mycoplasma Experience culture 
results for M. hominis and Ureaplasma species from 61 clinical specimens.  
Mycoplasma experience culture was performed on samples that were found 
positive for Ureaplasma species (52 clinical specimens) or M. hominis (11 
clinical specimens) by the MUP PCR.  Note that two clinical specimens were 
found positive for both Ureaplasma species and M. hominis. 
   MM/USM Culture 
   M. hominis Ureaplasma species 
   Positive Negative Positive Negative 
M
ul
tip
le
x 
re
al
-ti
m
e 
PC
R 
M
. h
om
in
is 
Positive 8 2   
Negative 0 1   
U
re
ap
la
sm
a 
sp
ec
ie
s 
Positive   15 34 
Negative   1 2 
M
U
P 
PC
R M
. h
om
in
is Positive 10 1   
U
re
ap
la
sm
a 
sp
ec
ie
s 
Positive   16 36 
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3.2.7 Detection of M. hominis and Ureaplasma species in neonates 
Endo-tracheal secretions from 45 intubated neonates (anonymised; South 
West) were tested for the presence of M. hominis and Ureaplasma species.  A total of 
194 clinical specimens were tested.  An additional 34 clinical specimens, collected in 
a hospital in Wales, from eight neonates were tested.  These eight neonates were 
treated with clarithromycin after collection of the first sample.  Multiplex real-time 
PCR results were compared to culture results for Ureaplasma species performed using 
specialised Ureaplasma-specific medium (USM) followed by differentiation into 
U. parvum or U. urealyticum using primers that generate different sizes of amplicons 
by standard PCR [320].  Culture for M. hominis was not performed. 
The multiplex real-time PCR detected a higher number of positive samples 
than culture; detecting 5/228 (2.2%; 95% CI: 0.78-5.2) positive M. hominis, 46/228 
(20.2%; 95% CI: 15.5-25.9) positive U. parvum and 46/228 (11.8%; 95% CI: 8.2-
16.7) positive U. urealyticum clinical samples compared to 39/228 (17.1%; 95% CI: 
12.7-22.6) positive U. parvum and 24/228 (10.5%; 95% CI: 7.1-15.2) positive 
U. urealyticum clinical samples detected by culture (Figure 3.3).  Mixed infections of 
M. hominis and U. parvum were detected in 3/228 (1.3%; 95% CI: 0.3-4.0) clinical 
specimens from two neonates (P162 and P164) using the multiplex real-time PCR.  
The multiplex real-time PCR had a statistically higher clinical sensitivity (p = 0.0001) 
than culture using USM for the detection of Ureaplasma species in the clinical 
specimens. 
Interestingly, when clinical samples from the South West and Wales were 
examined separately, a higher proportion of the samples were positive for Ureaplasma 
species in the Wales samples than the South West samples.  The multiplex real-time 
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PCR detected 13/34 (38.2%; 95% CI: 23.9-55.0) positive for U. parvum and 5/34 
(14.7%; 95% CI: 6.0-30.6) positive for U. urealyticum in the Wales clinical samples 
compared to 33/194 (17.0%; 95% CI: 12.3-23.0) positive for U. parvum and 22/194 
(11.3%; 95% CI: 7.6-16.6) positive for U. urealyticum in the South West clinical 
samples.  Additionally, M. hominis was only detected in the South West clinical 
samples (5/194; 2.6%; 95% CI: 0.9-6.1).  The higher proportion of positive results 
observed in the Wales clinical samples can be attributed to the sampling.  In Wales, 
clinical samples were only collected following prolonged ventilation requirement of 
the neonate and when sepsis/respiratory infection caused by other bacteria was ruled 
out by standard microbial culture.  However in the South West hospital, all ventilated 
neonates born at less than 28 weeks gestation that consented to study, were examined.   
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Figure 3.3.  Incidence of Mycoplasma hominis, Ureaplasma parvum and 
Ureaplasma urealyticum in intubated neonates.   
M. hominis, U. parvum and U. urealyticum were detected in neonatal clinical 
specimens (endotracheal secretions) by multiplex real-time PCR (purple) and by 
culture (green).  Data is presented as a percentage of neonatal clinical samples with 
95% CI.  A) Neonatal samples from both the South West and Wales; B) Neonatal 
samples from the South West only; C) Neonatal samples from Wales only. 
 
3.3 Discussion 
Direct detection techniques are the only methods adequate for genital 
mycoplasmas. Although culture is considered to be the reference technique for the 
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detection of M. hominis, it requires specialised media and expertise and does not yield 
results before 2-5 days [321].     
3.3.1 Analysis of the multiplex real-time PCR method used 
This chapter has described the successful combination of two previously 
published single-plex PCRs for the detection of M. hominis and Ureaplasma species.  
The combined assay is a rapid, sensitive, and specific multiplex real-time PCR for the 
simultaneous detection of M. hominis, U. urealyticum and U. parvum.  An increased 
number of positive clinical samples were detected for all three targets in comparison 
to M-duo culture and the MUP PCR and the assay also detected mixed infections 
within a clinical sample.  This is an improvement that was essential to the National 
Reference Laboratory for detection of M. hominis, U. parvum and U. urealyticum by 
qPCR in neonates.  Furthermore, this assay contains an internal, GFP control that can 
be used to monitor the efficiency of each PCR reaction and assess PCR inhibition that 
could adversely affect the result of the PCR. 
3.3.1.1 Choice of gene target 
Most PCR techniques detecting M. hominis target the 16S rRNA gene [322-
327]; however, minor sequence variations were observed in the 16S rRNA gene 
sequences [123] and may lead to a lower clinical sensitivity of these techniques.  
Additionally, variation has been described in the gap gene and the extent of variation 
was found to be larger than in the 16S rRNA gene [124, 315].  Sequence analysis of 
the gap gene from M. hominis isolated from MUP PCR negative clinical specimens 
revealed nucleotide mutations within the primer and probe binding sites, indicating a 
reason for amplification failure.  In comparison, a Taqman assay has been developed 
for the detection of M. hominis targeting the yidC gene [125], in which the yidC gene 
has been shown to have relatively low intra-species heterogeneity at the nucleotide 
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level, with no sequence polymorphisms identified within the primer and probe binding 
sites.  Therefore, the primer and probe sequences from this assay were used to develop 
the multiplex assay described in this chapter.  These primers and probes have been 
validated for use on urogenital clinical specimens [125] and this chapter has validated 
their use for detection of M. hominis in respiratory specimens. 
3.3.1.2 Sensitivity and specificity 
The LOD of the multiplex real-time PCR for M. hominis was 9 copies/µL in 
comparison to 7 copies/µL in the yidC single-plex assay (performed in another lab 
under different PCR conditions [125]).  However, both of these LOD were consistent 
with the sensitivities previously reported for real-time PCR techniques detecting 
M. hominis [124, 126]. However, as previously shown for M. pneumoniae [328], the 
analytical sensitivity may not predict the ability to detect the bacterial target in clinical 
specimens.  In highly variable species such as M. hominis [329], the PCR target 
conservation at the nucleotide level is essential for providing a high clinical sensitivity.  
Thus, it could be speculated that using the yidC gene as a target may result in a PCR 
assay with a higher clinical sensitivity than the previously reported PCRs. 
Additional validation could be performed to assess the robustness of the 
multiplex real-time PCR in the form of a spiking assay.  Analysis of the ability of the 
assay to detect low levels of M. hominis in the presence of high concentrations of 
Ureaplasma species (and vice-versa) will determine if there is any interference 
between detection of M. hominis and Ureaplasma species in clinical specimens.   
3.3.1.3 Analysis of clinical samples and comparison with culture 
The M-duo culture method has previously been evaluated for use in clinical 
diagnosis and is considered to have sensitivity comparable to conventional PCR and a 
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higher detection rate than culture using conventional A7 differential agar [330, 331].  
Higher rates of detection using PCR-based methodologies compared to culture have 
previously been reported for the detection of human Mycoplasma species and 
Ureaplasma species [125, 290, 332-335]; however, these have not always been 
statistically significant.  Nevertheless, this multiplex real-time PCR assay resulted in 
a significant increase in detection of all three targets in clinical samples in comparison 
to M-duo.  When the M-duo culture method was considered as a reference method, 
the new PCR assay showed 60% and 89.29% sensitivity, and 91% and 80.32% 
specificity for M. hominis and Ureaplasma species, respectively.  Conversely, when 
the MUP PCR assay is used as the reference method, the M-duo culture showed 
13.64% and 40.32% sensitivity, and 98.97% and 98.05% specificity for M. hominis 
and Ureaplasma species, respectively.   
When neonate clinical samples were tested for Ureaplasma species, the 
multiplex real-time PCR had a statistically higher clinical sensitivity (p = 0.0001) than 
culture on USM.  However, published data on the ureaseB primers for the detection 
and speciation of Ureaplasma (single-plex assay), found that a higher number of 
positive clinical specimens were detected using the assay than culture but that the 
difference in clinical sensitivity was not significant [290].  Furthermore, the sensitivity 
documented for the single-plex assay when culture was considered the reference 
method was 44.4% [290] compared to 83.3% when the multiplex real-time PCR was 
compared to USM culture.  However, different samples and PCR conditions could be 
responsible, in part, for the differences observed. 
Discrepancies between culture and PCR results have been documented for 
M. hominis [125].  When the Taqman assay was developed using the yidC gene as a 
target, 10 clinical specimens were found to be positive for M. hominis using the assay 
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but were negative using the culture method, resulting in a statistically higher clinical 
sensitivity, as observed in this chapter.  This is in contrast to results reported for assays 
utilising the gap gene as a target for M. hominis detection where 100% agreement 
between culture and PCR results has been documented [124].  However, an increase 
in detection using real-time PCR is consistent with results reported for conventional 
PCR techniques [336-338] and higher clinical sensitivity of PCR compared to culture 
has been widely reported [339-341]. 
One advantage of this multiplex real-time PCR over culture methods is the 
ability to determine the species of Ureaplasma present in the clinical sample, either 
U. parvum or U. urealyticum or mixed infections, without requiring any further 
testing.  This could be important as it has been proposed that the two different species 
may be responsible for differences in pathogenicity, ability to culture, or response to 
treatment and several studies [342-346] propose that certain species are more 
commonly associated with invasive disease and adverse pregnancy outcomes.  
Furthermore, mixed infections may have differing antibiotic resistance profiles 
depending on the species present.  However, in other studies [347-351], no correlation 
has been found between Ureaplasma species and pathogenicity.  It has also been 
widely reported that U. parvum is the more common of the two species to be isolated 
from clinical specimens [352], but both species may occur simultaneously in some 
people [3].  Previous studies used various methods such as liquid DNA hybridisation 
[326], PCR of 16S rRNA gene [343], or PCR of the MBA gene [348] to differentiate 
between U. parvum and U. urealyticum.  The results of these studies have indicated 
that U. parvum is present in 76-82% of Ureaplasma species positive clinical 
specimens whereas U. urealyticum is only present in 13.5-30%.  Results from the 
single-plex real-time assay distinguishing between U. parvum and U. urealyticum by 
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targeting the urease gene detected U. parvum and U. urealyticum in the same 
proportions as previously documented, 64.7% and 35.3%, respectively [290].  Results 
regarding numbers of U. parvum and U. urealyticum positive clinical specimens 
detected in this chapter are consistent with these observations.   
3.3.1.4 Further application of the multiplex real-time PCR assay 
This multiplex real-time PCR assay has been validated for respiratory, 
neonatal clinical samples; nevertheless, it has a wider application and could be used 
for urogenital and sexually transmitted infections as well as other invasive infections.  
This would, however require further validation.  Ureaplasma species and M. hominis 
have been included as targets in other multiplex assays and genital screening assays 
[314, 353, 354]; however, this is the first assay to simultaneously detect M, hominis 
and Ureaplasma species, and differentiate between U. urealyticum and U. parvum.  
The assay would be ideal for multiplexing with additional targets to be used as a wider 
screen for common pathogens in neonates and sepsis/meningitis patients, such as 
Streptococcus agalactiae, E. coli, coagulase-negative Staphylococci, S. pneumoniae 
and Listeria [355]. 
The assay developed in this study could be used to monitor the quantity of 
DNA of each target and may therefore have utility to monitor bacterial load in 
sequential patient specimens and growth in culture media.  The role of Ureaplasma 
species as a sexually transmitted pathogen has not yet been defined but both 
M. hominis and Ureaplasma species are found in a high percentage of female cervix 
and vaginal specimens and are present in the male urethra.  A positive PCR result on 
specimens from these sites may not be meaningful in the absence of clinical 
manifestations associated with these organisms, unless the bacterial load is 
significantly high [127].  However, an increased importance of infection based on 
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detected load has not been definitively associated with increased severity of clinical 
signs.  Therefore, it may be important to quantify bacterial load in relation to other 
bacterial flora and pathogens allowing for informed diagnosis of importance of 
infection with these species.  In the case of extra-genital specimens in adults or 
neonates positive PCR or culture result for M. hominis or Ureaplasma species should 
be considered clinically significant, especially in immunocompromised hosts.  This 
multiplex real-time PCR assay that can simultaneously detect and quantify 
M. hominis, U. parvum and U. urealyticum in neonate clinical specimens has further 
importance for detection of mixed infections that may inform relevant and appropriate 
therapeutic intervention. 
3.3.2 Review of previously described PCR detection methods for Mycoplasma 
hominis and Ureaplasma species 
Many PCR assays have been developed to detect M. hominis and Ureaplasma 
species in clinical specimens.  These are most commonly associated with other 
urogenital pathogens such as Chlamydia trachomatis, N. gonorrhoeae and 
M. genitalium in sexually transmitted infections (STI) and urethritis screening tests 
[314, 326, 356, 357].  In many cases, only U. urealyticum is included as a target, 
excluding U. parvum which is more commonly isolated from clinical specimens.  
However, it may be more common that the term U. urealyticum is misused as both 
species were defined as biovars of U. urealyticum prior to 2001 and therefore both 
species are identified by these PCRs but not speciated.  The most common gene target 
utilised for the detection of M. hominis and Ureaplasma species is the 16S rRNA [314, 
326, 358]; however, there is increasing use of the urease gene as a target for 
Ureaplasma species [338, 341, 358, 359].  In 2005, J. Yi, et al. (290) utilised the 
urease gene for the discrimination between U. urealyticum and U. parvum through the 
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use of a species-specific probe.  Since then discrimination using this gene target has 
been included in other multiplex assays with modifications to primers and probes [352, 
360, 361]. 
As previously mentioned, sequence variation in the 16S rRNA gene of 
M. hominis has been documented, along with variation in another gene target, the gap 
gene.  This instability has been shown to reduce the clinical sensitivity of PCR assays 
utilising these gene targets, therefore use of alternative targets, such as yidC, for 
M. hominis detection should be encouraged.  A real-time PCR assay has been 
developed targeting the ftsY gene of M. hominis [126] and although intra-species 
heterogeneity was not examined when the assay was developed, previous examination 
of recombination within M. hominis revealed low levels in ftsY in comparison to other 
genes such as gap [362].  
There are now several commercial assays that detect M. hominis and 
Ureaplasma species (Seegene, Korea; Fast-Track Diagnostics, Malta; SpeeDx, 
Australia; Sarace, Italy).  These are often combined with other pathogens involved in 
STI and urethritis.  The gene targets utilised by these assays are unknown (not present 
in manufacturer documentation) therefore direct comparison with the multiplex real-
time assay developed in this chapter cannot be performed.  The Fast-Track assay is a 
multiplex assay targeting common causes of urethritis, including M. hominis, 
U. parvum and U. urealyticum and reports sensitivities of 100% for all targets and 
specificities of 100%, 96% and 96%, respectively [363].  Additionally, Sacace have 
developed a multiplex assay targeting only M. hominis, U. parvum and U. urealyticum 
with reported sensitivities and specificities of 100% for all targets.  However, this 
diagnostic assay has been validated for genital rather than respiratory clinical 
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specimens with cross-reactivity only assessed against other common genital 
pathogens.   
Due to the availability of multiple diagnostic assays for M. hominis and 
Ureaplasma species, there is need for an independent reference test that can be used 
as the ‘gold standard’ for comparison of other diagnostic PCR assays.  This chapter 
has described the development of such an assay for the National Reference Laboratory 
that can be used an independent test to confirm diagnostic results from externally 
tested clinical specimens.    
3.3.3 Summary 
In conclusion, the multiplex real-time PCR developed in this chapter provides 
an improved nucleotide-based method, including an amplification control, for the 
detection of M. hominis and Ureaplasma species with a significantly higher clinical 
sensitivity than culture.   
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4.1 Introduction 
Definitive association of Ureaplasma species with disease in humans remains 
inconclusive, however evidence is increasingly being reported on an association with 
non-gonococcal urethritis [364], and with preterm birth and vertical transmission 
occurs in new-borns [365].  A study of U. parvum and M. hominis infection in pregnant 
macaque monkeys demonstrated that these bacteria induced preterm birth within six 
days of infection and caused bronchopulmonary dysplasia in the neonates, as sole 
pathogens [184].  Furthermore, two studies in 2016 continue to substantiate the 
association of Ureaplasma species with disease in humans [358, 366].  In neonates, 
these bacteria are associated with serious infections [3] including: pneumonia [367], 
bacteremia [368], meningitis [369], abscesses [206], intraventricular haemorrhage 
[370], necrotising enterocolitis (NEC) [371] and chronic lung disease (CLD) [372]. 
Antibiotic resistance among human pathogens continues to have a major impact 
on patient morbidity, mortality and economic cost to the health service [373].  Due to 
the limited number of antibiotics that are affective against M. hominis as well as the 
further treatment limitations in neonates, the emergence of resistant strains further 
complicates treatment.  Due to the technical difficulties in cultivation of M. hominis, 
antimicrobial susceptibility testing is predominantly carried out by the micro-broth 
dilution technique using a standardised 104-105 CCU [374].  M. hominis is resistant to 
14- and 15-membered ring macrolides and therefore treatment options are restricted 
to 16-membered ring macrolides, lincosamides, tetracyclines and fluorquinolones.  
Due to differences in intrinsic antibiotic resistance of both M. hominis and 
Ureaplasma species, targeted treatment and detection of mixed infections is important.  
Clindamycin (a lincosamide) is used to treat M. hominis infections however, this 
antibiotic has no effect on Ureaplasma species which are resistant to it.  Conversely 
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erythromycin (a 14-membered ring macrolide) is commonly used to treat Ureaplasma 
species infection but has no effect on M. hominis [321].  Acquired antibiotic resistance 
has also been documented for M. hominis; in clinical M. hominis isolates, tetracycline 
resistance is conferred by the expression of the horizontally acquired tetM gene. 
The objective of the work described in this chapter was to apply the multiplex 
real-time PCR developed in Chapter 3 to a cohort of neonatal specimens, quantifying 
bacterial load, with specific focus on several interesting cases.  Furthermore, this 
technique was applied to monitor the response of the bacteria to differing antibiotic 
classes. Tetracycline resistance of M. hominis was also examined. 
4.2 Results 
4.2.1 South West intubated neonate case studies 
The association between a positive PCR result for M. hominis, U. parvum and 
U. urealyticum and sex; gestation; method of delivery; clinical presentation; treatment 
with macrolides or steroids; being a twin; and survival is shown in Figure 4.1.  The 
highest number of neonates with detected M. hominis or Ureaplasma species infection 
were born between 23 and 25 weeks gestation (16/20; 80.0%; 95% CI: 57.8-92.5), 
with lower numbers detected at 26-28 weeks gestation (3/20; 15.0%; 95% CI: 4.4-
36.9) and one positive case at 31 weeks gestation (1/20; 5.0%; 95% CI: 0.01-25.4).  
Neonates were significantly more likely to be positive for Ureaplasma species and 
M. hominis if they were born earlier than 26 weeks gestation (p = 0.0141).  There was 
no association between sex and prevalence of M. hominis, U. parvum or 
U. urealyticum in the 20 neonates with positive PCR results.  Additionally, the highest 
number of positive neonates (for either M. hominis, U parvum or U. urealyticum) were 
detected in neonates delivered by vaginal delivery (VD; 6/20; 80.0%; 95% CI: 57.8-
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92.5), either normal vaginal delivery (NVD; 13/20; 65.0%; 95% CI: 43.2-82.0) or 
breech vaginal delivery (3/20; 15.0%; 95% CI: 4.4-36.9).  A significant increase 
(p = 0.0273) in detection of Ureaplasma species and M. hominis was observed in 
neonates delivered by vaginal delivery (including: NVD, breech VD and, forceps VD) 
in comparison to neonates delivered by Caesarean-section (CS).  U. parvum was 
detected in four neonates that were delivered via CS (20.0%; 95% CI: 7.5-42.2).  A 
majority of the neonates where M. hominis or Ureaplasma species were detected 
survived (15/20; 75.0%; 95% CI: 52.8-89.2).  Thirty-five of the neonates had chronic 
lung disease (CLD) at 36 weeks corrected gestational age (considered to reflect severe 
CLD), of these 16/35 (45.7%; 95% CI: 30.5-61.8) returned positive results using 
multiplex real-time PCR: M. hominis and U. parvum (3/35; 8.6%; 95% CI: 2.2-23.1), 
U. parvum (9/35; 25.7%; 95% CI: 14.0-42.3), U. urealyticum (4/35; 11.4%; 95% CI: 
3.9-26.6).   
A more detailed analysis of five intubated neonates from the South West 
sample set was undertaken due to either interesting clinical presentation or the 
presence of a mixed infection. 
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Figure 4.1.  Neonatal characteristics and clinical presentation in association with infection by Mycoplasma hominis and 
Ureaplasma species   
Proportion of positive neonate cases for each M. hominis (red), U. parvum (purple) and U. urealyticum (green) in relation to: sex, gestation, 
method of delivery, clinical concerns and presentation, treatment, twin, and survival.  NVD = normal vaginal delivery; VD = vaginal 
delivery; CS = Caesarean-section; CLD = chronic lung disease.  Data is presented as percentage of positive neonates with 95% CI.* 
(asterix) indicates significant difference (p < 0.01) within the indicated group.
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Twin patients 
Two neonates from the South West were a set of twins and presented a unique 
case study where the presenting twin (P130) was positive for U. parvum in 
endotracheal secretions in comparison to the second non-presenting twin (P131) that 
was positive for U. urealyticum.   
Twin P130 was transferred from birth hospital to a South West hospital on day 
1 post-birth.  She was extubated on day 20 to continuous positive airway pressure after 
commencing diuretics, but as a result of increasing apnoeas, bradycardias and 
desaturations, mandated re-intubation was commenced on day 23.  Re-intubation was 
accompanied by administration of antibiotics (teicoplanin and gentamicin).  Twin 
P130 was extubated on day 31.  In comparison, due to high ventilation requirements 
and recurrent pulmonary haemorrhages twin P131 was too unstable to be transferred 
on day 1 post-birth and arrived at a South West hospital on day 5 post-birth.  The twin 
remained on ventilation until death on day 32.  Primary cause of death was determined 
as necrotising enterocolitis with secondary causes listed as prematurity, chronic lung 
disease of prematurity and intracranial haemorrhage.   
Ureaplasma species were detected in endotracheal secretions by both culture 
and multiplex real-time PCR described in this chapter (Figure 4.2).  Samples from 
P130 were weakly positive by culture for Ureaplasma on day 2 post-birth (1 CCU) 
but progressively increased in titre with a maximum load of 104 CCU on day 6 post-
birth.  Ureaplasma titres then decreased and a negative result was obtained by day 24 
post-birth.  U. parvum was detected at day 6 post-birth by multiplex real-time PCR 
(139.26 copies/µl) with the maximum bacterial load observed at this time point.  The 
bacterial load was 121.02 copies/µl by day 10 post-birth and a negative result was 
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obtained by day 15 post-birth.  However, in contrast to culture, a low positive result 
(13.18 copies/µl) for U. parvum was detected by multiplex real-time PCR on day 24 
post-birth, the last sample tested.  Samples from P131 were positive for Ureaplasma 
species by culture on day 18 post-birth (102 CCU) and increased to high titres 
(107 CCU) by day 24 post-birth which were maintained until the neonate died on day 
32 post-birth.  High levels U. urealyticum were detected at day 24 post-birth 
(2.84x105 copies/µl) by multiplex real-time PCR and the bacterial then decreased to 
7.68x104 copies/µl by day 31 post-birth. 
 
Figure 4.2.  Quantification of Ureaplasma species by multiplex real-time PCR and 
culture from twins P130 and P131.   
Multiplex real-time PCR (circle + solid line) and culture (square + dashed line) results 
from endotracheal secretions during the course of infection for a set of neonatal twins.  
U. parvum was detected and isolated from P130 (green) and U. urealyticum was 
detected and isolated from P131 (blue).  CCU = colour changing units.
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Effect of steroid administration 
Ureaplasma urealyticum was detected in and isolated from a male neonate 
(P128), delivered via NVD at 25.1 weeks gestation.  Neonate P128 had CLD at 
36 weeks post-birth and was still supported by a ventilator at this time. 
Ureaplasma urealyticum was first detected in ETS at day four post-birth by 
both culture (50 CCU) and multiplex real-time PCR (2109.51 copies/µL; Figure 4.3).  
The maximum bacterial load was detected at day 21 post-birth; 1 x 106 CCU and 
9.73 x 105 copies/µL for culture and multiplex real-time PCR, respectively.  Levels of 
U. urealyticum then decreased and samples at day 30 and day 34 post-birth were found 
to be negative for U. urealyticum by both culture and multiplex real-time PCR.  
However, at day 35 post-birth, U. urealyticum was detected in ETS by both culture 
(1  x 102 CCU) and multiplex real-time PCR (47.46 copies/µL).  By day 41 post-birth 
culture results indicated the clearance of infection but U. urealyticum was still detected 
by multiplex real-time PCR (1.88 x 103 copies/µL).   
Clearance of U. urealyticum infection by day 30 post-birth coincides with the 
administration of azithromycin at day 26 post-birth however the increase in bacterial 
load detected at day 35 post-birth occurred whilst azithromycin was still being 
administered (Figure 4.3).  Additionally, neonate P128 was also treated with two 
courses of steroids.  The increase of U. urealyticum at day 35 post-birth coincided with 
the re-administration of steroids (Figure 4.3). 
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Figure 4.3.  Quantification of Ureaplasma urealyticum by multiplex real-time 
PCR and culture from P128.   
Multiplex real-time PCR (purple) and culture (green) results from endotracheal 
secretions during the course of infection for neonate P128.  U. urealyticum was 
detected and isolated from P128.  CCU = colour changing units.  Steroid (red) and 
macrolide (black) treatment are indicated by square brackets. 
 
Mixed infections 
Ureaplasma parvum and M. hominis were isolated from two male neonates 
(P162 and P164), both delivered via breech VD at 24.6 and 23.1 weeks gestation, 
respectively.  Both neonates had CLD at 36 weeks post-birth and both were supported 
by a ventilator at this time.  Both neonates survived. 
Neonate P162 was born eight days after rupture of membranes.  The first 
clinical specimen in which either Ureaplasma species or M. hominis was detected was 
at day seven post-birth, where U. parvum was detected by culture (1 x 102 CCU; Figure 
4.4).  It is important to note that this specimen was not tested using multiplex real-time 
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PCR.  Titres of U. parvum increased until day nine post-birth, where U. parvum was 
detected by both culture (1 x 104 CCU) and multiplex real-time PCR 
(3.82 x 104 copies/µL).  Additionally, at day 12 post-birth, M. hominis was detected 
by real-time qPCR (2.78 x 102 copies/µL).  Titres of both M. hominis and U. parvum 
then declined with negative results at day 14 post-birth for M. hominis and at days 12 
and 21 post-birth for U. parvum detected using multiplex real-time PCR and culture, 
respectively. This decline in titre coincides with administration of a ten-day course of 
erythromycin (Figure 4.4) but this is would not have an effect on M. hominis titre due 
to inherent resistance of this bacteria to erythromycin.  Upon the end of the course of 
erythromycin treatment, titres of both M. hominis and U. parvum then spiked at day 
38 post-birth at 3.63 x 105 copies/µL and 4.22 x 104 copies/µL (1 x 103 CCU), 
respectively.  This could be due to treatment failure or, less likely, re-infection.  A 
second course of antibiotics (azithromycin) was administered at day 42 post-birth, 
coinciding with negative multiplex real-time PCR and culture results for both 
M. hominis and U. parvum at day 44 post-birth (Figure 4.4). 
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Figure 4.4.  Quantification of Mycoplasma hominis and Ureaplasma parvum by 
multiplex real-time PCR and culture from P162.   
Multiplex real-time PCR M. hominis (red), U. parvum (purple) and culture (green) 
results from endotracheal secretions during the course of infection for neonate P162.  
U. urealyticum and M. hominis was detected and isolated from P162.  CCU = colour 
changing units.  Steroid (red) and macrolide (black) treatment are indicated by square 
brackets. 
 
Ureaplasma parvum was first detected in ETS from neonate P164 at day four 
post-birth by culture (1 x 101 CCU; Figure 4.5).  Titres of U. parvum then rose to a 
peak at day 11 (plus 18 hours) post-birth (1 x 102 CCU; 2.76 x 103 copies/µL) and 
then rapidly dropped resulting in negative results by both multiplex real-time PCR and 
culture at day 12 post-birth.  Following this initial peak, U. parvum was again detected 
in ETS at day 17 post-birth by multiplex real-time PCR (4.38 x 104 copies/µL) and by 
day 19 post-birth using culture (1 x 102 CCU).  Additionally, M. hominis was detected 
in the ETS at day 17 post-birth by multiplex real-time PCR (1.39 x 102 copies/µL; 
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Figure 4.5). Both titres of U. parvum and M. hominis peaked at day 19 post-birth, 
7.45 x 105 copies/µL and 1.13 x 105 copies/µL, respectively.  By day 22 post-birth 
multiplex real-time PCR and culture results were negative for U. parvum and 
M. hominis. However, U. parvum was detected by multiplex real-time PCR at day 45 
post-birth (4.19 x 103 copies/µL) but this re-infection was not consistent with culture 
results (Figure 4.5).   
 
Figure 4.5.  Quantification of Mycoplasma hominis and Ureaplasma parvum by 
multiplex real-time PCR and culture from P164.   
Multiplex real-time PCR M. hominis (red), U. parvum (purple) and culture (green) 
results from endotracheal secretions during the course of infection for neonate P164.  
U. urealyticum and M. hominis was detected and isolated from P164.  CCU = colour 
changing units.  Steroid (red) and macrolide (black) treatment are indicated by square 
brackets.
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4.2.1.1 Detection of Ureaplasma infection following clarithromycin treatment 
Thirty-four clinical specimens, collected in Wales, from eight intubated 
neonates were investigated to examine clearance of infection following treatment with 
clarithromycin.  Clinical specimens (ETS) were taken before (time-point 0) and at 
multiple time points following clarithromycin treatment. 
Ureaplasma species were detected in seven of the eight neonates, of which six 
were positive for U. parvum and only one positive for U. urealyticum.  M. hominis 
was not detected in any of the clinical specimens.  The positive neonates could be 
grouped into two groups: those that had no detectable infection by day two post 
clarithromycin treatment (rapidly cleared Ureaplasma DNA) and those for which 
reduction in detectable infection took longer than two days (persistent Ureaplasma 
DNA).  The rapidly cleared group contained four neonates, in which U. parvum was 
detected in ETS specimens by both multiplex real-time PCR and culture.  Of these 
four neonates, all but one had no detectable U. parvum DNA in the ETS by 24 hours 
post clarithromycin treatment (Figure 4.6).  Indeed, one neonate had non-detectable 
U. parvum infection by 18 hours post clarithromycin treatment, with negative results 
at this time point by both multiplex real-time PCR and culture.  
The persistent group contained three neonates, in which U. parvum was 
detected in two neonates and U. urealyticum in one.  When examining culture results 
for these three neonates, infection with Ureaplasma species was undetectable by day 
three post clarithromycin treatment, with no growth observed (Figure 4.6).  However, 
when examining multiplex real-time PCR results, Ureaplasma genomic DNA 
continued to persist with no negative result detected in the specimens collected (Figure 
4.6 B) up to day 5 post-treatment.  For two of the three neonates the latest time-point 
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at which a sample was obtained was day three post clarithromycin treatment, at which 
point titres for U. parvum were still high by multiplex real-time PCR 
(7.77 x 103 copies/µL and 2.66 x 105 copies/µL) in contrast to the negative culture 
results.  The latest time-point collected was for the third neonate in this group, which 
was positive for U. urealyticum, where a specimen was collected at day five post 
clarithromycin treatment.  This specimen was positive for U. urealyticum by multiplex 
real-time PCR (1.27 x 102 copies/µL) however, it was negative by culture.   
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Figure 4.6.  Detection of Ureaplasma species infection in intubated neonates after 
treatment with clarithromycin.   
Samples from seven neonates from Wales were grouped into “rapidly cleared” 
(purple) and “persistent” (red) depending on the length of time post clarithromycin 
treatment for Ureaplasma infection to clear.  The sensitive group contain samples from 
four neonates and the resistant group contained samples from three neonates.  A. qPCR 
(solid line) and culture (dashed line) results for sensitive and resistant groups plotted 
as mean ± SEM.  B.  Survival curve showing percent reduction in Ureaplasma titre 
determined by qPCR for sensitive and resistant groups.  Reduction in titre was defined 
as a 10-fold reduction in DNA concentration or a negative qPCR result. 
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4.2.2 Determination of minimum inhibitory concentration for Mycoplasma 
hominis 
Broth-dilution and agar methods can be used for susceptibility testing of 
M. hominis to different antimicrobial agents; however; the subtle colour change 
caused by the growth of M. hominis in MM renders MIC determination by broth-
dilution challenging.  Additionally, the supplementation of Mycoplasma-selective 
Agar with antimicrobial agents can have varying, batch-dependent results.  
The MIC was determined for 16 M. hominis strains using the antimicrobial 
agents: gentamicin and tetracycline, by broth-dilution and agar methods as described 
in section 2.5.  Additionally, MIC was monitored using the multiplex real-time PCR 
method described in this chapter by assessing M. hominis DNA concentration after 
incubation in MM supplemented with varying concentrations of antimicrobial agent.  
Using this method, DNA concentration is indicative of M. hominis growth and a 
reduction in DNA concentration to the base-line level (same inoculum) indicates lack 
of growth at that particular antimicrobial concentration (Figure 4.7).  
Minimum inhibitory concentrations of gentamicin and tetracycline for 
M. hominis can be seen in Table 4.1, including the control strain PG21.  Results 
between all three methods were consistent for six (6/16; 35.7%) M. hominis strains for 
gentamicin MIC determination and for seven (7/16; 43.75%) M. hominis strains for 
monitoring the response to tetracycline.  Of the ten strains where MIC calculations 
were inconsistent for gentamicin, eight (8/10; 80%) M. hominis strains had consistent 
results between broth-dilution and qPCR methods and only two (2/10; 20%) 
M. hominis strains had differing results for each method used.  The Clinical & 
Laboratory Standards Institute (CLSI) breakpoints define any isolate that has an MIC 
by broth or agar ≥ 8 µg/mL as resistant, while an MIC of ≤ 4 µg/mL is defined as 
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sensitive [374].  All M. hominis strains, except one strain, were sensitive to gentamicin 
with a range of MICs between 1 µg/mL to 4 µg/mL using the broth-dilution method.  
The exception, MH12 had an MIC of 8 µg/mL by both broth-dilution and qPCR 
methods, however an MIC of 2 µg/mL was calculated using the agar monitoring 
method.  Of the nine strains where results between MIC determination methods were 
inconsistent for tetracycline, eight (8/9; 88.89%) M. hominis strains had consistent 
results between broth-dilution MIC determination and qPCR monitoring methods.  
One (1/9; 11.11%) M. hominis strain had differing results using all three methods for 
tetracycline MIC determination.  Fifteen M. hominis strains were sensitive to 
tetracycline with a range of MICs between 0.125 µg/mL to 8 µg/mL however, one 
strain (MH9) has a high tetracycline MIC determined as 16 µg/mL by broth-dilution 
and agar-based methods, and a level indicative of >16 µg/mL by qPCR monitoring.  
Inconsistency in MIC calculation using the methods described is 
predominantly due to the agar-based method.  In all, bar two inconsistent results, the 
MIC for either gentamicin or tetracycline was higher when determined using the agar-
based method in comparison to the broth-dilution method and qPCR monitoring.  This 
is confirmed by the CLSI guidelines, where MIC ranges calculated from broth-dilution 
are 2-fold dilution lower than the agar method ranges for susceptibility for 
moxifloxacin, levofloxacin and clindamycin [374].  However, only both-dilution MIC 
ranges are available for tetracycline susceptibility and gentamicin was not examined. 
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Figure 4.7. Example graphs to calculate the MIC of M. hominis for both 
gentamicin and tetracycline by real-time qPCR.   
M. hominis DNA concentration following treatment with gentamicin (red) or 
tetracycline (blue) is indicated for six representative M. hominis strains. 
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Table 4.1. Gentamicin and Tetracycline MIC calculation for M. hominis by 
broth-dilution and agar methods, and monitoring using qPCR. 
Strain Gentamicin MIC (µg/ml) Tetracycline MIC (µg/ml) 
 Broth-
dilution 
Agar qPCR Broth-
dilution 
Agar qPCR 
PG21 4 4 4 0.125 0.125 0.125 
MH2 4 4 4 0.125 8 0.125 
MH9 4 4 4 16 16 >16 
MH10 2 2 2 0.125 4 8 
MH11 2 8 2 0.125 0.125 0.125 
MH12 8 2 8 0.125 1 0.125 
MH17 2 8 4 0.125 0.125 0.125 
MH18 2 4 2 0.125 1 0.125 
MH20 2 4 2 0.125 0.5 0.125 
MH21 2 2 2 0.125 1 0.125 
MH23 2 4 2 0.125 1 0.125 
MH26 2 8 2 0.125 0.125 0.125 
MH27 2 4 2 0.125 0.125 0.125 
MH41 2 2 2 0.125 0.125 0.125 
MH43 1 16 4 0.125 2 0.125 
MH44 4 32 4 0.125 8 0.125 
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4.2.2.1 Determination of tetracycline resistant M. hominis  
A total of 54 M. hominis isolates were examined for the presence of antibiotic 
resistance to tetracycline by PCR.  The presence of the tetracycline-resistance 
mediating transposon, tetM, was detected by PCR (described in section 2.5.4) in five 
M. hominis strains (MH9, MH104, MH108, MH110 and MH111; in Appendices 
Figure A.1).  Sensitivity to tetracycline was determined for four of these strains using 
the qPCR method. Additionally, the MIC for tetracycline for MH9 was calculated by 
broth-dilution and agar-based methods.   
The MIC for three of the M. hominis strains (MH9, MH108 and MH110) was 
determined to be >16 µg/mL, higher than the published standardised range 
(0.12-1 µg/mL) [235] and higher than the CLSI guidelines that determine resistant 
strains as having an MIC ≥ 8µg/mL [374], indicating that these strains are resistant to 
tetracycline (3/20; 15% incidence).  One strain, MH111, was sensitive to tetracycline 
(MIC: 1 µg/mL) despite the presence of tetM (Figure 4.8).  
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Figure 4.8. Example graphs to calculate the MIC of M. hominis containing tetM 
for both gentamicin and tetracycline by real-time qPCR.   
M. hominis DNA concentration following treatment with gentamicin (red) or 
tetracycline (blue) is indicated for four representative M. hominis strains containing 
tetM. 
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4.3 Discussion 
Ureaplasma species have been linked to disease such as non-gonococcal 
urethritis as well as septic arthritis in hypogammaglobulinemic patients, but the patient 
group which has been the focus of this chapter have been premature neonates.  
Ureaplasma species have been strongly linked as an infectious cause of premature 
birth where the organism can additionally be transmitted from mother to child either 
in utero, as a result of an ascending infection from the mother’s urogenital tract, or 
acquisition during birth.  
4.3.1 Neonatal twin case study 
This chapter presents a case study of dizygotic twins both with Ureaplasma 
positive endotracheal aspirates samples, but interestingly harbouring two separate 
species.   
For P130 the titres of U. parvum obtained from samples rapidly increased from 
the first sample, but a sample taken following reintubation on day 23 indicated 
complete natural clearance of Ureaplasma.  Although this negative result coincided 
with the administration of teicoplanin and gentamicin these will not have an impact 
on Ureaplasma due to the pathogens intrinsic resistance to these antibiotics [375].  The 
MIC of gentamicin for U. parvum is given as > 32 µg/mL which is not achievable in 
vivo due to nephrotoxicity [375]. 
With respect to P131, the first sample was not taken until day 10 post-birth as 
poor patient clinical status precluded transport to the research hospital.  This sample 
was weakly positive for U. urealyticum.  From day 24 through to death samples were 
positive for a high titre of U. urealyticum.  This high titre coincided with death as a 
result of NEC.  The role of Ureaplasma species in the development of NEC has 
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received greater attention in recent years.  Ureaplasma are thought to induce NEC by 
both direct and indirect mechanisms.  Ureaplasma have been detected directly in 
gastric aspirate samples which may then result in the generation of a local 
inflammatory response within the intestinal region.  In addition, the ingestion of 
amniotic fluid containing pro-inflammatory mediators, as a result of in utero infection, 
also have a contributory role [376, 377].  Work by Okogbule-Wonodi et al., have 
reported that neonates born <33 weeks and colonised with Ureaplasma have a 2-fold 
greater risk of developing NEC with the risk increasing to 3.3-fold in those born <28 
weeks [371].     
Previous reports have shown discordance in microbial infection between twins 
and have examined the role of in utreo infection during twin pregnancies.  Romero et 
al., carried out amniocentesis and culture on a cohort of 46 women presenting with 
twin deliveries [378].  They identified 11% with at least one sac positive for microbial 
growth to then result in preterm labour and 12% to result in premature birth.  
Ureaplasma were identified in three out of the five mothers and always in the 
presenting twin (never from the non-presenting alone).  Unfortunately this study 
predated the differentiation of Ureaplasma species.  In a second study examining 
microbial invasion of preterm twins, only the presenting twin was infected in five out 
of nine cases, and microbial titre was always higher for the presenting twin in the 
remaining cases where both twins were infected [379].  Ureaplasma species were the 
most commonly observed pathogen in this study.  A retrospective analysis study 
examining a greater number of twins (1156 twin placentas) further confirmed that the 
non-presenting twin was significantly less likely to experience chorioamnionitis when 
compared with the presenting twin [380].    
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4.3.2 Effect of steroid treatment on the detection of M. hominis and Ureaplasma 
species infection 
The single case study reported in this chapter regarding neonate P128 provides 
no clear evidence to the effect of steroid treatment on the clearance of Ureaplasma 
infection.  This study showed an increase in U. urealyticum titres, following previous 
clearance of infection, by both q-PCR and culture with re-administration of steroids.  
This occurred whilst a course of azithromycin was still being administered.  However, 
titres of U. urealyticum also declined during steroid treatment.   
Antibiotic administration is an effective standard therapy for bacterial lung 
infections, like pneumonia.  However, rapid release of bacterial cell wall components 
has been implicated in exaggerated host inflammation-induced lung injury [381, 382].  
Systemic glucocorticoid steroids have diverse anti-inflammatory and 
immunomodulatory properties [383, 384], and administering them in addition to 
antibiotics may constitute a useful method for treating pneumonia.  However, 
adjunctive glucocorticoid steroid therapy for pneumonia has long been a subject of 
debate.  A randomised placebo-controlled clinical trial showed that a significant 
reduction in hospital stay was associated with adjunctive steroid treatment [385].  In 
addition, studies have suggested that administration of steroids in patients with CAP 
might be beneficial, particularly in severe cases [386, 387].  Conversely, other studies 
have shown no benefit, or indeed harmful outcomes, of steroid treatment for 
pneumonia [388-390].  Furthermore, glucocorticoid steroids have been shown to 
impair host bacterial clearance from the pulmonary system, particularly at high doses 
[391, 392]. 
Currently, there is no documentation of the effect of steroid treatment on 
Ureaplasma species or M. hominis infection.  However, the use of steroids as 
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combination therapy with antibiotics has been examined for M. pneumoniae [393].  In 
an experimental model of M. pneumoniae respiratory tract infection, it was found that 
monotherapy with clarithromycin had the greatest effect on reducing concentrations 
of M. pneumoniae in bronchoalveolar lavage (BAL) but combination therapy had the 
greatest effect on decreasing levels of cytokines and chemokines as well as pulmonary 
histologic inflammation [393]. 
4.3.3 Monitoring of infection with Ureaplasma species following clarithromycin 
treatment 
Ureaplasma species infection was not detected in six of the seven neonates 
studied in this chapter following clarithromycin treatment.  Four neonates (rapidly 
cleared Ureaplasma DNA group) did not have detectable infection after two days post-
clarithromycin treatment whereas the other three neonates (persistant group) did not 
have detectable infection by day 3 (culture results).  However, PCR results for the 
persistent group indicated high levels of Ureaplasma species DNA at day 3 post-
clarithromycin treatment (last sample for two of the neonates).  It should be noted that 
treatment with clarithromycin was a two-week course and therefore the continuing 
course of antibiotics could have an effect on bacterial load at a later time-point.  As 
this was a retrospective study, further clinical samples at later time-points were not 
available. However, it would be interesting to assess Ureaplasma species detection 
and reduction in detectable load/colony isolation numbers following clarithromycin 
treatment with a larger patient cohort and over a time period that would allow 
reduction of less sensitive strains of Ureaplasma to be observed.  This would also 
allow discrepancies between culture and PCR methods to be further addressed.   
Macrolide resistance has been described in Ureaplasma species, with in vitro 
resistance associated with mutations in the 23S rRNA and L4 and L22 ribosome-
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associated proteins [394].  Further characterisation for antibiotic resistance of the 
resistant group of clinical specimens would provide further evidence for delayed 
clearance of infection by clarithromycin.  Research previously published within the 
research group has analysed Ureaplasma isolated from one of these neonates from the 
resistant group (UHWO10).  This isolate was found to be resistant to erythromycin, 
azithromycin and clarithromycin with a mutation documented in the L4 protein gene; 
6 bp deletion resulting in the deletion of two amino acids [299]. 
Due to toxic effects of tetracyclines and fluoroquinolones on bone and 
cartilage development, their use in the treatment of neonates is limited, therefore 
macrolides are the antibiotic of choice for the treatment of Ureaplasma and M. hominis 
infections.  Clarithromycin, a 14-membered ring macrolide, is commonly used for the 
treatment of Ureaplasma infection in neonates.  Several studies show that macrolides 
affect many inflammatory processes including the migration of neutrophils, oxidative 
burst in phagocytes, and production of pro-inflammatory cytokines [395].  
Clarithromycin has been reported to inhibit superoxide production by activated 
neutrophils and also has a membrane-stabilising activity [396].  In addition to this, 
clarithromycin has also been found to suppress interleukin 1β gene expression in 
human nasal epithelial cells [397].  These anti-inflammatory effects may contribute to 
successful treatment of severe pulmonary conditions caused by Ureaplasma [398].  
Previously, clarithromycin treatment for neonates in which Ureaplasma species were 
detected by PCR, showed an improved clinical outcome and ultimately eradication of 
Ureaplasma species infection [399]. 
4.3.4 Review of methods used to calculate minimum inhibitory concentration  
Methods for in vitro antimicrobial susceptibility testing of mycoplasmas were 
first described in the 1960s [400] however, until 2001 there was no universally 
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accepted or standardised broth dilution- or agar-based methods.  These were further 
clarified and limited break points for four to five antibiotics for each M. hominis, 
U. urealyticum and M. pneumoniae were published in 2011 and 2012 [235, 374].  Prior 
to this the lack of a consensus method for MIC determination, coupled with the 
complex growth requirements of mycoplasmas, resulted in considerable confusion 
regarding the antimicrobial activities of various drugs against mycoplasmas. 
Standardised antimicrobial susceptibility testing methods and designated 
quality-control parameters for human Mycoplasmas and Ureaplasmas were deemed 
necessary because culture is seldom performed for diagnostic purposes, and in vitro 
testing of individual isolates is even more rarely obtained.  Antimicrobial 
susceptibilities can vary geographically and in response to selective antimicrobial 
pressure.  Moreover, clinically significant acquired drug resistance, potentially 
affecting multiple antimicrobial classes, can occur in all of the Mycoplasma and 
Ureaplasma human pathogens.  Most Mycoplasma and Ureaplasma infections are 
treated empirically, therefore obtaining accurate and reproducible antimicrobial 
resistance surveillance data for currently available antibiotics and new therapeutics is 
important.   
The standardised methods described by Waites et al., [235] and the CLSI 
guidelines [374] require a defined inoculum of 104 to 105 CFU/mL.  The broth-dilution 
technique utilised in this chapter, as described by Beeton et al., [299], allows for 
simultaneous quantification of bacteria in the presence and absence of antibiotic, 
providing a more rapid approach for sensitivity determination.  However, broth-
dilution techniques require the accurate reading of colour changes in liquid media, 
which for M. hominis can be difficult due to subtle colour changes.  Using quality-
controlled media, like Mycoplasma Experience Ltd. Mycoplasma-selective Media 
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(used throughout this thesis), aids with this challenge but batch variation and 
inconsistencies in colour change still proved a challenge. 
To aid the determination of MIC for M. hominis, real-time PCR was used to 
monitor the quantity of the bacteria in the presence and absence of antibiotic.  
Consistent results from agar-, broth- and PCR-based methods were obtained for 36% 
and 44% of M. hominis isolates for gentamicin and tetracycline, respectively.  Higher 
consistency was observed between broth- and PCR-based methods; 88% and 94% of 
M. hominis isolates for gentamicin and tetracycline, respectively.  The inconsistency 
observed with the agar-based method may be due to the necessary incubation time 
required for growth of M. hominis and storage of media; it is generally accepted that 
agar containing antibiotics has a shelf-life of 72 hours before the antibiotics start to 
denature [235].  Therefore, incubation or storage of the media for longer than 72 hours 
would alter the concentration of antibiotic in the media, affecting the MIC.  It is 
important to note that the use of PCR to monitor response to antibiotics in this chapter 
represents a method to putatively detect and monitor phenotypic resistance, as bacteria 
are grown in medium containing antibiotic and quantified using qPCR. 
Quantitative PCR has been used to monitor the MIC for C. trachomatis [401] 
and the chlamydia-related bacterium Waddlia chondrophila [402].  Results from these 
studies showed that the MIC calculated using qPCR were within already published 
ranges and proved a reliable, less time-consuming and more sensitive method for 
monitoring the bacterial response to antibiotics.   
4.3.5 Tetracycline resistance 
Tetracyclines are one of the first-line treatments of M. hominis infections 
[239], with the exception of paediatric treatment.  High-level resistance to 
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tetracyclines in M. hominis has been associated with the presence of the tetM 
transposable element [280, 281], which is the only observed mechanism of 
tetracycline resistance in clinical isolates of M. hominis [239].  The presence of tetM 
was identified in five M. hominis strains with phenotypic resistance observed in three 
of the five strains (Section 4.2.2.1).  An increase in tetracycline-resistant M. hominis 
has been observed, with 18.75% resistance (1999-2002) compared to 2.8% (1992) in 
Bordeaux, France [403].  Indeed, increased antimicrobial resistance in genital 
mycoplasmas has been reported globally [404-406]; for example 40% of M. hominis 
detected in vaginal specimens in Iran were tetracycline-resistant (2015) [407].  
Country-dependent antibiotic prescription guidelines and recommendations may 
account for the varying tetracycline resistance patterns observed globally.  Antibiotic 
resistance is often determined using molecular methods, such as PCR followed by 
sequencing, to identify mutations associated with resistance, and phenotypic 
susceptibility testing is not always undertaken.   
As shown in this chapter, the presence of the tetM gene does not necessarily 
confer phenotypic resistance to tetracyclines.  Degrange et al identified two tetM-
positive M. hominis isolates that were tetracycline susceptible [403].  One of these 
M. hominis isolates had a 1,260 bp insertion in the leader peptide sequence (likely 
preventing successful transcription), while no mutations were found within the tetM 
gene or promoter region of the second isolate; no mutations were observed within the 
tetM sequence itself.  This has also been observed in Ureaplasma [403].  Therefore 
interrogation of the sequence of tetM did not elucidate the lack of function and 
subsequent susceptibility to tetracyclines.  This confirms the requirement for 
phenotypically determined susceptibility of an organism to antimicrobial agents, as 
genotypic resistance does not necessarily confer phenotypic resistance.  Conversely, 
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in one tetM positive, tetracycline-sensitive M. hominis strain, tetracycline resistance 
was induced in vivo during short-term passage in media containing tetracycline with 
no changes in sequence observed [403].  This observation led to suggestions that tetM 
regulation might involve transcriptional attenuation, as described for Enterococcus 
faecalis [408], and that tetracycline-susceptible strains that carry tetM should be 
reported as potentially resistant to all tetracyclines [403].  
A further explanation for the lack of expression may be due to gene silencing. A study 
by Enne et al., demonstrated that in a selection or E. coli isolates, all of which 
containing the pVE46 resistance plasmid, a sub-population were phenotypically 
sensitive [409].  The plasmid DNA sequence of the sensitive isolates were found to be 
identical to that of the resistant strains, but interestingly when the plasmid from the 
sensitive strain were introduced to a different E. coli strain, the resistant phenotype 
was restored.  This suggested that chromosomal differences were to explain these 
differences in gene silencing and could potentially be the mechanism for tetM 
silencing in M. hominis. 
4.3.6 Summary 
The multiplex real-time PCR assay developed in Chapter 3 has multiple uses, 
along with a diagnostic purpose.  It can be used to quantify bacterial load within 
clinical specimens and monitor clearance of infection, and be used as a novel method 
for monitoring the bacterial response to antibiotics, enhancing information obtained 
by traditional MIC determination in M. hominis.  Tetracycline resistance was observed 
in M. hominis and the presence of the transferable genetic element tetM was confirmed 
in resistant isolates.  In addition, a tetM positive, phenotypically sensitive M. hominis 
isolate was identified. 
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5.1 Introduction 
Mycoplasma hominis is an opportunistic human pathogen and resides as a 
commensal on the mucosal surfaces of the cervix or vagina in 21 to 53% of sexually 
mature, asymptomatic women; this is somewhat lower in the urethra of males [3].  
However, M. hominis has also been associated with clinically diverse diseases 
including; urogenital diseases [311, 312], postpartum fever [313], pneumonia [410], 
meningitis [186, 205], post-operative wound infection [201], post-organ transplant 
infection [411] and septic arthritis [187, 189].  Although this organism has only been 
isolated from humans, the capacity of M. hominis to cause disease as a sole pathogen 
has been proven by induction of preterm labour and development of foetal chronic 
lung disease following experimental in utero administration of M. hominis to pregnant 
macaque monkeys [184].   
Current discriminatory methods for typing of M. hominis to improve 
understanding of epidemiology of infection and genetic diversity are not in clinical 
use.  Several molecular typing mechanisms have been developed for M. hominis 
including: pulsed-field, gel electrophoresis (PFGE) [329, 412], restriction fragment 
length polymorphism (RFLP) analysis [413], amplified length polymorphism (AFLP) 
[414] and random amplified polymorphic DNA (RAPD) [415].  These techniques have 
displayed poor reproducibility (RAPD), requirement for specialised equipment and 
time required (PFGE) and large quantities of biological material.  Typing based on 
sequence analysis of the p75, p120’ and vaa genes was not comparable, indicating that 
the three genes vary by different mechanisms (16-19).   
Previous studies have indicated that the surface antigenic profiles of M. hominis 
strains are highly heterogeneous, expressing both size and phase variants of surface 
exposed membrane proteins [78, 86-88].  Several M. hominis surface proteins have 
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been characterised including P120, P135 and Vaa; however, the molecular basis of 
variation in M. hominis has only been elucidated in some cases.  The mechanisms 
involved in the diversification of mycoplasma surface proteins are highly complex and 
include: size variation caused by gain or loss of intragenic repetitive sequences; phase 
switching by deletion/insertion mutations or DNA inversion affecting promoter 
activity; and presence of multigene families or multiple copies of partial genes in the 
mycoplasmal chromosome [89].   
Variation in the composition and size of the Vaa proteins results from allelic 
variant forms of the single copy vaa gene in M. hominis [91, 92].  Size variation has 
been observed in Vaa using the monoclonal antibody H3 that was used to: initially 
identify this protein, inhibit the growth of M. hominis, and block attachment to host 
cells [78].  The size of Vaa observed in different isolates ranged from 28 kDa to 72 kDa 
and resulted from the gain or loss of intragenic repetitive sequences.  These repeats 
form the basis of “modules” which provide a platform for further separation of Vaa 
types into categories.  M. hominis can be characterised based on the size variation 
observed in Vaa variants.  This variation derives from interchangeable cassette 
sequences within Vaa; Modules III, IV, V, VII and VIII. 
Multiple locus variable-number tandem-repeat (VNTR) analysis (MLVA) has 
been used to successfully subtype other Mycoplasma species [132, 416-419].  
However, when used for M. hominis, high genetic heterogeneity was found resulting 
in a method that was limited for use at individual level studies, it being too 
discriminatory for large epidemic studies [133].   
Multi-locus sequence typing (MLST) is a typing system using housekeeping 
genes considered to be under less selective pressure than other genes.  It has been 
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successfully employed for many mycoplasma species such as M. bovis [420], 
Mycoplasma agalactiae [421], M. hyorhinis [422], M. hyopneumoniae [423] and 
M. pneumoniae [424].  A previous study examined six housekeeping gene sequences 
to investigate evidence of genomic recombination in M. hominis [362] and revealed a 
high degree of variability between these genes.  However, the authors did not utilise 
the data to create a genotyping scheme.   
The ability to discriminate strains of M. hominis can provide information to 
study transmission chains in nosocomial, maternal and neonate infection, and increase 
understanding of sexual transmission of the organism in the community. 
In this results chapter, M. hominis was characterised based on sequences of the 
vaa gene and derived amino acid sequences, resulting in the assignment of a Vaa type.  
Genetic diversity of M. hominis was investigated using: sequence based typing (SBT) 
of eight housekeeping genes, genomic sequence SNP analysis and, bioinformatics 
analysis of genomic sequence to further characterise M. hominis. 
5.2 Results 
5.2.1 Characterisation of Mycoplasma hominis using the variable adherence-
associated antigen 
5.2.1.1 Vaa cassette determination and variability 
Vaa category was determined as described in Section 2.4.6, where Vaa type is 
based on module composition shown in Figure 1.3, Vaa category was determined 
either by PCR of the entire open reading frame or from whole genome sequence and 
subsequent amino acid composition prediction for 31 M. hominis isolates. Thirteen 
isolates belonged to category 1, 12 to category 2, one to category 3 and five to category 
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4. Deduced amino acid sequences were aligned against prototype strains for each Vaa 
category observed (Figure 5.1-Figure 5.4). Strains in Vaa category 1 showed very high 
homology for modules I, II, and II'' with 92.6%, 94.8% and 100% homology, 
respectively (Table 5.1). Lower levels of homology were observed in modules III and 
IV; however this was still above the 82% homology threshold suggested by Boesen et 
al [97]. As observed in category 1, high levels of homology were observed for modules 
I, II and II’ for strains belonging to categories 2, 3 and 4 (Table 5.1). In the strains 
analysed, the modules that contain the highest levels of variation occur at the C-
terminal end of the interchangeable cassette region, module V and module VIII in Vaa 
category 1 and Vaa category 2, respectively. In both cases, these modules fail to 
maintain the 82% homology between isolates required for inclusion in a particular 
module, with observed homology of 72.0% and 77.0% for module V of category 1 and 
module VIII of category 2, respectively. However, the sequences of these strains share 
higher homology with the module to which they are assigned than to other described 
modules present in the interchangeable cassette region. In Vaa category 4, varying 
numbers of Module III have been documented and in the five clinical isolates 
determined to have Vaa category 4 proteins, only two repeats of the module are 
present. In comparison, the prototype for Vaa category 4 used as a comparison, 
M. hominis 1620, had three repeats of Module III. 
In all strains analysed, the SFKE and ELESFKE motifs were conserved in 
module II and in the interchangeable cassettes, respectively. The conserved tryptophan 
residues can also be observed in the interchangeable cassettes (Figure 5.1-Figure 5.4).  
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Figure 5.1. Amino acid alignment of Vaa category 1 strains. Amino acid sequence alignments for 13 M. hominis clinical isolates 
and two prototype strains, FBG and PG21.  
Modules are separated by red dotted lines; polymorphisms are highlighted by blue boxes; conserved tryptophan residues indicated by 
triangle; and conserved ELESFKE motif indicated by arrow. 
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Figure 5.2. Amino acid alignment of Vaa category 2 strains.  
Amino acid sequence alignments for 12 M. hominis clinical isolates and a prototype strain, 132. Modules are separated by red dotted lines; 
polymorphisms are highlighted by blue boxes; conserved tryptophan residues indicated by triangle; and conserved ELESFKE motif 
indicated by arrow. 
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Figure 5.3. Amino acid alignment of Vaa category 3 strains.  
Amino acid sequence alignment for a single M. hominis clinical isolates and one prototype strain, 4195. Modules are separated by red 
dotted lines; polymorphisms are highlighted by blue boxes; conserved tryptophan residues indicated by triangle; and conserved ELESFKE 
motif indicated by arrow. 
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Figure 5.4. Amino acid alignment of Vaa category 4 strains.  
Amino acid sequence alignments for 5 M. hominis clinical isolates and a prototype strain, 1620. Modules are separated by red dotted lines; 
polymorphisms are highlighted by blue boxes; conserved tryptophan residues indicated by triangle; and conserved ELESFKE motif 
indicated by arrow. 
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Table 5.1. Variation of amino acid sequence in M. hominis Vaa categories.  
The number of polymorphic sites in the amino acid sequence for each module is shown with the percentage homology shown in brackets, between 
the Vaa sequences determined in this study and prototype strains. Total number of strains analysed, including prototype strains, are shown in brackets. 
  Number of polymorphic sites (% polymorphic sites) 
Vaa 
Category 
No. of 
M. hominis 
strains 
Module I Module II Module II’ Module II’’ Module III Module IV Module V Module VI Module VII Module VIII 
1 13 (15) 2 (92.6%) 4 (94.8%)  0 (100.0%) 10 (91.8%) 10 (90.4%) 33 (72.0%) 0 (100.0%)   
2 12 (13) 3 (89.9%) 10 (87.0%) 2 (92.3%)     2 (80.0%) 8 (91.7%) 26 (77.0%) 
3 1 (2) 2 (92.6%) 2 (97.4%) 0 (100%)    0 (100.0%) 0 (100.0%) 0 (100.0%)  
4 5 (6) 2 (92.6%) 4 (94.8%)  0 (100.0%) 6 (95.1%) 5 (95.2%)  1 (90.0%)   
Blank spaces indicate that the module is not present in the Vaa category 
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5.2.1.2 Phylogenetic analysis of vaa 
Phylogenetic analysis of the vaa gene of 31 M. hominis clinical strains and five 
prototype strains showed four distinct clusters (Figure 5.5; method described in section 
2.4.8.2), corresponding to the four Vaa categories observed. Phylogenetic 
relationships were more apparent using the Neighbour-joining method, where clear 
separation between Vaa categories could be observed. Vaa categories 1 and 2 and Vaa 
categories 3 and 4 co-localised to the same major clade, respectively. SNP analysis of 
the vaa gene for the 36 M. hominis strains resulted in 26 ATs with a discriminatory 
ability of 0.72 ATs per strain.  Examination of the Hunter-Gaston DI (DI, ranges from 
0.0 = no diversity to 1.0 = complete diversity; method described in Section 2.7) 
confirmed large diversity in this gene (DI: 0.981; 95% CI: 0.967-0.994).  However, 
when Vaa category, based on amino acid sequence, was examined as a discriminatory 
method  it resulted in a discriminatory ability of 0.11 categories per strain and Hunter-
Gaston DI showed reduced diversity in the protein (DI: 0.684; 95% CI: 0.612-0.756). 
The Vaa antigen is a major adhesin of M. hominis and displays pronounced mutational 
variation in size as well as sequence and antigenic variation, therefore the 
heterogeneity observed in the nucleotide sequence of the 36 M. hominis isolates 
examined is not unexpected. 
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Figure 5.5. Phylogenetic trees based on the sequence of the vaa gene of 
M. hominis.  
Phylogenetic trees were constructed based on the nucleotide sequence of the vaa gene 
for 31 clinical M. hominis strains and five prototype strains using Maximum likelihood 
(A) and Neighbour-joining (B) methods. Bootstrap support values of over 70% are 
shown. Vaa categories are indicated by square brackets. 
 
5.2.2 Sequence based typing of M. hominis 
5.2.2.1 Determining sequence based typing loci 
Housekeeping genes considered conserved in other bacterial species under a 
low rate of selective pressure were chosen for analysis (Table 5.2). Locus sequences 
were selected using the available genome sequence of M. homins PG21 
(NC_013511.1). Ten genes were included for initial analysis: recA protein (recA), 
inorganic phosphatase (ppa), cell division protein FtsZ (ftsZ), lysyl-tRNA synthetase 
(lysS), methionine-tRNA ligase (metG), serine hydroxymethyltransferase (glyA), 
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nitrogen fixation protein NifS (nifS), ATP synthase subunit α (atpA), carbamate kinase 
(arcC), and adenylate kinase (adk). After initial PCR amplification and sequencing of 
all loci (methods detailed in sections 2.4.2, 2.4.3 and 2.4.5) with the available 
M. hominis strains, ppa and nifS were excluded from the SBT scheme due to 
amplification failure in multiple strains. 
Table 5.2. Choice of MLST loci based on targets used in already established 
bacterial MLST schemes. 
Bacterial species MLST loci a 
 adk arcC atpA glyA recA ftsZ lysS metG 
Escherichia coli         
Bartonella henselae         
Chlamydia trachomatis         
Campylobacter jejuni         
Enterococcus faecium         
Haemophilus influenzae         
Helicobacter pylori         
Moraxella catarrhalis         
Neisseria meningitidis         
Staphylococcus aureus         
Staphylococcus 
epidermidis 
        
Streptococcus suis         
Vibrio vulnificus         
Yersinia 
pseudotuberculosis 
        
a MLST loci were chosen based on the frequency of use in other bacterial MLST schemes  
(http://www.mlst.net/) and the presence of the gene in the published PG21 whole genome. 
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5.2.2.2 Sequence based typing of M. hominis 
PCR and sequencing (described in section 2.4.5) of all eight targets for the 21 
isolates and type strain resolved a total of 20 STs (Table 5.3).  The discriminatory 
typing ability for M. hominis was 0.9 ST per isolate.  The number of SNPs observed 
within each individual locus and the percentage of polymorphic sites are indicated in 
Table 5.4, with glyA having the highest number of SNPs (26 SNPs) and recA having 
the highest percentage of polymorphic sites corrected for sequence length (6.8%).  The 
number of alleles per locus ranged from six (atpA) to 13 (glyA) (Table 5.4).  
Examination of the Hunter-Gaston DI indicated large diversity between the STs (DI: 
0.987; 95% CI: 0.961-1.000) with the greatest diversity shown in glyA (DI: 0.944; 
95% CI: 0.903-0.984) and the lowest diversity in ftsZ (DI: 0.597; 95% CI 0.369-
0.826).   
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Table 5.3. Description of M. hominis strains used in this study, their sequence type (ST) and allelic profile. 
Strain Year of isolation Isolation site ST Allelic profile MLST Amino 
Acid ST 
    adk arcC atpA glyA recA ftsZ lysS metG  
NCTC 10111 1953 Rectal swab 1 7 3 3 12 4 2 4 2 A 
MH2 1989 CSF 2 1 4 2 13 8 5 5 1 B 
MH8 2012 Genital 3 8 3 2 6 10 6 7 3 C 
MH9 2012 Genital 4 6 5 3 8 5 6 1 3 D 
MH10 2012 Genital 5 8 3 2 8 5 6 1 2 E 
MH11 2012 Peritoneal fluid 6 5 3 4 6 9 6 8 4 F 
MH12 2012 Peritoneal fluid 6 5 3 4 6 9 6 8 4 F 
MH13 2012 Peritoneal fluid 6 5 3 4 6 9 6 8 4 F 
MH15 2004 Blood culture 7 6 7 5 13 9 6 2 7 C 
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Strain Year of isolation Isolation site ST Allelic profile MLST Amino 
Acid ST 
    adk arcC atpA glyA recA ftsZ lysS metG  
MH16 2004 Neck swab 8 8 4 3 3 2 6 6 5 C 
MH17 2004 Unknown 9 8 5 3 2 2 6 6 5 G 
MH18 1993 Genital 10 4 8 3 5 1 4 6 6 H 
MH20 1990 Genital 11 8 7 6 10 5 6 9 7 C 
MH21 1986 Knee aspirate 12 1 4 2 13 8 5 6 1 I 
MH22 1990 Breast abscess 13 4 3 2 7 1 4 6 6 H 
MH23 2005 Endo-tracheal secretions 14 8 5 1 11 3 3 10 7 G 
MH25 2006 Ear swab 15 3 3 2 5 7 1 4 7 J 
MH26 2008 Cerebral abscess 16 1 1 2 9 6 6 4 7 K 
MH27 2009 Abdominal pus 17 10 2 3 1 9 6 11 7 L 
MH28 2004 Pelvic aspirate 18 9 5 1 11 3 7 3 7 M 
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Strain Year of isolation Isolation site ST Allelic profile MLST Amino 
Acid ST 
    adk arcC atpA glyA recA ftsZ lysS metG  
MH29 1989 Pleural fluid 19 6 5 3 9 1 6 10 7 G 
MH41 2012 Endo-tracheal secretions 20 2 6 2 4 9 6 4 6 N 
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Table 5.4. Primer pairs developed in this study and variability of the different loci. 
Name  Primer Sequence (5’-3’) Tm 
(°C) 
Amplicon 
a (bp) 
Sequence 
b (bp) 
Location 
of MLST 
locus in 
CDS 
No. of 
alleles 
No. of 
polymorphic 
sites 
% of 
polymorphic 
sites 
Average 
G + C 
content 
(%) 
Hunter-
Gaston 
Diversity 
Index c 
95% 
confidence 
interval 
adk  F GAAGTGTACAACGAACACGC 56 676 406 234-639 10 14 3.45 26.85 0.892 0.822-0.962 
 R ATGACCATTTTAAAGCCTCTTCT           
arcC F AGTTATTGTCGGACACGGAA 57 735 383 384-766 8 10 2.61 36.03 0.818 0.714-0.922 
 R CCGCCTTCTTCAACGAATTT           
atpA F ATTGCCGAAGAATGAATGGC 57 712 327 978-1304 6 6 1.83 33.94 0.771 0.672-0.869 
 R CATTTGCTTCAGAAACGGCT             
glyA F CATGGCAATGGTTGATCCTG 57 785 411 450-860 13 26 6.32 34.55 0.944 0.903-0.984 
 R TTGCCGCAGATCCTATTCTT           
recA F ACGCTATTGCCGAAATACAA 56 648 309 457-765 10 21 6.80 33.33 0.896 0.826-0.966 
 R TGAAACTATATCACGAGCCCT           
ftsZ F GCAAAACTGCTGCTGAATCT 57 714 214 492-705 7 8 3.74 31.78 0.597 0.369-0.826 
 R TGGCGATTACCGAGACAAAT           
lysS F TTCGTGGCCCATTTATTGTT 56 656 343 307-649 11 19 5.54 30.61 0.909 0.851-0.967 
 R ATGTTTGAAAACGCCTTCAGT           
metG F CCAAGTGGTAATCTTCACATAGG 56 646 230 304-649 7 11 4.78 25.65 0.835 0.733-0.938 
 R TGTGTTGCTTTTCAGCATCTT           
a Amplicon sequence sizes in base pairs according to PG21 data 
b Trimmed sequence sizes in base pairs after alignment of the different loci 
c Hunter-Gaston diversity index (DI, ranges from 0.0 no diversity to 1.0 complete diversity) 
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5.2.2.3 Phylogenetic analysis of SBT loci 
Neighbour-joining and maximum-likelihood trees constructed from 
concatenated sequences of the eight loci for the 22 M. hominis isolates (Figure 5.6; 
method described in section 2.4.8.1) confirmed a high level of intra-species diversity 
as indicated by the Hunter-Gaston DI.  Three homogenous strains (MH11, M12 and 
MH13) with identical STs originated from peritoneal fluid of the same patient 
following a recent renal transplant undergoing organ rejection.  Conversely, MH8, 
MH9 and MH10, originated from a Caesarean-section patient clinical specimen, taken 
from an area outside, yet proximal to, the surgical wound and had different STs: ST3, 
ST4 and ST5, respectively.   This indicates population variation within a single clinical 
sample.  ST4 and ST5 co-located to the same phylogenetic clade whereas ST3 located 
to a distal clade suggesting two distinct lineages of M. hominis within a single patient 
specimen. 
Neighbour-joining and maximum-likelihood trees constructed for the eight 
loci individually (Figure 5.7).  MH11, MH12 and MH13 consistently co-located to the 
same clade and were found to be indistinguishable for all loci.  Topology of both 
neighbour-joining and maximum-likelihood trees was consistent for all loci and 
concatenated sequences.   
Unfortunately, other paired specimens including: MH42-MH44, MH13-
MH15, and MH123-MH124 were not examined due to poor growth and subsequent 
DNA yield of the M. hominis strains.  
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Figure 5.6. Phylogenetic trees based on concatenated sequences of eight SBT loci 
for M. hominis.  
Phylogenetic trees were constructed based on concatenated sequences of eight 
housekeeping loci for 20 unique STs using maximum-likelihood (A) and neighbour 
joining (B) methods. Strains originating from the same patient sample are indicated 
by boxes. Bootstrap support values of over 70% are shown. 
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Figure 5.7. Phylogenetic trees for each of the eight SBT loci.  
Phylogenetic trees were constructed for each of the eight SBT loci using maximum-
likelihood (A, C, E, G, I, K, M, O) and neighbour-joining (B, D, F, H, J, L, N, P) 
methods.  arcC = A+B, atpA = C+D, glyA = E+F, recA = G+H, ftsZ = I+J, metG = 
K+L, lysS = M+N, and adk = O+P.  Strains originating from the same patient are 
indicated by coloured boxes. Bootstrap support values of over 70% are shown. 
 
5.2.2.4 Determination of synonymous sequence changes in sequence based 
typing loci 
Since SNPs may not result in altered amino acid sequence, the possibility of 
synonymous sequence changes (indicating a pressure to conserve amino acid sequence 
and protein structure) was investigated by comparing predicted translated sequence 
(ST based on amino acid sequence is included in Table 5.3).  Analysis of deduced 
amino acid sequences of the eight loci for the 22 strains indicated that both 
synonymous and non-synonymous SNPs occurred.  Non-synonymous SNPs are 
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highlighted in Figure 5.8.  Amino acid sequence alignment analysis of RecA and AtpA 
yielded homologous sequences for all ATs, numbering ten and six ATs respectively.  
In comparison Adk analysis resulted in the largest number of non-synonymous 
changes in the amino acid sequence, with six changes in the sequence between 11 ATs.  
Generation of STs using the deduced amino acid sequences for each of the 22 
M. hominis isolates resulted in 14 STs, with a discriminatory ability of 0.6 ST per 
isolate.  Examination of the Hunter-Gaston DI indicated large diversity between ST 
generated from the amino acid sequences (DI: 0.944; 95% CI: 0.898-0.989); this is 
only slightly lower than the DI for STs generated from nucleotide sequences, 
indicating poor pressure for conservation even at the protein level.  The greatest 
diversity was shown in Adk (DI: 0.866; 95% CI: 0.799-0.932) and the lowest diversity 
in both AtpA and RecA (DI: 0.000; 95% CI: 0.000-0.261). 
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Figure 5.8. Alignments of amino acid sequences of each allelic type at each of the 
eight SBT loci.  
Amino acid sequence alignments were generated for each of the eight loci based on 
nucleotide sequence of each allelic type. Non-synonymous changes in amino acid 
sequence are highlighted in yellow. * (asterix) indicates positions which have a single, 
fully conserved residue; : (colon) indicates conservation between groups of strongly 
similar properties – scoring > 0.5 in the Gonnet PAM 250 matrix. 
 
5.2.2.5 Assessment of SBT loci stability 
No previous classification scheme for mycoplasmas has confirmed that the ST 
classification is maintained following limited in vitro subculture.  Therefore, the 
genetic stability of the eight SBT loci were examined by comparing sequences for 
each loci in six strains before and after ten subculture passages (Table 5.5).  All ten 
strains co-located before and after ten passages to the same topological position within 
both maximum-likelihood and neighbour-joining trees (Figure 5.9).  However, 
diversity between strains before and after ten passages was observed by SNP 
differences within the locus glyA (Table 5.5).  The sequence alteration required the 
assignment of a new ST for one (MH17) of the six strains, where a SNP change was 
observed. 
Examination of the Hunter-Gaston DI between the ten strains before and after 
ten passages indicated that strain MH17 had a diversity index indicative of complete 
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diversity (DI: 1.000; 95% CI: -0.522-1.000).  However, the relationship between 
progenitor and daughter strains was apparent by clade relationship (co-localisation by 
phylogeny; Figure 5.9).  Conversely, no diversity was seen in strains MH2, MH11, 
MH20, MH23 and MH26 after 10 passages (DI: 0.000; 95%CI: 0.000-0.266).  In 
MH17 the only loci that displayed diversity after ten passages was glyA (DI: 1.000; 
95% CI:-0.522-1.000).  This indicates that there is differential strain variation over ten 
passages and that there is variable genetic fidelity of the genes included in this study.  
 
Table 5.5. SNP differences between the original strain and following 10 
passages in MM.  
SNP differences and the position of the SNP are shown for each of the 8 loci. New 
assignment of a sequence types (STs) caused by the changes are indicated in bold. 
Strain ST SNP difference number (position)  per allele 
  adk arcC atpA glyA recA ftsZ lysS metG 
MH2 2 0 0 0 0 0 0 0 0 
MH11 6 0 0 0 0 0 0 0 0 
MH17 21 0 0 0 1 (349) 0 0 0 0 
MH20 11 0 0 0 0 0 0 0 0 
MH23 14 0 0 0 0 0 0 0 0 
MH26 16 0 0 0 0 0 0 0 0 
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Figure 5.9. Phylogenetic trees based on concatenated sequences of eight SBT loci 
from the original strains tested and the strains after short-term passage in liquid 
culture.  
Phylogenetic trees were constructed based on concatenated sequences of eight 
housekeeping loci for ten strains before and after ten passages in liquid culture using 
maximum-likelihood (A) and neighbour joining (B) methods. The strain after short-
term passage are indicated by a * (asterix). Bootstrap values of over 70% are shown. 
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5.2.2.6 Genomic sequence analysis 
The genomes of 16 M. hominis strains were sequenced and assembled using 
the PG21 reference genome as described in sections 2.6.2-2.6.5.  Phylogenetic analysis 
based on SNP variant calling (section 2.6.8.1) of 18 M. hominis isolates and ATCC 
27545 (NZ_CP009652.1) whole genome sequences (Figure 5.10) showed similarity 
in topology to the phylogenetic trees constructed from the concatenated SBT loci 
(Figure 5.6).  Analysis of the two strains from a single wound swab (MH9 and MH10) 
confirmed observations from SBT, where MH9 and MH10 consistently collocated to 
the same clade in both SBT and genomic SNP analysis.  MH11 and MH12, two 
isolates from a single peritoneal sample were found to have the same ST, collocating 
to the same clade after SNP analysis of partial whole genome sequencing and were 
found to be indistinguishable. Phylogenetic SNP analysis of the partial whole genome 
sequence of 19 of the M. hominis strains confirmed a high level of intra-species 
diversity, concordant with SBT Hunter-Gaston DI and phylogenetic analysis. 
Interestingly, an additional group of two unrelated strains were indistinguishable by 
SNP analysis, MH2 and MH21. MH2 and MH21 are strains from patients with extra-
genital infections, and are considered invasive strains.  
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Figure 5.10. Phylogenetic tree based on the single nucleotide polymorphism 
profile of 19 M. hominis whole genome sequences.  
The phylogenetic tree was constructed based on SNP variant calling for 16 M. hominis 
partial whole genome sequences and the prototype strain ATCC 27545 in comparison 
to PG21 using the maximum-likelihood method. Strains originating from the same 
patient sample are indicated by boxes. 
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5.2.3 Genomic sequence analysis and development of minimum MLST scheme 
Bioinformatics analysis of M. hominis genomic sequence was used to derive 
the minimum number of genes required to accurately reflect genomic phylogeny and 
to identify possible minimal MLST (mMLST) schemes. 
5.2.3.1 Pan-genome 
Raw genomic sequence reads from 18 M. hominis clinical strains were 
assembled and scanned against a database of Hidden Markov Models (HMM) 
representing gene coding families constructed using the four complete genomes 
published on NCBI: ATCC 27545 (NZ_CP009652; 533 genes), PG21 (NC_013511; 
497 genes), Sprott (NZ_CP011538; 524 genes) and AF1 (NZ_CP009677; 531 genes), 
as described in Section 2.6.6.  On average, M. hominis pan-genome clustering was 
able to detect 550 (median 553) genes per sample, which is comparable to the mean 
number of genes found in the four reference genomes (521 genes).  The M. hominis 
pan-genome contained a total of 777 genes (Figure 5.11) with 427 genes (54.95%; 
95% CI: 51.44%-58.42%) present across all samples and the reference strain 
ATCC 27545 at least once.  The shoulders in the pan-genome frequency distribution 
are likely to correspond to the genes found in the specific phylogenetic clades (Figure 
5.11).  The number of alleles per gene family has a bi-modal distribution (Figure 5.12); 
one peak at 1 allele per gene (representing sample-specific genes) and a second peak 
at 11 alleles per gene.  The second peak is likely to contain a set of core genes, common 
to all samples, yet have unique alleles in each one.  This is as expected given the 
relatively long phylogenetic distance from the reference genome in the whole genome 
SNP tree (Figure 5.10).  No hyper-variant, large copy number genes, such as 
transposases and integrases, were detected in the pan-genome data analysis.  
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Figure 5.11.  Frequency of genes in the Mycoplasma hominis pan-genome.   
Grey line indicates the core number of genes appearing in all isolates and the reference 
strain ATCC 27545 at lease once (427 genes). 
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Figure 5.12. Bimodal distribution of alleles per gene in the Mycoplasma hominis 
pan-genome.   
The median (red dotted line) and mean (orange dotted line) number of alleles per gene 
family in the pan-genome. 
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5.2.3.2 Core-genome MLST 
A subset of genes found across all samples are likely to be highly conserved 
and carry little phylogenetic signal.  Conversely, a small subset of genes could act as 
hotspots for the phylogenetic signal that drives tree topology.  In order to identify 
genes that carry increased discriminatory potential, leave-one-out analysis was 
performed as described in section 2.6.9.  This involved removing one gene at a time 
from the set of 427 core genes and constructing a phylogenetic tree using the 
remaining alleles from the 426 genes.  The resulting phylogenetic tree was compared 
with the phylogeny derived using whole genome variants (considered the gold 
standard).  Of the 427 genes, 379 genes (88.76%; 95% CI: 85.39-91.44) conferred the 
same phylogenetic topology as the whole genome tree whilst 48 genes (11.24%; 95% 
CI: 8.56-14.61) disrupted the phylogenetic relationship of the strains to a varying 
extent.  These results suggest that these 48 genes are necessary for reconstructing the 
correct relationships between the strains.  To assess the sufficiency of these genes to 
replicate the topology, a phylogenetic tree was constructed using only these 48 genes 
(Figure 5.13), confirming that these 48 genes were necessary and sufficient for tree 
reconstruction.  These genes are considered the minimum gene set to construct a core-
genome MLST scheme as they are present in all reference genomes and the 18 
sequenced M. hominis strains, and are each required to reconstruct the whole genome 
topology.
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 Figure 5.13. MLST mosaic of 48 core genes found after leave-one-out analysis.   
The genes listed are necessary and sufficient for the reconstruction of the phylogenetic relationship of the strain observed using whole 
genome data.  The coloured ‘mosaic’ tiles represent different alleles. 
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5.2.3.3 Seven-gene MLST (mMLST) 
Whole genome sequencing is growing in ubiquity with decrease cost-per-
sample however, culturing M. hominis to produce a high enough yield of DNA for 
whole genome sequencing is challenging and not routinely possible direct on clinical 
specimens.  Routine whole genome sequencing for M. hominis is not currently 
performed therefore typing with a technique utilising PCR and Sanger sequencing, 
such as MLST and SBT, is preferred and more widely accessible.  Although 48 genes 
are required to recapture the original phylogenetic relationships observed using whole 
genome SNP analysis, the aim of this section was to identify a reduced gene set that 
could be used to confer good discrimination between strains and could be of practical 
use in future studies direct on clinical specimens.  To reduce the number of 
combinations of seven genes to search (48C7 = 73629072 total combinations), three 
sets of genes were selected: genes that caused the lowest overlap with the whole 
genome SNP tree in leave-one-out analysis (n = 10), manually selected genes for their 
biological functions (n = 9), and combination of the above two sets (n = 12).  Two sets 
of M. hominis strains originating from the same patient samples, MH9 and MH10, and 
MH11 and MH12 were used to identify which genes sets conferred identical mMLST 
profiles for these strains.  This reduction in genes resulted in 948 possible 
combinations of the three gene sets.  All combinations were analysed for phylogenetic 
topology closest to the whole genome SNP tree (methodology described in section 
2.6.9).  Fifteen combinations (Table 5.6) were identified to produce the highest 
topological similarity among all tested combinations and three schemes were found to 
confer the highest similarity to the whole genome SNP tree.  All 15 phylogenetic trees 
classified MH23 and MH28 into a different subtree compared to the original whole 
genome analysis.  In addition some trees also classified MH17 into a different 
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topological position.  Three selected schemes had overall very similar topology to the 
original whole genome SNP tree representing two general clades and correct 
bifurcations.  The branch length of the whole genome SNP tree could not be 
reproduced as shorter sequences with a different number of SNPs were used.  Overall 
the three schemes almost completely reproduced the phylogenetic relationship found 
using whole genome SNP data. 
Table 5.6. Summary of Mycoplasma hominis mMLST schemes.   
15 potential seven gene MLST schemes.  All schemes were found to reproduce the 
desired topology of the whole genome sequence SNP tree.  Genes that are 
important for distinguishing between MH2 and MH21 are in red. * indicates the 
schemes that produced a tree most similar to whole genome SNP tree. 
mMLST Genes Topological score ([0,1]) 
20,58,94,236,374,428,519 0.7692308 
20,58,94,183,265,428,519 0.7692308 
20,58,94,236,374,428,498 0.7692308 
20,58,94,265,374,428,519 0.7692308 
20,58,94,138,183,265,428* 0.7692308 
20,58,94,172,265,428,519 0.7692308 
20,58,94,138,183,236,519* 0.7692308 
20,58,94,172,236,374,428 0.7692308 
20,58,94,138,183,428,519 0.7692308 
20,58,94,236,265,428,519* 0.7692308 
20,58,94,138,183,236,374 0.7692308 
20,58,94,183,374,428,519 0.7692308 
20,58,94,172,183,265,519 0.7692308 
20,58,183,236,374,428,519 0.7692308 
20,58,94,172,183,236,265 0.7692308 
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5.2.3.4 Diversity of mMLST genes and determination of synonymous sequence 
changes 
All three mMLST schemes revealed a discriminatory power of 0.97 ST per 
M. hominis strain.  The Hunter-Gaston DI was calculated for each scheme (Table 5.7) 
and revealed that schemes 1 and 2 were equally discriminatory (DI: 0.97) in 
comparison to scheme 3 which was slightly less discriminatory (DI: 0.96).  All three 
mMLST schemes are close together in terms of their diversity index indicating that 
there is no clear ideal combination of seven genes.  Indeed, the schemes only differ by 
two genes (Table 5.7). 
Genes under negative selective pressure are preferred for an MLST scheme as 
they are purifying and actively kept by the host.  For each of the three proposed 
mMLST schemes the ratio of non-synonymous to synonymous (dN/dS) changes were 
calculated using the Nei and Gojobori method (Table 5.7).  All genes in all three 
mMLST schemes have a dN/dS ratio of <1. Schemes 1 and 3 have two genes under 
moderate selective pressure (oppA: 0.23 [95% CI: 0.21-0.25] and GENE-58: 0.27 
[95% CI: 0.25-0.30], GENE-58: 0.27 [95% CI: 0.25-0.30] and dnaG: 0.11 [95% CI: 
0.08-0.13], respectively), and scheme 2 has three genes under moderate selective 
pressure (oppA: 0.23 [95% CI: 0.21-0.25], GENE-58: 0.27 [95% CI: 0.25-0.30], dnaG: 
0.11 [95% CI: 0.06-0.13]).  The remaining genes have a dN/dS ration below 0.1, 
indicating strong negative selection.  Overall, scheme 3 appears to contain, on average, 
a more strongly selected gene set (average dN/dS ratio: 0.09), than the other two 
schemes (average dN/dS ratio: 0.11 and 0.13 for schemes 1 and 2, respectively). 
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Table 5.7. dN/dS ration and Hunter-Gaston Diversity Indices for the three proposed 
mMLST schemes 
Gene name Scheme 1 Scheme 2 Scheme 3 dN/dS (95% CI) Hunter-Gaston 
Diversity Index (95% 
CI) 
MHO_4840a GENE-20 GENE-20 GENE-20 0.09(0.08-0.1) 0.99 (0.97-1.00) 
MHO_0720a GENE-58 GENE-58 GENE-58 0.27(0.25-0.3) 0.98 (0.95-1.00) 
secD GENE-94 GENE-94 GENE-94 0.07(0.04-0.09) 0.95 (0.89-1.00) 
oppA GENE-138 GENE-138  0.23(0.21-0.25) 0.98 (0.96-1.00) 
argS GENE-183 GENE-183  0.07(0.05-0.09) 0.99 (0.97-1.00) 
hisS  GENE-236 GENE-236 0.09(0.06-0.13) 0.91 (0.8-1.00) 
MHO_1160a GENE-265  GENE-265 0.02(0.01-0.03) 0.96 (0.91-1.00) 
tyrS GENE-428  GENE-428 0.01(0.01-0.02) 0.97 (0.92-1.00) 
dnaG  GENE-519 GENE-519 0.11(0.08-0.13) 0.97 (0.92-1.00) 
Mean 
dN/dS 
(95% CI) 
0.11 
(0.01-0.2) 
0.13 
(0.06-0.21) 
0.09 
(0.01-0.17) 
  
Mean 
Diversity 
(95% CI) 
0.97 
(0.96-0.99) 
0.97 
(0.94-0.99) 
0.96 
(0.94-0.99) 
  
a gene encoding a hypothetical protein. Gene name relates to annotation in ATCC 23114. 
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5.2.3.5 Seven gene mMLST stability 
Stability of the genes for all three schemes was assessed in two M. hominis 
strains.  Whole genome sequencing was performed following short-term passage 
(10 passages) in liquid culture and compared to the original sequence.  All genes were 
completely stable in the two strains examined (Figure 5.14). 
 
Figure 5.14. MLST mosaic indicating stability of the nine genes used in the three 
proposed mMLST schemes.   
Strains that have undergone short-term passage are indicated by _10.  The coloured 
‘mosaic’ tiles indicate differing alleles.  All genes are stable between original and 
passaged strains. 
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5.2.3.6 Recombination analysis 
Genomic sequences of the M. hominis strains were assessed for predicted 
regions of variation arising from homologous recombination using Gubbins (section 
2.6.10).  Multiple potential areas of recombination were identified across all 
M. hominis strains (Figure 5.15).  In particular, high levels of recombination were 
predicted in the phylogenetic clade containing the reference strain ATCC 27545, with 
multiple recombination events predicted at the same loci. 
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Figure 5.15. Prediction of recombination in the M. hominis isolates chromosomes.  
Regions of variation in the genomes of the 18 clinical M. hominis isolates and the prototype strain ATCC 27545 which are predicted to 
have arisen by homologous recombination are shown in the panel on the right. Red blocks indicated recombination predicted to have 
occurred on internal nodes, blue indicates taxa-specific recombination, isolates are ordered according to the phylogenetic tree displayed 
on the left. The track along the top of the figure displays the PG21 chromosome and annotation, where protein coding sequences (CDS) 
are indicated in light blue. 
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5.3 Discussion 
In this chapter, M. hominis has been characterised by: Vaa type, SBT of eight 
housekeeping genes (adk, arcC, atpA, glyA, recA, ftsZ, lysS and metG), genomic 
sequence SNP analysis, and bioinformatics analysis of genomic sequence to derive the 
minimum number of genes required to accurately reflect genomic phylogeny. These 
were used to examine the genetic diversity of M. hominis isolates (collected from 
1986-2012), including triplicate isolates from two separate patients in the UK.  
Patients had a variety of urogenital and extra-genital clinical circumstances (detailed 
in Table 2.2). 
5.3.1 Analysis of the variable adherence-associated antigen of Mycoplasma 
hominis 
The Vaa antigen is a major adhesin of M. hominis displaying pronounced 
mutational variation in size, sequence and antigenic properties.  High levels of 
sequence variation was observed in the 36 M. hominis isolates examined in this 
chapter, particularly in the C-terminal of the interchangeable cassette region of the 
protein.  C-terminal modules appear to be hyper-variable in comparison to the other 
modules of the protein, indicating that there may be higher selective pressure to vary 
this region of the protein.  This suggests that the C-terminus of Vaa may be more 
important to immune surveillance than more membrane-proximal modules.  Antigenic 
variation is important to the expression of functionally conserved moieties within a 
clonal population that are antigenically distinct [28].   
As a method of discriminating between M. hominis strains, Vaa categories 
provide a limited mechanism for characterisation.  Of the isolates examined in this 
chapter, four Vaa categories were identified (0.11 categories per strain) with a Hunter-
Gaston DI of 0.684.  However, when examining nucleotide sequence, higher levels of 
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heterogeneity are observed (0.72 ATs per strain) and large diversity is observed 
between vaa sequences (Hunter-Gaston DI: 0.981).   
The vaa locus has previously been described as a highly dynamic region of the 
M. hominis genome [135].  A divergent genetic islet encoding a large, putative 
membrane protein, has been identified within the vaa locus of some M. hominis 
isolates.  The vaa gene in this case was found to be conserved 5’ end and a highly 
variable region towards the 3’ end containing the genetic islet.  It has been proposed 
that the mechanism underlying variation in the vaa gene is intra-species recombination 
whereby variable regions of vaa are exchanged resulting in a variable and dynamic 
hot-spot in the M. hominis genome [135]. 
5.3.2 Analysis of SBT for M. hominis 
The development of SBT schemes has been important both individually and 
epidemiologically for pathogenic bacteria.  At the level of an individual patient, this 
approach allows discrimination between relapse or persistence and new infection.  In 
this case M. hominis isolate SBT analysis was applied to three isolates from peritoneal 
fluid from a single transplant patient undergoing organ rejection.  These isolates all 
had identical sequence in the eight genetic loci, co-locating by phylogenetic topology 
with zero detected SNP differences (ST6).   
Analysis of three strains from a single wound swab (MH8-10), showed two 
closely related clones (MH9/10), and one strain that was distinctly different (MH8) in 
target gene sequence.  The presence of single or multiple M. hominis isolates within 
one patient has been examined previously.  Olson et al. [86] described multiple isolates 
of M. hominis obtained from the same joint of a septic arthritis patient over a six year 
period which exhibited differences in the expression of surface proteins.  However, 
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these strains were indistinguishable by restriction endonuclease analysis.  Conversely, 
Jensen et al. [412] demonstrated that M. hominis isolates from the same patient were 
identical when analysed with SDS-PAGE and PFGE, while isolates from different 
women exhibited a high degree of variation.  It was originally suggested that strains 
isolated from the same anatomical region should reveal a higher degree of similarity 
than strains isolated from different anatomical sites [425].  Strains obtained from the 
same anatomical site or from patients with the same diagnosis have been reported by 
others to have different patterns by RFLP analysis [413] and comparison of 12 genital 
isolates with other strains from different origins demonstrated that the genital isolates 
varied as much from each other as strains of non-genital origin [84]. 
5.3.3 Fidelity of SBT loci 
The accumulation of sequence changes in the glyA locus of MH17 after 10 
subculture passages resulted in loss of SBT assignment.  This indicates that this locus 
is unsuitable for use in the SBT scheme.  The failure to amplify the genes atpA and 
ftsZ each for two strains using the original primer sets was caused by sequence 
alteration in the primer footprint itself and the same DNA sample was readily 
amplified by the seven other primer pairs.  Thus, even though no changes were 
observed in the SBT locus sequence, SNPs were accumulated in the flanking regions 
required for amplification showing a high level of genetic variation in subsequent 
generations of this bacterial species. 
While phylogenetic analysis of the strains before and after subculture showed 
clear association between progenitor and progeny strains, a question arises regarding 
how many cell divisions would be required to lose the ability to relate progenitor to 
progeny.  Variation in strain and gene diversification rate was observed; MH17 
acquired an additional SNP in the glyA locus; and two loci failed to amplify using the 
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original primers.  These findings are in contrast to the complete conservation in ST’s 
observed for eight MLST loci in ten strains of M. pneumoniae following ten passages 
(0) [424].  This indicates that there may be reduced replication fidelity in M. hominis 
compared to other Mycoplasma species.  The relationship between genetic fidelity and 
pathogenicity, or degree of fidelity across the M. hominis genome requires further 
investigation.   
This is the first study to examine genetic drift in M. hominis after a limited 
number of subculture passages and our primary finding demonstrates that the 
separation of clinical isolates into such a wide number of ST for more discriminative 
methods is directly related to the poor fidelity of the replicating genome.  The reason 
for such varied strain genetic variation has not been identified and could be a reflection 
of recombination or integration of mobile genetic elements.  In comparison to MLST 
schemes developed for M. hyopneumoniae and M. agalactiae, higher levels of 
variation and diversity can be observed at the SBT loci used for M. hominis [421, 423] 
and discriminatory power seen in this study is higher than for that of Ureaplasma 
(0.9 ST per M. hominis isolated versus 0.35 ST per Ureaplasma isolate) [426]; 
confirming that M. hominis is highly variable in comparison to other Mycoplasma 
species.  While M. hominis was not included in the analysis, examination of four 
mycoplasma species; M. pneumoniae, M. genitalium, M. pulmonis and U. urealyticum, 
indicated a large number of repeats suggesting the existence of a large potential for 
recombination in these genomes [246].  These Mycoplasma species have high 
mutation rates and lack part of the SOS response and also a considerable number of 
the DNA repair proteins existing in E. coli  and Bacillus subtilis [5].  The four genomes 
reveal the absence of MutSLH system for mismatch repair and therefore higher 
frequencies of recombination between divergent strains are predicted, contributing to 
201 
 
Chapter 5 – Molecular typing of and characterisation of Mycoplasma hominis 
the accelerated evolution observed within the genus [246].  It would be interesting to 
determine if M. hominis also lacks these factors. 
5.3.4 Application of SBT for Mycoplasma hominis infection 
The potential for poor fidelity of M. hominis raises the question of the value of 
an SBT scheme, applied to M. hominis isolates, to identify sexual transmission of 
M. hominis infections or horizontal transmission between mother and baby.  However, 
transformation of the target gene sequence into concatenated form and analysis for 
phylogenetic topological positioning association clearly showed the relationship 
between progenitor and progeny strains was retained after subculture and the capacity 
to use such analysis requires validation with serial samples from infected individuals 
to determine if this could be of use in typing this bacterial species.  It is not known 
over how many generations such retention would be stable, nor is it known if in vivo 
pressure (e.g. symbiotic nutrient acquisition, innate/adaptive immunity, or other 
impacting factors) may limit the long term genetic drift.  Genomic sequencing may 
eventually displace SBT based on multiple gene target PCR and sequencing.  
However, the international availability of genome sequence technology and the time 
required for processing enough high quality DNA and contig analysis with the 
specialised culture requirements of mycoplasmas and volume of biomass required to 
obtain sufficient high quality DNA for analysis is unlikely to ever lend whole genome 
sequencing analysis to provide practical clinical guidance for this bacterial species and 
other fastidious organisms.  Other methods including MLVA typing of M. hominis 
isolates from two mother-neonate pairs resulted in the identification of identical 
MLVA types in each case studied, confirming mother-to-child transmission [133].  
Additionally, PFGE results reported by Jensen et al. found that M. hominis isolates 
obtained from the cervices of pregnant women and from the ears or pharynges of their 
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new-born infants yielded the same genomic profile [412].  Similarly, identical 
arbitrarily primed-PCR patterns were observed in strains isolated within a mother-
neonate pair [427].  It will be interesting to apply this SBT phylogenetic topological 
analysis of concatenated gene targets to similar mother-to-child transmission or 
between sexual contacts.   
The major advantage of utilising SBT, relative to whole genome sequencing, 
is direct PCR amplification from clinical samples to provide rapid typing following 
detection in a clinical sample prior to culture.  The advent and improvements of 
metagenomic processes and analysis may eventually supersede this; however, 
practical use on infections with mycoplasmas and mixed strains is not yet tested.  
Determination of SBT phylogenetic topological analysis with a mixed population of 
M. hominis strains would not be possible directly on a clinical sample, however, this 
may be feasible on infections originating from a clonal M. hominis infection.   
At the population level, SBT assesses the genetic diversity of M. hominis 
strains.  This study describes 20 SBT STs, revealing a genetic heterogeneity among 
this species.  This finding is in agreement with the data obtained by studies using other 
molecular typing methods.  MLVA typing of 210 M. hominis clinical isolates revealed 
high genetic heterogeneity within the species and this method was considered too 
discriminatory to be used for epidemiological studies at the population level [133].  
Genetic heterogeneity of M. hominis was also detected by RAPD and confirmed by 
PFGE [415], describing changes in the genomes of M. hominis clinical isolates from 
patients with chronic infection.  AFLP analysis provided further evidence of high level 
intra-species variability in M. hominis, by examining five randomly chosen clinical 
isolates [414].  RFLP analysis identified high heterogeneity among 20 M. hominis 
isolates obtained from colonised women and women with urogenital infections, 
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however, two strains sequentially isolated from one patient showed identical patterns 
after SmaI and MluI digestion [413].  Since the accumulation of SNP within the 
restriction enzyme recognition site is required to alter the less sensitive analysis 
methods, it is not surprising that these show the least amount of diversity.  The 
mounting evidence suggests that lower resolution methods of typing are more 
successful for epidemiology and transmission studies for M. hominis for example, 
classification of the strain in this chapter by Vaa type (common practice for 
M. pneumoniae and Ureaplasma species) identified 13 category 1 strains, 12 category 
2 strains, 1 category three strain, and five type 4 strains; however, allelic typing by 
vaa sequence results in 26 ATs for 36 strains.  
5.3.5 The use of bioinformatics to develop minimum MLST schemes that 
represent genomic phylogeny 
This chapter has successfully employed bioinformatics methodologies to 
develop seven gene mMLST schemes for the characterisation of M. hominis.  The 
three potential mMLST schemes identified are representative of whole genome SNP 
phylogeny and therefore provide an accurate method for examining the relationship 
between strains. 
Assessment of the pan-genome assembled for M. hominis revealed 427 core 
genes.  Previous examination of Mycoplasma species pan-genome identified a core-
genome of only 196 genes; however, this was an inter-species analysis and lower 
levels of conserved genes than observed in this chapter is to be expected.  Of the entire 
pan-genome, the core genome represents 55% of all genes.  This level of similarity 
between M. hominis strains is in stark contrast to M. pneumoniae where over 99% 
identity has been observed between genomes [17].  Congruence of the M. hominis pan-
genome to other Mycoplasma species was assessed by comparison to M. pneumoniae 
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(strain M129) and U. parvum serovar 3 (strain AF222894).  No significant hits to any 
of the genes in the M. hominis pan-genome were identified, suggesting that M. hominis 
is a distant relative to these Mycoplasma species, sharing little sequence similarity in 
the coding genes.  This is concordant with Mycoplasma species phylogeny based on 
16S rRNA sequences [6].  
To determine the suitability of the proposed genes for the seven gene mMLST 
schemes, sequences were compared before and after short-term passage in two 
M. hominis strains.  Genes found to be genetically variable after short-term passage 
would be unsuitable candidates for an mMLST scheme.  From the set of 48 genes 
required to replicate whole genome sequence SNP phylogeny, one gene (GENE-220; 
pcrA) was found to have acquired mutations and was therefore not suitable for use in 
the mMLST schemes.  As genomic stability was only assessed in two M. hominis 
strains, it is likely that further instability would be identified upon assessment of a 
larger number of strains.  Sequence heterogeneity has been well documented for 
M. hominis [362] and therefore it is essential that the stability of the genes chosen for 
the three MLST schemes is further assessed. 
The three mMLST schemes proposed in this chapter require further 
development to generate PCR-based schemes that can be widely utilised for the 
characterisation of M. hominis.  Areas of the genes containing regions of variation 
responsible for the topology of the phylogenetic trees need to be identified; these can 
then be used as amplicons for a PCR-based method whilst retaining the conserved 
phylogeny.  In addition, the ability to perform mMLST directly on clinical specimens 
would by-pass the need for specialised culture methodologies, allowing for a more 
rapid characterisation of M. hominis. 
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5.3.6 Recombination in Mycoplasma hominis 
Recombination has previously been examined for M. hominis; however, only 
a limited number of genes were examined [362].  Nevertheless, analysis revealed inter- 
and intra-genic recombination in M. hominis and recombination was proposed as a 
method for the high intra-species variability of M. hominis.  In addition, examination 
of M. pneumoniae, M. genitalium, M. pulmonis and U. urealyticum indicated a large 
number of repeats within the genomes of these organisms suggest the existence of a 
large potential for recombination [246].  In concordance with this, a large number of 
predicted recombination sites were identified in this chapter.  This could be due to the 
diversity of the isolates from the reference used for mapping. The reference is on average 
8500 SNPs from the isolates and each isolate is on average 9100 SNPs from each other 
isolate, indicating a large degree of diversity. This is, in part, due to low availability 
of previously sequenced M. hominis reference genomes. Therefore, when more fully 
sequenced and assembled genomes will become available the true extent of 
recombination in the species may be unravelled. Currently, with a potential presence 
of a large number of recombinations, any method that relies on phylogenetic tree has 
limitation. In this case, the phylogenetic tree is influenced to a greater extent by 
horizontal transfer of genetic material, rather than vertical inheritance from the parent 
strain. 
5.3.7 Consequences of the genetic variability of Mycoplasma hominis 
The ability of M. hominis to evade the immune system and persist in the human 
host may be related to the highly variable nature of the M. hominis genome as observed 
in this chapter.  Genetic variation within genes studied in this chapter resulted in non-
synonymous changes within the amino acid sequence and therefore changes in 
resulting expressed protein, providing a mechanism by which M. hominis can evade 
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the host defences.  This could result in persistent infections and explain the 
carriage/commensal nature of M. hominis in humans.  Assessment of the pathogenic 
potential of M. hominis is complicated by the high degree of genomic and antigenic 
heterogeneity observed within the species.  Equally, as non-synonymous mutations in 
sequence is the basis for antibiotic resistance in many genes (for example, quinolone 
resistance determining regions of GyrA/B, ParC/E) [428], M. hominis may have an 
increased propensity to rapid development of antibiotic resistance mutations.   
5.4 Summary 
In this chapter, M. hominis has been characterised by the Vaa protein, SBT, 
whole genome sequence analysis and a novel method for developing MLST schemes.  
SBT phylogenetic topological analysis using either concatenated multi-gene 
sequences or partial whole genome sequences may enable meaningful epidemiological 
and transmission studies and may assist in increasing understanding of the 
characterisation and molecular typing of M. hominis.  However, bioinformatics 
analysis has identified a minimal set of genes required to recapitulate the relationships 
observed in whole genome phylogeny constructed using SNP data.  This chapter has 
identified three sets of seven genes that could be used to construct an mMLST typing 
scheme.  The three mMLST schemes proposed in this chapter can be further developed 
for use in widely available PCR-based typing methods and ultimately MLST could be 
performed directly on clinical specimens where further information regarding 
potential strain transmission is warranted. 
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6.1 Introduction 
Typing of clinical isolates by molecular methods is of importance for the 
understanding of the epidemiology of M. pneumoniae infection and for analysis of 
endemic outbreaks. Initial molecular typing targeted the gene encoding the major 
surface protein (P1) of M. pneumoniae, enabling the separation of isolates into two 
types, type 1 and 2 [128, 129, 222]. Recent studies have identified an additional six 
variants by utilising the repetitive regions, RepMp2/3 and RepMp4 [292, 429]. Multi-
locus variable-number tandem-repeat (VNTR) analysis (MLVA) has also been used 
based on the variation in the copy number of tandem repeated sequences, called 
VNTRs, found at different loci across the genome. The variation of the copy number 
of these TRs depends on the isolate tested. Initially, 265 strains were grouped into 
twenty-six MLVA types, based on five VNTR loci (Mpn1, Mpn13-16) and an 
additional 18 novel types have since been reported [130, 132, 228]. However, locus 
Mpn1 is unstable in both clinical strains and in laboratory passages, and as most of the 
novel types came from variations in Mpn1 there is international consensus that this 
locus should be removed from the typing scheme [221].  
Multi-locus sequence typing has also previously been attempted for the 
molecular typing of M. pneumoniae. However, due to the homogeneity of the 
M. pneumoniae species, very little polymorphism was found in the housekeeping 
genes examined and it has been concluded that the use of an MLST with housekeeping 
and structural genes is not useful for molecular typing [131]. In this study only three 
housekeeping genes were thoroughly examined for polymorphisms across 30 isolates 
of either P1 type 1, 2, or a variant strain. The other genes selected for analysis were 
examined against a single representative strain from each subtype.  
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This chapter describes an MLST scheme that has been developed with a high 
discriminatory ability to differentiate M. pneumoniae isolates based on sequence 
polymorphisms within eight housekeeping genes, improving on all published typing 
methods for M. pneumoniae. 
6.2 Results 
6.2.1 Determining MLST loci 
Housekeeping genes that are considered to be conserved in other bacterial 
species under a low rate of selective pressure were chosen for analysis (Table 6.1). 
Locus sequences were selected using the available genome sequences of 
M. pneumoniae FH and M129 (FH: NC_017504.1; M129: NC_000912.1) and 
available whole genome sequences of 35 clinical isolates. Ten genes were included 
for initial analysis: recA protein (recA), inorganic phosphatase (ppa), 
phosphoglycerate mutase (pgm), DNA gyrase subunit B (gyrB), guanylate kinase 
(gmk), serine hydroxymethyltransferase (glyA), elongation factor P (efp), ATP 
synthase subunit α (atpA), carbamate kinase (arcC), and adenylate kinase (adk). Locus 
regions for PCR amplification were selected based on areas of the coding sequence 
(CDS) containing nucleotide polymorphisms. Initial examination of ten gene targets 
in the two type strains M129 and FH and genomic sequence from 35 M. pneumoniae 
clinical isolates identified variation, SNP differences, in eight out of the ten genes.  
Genes recA and efp were 100% conserved in all sequences analysed and were therefore 
excluded from the MLST scheme. 
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Table 6.1. MLST loci used in established bacterial MLST schemes also present in 
M. pneumoniae. 
Bacterial Species MLST Loci a 
 reca ppa pgm gyrb gmk glya efp atpa arcc adk 
Bacillus cereus           
Chlamydia trachomatis           
Campylobacter jejuni           
Escherichia coli           
Enterococcus faecium           
Haemophilus influenzae           
Helicobacter pylori           
Moraxella catarrhalis           
Neisseria meningitidis           
Staphylococcus aureus           
Staphylococcus epidermidis           
Streptococcus suis           
Vibrio vulnificus           
Yersinia pseudotuberculosis           
a MLST loci were chosen based on the frequency of use in other bacterial MLST schemes  (http://www.mlst.net/) 
and the presence of the gene in the published M129 and FH whole genomes. 
 
6.2.2 MLST of M. pneumoniae 
Genomic sequence analysis and additional PCR and sequencing (described in 
section 2.4.5) of a further 20 clinical isolates of all eight targets resolved a total of 12 
STs (Table 6.2). The discriminatory typing ability for M. pneumoniae was 0.21 ST per 
isolate. The number of SNPs observed within each individual locus and the percentage 
of polymorphic sites are shown in Table 6.3, with pgm having the highest number of 
SNPs (10 SNPs) and the highest percentage of polymorphic sites corrected for 
sequence length (0.93%). The number of alleles per locus ranged from two (ppa, gyrB, 
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gmk and arc) to four (atpA) (Table 6.3). Examination of the Hunter-Gaston DI (which 
ranges from 0.0 = no diversity to 1.0 = complete diversity) indicated moderate 
diversity between the STs (DI: 0.784; 95% CI: 0.716-0.852) with the greatest 
individual diversity shown in pgm (DI: 0.620; 95% CI: 0.566-0.674) and the lowest 
diversity in arcC (DI: 0.069; 95% CI: 0.000-0.158).  
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Table 6.2. Mycoplasma pneumoniae strains, their sequence type (ST) and allelic 
profile, and their MLVA and P1 types.  
Strains isolated from the same patient are indicated by grey shading. 
Strain ST Allelic profile MLVA 
type 
P1 
type 
  ppa pgm gyrB gmk glyA atpA arcC adk   
M129 (ATCC 
29342) 
1 1 2 1 1 1 3 2 1 4572 1 
MPN135 1 1 2 1 1 1 3 2 1 4572 V1 
FH (ATCC 
15531) 
2 2 3 2 2 2 4 1 1 3662 2 
MPN007 2 2 3 2 2 2 4 1 1 NTa 2 
MPN021 2 2 3 2 2 2 4 1 1 3662 NTa 
MPN022 2 2 3 2 2 2 4 1 1 3562 2c 
MPN023 2 2 3 2 2 2 4 1 1 3662 2 
MPN101 2 2 3 2 2 2 4 1 1 3562 2 
MPN102 2 2 3 2 2 2 4 1 1 3662 2 
MPN107 2 2 3 2 2 2 4 1 1 3562 2 
MPN114 2 2 3 2 2 2 4 1 1 3662 NTa 
MPN117 2 2 3 2 2 2 4 1 1 3562 2 
MPN119 2 2 3 2 2 2 4 1 1 3562 2 
MPN121 2 2 3 2 2 2 4 1 1 3662 2c 
MPN123 2 2 3 2 2 2 4 1 1 3662 2 
MPN125 2 2 3 2 2 2 4 1 1 3562 2 
MPN126 2 2 3 2 2 2 4 1 1 3662 2 
MPN128 2 2 3 2 2 2 4 1 1 3662 NTa 
MPN132 2 2 3 2 2 2 4 1 1 3562 2 
MPN133 2 2 3 2 2 2 4 1 1 3662 2 
MPN134 2 2 3 2 2 2 4 1 1 3662 2 
MPN005 3 1 2 1 1 1 3 1 1 4572 1 
MPN006 3 1 2 1 1 1 3 1 1 4572 NTa 
MPN013 3 1 2 1 1 1 3 1 1 4572 1 
MPN014 3 1 2 1 1 1 3 1 1 4572 1 
MPN015 3 1 2 1 1 1 3 1 1 4572 1 
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Strain ST Allelic profile MLVA 
type 
P1 
type 
  ppa pgm gyrB gmk glyA atpA arcC adk   
MPN016 3 1 2 1 1 1 3 1 1 4572 1 
MPN017 3 1 2 1 1 1 3 1 1 4572 1 
MPN020 3 1 2 1 1 1 3 1 1 4572 NTa 
MPN103 3 1 2 1 1 1 3 1 1 4572 1 
MPN105 3 1 2 1 1 1 3 1 1 4572 1 
MPN108 3 1 2 1 1 1 3 1 1 4572 1 
MPN109 3 1 2 1 1 1 3 1 1 4572 NTa 
MPN113 3 1 2 1 1 1 3 1 1 4572 1 
MPN116 3 1 2 1 1 1 3 1 1 4572 1 
MPN118 3 1 2 1 1 1 3 1 1 4572 1 
MPN120 3 1 2 1 1 1 3 1 1 4572 1 
MPN122 3 1 2 1 1 1 3 1 1 4572 1 
MPN136 3 1 2 1 1 1 3 1 1 4572 1 
MPN004 4 2 1 2 2 2 4 1 1 3662 2 
MPN104 4 2 1 2 2 2 4 1 1 3662 2 
MPN106 4 2 1 2 2 2 4 1 1 3662 2 
MPN110 4 2 1 2 2 2 4 1 1 3662 2 
MPN124 4 2 1 2 2 2 4 1 1 3662 2 
MPN131 4 2 1 2 2 2 4 1 1 3662 2 
MPN111 5 1 2 1 1 1 2 1 1 4572 1 
MPN011 6 2 3 2 2 2 1 1 1 3662 2 
MPN112 6 2 3 2 2 2 1 1 1 3662 2 
MPN127 7 2 3 2 2 2 4 1 2 3662 2 
MPN129 8 2 3 2 2 2 4 1 3 3662 2 
MPN130 9 1 2 1 1 1 3 1 4 4572 1 
MPN008 10 2 1 2 2 2 4 1 2 3662 2 
MPN018 10 2 1 2 2 2 4 1 2 3662 2 
MPN010 11 1 2 1 1 3 3 1 1 3662 1 
MPN003 11 1 2 1 1 3 3 1 1 4572 1 
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Strain ST Allelic profile MLVA 
type 
P1 
type 
  ppa pgm gyrB gmk glyA atpA arcC adk   
MPN012 11 1 2 1 1 3 3 1 1 3562 NTa 
MPN019 12 2 2 1 1 3 3 1 4 4572 1 
aNT M. pneumoniae not classified by MLVA/P1 typing 
 
 
Table 6.3. Variability of the M. pnueomoniae MLST loci 
Name No. of 
alleles 
No. 
polymorphic 
sites 
% 
polymorphic 
sites 
Average G + 
C content 
(%) 
Hunter-Gaston 
Diversity Index 
a 
95% 
Confidence 
Interval 
ppa 2 1 0.39 38.4 0.501 0.470-0.533 
pgm 3 10 0.93 43.7 0.620 0.566-0.674 
gyrB 2 2 0.47 39.9 0.505 0.482-0.528 
gmk 2 1 0.25 40.1 0.505 0.482-0.528 
glyA 3 2 0.30 45.6 0.560 0.493-0.627 
atpA 4 3 0.38 44.8 0.557 0.502-0.612 
arcC 2 1 0.18 45.5 0.069 0.000-0.158 
adk 4 3 0.63 47.5 0.199 0.063-0.335 
a Hunter-Gaston diversity index (DI, ranges from 0.0 indicates no diversity to 1.0 indicates complete 
diversity) 
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6.2.3 Phylogenetic analysis of M. pneumoniae sequence types 
The construction of Neighbour-joining and maximum-likelihood trees from 
concatenated sequences of the eight loci for the 57 M. pneumoniae isolates (Figure 
6.1; method described in section 2.4.8.1) illustrated two genetically distinct clusters 
which were confirmed by eBURST examination of relatedness (Figure 6.2; section 
2.4.8.3). The two clusters, clonal complexes (CC) designated CC1 and CC2, contained 
ST1, ST3, ST5, ST9 and ST11, and ST2, ST4, ST6, ST7, ST8 and ST10, respectively. 
ST12 was located distal to the two main clusters; however, phylogenetic analysis 
revealed closer positioning to CC1. Neighbour-joining and maximum-likelihood trees 
were also constructed for the eight loci individually (Figure 6.3-Figure 6.10) and 
topology of both neighbour-joining and maximum-likelihood trees was consistent for 
all loci and concatenated sequences, confirming segregation into two distinct clusters. 
Five homogenous strains (MPN13-MPN17) originating from nose and throat 
swabs from the same patient with Stevens-Johnson syndrome had identical STs (ST3). 
Additionally, two clinical isolates (MPN104 and MPN106) originating from separate 
sputum samples from a patient with bronchopneumonia taken four days apart also had 
identical STs (ST4). This indicates a single, clonal population responsible for infection 
in these cases. Phylogenetic positions of individual strains based on concatenated 
sequences of the eight MLST loci are shown in Figure 6.11.
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Figure 6.1. Phylogenetic trees based on concatenated sequences of eight MLST 
loci.  
Phylogenetic trees were constructed based on concatenated sequences of eight 
housekeeping loci for 12 unique STs using Maximum-likelihood (A) and Neighbour-
joining (B) methods. Bootstrap support values of over 70% are shown. STs are 
indicated by differential shading. 
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Figure 6.2. Analysis of M. pneumoniae using eBURST. 
eBURST version 3 was used to analyse the 12 unique STs resolved for all 57 
M. pneumoniae isolates. Two main clonal complexes (CC) were defined. The size of 
each dot is proportional to the number of isolates included in the analysis for each ST.
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Figure 6.3. Phylogenetic trees based on the adenylate kinase locus for each 
individual strain.  
Phylogentic trees were constructed based on the sequence of the adk locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.4. Phylogenetic trees based on the carbamate kinase locus for each 
individual strain.  
Phylogentic trees were constructed based on the sequence of the arcC locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.5. Phylogenetic trees based on the ATP synthase subunit α locus for each 
individual strain.  
Phylogentic trees were constructed based on the sequence of the atpA locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.6. Phylogenetic trees based on the serine hydroxymethlytransferase 
locus for each individual strain.  
Phylogentic trees were constructed based on the sequence of the glyA locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.7. Phylogenetic trees based on the DNA gyrase subunit B locus for each 
individual strain.  
Phylogentic trees were constructed based on the sequence of the gyrB locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.8. Phylogenetic trees based on the guanylate kinase locus for each 
individual strain.  
Phylogenetic trees were constructed based on the sequence of the gmk locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.9 Phylogenetic trees based on the phosphoglycerate mutase locus for 
each individual strain.  
Phylogenetic trees were constructed based on the sequence of the pgm locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.10. Phylogenetic trees based on the inorganic phosphatase locus for each 
individual strain.  
Phylogenetic trees were constructed based on the sequence of the ppa locus for all 57 
M. pneumoniae isolates using Maximum-likelihood (A) and Neighbour-joining (B) 
methods. Bootstrap support values of over 70% are shown. 
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Figure 6.11. Phylogenetic trees based on concatenated sequences of eight MLST 
loci showing individual M. pneumoniae strain position.  
Phylogenetic trees were constructed based on concatenated sequences of eight 
housekeeping loci for 12 unique STs using Maximum-likelihood (A) and Neighbour-
joining (B) methods. Individual strains and STs can be identified in the traditional 
rectangular branch style. Bootstrap support values of over 70% are shown. 
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6.2.4 Determination of synonymous sequence changes in MLST loci 
The possibility of synonymous sequence changes (indicating a pressure to 
conserve amino acid sequence and protein structure) was investigated by comparing 
predicted translated sequences for each locus. Analysis of deduced amino acid 
sequences of the eight loci for the 57 strains indicated that both synonymous and non-
synonymous SNPs occurred, of which approximately 44% resulted in an amino acid 
change. Non-synonymous SNPs are highlighted in Figure 6.12. Amino acid sequences 
for ArcC, Gmk and GyrB yielded identical sequences for all ATs, numbering at two 
ATs for each locus. In comparison, Pgm analysis resulted in the largest number of 
non-synonymous changes in amino acid sequence, with four changes in the sequence 
between three ATs. 
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Figure 6.12. Alignments of amino acid sequences of each allelic type at each of 
the eight MLST loci.  
Amino acid sequence alignments were generated for each of the eight loci based on 
nucleotide sequence of each allelic type. Non-synonymous changes in amino acid 
sequence are highlighted in yellow. * (asterix) indicates positions which have a single, 
fully conserved residue; : (colon) indicates conservation between groups of strongly 
similar properties – scoring > 0.5 in the Gonnet PAM 250 matrix; . (period) indicates 
conservation between groups of weakly similar properties – scoring < 0.5 in the 
Gonnet PAM 250 matrix; blank space indicates no similarity between amino acid 
residues. 
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6.2.5 Application of MLST scheme to published genomic sequences of 
M. pneumoniae 
The MLST scheme was applied to the published complete genome sequences 
of M. pneumoniae available from NCBI: 309 (NC_016807.1), M129-B7 
(CP003913.2), M29 (NZ_CP008895.1), PO1 (GCA_000319655.1), PI 1428 
(GCA_000319675.1) and 19294 (GCA_000387745.1). These strains were determined 
as ST2, ST1, ST3, ST2, ST1 and ST7, respectively. 
6.2.6 Assessment of MLST loci stability 
The stability of each MLST locus was assessed in ten M. pneumoniae isolates. 
Isolates were re-typed following short-term passage (ten sequential sub-culture 
passages) in liquid medium. All loci were found to be completely stable, with no new 
SNPs detected in the short-term passage strains compared to the original isolates.  
6.2.7 Genomic sequence analysis 
Phylogenetic analysis of the whole genome sequence (method described in 
section 2.6.8.2) of 41 clinical M. pneumoniae isolates and the available published 
whole genomes sequences of eight additional strains revealed two distinct genomic 
clades (GC), GC1 and GC2, corresponding to P1 type 1 and type 2 , respectively 
(Figure 6.13).  There was no strong clustering observed associated with the year when 
the strains were collected, the patient’s age, sample origin or the patient’s symptoms. 
This also includes non-exact clustering by STs; however this is not unexpected due to 
the high genome similarity and low clonality within the data set. Nevertheless, 
excellent parity was found in the phylogeny of both whole genome and concatenated 
MLST sequences, with all strains co-locating to the corresponding CC and GC. 
232 
 
Chapter 6 – Development of a multi-locus sequence typing scheme for the molecular 
typing of Mycoplasma pneumoniae 
 
Alignment of genomic sequence from 35 clinical isolates to M129 revealed 
two general areas of differences between GC1 and GC2 (Figure 6.14; section 2.6.8.2). 
The first area in which similarity is reduced to M129 is between 150,000-200,000 bp, 
where strains belonging to GC2 contain divergent sequences or the sequence is absent 
and strains belonging to GC1 contain sequences similar/identical to M129. The second 
area is around 550,000 bp., where the similarity between the two genomic clades is 
reduced.  
Three regions of SNPs were predicted to have arisen by homologous 
recombination in the chromosomes of the 35 clinical M. pneumoniae isolates (Figure 
6.15); one of which distinguished GC1 from GC2; and the other two which occur 
within GC1. Area one was predicted to occur in all strains in GC1 at 169,233-
169,591 bp (M129 numbering) in a gene encoding a hypothetical protein (MPN130 
[C09_orf140o]). Area two was predicted in ten strains within GC1 and occurs in an 
inter-genic region (position 570,767-570,790 bp in M129). Both these predicted 
recombination regions correspond to drops in similarity observed in the alignment of 
the strains to M129 (Figure 6.14). Area three is predicted in a single strain, MPN113, 
and occurs at position 322,651-322,692 bp (M129 numbering) in an inter-genic region. 
Following the removal of predicted areas of recombination, the two distinct genetic 
clades could still be identified (Figure 6.15). 
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Figure 6.13. Phylogenetic tree based on whole genome alignments of 49 
M. pneumoniae genomic sequences.  
Phylogenetic tree was constructed based on whole genome alignments of 41 clinical 
M. pneumoniae strains and the eight available strains on NCBI using the Neighbour-
joining method. 
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Figure 6.14. Overall sequence identity of the whole genome sequences of 35 
M. pneumoniae clinical strains to the reference M129.  
Strains were aligned to M129 (black) and G+C content is indicated in the middle. 
Strains belonging to GC1 are displayed in red and strains belonging to GC2 are 
displays in blue. Areas of differences to M129 are indicated by white shading in the 
strains. Each strain is represented by a separate circle. Genes are annotated based on 
M129. Location in the reference genome is indicated by numeration on the inside of 
the ring. GC content in the reference genome is indicated by the black bar graphs 
between the genomic coordinates and the coloured rings (bars pointing toward the 
outside of the circle indicate high GC content). 
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Figure 6.15. Prediction 
of recombination in the 
M. pneumoniae isolates 
chromosomes.  
Regions of variation in 
the genomes of the 35 
clinical M. pneumoniae 
isolates and the type 
strain M129 which are 
predicted to have arisen 
by homologous 
recombination are shown 
in the panel on the right. 
Red blocks indicated 
recombination predicted 
to have occurred on 
internal nodes, blue 
indicates taxa-specific 
recombination. Isolates 
are ordered according to 
the phylogenetic tree 
displayed on the left. The 
track along the top of the 
figure displays the M129 
chromosome and 
annotation, where protein 
coding sequences (CDS) 
are indicated in light blue. 
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6.2.8 Comparison to MLVA and P1 typing methods 
The results have shown that MLST ST was related to P1 type (determined as 
described in section 2.4.4; Table 6.2), with the two most common STs, ST2 and ST3, 
containing strains that were P1 type 2 and P1 type 1, respectively. The MLST scheme 
was also comparable to MLVA typing (determined as described in section 2.4.7). The 
two major clusters observed, CC1 and CC2, could be directly linked to MLVA types; 
CC1 contained MLVA type 4572 whereas CC2 contained MLVA types 3662 and 
3562. Each ST contained only one MLVA type with the exception of ST2 which 
contained both 3662 and 3562, and ST11 which contained 4572, 3662 and 3562 (Table 
6.2). Distribution of MLVA type, P1 type and MLST ST can be observed in Figure 
6.16, indicating that P1 type 1, MLST ST2 and MLVA types 3662 and 4572 were the 
most frequently occurring in the isolates tested.  
For the M. pneumoniae isolates examined, MLST was deemed to be more 
discriminatory than both MLVA and P1 typing with the types per isolate being 0.21, 
0.05 and 0.07, respectively. This was confirmed by examination of Hunter-Gaston DI, 
indicating larger discriminatory ability for the MLST scheme (DI: 0.784; 95% CI: 
0.716-0.852) than the current MLVA scheme (DI: 0.633; 95% CI: 0.583-0.683) and 
P1 typing (DI: 0.567; 95% CI: 0.510-0.625). 
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Figure 6.16. Distribution of MLVA, P1 type and MLST ST for 57 M. pneumoniae 
isolates.  
The 57 isolates were separated independently for MLVA type, P1 type and MLST 
type (each group defined by line). 
 
6.2.9 Molecular typing and epidemiology in the UK 
There was no obvious link between the MLST ST and the year when the strains 
were collected, the patient’s age and the sample origin; however, limited numbers of 
strains were available per year and for some years there were no strains. Indeed, 
multiple STs can be observed in a single year (Table 6.2). Typing data for strains were 
grouped into four-yearly intervals, representing the epidemic cycles of M. pneumoniae 
observed in the UK. Multiple MLST, MLVA and P1 types were observed in each four-
yearly interval (Figure 6.17 - Figure 6.19); however a predominance of P1 type 1 can 
be seen for all intervals except 1981-1984 where equal numbers of P1 type 1 and type 
2 strains were observed. Due to the low sample number in some four-yearly intervals 
and limited typing data, the variation in P1 types observed is likely to be an 
underestimate of the actual M. pneumoniae population present. 
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Figure 6.17. Distribution of MLST sequence types for 57 M. pneumoniae clinical 
isolates in the four-yearly epidemic cycles observed in the UK. 
 
 
 
Figure 6.18. Distribution of MLVA types in positive M. pneumoniae clinical 
isolates collated into the four-yearly epidemic cycles observed in the UK.  
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Figure 6.19. Distribution of P1 type in four-yearly epidemic cycles observed in 
the UK for positive M. pneumoniae clinical isolates. 
 
6.2.10 Online database 
A M. pneumoniae MLST online database has been created for both MLST allele 
and profile definitions and isolate data [297]; website 
http://pubmlst.org/mpneumoniae.  This website combines two databases powered by 
the BIGSdb genomics platform [430]; the sequence definition database contains allele 
sequences and MLST profile definitions described in this chapter, whereas the isolate 
database contains provenance and epidemiological information. All 57 
M. pneumoniae isolates included in this chapter have been added to the isolate 
database. 
6.3 Discussion 
MLST has been used to genotype several species of bacteria, including several 
mycoplasma species; M. agalactiae, M. bovis and M. hyorhinis [422, 431, 432]. This 
chapter has described the results of the successful development of a novel 
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M. pneumoniae MLST scheme to allow the characterisation of clinical isolates. This 
scheme was successfully used to discriminate between 55 clinical isolates of 
M. pneumoniae from respiratory and extra-pulmonary infection sites, the two type 
strains M129 and FH, and six additional strains with genomes published on NCBI. 
6.3.1 Analysis of the MLST loci 
Eight housekeeping genes were identified as suitable targets for the scheme 
and these were used to genotype M. pneumoniae isolates by either PCR followed by 
sequencing or whole genome sequence analysis.  
gyrB contains a QRDR with documented in vitro mutations at amino acid 
positions 443, 464 and 483. Clinical use of quinolones may increase selective pressure 
in vivo resulting in a high mutation rate [289]. Nevertheless, the gyrB locus sequence 
amplified in this MLST scheme is in a different region of the gene from the QRDR 
and is therefore considered a suitable MLST target.  
The stability of the eight loci was evaluated in vitro and was confirmed before 
and after ten repeated passages of ten strains in liquid medium. However, stability over 
a larger number of passages in liquid medium and evaluation of stability using in vitro 
tissue culture was not assessed.   
6.3.2 Improved discrimination between M. pneumoniae isolates in comparison 
to MLVA and P1 typing 
The discriminatory power of this MLST scheme with the eight loci was 0.784 
for the collection of 57 isolates. In comparison, the Hunter-Gaston DI of the P1-typing 
method for the 57 isolates was 0.567 and the DI of the MLVA scheme was 0.633.  
This MLST scheme was therefore more discriminatory for the isolates tested. It has 
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previously been shown that the established MLVA method is more discriminatory 
than P1 typing [132], which has been confirmed in this study.  
The allelic diversity of each of the MLST loci varied significantly at each 
locus, with the pgm, glyA, atpA, gyrB, gmk and ppa loci being more discriminatory 
than the adk and arcC loci. The association of this set of markers with variable Hunter-
Gaston DIs makes this MLST, in theory, more optimal for epidemiological studies 
than other existing methodologies. 
6.3.3 Analysis of M. pneumoniae infection within an individual patient 
Analysis of M. pneumoniae infection at an individual patient level was possible 
using this scheme. Multiple clinical isolates were available from two of 50 patients: 
five from a patient with Stevens-Johnson syndrome (MPN013-MPN017), and two 
from a patient with bronchopneumonia clinical specimens taken four days apart. In 
both cases the MLST ST, MLVA type and P1 type remained the same, indicating a 
single clonal isolate was responsible for infection. Additionally, genomic sequences 
of the strains from a patient with bronchopneumonia co-locate phylogenetically. 
Recurring or re-infection of M. pneumoniae could be determined using this 
scheme. Recurring infection would have the same ST as the original infection whereas 
re-infection with M. pneumoniae would likely be a different ST. Genetic MLST 
instability in isolates could occur but this was not seen over ten passages in this study. 
6.3.4 Population modelling using MLST sequence types 
The eBURST analysis illustrates the relationship of STs on the basis on the 
number of MLST loci that differ between two STs. Analysis of this population 
modelling indicates that the two clusters, CC1 and CC2, differed by more than one 
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locus, but within each cluster the STs did not differ by more than one locus. Within a 
cluster, this highlights the homogenous nature of the M. pneumoniae species, although 
a definitive split can be observed between the two clusters in both MLST ST and 
MLVA type. A possible divergent clade with ST12 from CC1 is also apparent but 
more isolates would need to be typed by this method to confirm this observation. 
Few typing methods have previously been able to detect significant differences 
between strains, including one previous attempt to subtype M. pneumoniae by MLST 
with housekeeping and structural genes [129, 131, 292]. The previous MLST was 
determined to be not sufficiently discriminatory to be used for epidemiological 
purposes. However, results for the MLST scheme presented in this chapter illustrates 
a scheme that is able to discriminate between M. pneumoniae isolates, resulting in two 
genetically distinct clusters, indicating significant differences between strains. 
6.3.5 Genomic sequence comparison 
Whole genome sequencing has greatly facilitated the understanding of 
M. pneumoniae and currently there are nineteen distinct M. pneumoniae strains 
completely sequenced, excluding M129-B7 which is a chimera sequence generated by 
combining the re-sequenced M129 genome (by next generation sequencing) and the 
first Sanger-based M129 genome. The genome of the GC1 strain, M129, was the first 
M. pneumoniae genome sequenced and was reported in 1996 and subsequently re-
annotated in 2000 as having 816,394 bp, 730 genes, and an average GC content of 
40% [16, 433]. The genome sequence of the GC2 strains, FH and 309 were completed 
using next generation sequencing methods [434, 435]. An additional strain, M29 has 
also been sequenced but at this time has not yet been annotated. Preliminary 
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comparison of the three genomes M129, FH and 309 indicated that they are genetically 
very similar, except for variation in a 6-kb insertion region coding lipoproteins [435]. 
A comparative genomic study of 15 M. pneumoniae genomes indicated that 
SNP and indel variants occur between type 1 and type 2 strains but that overall there 
was a high degree of sequence homology between the strains [17].  Overall genomes 
were described as being 99->99% identical with less than 0.1% difference between 
strains belonging to the subgroups (i.e. type 1 and type 2).  One distinct region was 
identified where sequence identity dropped to ~95% in type 2 strains in comparison to 
the type 1 strain M129 which corresponded with the p1 gene.  Additionally two 
subtype-specific insertions were observed; type 1-specific insertion at 557,178-
560,601 bp (M129 numbering) and a type 2-specific insertion at 713,023-713,984 bp 
(M129 numbering).  The type-1 specific insertion corresponds with the reduction in 
sequence identity observed between the 35 M. pneumoniae genomes described in this 
chapter along with positioning next to the predicted recombination region Area two.  
In comparison, the type 2-specific insertion observed by Xiao et al. [17] was not 
identified in the GC2 strains examined in this chapter.  This type 2 insertion event was 
initially only described in strain 309 [436] but it was also found in all sequenced type 
2 strains and FH by Xiao et al. [17].  It was therefore proposed that this insertion was 
a signature of type 2 strains rather than a unique feature of strain 309 but data in this 
chapter suggests that this is not the case.  The presence of two different phylogenetic 
lineages observed by Xiao et al. [17] supports the findings in this chapter and confirms 
that clade-specific variation occurs.  
Analysis of the 15 M. pneumoniae strains, performed by Xiao et al. revealed 
182 genes with no variants (using M129 as a reference), including the genes recA and 
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efp [17], which were excluded from the MLST scheme in this chapter due to 100% 
sequence identity.  Additionally, all other MLST targets were found to contain 
variants, supporting the use of these gene loci in an MLST scheme for M. pneumoniae. 
Comparison between genomic sequence analysis after the removal of 
predicated areas of recombination and phylogenetic analysis of concatenated MLST 
sequences showed similar topology and the same distinct genetic clustering.  This 
indicates that this MLST scheme is representative of the genome and confirms 
M. pneumoniae can be subdivided into two distinct genetic lineages.  
Strains belonging to GC1 and GC2 appear to be clonal as seen for some other 
bacterial species such as Mycobacterium tuberculosis [437].  It is thought that strains 
of M. pneumoniae may have only recently diverged, despite geographical separation, 
as the differences between type 1 and type 2 strains are concentrated to specific areas 
of the genome, rather than being evenly distributed across the genome.  It is thought 
that this may suggest the existence of positive selective pressure for particular variants, 
as might be expected for genes encoding proteins that interact with host cells, such as 
the P1 adhesin [17].  In comparison, it has been estimated based primarily on rRNA 
analysis that mycoplasmas are evolving more rapidly than most bacteria and that 
M. pneumoniae and closely related species are evolving more rapidly than most other 
mycoplasmas, suggesting a high mutation rate [15, 438].  Nevertheless, conservation 
of the majority of genes within the two subtypes, including the CARDS toxin gene, a 
major virulence factor, indicates a slow rate of evolution [17]. 
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6.3.6 Clinical relevance and use in epidemiology 
Typing of clinical M. pneumoniae isolates is becoming increasingly important 
due to the changing epidemiology of M. pneumoniae infections and the increase in 
macrolide-resistant strains [439, 440].  This scheme provides a more discriminatory 
method than both the MLVA and P1 typing methods currently in use, allowing further 
and more detailed analysis of observed epidemic peaks of M. pneumoniae infection. 
Community outbreaks of pneumonia caused by M. pneumoniae have been 
described worldwide [27, 441, 442], and it would be interesting to evaluate this MLST 
scheme in such epidemic situations.  The level of discrimination of this typing method 
and usefulness in epidemic analysis chould be confirmed by comparing outbreak-
related strains to a set of control strains that were isolated from a similar time period 
and geographical area but that are not epidemiologically related.  
More severe or adverse infections with M. pneumoniae are seen in some 
patients.  The reason for this is not clear however, it can be postulated that this is due 
to specific microbe pathogenicity (identified through genetic markers) or variance in 
host susceptibility.  This method could assist in determining if this is a strain specific 
phenomenon.  
One advantage of MLST is that it is PCR based and does not require the growth 
of bacteria, which can be a lengthy process for M. pneumoniae, and it does not limit 
investigation through the requirement of specialist methodology.  However, there is a 
large amount of sequencing required for this method which can be laborious and 
expensive; therefore, adaptation for wide-spread use directly on clinical specimens 
would be beneficial. 
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6.3.7 Review of current molecular typing methods for M. pneumoniae 
Traditionally, molecular typing is used to characterise epidemic outbreaks of 
M. pneumoniae; however it is generally considered that molecular typing of 
M. pneumoniae is hampered by the fact that the pathogen is a genetically homologous 
species [128]. Despite this, molecular typing methods have been developed for this 
organism including: RFLP of the major surface adhesin P1 [128], MLVA [132], and 
MLST [424] and the SNaPshotTM mini-sequencing assay [443].  The mechanisms 
driving fluctuations in incidence of M. pneumoniae infections have not been defined.  
It has been postulated that shifts in the proportion of individual strains with specific 
P1 type or concurrent increased incidence of several strains may result in epidemics 
or immunity.  Additionally, it is believed that the genotype of M. pneumoniae may be 
changing, generating diverse genetic material in each epidemic with a study reporting 
the detection of polyclonal strains in a single epidemic [444].  
Speculation that a shift in P1 adhesin type may be the cause of epidemics has 
been disputed with evidence indicating the presence of multiple P1 adhesin types in 
observed increases of infection [132, 222, 444].  It was hypothesised that a decline in 
immunity or an increase of the immunologically naïve population may result in the 
four-year cycle of epidemic periods [134].  In other geographical locations, it has also 
been observed that multiple P1 types can be detected during outbreaks, and it has been 
suggested that although immunological pressure may favour shifts of P1 type, a co-
circulation of P1 types appears to be common [445].  
MLVA has been increasingly used internationally for strain characterisation 
and was documented to be more discriminatory for M. pneumoniae strains than P1 
typing, providing an additional level of classification for transmission studies. 
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However, reports of observed instability in the Mpn1 locus has called into question 
the reliability of the marker.  Additionally, inconsistency in nomenclature and 
identification of repeat regions has led to international standardisation of the MLVA 
with the removal of Mpn1 as a locus [221].  Analysis of the 2010/2011 epidemic in 
the UK revealed a total of 11 distinct MLVA types present using the original typing 
method [134] but reanalysis using international guidelines reduces the MLVA types 
detected to five distinct types.  The discriminatory power of the MLVA for 
characterisation of M. pneumoniae strains has been reduced with the removal of the 
Mpn1 locus, necessitating either the identification of new loci or alternative typing 
methods. 
Development of a SNaPshotTM mini-sequencing assay has resulted in 
identification of 9 SNP types [443].  This method is rapid and appears to have greater 
discriminatory ability than MLVA and P1 typing.  A direct comparison of MLST and 
SNaPshotTM mini-sequencing assay has not been undertaken and both methods may 
have similar discriminatory abilities.  However, MLST resulted in a larger number of 
defined sequence types. 
These typing methods are all PCR based and do not necessarily require the 
growth of bacteria.  P1 typing, MLVA and MLST do not limit investigation through 
the requirement of specialist methodology.  However, MLST can be laborious and 
expensive and with the cost of genomic sequencing reducing it is becoming a more 
attractive option for genetic analysis of strains.  Genomic sequencing may allow the 
concurrent identification of P1 type, MLVA profile and MLST sequence type directly 
from the genomic sequence as well as providing additional information such as the 
presence of antibiotic-resistance and toxin markers.  Improvements in sequencing 
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technology and the development of methodologies to produce longer sequence reads 
with an increase in the reliable sequence, means that the determination of repeated 
DNA is possible [446].  This is important for species such as Mycoplasma, in which 
large tracts of repeated sections within AT rich genomes are common.  For genetically 
homologous species such as M. pneumoniae, the use of genomic sequencing to analyse 
phylogeny inferred from single nucleotide polymorphism analysis will improve the 
ability to accurately segregate this species into distinct lineages allowing in depth 
epidemiology studies.  Due to the fastidious nature of M. pneumoniae and other human 
Mollicutes such as Mycoplasma amphoriforme the use of metagenomic approaches to 
identify pathogens in studies of human infections [447] will no doubt improve 
detection of infections caused by Mollicutes whilst obviating the need for expensive 
and laborious culture and typing methods and simultaneously providing additional 
data such as the detection of mutations known to confer resistance.  But, genomic 
sequencing is not currently widely available, therefore methodologies, like MLST, 
that can be widely accessible remain necessary for the characterisation of 
M. pneumoniae.  
6.4 Summary 
This chapter presents a robust MLST scheme that has proven discriminatory for 
M. pneumoniae, providing isolate characterisation and a higher level of discrimination 
than MLVA and P1-typing methods. In addition, phylogenetic analysis of both MLST 
STs and whole genome sequence data revealed two genetically distinct clusters. 
Crucially, this scheme for M. pneumoniae is also supported by a public web-based 
database (http://pubmlst.org/mpneumoniae). 
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This thesis has addressed and answered a diverse range of novel research 
questions with the central theme being bacteria from the genus Mycoplasma.  The first 
two results chapters described the validation of a multiplex real-time PCR assay that 
can simultaneously detect M. hominis, U. parvum and U. urealyticum in clinical 
specimens and the application of this assay as a tool for monitoring bacterial response 
to antibiotics.  The third results chapter examined the genetic heterogeneity of 
M. hominis through the development of MLST schemes using novel bioinformatics 
techniques.  Finally, this thesis addressed the molecular typing of M. pneumoniae with 
the development of an MLST scheme.  In addition, analysis of M. pneumoniae 
genomic sequence was also performed. 
7.1 Diagnosis of mycoplasma infections 
Mycoplasma hominis and M. pneumoniae have been linked to a diverse range 
of diseases with varying prevalence, severity and pathogenicity.  Effective and rapid 
diagnosis of infection is vital when considering particular patient cohorts, such as 
preterm neonates.  The detection of M. hominis in neonates is often coupled with the 
detection of Ureaplasma species; both are genital mycoplasmas that can cause disease 
in neonates.  Ureaplasma species have been strongly linked to an infectious cause of 
premature birth where the organism can additionally be transmitted from mother to 
child either in utero, as a result of ascending infection from the mother’s urogenital 
tract, or acquisition during birth. 
Culture is considered to be the reference standard for detection of M. hominis 
and Ureaplasma species; indeed culture is required to identify active infection.  
However, culture is expensive and requires specialised media and expertise that are 
not widely available outside of larger medical centres or mycoplasma research and 
reference laboratories.  In addition, upon specimen receipt, confirmed culture results 
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are usually only available after 2-5 days [3].  Diagnostic focus has shifted towards 
nucleic acid amplification and the development of PCR assays for rapid detection of 
mycoplasmas in clinical specimens.  The literature now describes multiple PCR assays 
for the detection of M. hominis and Ureaplasma species, most commonly associated 
with other urogenital pathogens forming STI and urethritis screening tests.  This thesis 
describes an assay specifically developed for detection of M. hominis and Ureaplasma 
species in neonatal respiratory samples (Chapter 3).  The notorious genetic 
heterogeneity of M. hominis has added challenges to developing reliable PCR targets 
for sensitive and specific diagnosis.  Many of the published PCR assays utilise the 16S 
rRNA of M. hominis as the target for detection.  Minimal genetic heterogeneity exists 
in this target but other targets, such as the gap gene, exhibit high levels of sequence 
intra-species heterogeneity and regions of recombination [315, 362].  The yidC target 
was used in this thesis.  The M. hominis strains examined in this thesis along with 
strains examined by Ferandon et al. [125] indicated that although intra-species 
heterogeneity is observed within the gene, this is at a much lower level than other 
utilised PCR targets and lies outside of the primer and probe binding sites utilised in 
the assay.  In order to improve the reliability of PCR assays for the detection of 
M. hominis, further robust targets need to be identified with low levels of intra-species 
heterogeneity.  Multiple genomic targets have been utilised for the detection of other 
bacterial species, such as Francisella tularensis, in order to enhance the specificity of 
diagnostic tests [448].  The use of multiple targets in a single assay for M. hominis 
detection may alleviate detection failure in clinical specimens and increase the 
specificity of PCR assays.   
The improvement of diagnostic techniques for mycoplasmas is beneficial to 
patients and public health.  As well as M. hominis, culture is a definitive method for 
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diagnosis of M. pneumoniae infection.  Culture is essential for the ongoing 
maintenance of a collection of clinical isolates which is critical for monitoring trends 
in epidemiology, antimicrobial resistance typing and for further characterisation of 
these species.  However, culture is slow and the recovery of isolates is highly variable 
and may be low, even in specialised laboratories and is therefore not practical for rapid 
detection of acute infection [449, 450].   
7.1.1 Importance of diagnosis in neonates and pregnancy 
Genital mycoplasmas as neonatal pathogens are becoming of increasing 
importance, with Ureaplasma species in particular having links with lung disease in 
neonates.  The rates of lung colonisation by Ureaplasma species has, on numerous 
occasions, been shown to be inversely proportional to gestational age [451, 452] and 
vertical transmission of Ureaplasma species from mother to baby has been reported 
from 18% to 88% [3].  The rate of M. hominis colonisation is lower than that for 
Ureaplasma species (Chapter 4); however, it has been reported that approximately 
30% of exposed infants are colonised with M. hominis [453].  It has been documented 
that in utero infection of the foetus is common, but neonates may also be colonised 
initially at the time of delivery [310].  Data from a cohort of 45 intubated neonates 
confirmed that neonates were statically more likely to be colonised with either 
Ureaplasma species or M. hominis when born earlier than 26 weeks gestation than 
those born closer to full term (Chapter 4).   
Due to the residence of these bacteria in the normal vaginal flora, controversies 
exist regarding their true role in pregnancy and therefore the need to screen for and 
treat these organisms.  There is growing evidence for the association and implication 
of Ureaplasma species and M. hominis in adverse pregnancy outcomes; suggesting a 
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role of cervicovaginal colonisation as well as amniotic fluid infection with both 
pathogens in adverse pregnancy outcomes [454].   
Given the large amount of evidence that links subclinical maternal infection 
with preterm labour, it has been postulated that the prophylactic use of antibiotics in 
pregnancy or adjunctive use of antibiotics for preterm labour should result in improved 
perinatal outcome.  The results of published studies addressing the issue of antibiotic 
intervention to prolong gestation vary.  In a recent review of 15 trials [455], the authors 
concluded that, despite eradication of bacterial vaginosis in pregnancy, antibiotic 
treatment did not reduce the risk of preterm delivery.  Meta-analysis of randomised 
clinical trials showed that treatment with macrolides and clindamycin during the 
second trimester of pregnancy was associated with a lower rate or preterm birth [456].  
In addition, further analysis confirmed that infection screening and treatment 
programs in pregnant women may reduce preterm birth and preterm low birth weights 
[457].  Experimental data in the rhesus monkey supports the use of antibiotic treatment 
of pregnant women, as it was shown that preterm birth can be delayed in this non-
human primate model by the administration of specific antibiotics such as 
azithromycin combined with anti-inflammatory agents.  Maternally administered 
azithromycin was shown to accumulate in the amniotic fluid and resulted in 
eradication of detectable U. parvum infection within four days.  Eradication of 
U. parvum from foetal tissues using this treatment also reduced foetal lung injury 
[184].  Diagnosis of maternal ureaplasma and mycoplasma infection would allow 
targeted antibiotic treatment of these infections, potentially reducing mother-to-infant 
transmission and adverse pregnancy outcomes.   
Accurate diagnosis of the causative agent of infection allows targeted 
treatment.  This reduces unnecessary and prolonged broad-spectrum antibiotic usage 
254 
 
Chapter 7 – General discussion 
 
and concurrent development of antibiotic resistance.  Limited data is available on the 
clinical and microbiological efficacy of antibiotics for treating clinically significant 
systemic infections caused by Ureaplasma species and M. hominis such as pneumonia, 
bacteraemia and meningitis in neonates, and what is known originates from reports of 
individual case studies.  Erythromycin has been the most commonly used antibiotic to 
treat Ureaplasma species infection in neonates but varying rates of organism 
eradication from the respiratory tract have been reported [3] and this antimicrobial 
agent is not effective against M. hominis.  Results presented in this thesis have shown 
successful clearance of Ureaplasma species from respiratory specimens collected 
from intubated neonates following clarithromycin treatment (Chapter 4).  Clindamycin 
has been used to successfully treat neonatal infections due to M. hominis [310].  
Tetracyclines have been used to successfully treat neonates with meningitis caused by 
M. hominis and Ureaplasma species, but they are rarely used due bone toxicity effects 
when given to infants.  Lower rates of M. hominis detection than Ureaplasma species 
in neonates could be due to their susceptibility to gentamicin (Chapter 4) compared to 
the intrinsically high MICs of gentamicin for Ureaplasma species [375].  Neonates 
presenting with respiratory symptoms or pneumonia are commonly given ampicillin 
and gentamicin as a first-line treatment option [458]; so, empiric treatment with 
gentamicin will theoretically affect M. hominis infection, potentially prior to 
subsequent isolation, detection and identification of the aetiology of infection.  
The use of antibiotics in premature neonates is often necessary and indeed it is 
common practice for antibiotics to be prescribed shortly after birth.  In the majority of 
very low birth rate infants, antibiotics are usually administered immediately after birth 
with the rationale that many babies have respiratory distress, which is difficult to 
distinguish from pneumonia [459].  Additionally, routine antibiotic treatment 
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(penicillin and gentamicin) is given to premature neonates due to the possibility of 
maternal infection-induced pre-term labour; Ureaplasma species have been 
documented to have a causal role in premature labour [310].  The prolonged use of 
antibiotics in neonates has been associated with an increased odds ratio of the 
development of NEC, an acute inflammatory disease of the gastrointestinal tract 
characterised by variable damage to the intestinal tract ranging from mucosal injury 
to full-thickness necrosis and perforation [460].  The pathophysiology of NEC is 
poorly understood but it is considered that a relationship between nutrition, the 
intestinal microbes, and the interaction of the host with these factors is likely to have 
a major role in the pathogenesis of the disease [459].  Treatment with antibiotics from 
birth can lead to a dysbiosis of the developing intestinal microflora of a neonate and 
is likely to contribute to the development of NEC [459].  Implications associated with 
antibiotic usage in premature neonates’ cements the need for improved and rapid 
diagnosis of bacterial infections to prevent unnecessary antibiotic usage and allow 
targeted treatment. 
7.2 Genetic characterisation of Mycoplasma hominis and Mycoplasma 
pneumoniae  
Beyond the use of molecular methods for detection of M. hominis and 
M. pneumoniae in clinical specimens, numerous molecular methods have been 
developed that exploit the limited genomic diversity of M. pneumoniae isolates in 
order to characterise isolates for epidemiological purposes, although no clear 
correlation of strain type with clinical presentation, disease severity, or patient 
outcome has been observed to date [450].   
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7.2.1 The usefulness of molecular typing for Mycoplasma epidemiology 
Localised outbreaks of M. pneumoniae have been frequently reported, especially 
in closed settings, and transmission between household contacts is known to occur 
[461-465].  The long incubation period of up to three weeks and prolonged shedding 
after infection allows outbreaks of M. pneumoniae to often go unnoticed and extend 
for long periods of time [11, 144, 461, 462].  In England and Wales, seasonal peaks of 
infection are detected from December to February each year with epidemics at 
approximately four-yearly intervals [146, 221].  Cyclical patterns are also seen in 
Denmark, Sweden, Norway, Finland, Korea and Japan [466-471].  Epidemic peaks 
have recently been attributed to minor variations in the duration of immunity at the 
population level [472].  A con-current increase in reported M. pneumoniae cases was 
documented in several European countries in 2011 [473] and, in England and Wales, 
the most recent increase has been noted in 2015 [220].  The recent global increase in 
macrolide resistance observed in cases of M. pneumoniae infection is of increasing 
concern and importance to the international community [474], making it all the more 
important to monitor the epidemiology of M. pneumoniae infection.   
Mycoplasma pneumoniae is considered a highly genetically conserved species, 
with genomic comparisons indicating >99% sequence similarity between strains [17].  
Nevertheless, methods have been developed to characterise M. pneumoniae strains 
based on genetic variation, allowing for the classification of M. pneumoniae for 
epidemiological purposes.  In addition to the well documented P1 and MLVA typing 
methods established for M. pneumoniae, this thesis has established a robust MLST 
scheme for M. pneumoniae with a higher discriminatory ability than both P1 typing 
and MLVA.  The use of whole genome sequencing aided the identification of areas 
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within the genome containing variation that could be targeted to achieve an MLST 
scheme with greater discriminatory power.   
Effective infection control is achieved through active surveillance of infection and 
recognition of burgeoning disease outbreaks in addition to preventative measures 
[475].  Molecular epidemiological investigations have become increasingly important 
in maintaining infection control and rely on methods that can assess the genetic 
relatedness between strains [475-477].  The main role of microbial molecular typing 
is to assess the relationships between microbial isolates.  Understanding clonal 
relatedness between bacterial strains is essential for the determination of the source 
and routes of infections, confirmation of outbreaks, trace cross-transmission of 
healthcare-associated pathogens, the recognition of virulent strains, and to evaluate 
the effectiveness of infection control measures [478].   
For large epidemiological studies, molecular typing appears to hold little value.  
Analysis of M. pneumomniae epidemics in 0, revealed multiple MLST, MLVA and 
P1 types present within epidemic cycles; however, a predominance of a particular P1 
type can be observed (Figure 6.19).  In addition, no obvious link was observed between 
molecular ST and the year when the strain was collected, the patient’s age, and the 
sample origin.  However, molecular typing within community and localised outbreaks 
has the ability to trace transmission and confirm the presence of an outbreak of 
infection; for example localised clusters of particular MLVA types have been 
observed in Hong Kong, China [479]. 
Population modelling of M. pneumoniae MLST STs revealed two clonal clusters 
(Figure 6.2) correlating to P1 typing and MLVA types.  Furthermore, genomic 
sequence analysis of M. pneumoniae strains revealed two genomic complexes, with 
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the same distinct split as observed for MLST ST.  The development of typing schemes 
from genomic sequences provides the ability to design a scheme that mirrors genomic 
phylogeny, thereby accurately representing the whole genome sequence.  This thesis 
reports the first use of bioinformatics analysis to develop such an MLST scheme 
(Section 5.2.3).  Three mMLST schemes have been proposed for the typing of 
M. hominis strains in this thesis, all of which reflect the relationships observed in 
genomic phylogeny.  Due to the commensal nature of M. hominis, detailed 
epidemiological studies of this bacteria have not been undertaken.  The application of 
typing schemes for M. hominis have not been examined for large epidemiological 
studies, however transmission trails between mother and baby and in nosocomial 
infections have been examined [133].  In the three mMLST schemes proposed, strains 
originating from the same patient sample were assigned the same ST (Section 5.2.3.5).  
Unfortunately, no two strains originating from documented mother to baby 
transmission were available to study.  It would have been interesting to assess the 
relatedness of epidemiologically linked strains by this method.  The use of MLST for 
both M. hominis and M. pneumoniae would allow the differentiation between 
recurring infection and re-infection of a patient with a differing ST.    
7.2.2 Is genomic sequencing the way forward? 
Whole genome sequencing has the potential to permanently change the field of 
Mycoplasma biology and epidemiology by allowing improved characterisation of 
strains and better discriminatory power compared to any previous typing method.  
Within this thesis the genomes of 18 M. hominis and 41 M. pneumoniae strains were 
sequenced and these sequences were used to inform MLST assay design in chapters 
Chapter 5 and 0, respectively.  Further to this, whole genome sequencing of M. 
pneumoniae was also used to develop a SNaPshot mini-sequencing assay for typing 
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of M. pneumoniae [443].  Eventually, whole genome sequencing directly on clinical 
specimens may become the standard methodology for determining the aetiology of 
respiratory infections; however, whilst the cost of bacterial genomic sequencing has 
reduced, sequencing on the whole is still only performed on bacterial isolates.  
Nevertheless, genomic sequencing directly on clinical specimens has already been 
demonstrated for the detection of respiratory viruses [480] and M. tuberculosis [481].  
Further development of genomic sequencing techniques will progress the field of 
diagnostics with the potential for direct metagenomics analysis of a patient specimens.  
There is established proof-of-principle describing the use of metagenomics to not only 
detect, but also to characterise bacterial pathogens; allowing typing data and 
phylogenetic profiles to be determined [482, 483].  This technique would also allow 
the entire microbial flora within the specimen to be identified, providing data for 
detailed epidemiological tracking of temporal and geographical trends in strain 
circulation.  The data created in this thesis will serve as a bank to inform future 
metagenomics analysis for M. hominis and M. pneumoniae. 
7.3 Scope for future lines of investigation 
The data presented in this thesis has answered multiple questions, but has, at the 
same time, produced many more.   
7.3.1 Multiplex real-time PCR 
With regards to the development of the multiplex real-time PCR for the simultaneous 
detection of M. hominis and Ureaplasma species, further validation of the assay would 
be beneficial.  Even though mixed infections of M. hominis and Ureaplasma species 
were identified in clinical specimens using the multiplex real-time PCR, investigation 
of possible inhibition in patients’ specimens should be assessed.  The ability of the 
assay to detect low levels of M. hominis in the presence of high concentrations of 
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either U. parvum or U. urealyticum and vice versa will determine if there is any 
inhibition of the primers and probes for the organism present at the lower 
concentration.  Furthermore, spiking of clinical specimens with low concentrations of 
either M. hominis, U. parvum, or U. urealyticum will determine if inhibition is present 
in the patient specimens and the efficiency of the PCR in clinical specimens (Figure 
7.1 A).  In the validation of the reproducibility of the multiplex real-time PCR, the CV 
of the concentration was markedly increased for concentrations of <102 copies/µL 
(Chapter 3, Table 3.2).  This increased variation for low copy number was most likely 
due to the logarithmic scale and natural random variation; however, further analysis 
of the control plasmid stability is warranted (Figure 7.1 A).   
Comparison of the multiplex real-time PCR to commercially available assays that 
detect M. hominis and Ureaplasma species would provide a useful comparator to 
assess the sensitivity and specificity of the multiplex assay.  Furthermore, direct 
comparison between the multiplex real-time PCR and the singleplex assays from 
which the primers and probes originates would be of interest [125, 290] (Figure 7.1 
B).  Clinical specimens would be tested by both the multiplex real-time PCR and the 
singleplex assays for both M. hominis and Ureaplasma species, allowing statistical 
analysis (Fisher’s exact test) to determine if the multiplex has higher or lower clinical 
sensitivities and specificities that the singleplex assays.  In addition, DNA 
concentration detected in clinical specimens could be compared between the multiplex 
real-time PCR and singleplex assay and correlation between the two methods could 
be assessed.  The logarithm of the DNA concentrations determined by the multiplex 
real-time PCR and the singleplex assays could be compared by linear regression 
analysis using log concentration of the singleplex assays as the dependent variable.   
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Figure 7.1. Work-flows for future validation of the multiplex real-time PCR assay 
for the detection of M. hominis and Ureaplasma species. A) Continued validation 
of the assay incorporating a spiking assay and further analysis of control plasmid 
stability. B) Prospective validation study using clinical specimens to compare to 
conventional culture and singleplex PCR assays. 
The availability of multiple-pathogen detection technologies has the potential to 
improve the identification and aetiology in a variety of infectious disease syndromes, 
ultimately resulting in a more comprehensive clinical evaluation.  In recent years, a 
number of multiple-pathogen detection systems have been developed and evaluated 
on respiratory clinical specimens.  These systems use multiplex PCR assays combined 
with various detection systems, including mass spectroscopy [484], bead sorting 
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[485], dye-labelled probes [486], and microarray technology [487].  However, these 
systems require extensive validation and the inclusion of new primers and probes or 
changes to existing primers and probes requires revalidation of the entire multiple-
pathogen detection assay.  Further technology developments have led to the increased 
use of microfluidic-technology for infectious pathogen detection.  TaqMan low-
density array cards utilise such technology and is based on singleplex qPCR assays 
[488].  This technology has previously been described for research in neonatal and 
respiratory screening [488, 489] and is currently used routinely for clinical diagnosis 
of hepatitis and respiratory screening by PHE.  Further development of a neonatal 
multi-pathogen screening test that includes the primers and probes described in 
Chapter 3 would provide a useful tool for rapid determination of the aetiology of 
infection in this vulnerable patient cohort and prevent unnecessary antibiotic usage.  
The current published neonatal screening array [489] includes Ureaplasma species as 
a target but utilises the ureaseA gene and is unable to differentiate between the two 
species.  Furthermore, M. hominis is not included as a target pathogen.   
7.3.2 Mycoplasma hominis antibiotic susceptibilities 
This project has only examined the susceptibility of M. hominis strains to two 
antibiotics, gentamicin and tetracycline.  Follow on work could assess the 
susceptibility of M. hominis to additional antibiotics such as clindamycin, 
moxifloxacin and levofloxacin, using all three methods described in Chapter 3.  
Comparison to published quality-control ranges [235] would allow verification of the 
use of qPCR to quantify bacterial load at varying concentrations of antibiotics, thereby 
determining the break-point at which the concentration of antibiotic prevents bacterial 
growth.  M. hominis strains from diverse origins and clinical presentations were used 
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throughout this thesis and it would be interesting to assess if any antibiotic resistance 
coincides with severe or invasive clinical presentation. 
If more time had been available then work would have been carried out upon 
understanding the failure of the tetM gene in MH111 to confer a resistant phenotype.  
Sequencing of the entire tetM and comparing to the tetracycline resistance strain Sprott 
(ATCC 33131) [490] would enable the identification of mutations within the coding 
region of the tetM and could account for the inability of the resultant protein to mediate 
tetracycline resistance.  If any mutations were identified, they should be assessed as to 
whether they confer changes in amino acid sequence.  The endogenous tetM gene 
promoter should also be assessed for alterations that may stop TetM protein 
expression.  Additional genetic comparison should be undertaken with ISMhom1, an 
insertion element detected in a single tetracycline-susceptible tetM carrying 
M. hominis strain, whereby an insertion of 1,260 bp in the leader peptide sequence 
upstream of tetM was proposed to be involved in the lack of transcription of tetM 
[403].  The questions of successful transcription of tetM in MH111 should be assessed.  
By isolating mRNA from actively growing MH111, cDNA could be produced by 
reverse transcription to identify if tetM was transcribed.  Furthermore, Dégrange et al. 
[403] successfully induced resistance conferred by tetM via sequential short-term 
passage in media containing doxycycline.  It would be interesting to see if resistance 
could be induced in MH111 using this method. 
7.3.3 mMLST 
This project has piloted the use of bioinformatics analysis to develop an MLST 
scheme that is representative of the whole genome sequence and accurately reflects 
genomic sequence phylogeny (mMLST; Chapter 5).  The three potential schemes 
identified require development into a PCR-based method that can be utilised by labs 
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without the need for whole genome sequencing (Figure 7.2).  Ideally, MLST loci of 
400-700 bp need to be identified for each gene in each scheme that can be reliably 
amplified by PCR and sequenced.  The gene targets will be examined in silico to 
identify the regions that contain variability and these will be utilised as regions for 
PCR amplification.  As MLST loci used in PCR-based methods target only a region 
of the gene, the number of SNPs used to generate phylogeny will be reduced.  In order 
to ensure that genomic phylogeny is still represented, gene areas for PCR will have to 
be assessed individually and in combination to see the effect of the loci size reduction 
on the overall phylogeny.  It is assumed that phylogeny produced using a PCR-based 
method will reflect the phylogeny of the genomic sequence SNP tree with reduced 
branch length, as shorter sequences with a different number of SNPs will be used (as 
seen for the mMLST). 
 
Figure 7.2. Work-flows for the development of mMLST by conventional PCR 
methods and expansion to additional M. hominis strains.  
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Epidemiological knowledge of M. hominis is limited and most cases of M. hominis 
infection have been reported as individual case studies.  The genotypic diversity of 
M. hominis has previously been assessed across a wide range of M. hominis clinical 
isolates from both genital and extra-genital infections using MLVA [133], revealing 
high levels of genetic heterogeneity at a population level.  Application of the mMLST 
to a large cohort of M. hominis isolates will provide further information on the genetic 
heterogeneity of M. hominis (Figure 7.2).  Furthermore, as mMLST is representative 
of genomic phylogeny, relationships between strains and clinical presentation, year 
isolated and geographical location could be examined in detail.   
At the level of an individual patient, it would be interesting to apply mMLST for 
M. hominis to allow discrimination between relapse and persistent, and new infections.  
In the first case, the mMLST type would remain the same, whereas in the second case 
a different mMLST type would be expected.  Application of mMLST to mother-
neonate pairs would allow confirmation of mother-to-child transmission if mMLST 
STs were identical.  This has been previously documented for M. hominis using 
MLVA [133], PFGE [412] and AP-PCR [427].  M. hominis has been isolated from 
surgical wounds and has been noted as the causative agent of post-operative infections.  
Testing the mMLST method on a cohort of isolates from surgical sites of infection 
within hospitals would allow identification of transmission chains and identification 
of nosocomial infections, aiding infection prevention methods.  As M. hominis 
infection is rarely identified, acquisition of a suitable number of isolates to extensively 
examine the use of mMLST in this scenario could prove challenging and would be 
limited to presentation of a suitable opportunity. 
The bioinformatics technique used to identify the three mMLST schemes for 
M. hominis has a wider application.  The methodology could be applied to any 
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bacterial species where there is interest in developing an MLST scheme that accurately 
represents genomic phylogeny.  Utilisation of the 35 M. pneumoniae genomic 
sequences described in 0 and the 19 published sequences would allow for further 
validation of this methodology using a minimal genome.  Furthermore, it would be 
interesting to compare any mMLST developed for M. pneumoniae with the MLST 
scheme developed in 0.  Although the M. pneumoniae MLST is considered 
representative of the whole genome via phylogenetic positioning into the two genomic 
clades, an mMLST scheme will provide further evidence of relatedness between 
strains without the requirement for whole genome sequencing. 
7.3.4 Mycoplasma pneumoniae MLST 
Further interesting lines of research would be to validate the M. pneumoniae 
MLST for use directly on clinical specimens without the need for isolation of 
M. pneumoniae.  The PCR primers detailed in Section 2.4.5 can initially be used to 
see if M. pneumoniae DNA can be amplified directly from clinical specimens with 
adequate DNA concentration for sequencing.  If adequate DNA is obtained, then 
MLST can be performed on clinical specimens as for isolates of M. hominis.  However, 
in the absence of sufficient DNA for sequencing or amplification failed directly on 
clinical specimens, nested PCR could be developed for the MLST loci as described 
for P1-typing [292].  This work is currently underway at PHE. 
The epidemiology of M. pneumoniae is changing.  In England and Wales, 
epidemics occur approximately every four years and globally epidemics are observed 
every 4-7 years.  However, in some countries, such as Israel, a persistent and ongoing 
epidemic has been observed since 2010 [229], where cyclical epidemics used to be the 
norm.  These changes in epidemic patterns emphasise the need to understand the 
epidemiology and pathogenesis of epidemics of M. pneumoniae infection better.  
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MLST can be used to characterise epidemics of M. pneumoniae infections.  This was 
undertaken to a limited extent in 0; however, sample numbers were low, particularly 
in recent years. Examination of the most recent epidemics, notably the 2010-2011 and 
2014-2015 epidemics in England and Wales, using MLST would provide 
discriminatory information to the clonality of the epidemics in England and Wales.  
The expectation is for the identification of a polyclonal population, as has been 
observed in both France and Israel using MLVA typing.  However, MLST is 
representative of the genomic sequence phylogeny, and as it is more discriminatory 
than MLVA, it could shed more light on the phylogenetic relationship between 
M. pneumoniae strains in an epidemic period. 
Finally, the incidence of macrolide-resistant M. pneumoniae is increasing globally 
and is becoming a major concern.  Macrolide resistance-conferring mutations are 
identified in M. pneumoniae via the sequencing of a region of the 23S rRNA [275].  
This could easily be added as an additional loci to the MLST scheme, providing 
clinically relevant information alongside epidemiological knowledge. 
7.4 Concluding statement 
Mycoplasma hominis and M. pneumoniae are human pathogens with differing 
epidemiology, clinical presentation and genetic heterogeneity.  This thesis has 
contributed to the rapid diagnosis and characterisation of these bacterial species, which 
is becoming of increasing importance, particularly in preterm neonates and with the 
emergence of increasing antibiotic resistance.  The genetic characteristics of these two 
Mycoplasmas are markedly different with implications for the development of 
reproducible and representative typing schemes for these organisms.   
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Table A.1.  Reference strains used for specificity testing of multiplex assay. 
Bacteria and virus species are listed, along with their collection ID or source, that were 
used to test the multiplex assay for specificity against U. parvum, U. urealyticum and 
M. hominis. 
Species Collection ID or Source 
Acholeplasma laidlawii NCTC 10116 
Acinetobacter baumannii ATCC 19606 
Acinetobacter calcoaceticus NCTC 23055 
Acinetobacter haemolyticus ATCC 17906 
Acinetobacter johnsonii ATCC 17909 
Acinetobacter junii ATCC 17908 
Acinetobacter iwoffi NCTC 5866 
Bordetella pertussis NCTC 8467 
Chlamydia trachomatis (and serotypes F,G,H,I,J) ATCC VR 902B 
Chlamydophila pneumoniae  ATCC VR 1360 
Chlamydophila psittaci ATCC VR 125 
Corynebacterium diphtheria NCTC 10356 
Corynebacterium ulcerans PHE Colindale 
Enterococcus faecalis NCTC 775 
Enterococcus faecium NCTC 7171 
Escherichia coli NCTC 9001 
Fusobacterium necroforum  NCTC 10575 
Haemophilus ducreyi PHE Colindale 
Haemophilus influenzae non-capsulated NCTC 12699 
Haemophilus influenzae type a ATCC 9006 
Haemophilus influenzae type b ATCC 10211 
Haemophilus influenzae type c ATCC 9007 
Haemophilus influenzae type d ATCC 9008 
Haemophilus influenzae type e ATCC 8142 
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Species Collection ID or Source 
Haemophilus influenzae type f ATCC 9833 
Haemophilus parainfluenzae ATCC 33392 
Herpes simplex virus PHE Colindale 
Legionella pneumophila  Cambio (Cambridge, UK; Cat.  No.  52-0101) 
Mobiluncus mulieris NCTC 11658 
Mycobacterium tuberculosis H37Rv NCTC 7416 
Mycoplasma amphoriforme NCTC 11740 
Mycoplasma buccale NCTC 10136 
Mycoplasma faucium NCTC 10174 
Mycoplasma fermentans NCTC 10117 
Mycoplasma genitalium NCTC 10195 
Mycoplasma lipophilum NCTC 10173 
Mycoplasma orale NCTC 10112 
Mycoplasma penetrans ATCC 55252 
Mycoplasma pirum NCTC 11702 
Mycoplasma pneumoniae NCTC 10119 
Mycoplasma primatum NCTC 10163 
Mycoplasma salivarium NCTC 10113 
Mycoplasma spermatophilum NCTC 11720 
Neisseria gonorrhoea PHE Colindale 
Prevotella bivia NCTC 11156 
Proteus mirabilis NCTC 2896 
Pseudomonas aeruginosa NCTC 10332 
Pseudomonas fluorescens NCTC 10038 
Pseudomonas putida NCTC 10936 
Pseudomonas stutzeri CIP 103022 
Staphylococcus aureus (MRSA) NCTC 13435 
Staphylococcus aureus (MSSA) NCTC 13434 
Staphylococcus auricularis NCTC 12101 
Staphylococcus capitis NCTC 11045 
Staphylococcus cohnii NCTC 11041 
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Species Collection ID or Source 
Staphylococcus epidermidis NCTC 11047 
Staphylococcus haemoliticus NCTC 11042 
Staphylococcus hominis NCTC 11320 
Staphylococcus intermedius NCTC 11048 
Staphylococcus lugdunensis NCTC 12217 
Staphylococcus saccharolyticus NCTC 11807 
Staphylococcus saprophyticus NCTC 7292 
Staphylococcus schleiferi NCTC 12218 
Staphylococcus simulans NCTC 11046 
Staphylococcus warneri NCTC 11044 
Staphylococcus xylosus NCTC 11043 
Streptococcus (Group C) PHE Colindale 
Streptococcus (Group G) NCTC  9603 
Streptococcus agalactiae (Group B) NCTC 11360 
Streptococcus pyogenes (Group A) NCTC 12696 
Treponema pallidum PHE Colindale 
Yersinia enterocolitica NCTC 12982 
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Figure A.1. Agarose gel showing the results of a PCR for the presence of tetM in 
Mycoplasma hominis strains.   
The PCR detected a 397 bp fragment of the trasnferable element tetM in M. hominis 
strains MH9, MH110, MH104, MH111 and MH108. 
 
272 
 
References 
 
References 
1. Dienes L, Edsall G. 1937. Observations on the L-organism of Klieneberger. 
Proceedings of the Society for Experimental Biology and Medicine 36:740-
744. 
2. Eaton MD, Meiklejohn G, van Herick W. 1944. Studies on the Etiology of 
Primary Atypical Pneumonia : A Filterable Agent Transmissible to Cotton 
Rats, Hamsters, and Chick Embryos. J Exp Med 79:649-668. 
3. Waites KB, Katz B, Schelonka RL. 2005. Mycoplasmas and ureaplasmas as 
neonatal pathogens. Clinical microbiology reviews 18:757-789. 
4. Weisburg WG, Tully JG, Rose DL, Petzel JP, Oyaizu H, Yang D, 
Mandelco L, Sechrest J, Lawrence TG, Van Etten J, et al. 1989. A 
phylogenetic analysis of the mycoplasmas: basis for their classification. J 
Bacteriol 171:6455-6467. 
5. Razin S, Yogev D, Naot Y. 1998. Molecular Biology and Pathogenicity of 
Mycoplasmas. Microbiology and molecular biology reviews 62:1094-1156. 
6. Pettersson B, Tully JG, Bolske G, Johansson KE. 2000. Updated 
phylogenetic description of the Mycoplasma hominis cluster (Weisburg et al. 
1989) based on 16S rDNA sequences. Int J Syst Evol Microbiol 50 Pt 1:291-
301. 
7. Waites KB, Xiao L, Paralanov V, Viscardi RM, Glass JI. 2012. Molecular 
methods for the detection of Mycoplasma and ureaplasma infections in 
humans: a paper from the 2011 William Beaumont Hospital Symposium on 
molecular pathology. The Journal of molecular diagnostics : JMD 14:437-450. 
8. Rottem S. 2003. Interaction of Mycoplasmas with Host Cells. Physiological 
Reviews 83:417-432. 
9. Waites KB, Talkington DF. 2004. Mycoplasma pneumoniae and its role as a 
human pathogen. Clinical microbiology reviews 17:697-728, table of contents. 
10. Maniloff J. 1969. Electron microscopy of small cells: Mycoplasma hominis. 
J Bacteriol 100:1402-1408. 
11. Atkinson TP, Balish MF, Waites KB. 2008. Epidemiology, clinical 
manifestations, pathogenesis and laboratory detection of Mycoplasma 
pneumoniae infections. FEMS microbiology reviews 32:956-973. 
12. Pollack JD, Williams MV, McElhaney RN. 1997. The comparative 
metabolism of the mollicutes (Mycoplasmas): the utility for taxonomic 
classification and the relationship of putative gene annotation and phylogeny 
to enzymatic function in the smallest free-living cells. Crit Rev Microbiol 
23:269-354. 
13. Miles RJ. 1992. Catabolism in mollicutes. J Gen Microbiol 138:1773-1783. 
14. Pereyre S, Sirand-Pugnet P, Beven L, Charron A, Renaudin H, Barre A, 
Avenaud P, Jacob D, Couloux A, Barbe V, de Daruvar A, Blanchard A, 
Bebear C. 2009. Life on Arginine for Mycoplasma hominis: Clues from its 
Minimal Genome and Comparison with Other Human Urogenital 
Mycoplasmas. PloS Genetics 5. 
15. Maniloff J. 1992. Phylogeny of mycoplasmas, p 549-559. In Maniloff J, 
McElhaney RN, Finch LR, Baseman JB (ed), Mycoplasmas molecular biology 
and pathogenesis. American Society for Microbiology, Wasington D.C. 
273 
 
References 
 
16. Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li B-C, Herrmann R. 1996. 
Complete sequence analysis of the genome of the bacterium Mycoplasma 
pneumoniae. Nucleic Acids Research 24:4420-4449. 
17. Xiao L, Ptacek T, Osborne JD, Crabb DM, Simmons WL, Lefkowitz EJ, 
Waites KB, Atkinson TP, Dybvig K. 2015. Comparative genome analysis of 
Mycoplasma pneumoniae. BMC Genomics 16:610. 
18. Inamine JM, Ho KC, Loechel S, Hu PC. 1990. Evidence that UGA is read 
as a tryptophan codon rather than as a stop codon by Mycoplasma pneumoniae, 
Mycoplasma genitalium, and Mycoplasma gallisepticum. J Bacteriol 172:504-
506. 
19. Kuhner S, van Noort V, Betts MJ, Leo-Macias A, Batisse C, Rode M, 
Yamada T, Maier T, Bader S, Beltran-Alvarez P, Castano-Diez D, Chen 
WH, Devos D, Guell M, Norambuena T, Racke I, Rybin V, Schmidt A, 
Yus E, Aebersold R, Herrmann R, Bottcher B, Frangakis AS, Russell RB, 
Serrano L, Bork P, Gavin AC. 2009. Proteome organization in a genome-
reduced bacterium. Science 326:1235-1240. 
20. Guell M, Yus E, Lluch-Senar M, Serrano L. 2011. Bacterial 
transcriptomics: what is beyond the RNA horiz-ome? Nat Rev Microbiol 
9:658-669. 
21. Wodke JA, Puchalka J, Lluch-Senar M, Marcos J, Yus E, Godinho M, 
Gutierrez-Gallego R, dos Santos VA, Serrano L, Klipp E, Maier T. 2013. 
Dissecting the energy metabolism in Mycoplasma pneumoniae through 
genome-scale metabolic modeling. Mol Syst Biol 9:653. 
22. Lluch-Senar M, Cozzuto L, Cano J, Delgado J, Llorens-Rico V, Pereyre 
S, Bebear C, Serrano L. 2015. Comparative "-omics" in Mycoplasma 
pneumoniae Clinical Isolates Reveals Key Virulence Factors. PLoS One 
10:e0137354. 
23. Balish MF. 2014. Mycoplasma pneumoniae, an underutilized model for 
bacterial cell biology. J Bacteriol 196:3675-3682. 
24. Carnrot C, Wehelie R, Eriksson S, Bolske G, Wang L. 2003. Molecular 
characterization of thymidine kinase from Ureaplasma urealyticum: 
nucleoside analogues as potent inhibitors of mycoplasma growth. Mol 
Microbiol 50:771-780. 
25. Wasinger VC, Pollack JD, Humphery-Smith I. 2000. The proteome of 
Mycoplasma genitalium. Chaps-soluble component. Eur J Biochem 267:1571-
1582. 
26. Regula JT, Ueberle B, Boguth G, Gorg A, Schnolzer M, Herrmann R, 
Frank R. 2000. Towards a two-dimensional proteome map of Mycoplasma 
pneumoniae. Electrophoresis 21:3765-3780. 
27. Meyer Sauteur PM, van Rossum AM, Vink C. 2014. Mycoplasma 
pneumoniae in children: carriage, pathogenesis, and antibiotic resistance. Curr 
Opin Infect Dis doi:10.1097/QCO.0000000000000063. 
28. Halbedel S, Hames C, Stulke J. 2007. Regulation of carbon metabolism in 
the mollicutes and its relation to virulence. J Mol Microbiol Biotechnol 
12:147-154. 
29. Somerson NL, Purcell RH, Taylor-Robinson D, Chanock RM. 1965. 
Hemolysin of Mycoplasma Pneumoniae. J Bacteriol 89:813-818. 
30. Pilo P, Vilei EM, Peterhans E, Bonvin-Klotz L, Stoffel MH, Dobbelaere D, 
Frey J. 2005. A metabolic enzyme as a primary virulence factor of 
274 
 
References 
 
Mycoplasma mycoides subsp. mycoides small colony. J Bacteriol 187:6824-
6831. 
31. Halbedel S, Hames C, Stulke J. 2004. In vivo activity of enzymatic and 
regulatory components of the phosphoenolpyruvate:sugar phosphotransferase 
system in Mycoplasma pneumoniae. J Bacteriol 186:7936-7943. 
32. Hames C, Halbedel S, Hoppert M, Frey J, Stulke J. 2009. Glycerol 
metabolism is important for cytotoxicity of Mycoplasma pneumoniae. J 
Bacteriol 191:747-753. 
33. Schmidl SR, Otto A, Lluch-Senar M, Pinol J, Busse J, Becher D, Stulke J. 
2011. A trigger enzyme in Mycoplasma pneumoniae: impact of the 
glycerophosphodiesterase GlpQ on virulence and gene expression. PLoS 
Pathog 7:e1002263. 
34. Razin S. 1999. Adherence of pathogenic mycoplasmas to host cells. Biosci 
Rep 19:367-372. 
35. Razin S, Jacobs E. 1992. Mycoplasma adhesion. Journal of General 
Microbiology 138:407-422. 
36. Proft T, Hilbert H, Layh-Schmitt G, Herrmann R. 1995. The proline-rich 
P65 protein of Mycoplasma pneumoniae is a component of the Triton X-100-
insoluble fraction and exhibits size polymorphism in the strains M129 and FH. 
J Bacteriol 177:3370-3378. 
37. D'Souza SE, Ginsberg MH, Plow EF. 1991. Arginyl-glycyl-aspartic acid 
(RGD): a cell adhesion motif. Trends Biochem Sci 16:246-250. 
38. Krause DC. 1998. Mycoplasma pneumoniae cytadherence: organization and 
assembly of the attachment organelle. Trends in microbiology 6:15-18. 
39. Meng KE, Pfister RM. 1980. Intracellular structures of Mycoplasma 
pneumoniae revealed after membrane removal. J Bacteriol 144:390-399. 
40. Gobel U, Speth V, Bredt W. 1981. Filamentous structures in adherent 
Mycoplasma pneumoniae cells treated with nonionic detergents. J Cell Biol 
91:537-543. 
41. Kirchhoff H. 1992. Motility. In Maniloff J, McElhaney RN, Finch LR, 
Baseman JB (ed), Mycoplasmas: Molecular Biology and Pathogenesis. 
American Society for Microbiology, Washington, DC. 
42. Seto S, Layh-Schmitt G, Kenri T, Miyata M. 2001. Visualization of the 
attachment organelle and cytadherence proteins of Mycoplasma pneumoniae 
by immunofluorescence microscopy. J Bacteriol 183:1621-1630. 
43. Krause DC, Balish MF. 2001. Structure, function, and assembly of the 
terminal organelle of Mycoplasma pneumoniae. FEMS microbiology letters 
198:1-7. 
44. Krause DC. 1996. Mycoplasma pneumoniae cytadherence: unravelling the tie 
that binds. Molecular Microbiology 20:247-253. 
45. Baseman JB, Cole RM, Krause DC, Leith DK. 1982. Molecular basis of 
cytadsorption of Mycoplasma pneumoniae. Journal of bacteriology 151:1514-
1522. 
46. Collier AM, Hu PC, Clyde WA, Jr. 1983. Location of attachment moiety on 
Mycoplasma pneumoniae. Yale J Biol Med 56:671-677. 
47. Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, 
Coalson JJ, Baseman JB, Hardy RD. 2010. Variation in colonization, ADP-
ribosylating and vacuolating cytotoxin, and pulmonary disease severity among 
mycoplasma pneumoniae strains. Am J Respir Crit Care Med 182:797-804. 
275 
 
References 
 
48. Kannan TR, Baseman JB. 2006. ADP-ribosylating and vacuolating cytotoxin 
of Mycoplasma pneumoniae represents unique virulence determinant among 
bacterial pathogens. Proc Natl Acad Sci U S A 103:6724-6729. 
49. Kannan TR, Provenzano D, Wright JR, Baseman JB. 2005. Identification 
and characterization of human surfactant protein A binding protein of 
Mycoplasma pneumoniae. Infection and immunity 73:2828-2834. 
50. Kannan TR, Musatovova O, Balasubramanian S, Cagle M, Jordan JL, 
Krunkosky TM, Davis A, Hardy RD, Baseman JB. 2010. Mycoplasma 
pneumoniae Community Acquired Respiratory Distress Syndrome toxin 
expression reveals growth phase and infection-dependent regulation. Mol 
Microbiol 76:1127-1141. 
51. Srivastava R, Sinha VB, Srivastava BS. 1980. Events in the pathogenesis of 
experimental cholera: role of bacterial adherence and multiplication. J Med 
Microbiol 13:1-9. 
52. Tuomanen E, Weiss A. 1985. Characterization of two adhesins of Bordetella 
pertussis for human ciliated respiratory-epithelial cells. J Infect Dis 152:118-
125. 
53. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a 
common cause of persistent infections. Science 284:1318-1322. 
54. Mohamed JA, Huang DB. 2007. Biofilm formation by enterococci. J Med 
Microbiol 56:1581-1588. 
55. Vu B, Chen M, Crawford RJ, Ivanova EP. 2009. Bacterial extracellular 
polysaccharides involved in biofilm formation. Molecules 14:2535-2554. 
56. McAuliffe L, Ellis RJ, Miles K, Ayling RD, Nicholas RA. 2006. Biofilm 
formation by mycoplasma species and its role in environmental persistence 
and survival. Microbiology 152:913-922. 
57. Simmons WL, Dybvig K. 2007. Biofilms protect Mycoplasma pulmonis cells 
from lytic effects of complement and gramicidin. Infect Immun 75:3696-3699. 
58. Kornspan JD, Tarshis M, Rottem S. 2011. Adhesion and biofilm formation 
of Mycoplasma pneumoniae on an abiotic surface. Arch Microbiol 193:833-
836. 
59. Simmons WL, Daubenspeck JM, Osborne JD, Balish MF, Waites KB, 
Dybvig K. 2013. Type 1 and Type 2 Strains of Mycoplasma pneumoniae Form 
Different Biofilms. Microbiology doi:mic.0.064782-0 [pii] 
10.1099/mic.0.064782-0. 
60. Branda SS, Vik S, Friedman L, Kolter R. 2005. Biofilms: the matrix 
revisited. Trends Microbiol 13:20-26. 
61. Conlon KM, Humphreys H, O'Gara JP. 2002. icaR encodes a 
transcriptional repressor involved in environmental regulation of ica operon 
expression and biofilm formation in Staphylococcus epidermidis. J Bacteriol 
184:4400-4408. 
62. Kropec A, Maira-Litran T, Jefferson KK, Grout M, Cramton SE, Gotz F, 
Goldmann DA, Pier GB. 2005. Poly-N-acetylglucosamine production in 
Staphylococcus aureus is essential for virulence in murine models of systemic 
infection. Infect Immun 73:6868-6876. 
63. Toledo-Arana A, Merino N, Vergara-Irigaray M, Debarbouille M, 
Penades JR, Lasa I. 2005. Staphylococcus aureus develops an alternative, ica-
independent biofilm in the absence of the arlRS two-component system. J 
Bacteriol 187:5318-5329. 
276 
 
References 
 
64. Hultgren SJ, Abraham S, Caparon M, Falk P, St Geme JW, 3rd, Normark 
S. 1993. Pilus and nonpilus bacterial adhesins: assembly and function in cell 
recognition. Cell 73:887-901. 
65. Finlay BB, Cossart P. 1997. Exploitation of mammalian host cell functions 
by bacterial pathogens. Science 276:718-725. 
66. Bendtsen JD, Kiemer L, Fausboll A, Brunak S. 2005. Non-classical protein 
secretion in bacteria. BMC Microbiol 5:58. 
67. Grundel A, Friedrich K, Pfeiffer M, Jacobs E, Dumke R. 2015. Subunits 
of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are 
Surface-Displayed Proteins that Bind and Activate Human Plasminogen. PLoS 
One 10:e0126600. 
68. Pancholi V, Fischetti VA. 1992. A major surface protein on group A 
streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple 
binding activity. J Exp Med 176:415-426. 
69. Pancholi V, Fischetti VA. 1998. alpha-enolase, a novel strong plasmin(ogen) 
binding protein on the surface of pathogenic streptococci. J Biol Chem 
273:14503-14515. 
70. Henderson B, Martin A. 2011. Bacterial virulence in the moonlight: 
multitasking bacterial moonlighting proteins are virulence determinants in 
infectious disease. Infect Immun 79:3476-3491. 
71. Pancholi V, Chhatwal GS. 2003. Housekeeping enzymes as virulence factors 
for pathogens. Int J Med Microbiol 293:391-401. 
72. Copley SD. 2012. Moonlighting is mainstream: paradigm adjustment required. 
Bioessays 34:578-588. 
73. Dallo SF, Kannan TR, Blaylock MW, Baseman JB. 2002. Elongation factor 
Tu and E1 β subunit of pyruvate dehydrogenase complex act as fibronectin 
binding proteins in Mycoplasma pneumoniae. Molecular Microbiology 
28:1041-1061. 
74. Dumke R, Hausner M, Jacobs E. 2011. Role of Mycoplasma pneumoniae 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mediating 
interactions with the human extracellular matrix. Microbiology 157:2328-
2338. 
75. Balasubramanian S, Kannan TR, Hart PJ, Baseman JB. 2009. Amino acid 
changes in elongation factor Tu of Mycoplasma pneumoniae and Mycoplasma 
genitalium influence fibronectin binding. Infect Immun 77:3533-3541. 
76. Bergmann S, Hammerschmidt S. 2007. Fibrinolysis and host response in 
bacterial infections. Thromb Haemost 98:512-520. 
77. Regula JT, Boguth G, Gorg A, Hegermann J, Mayer F, Frank R, 
Herrmann R. 2001. Defining the mycoplasma 'cytoskeleton': the protein 
composition of the Triton X-100 insoluble fraction of the bacterium 
Mycoplasma pneumoniae determined by 2-D gel electrophoresis and mass 
spectrometry. Microbiology 147:1045-1057. 
78. Olson LD, Shane SW, Karpas AA, Cunningham TM, Probst PS, Barile 
MF. 1991. Monoclonal Antibodies to Surface Antigens of a Pathogenic 
Mycoplasma hominis Strain. Infection and immunity 59:1683-1689. 
79. Henrich B, Feldmann RC, Hadding U. 1993. Cytoadhesins of Mycoplasma 
hominis. Infect Immun 61:2945-2951. 
80. Hopfe M, Hoffmann R, Henrich B. 2004. P80, the HinT interacting 
membrane protein, is a secreted antigen of Mycoplasma hominis. BMC 
microbiology 4:46. 
277 
 
References 
 
81. Kitzerow A, Hadding U, Henrich B. 1999. Cyto-adherence studies of the 
adhesin P50 of Mycoplasma hominis. Journal of medical microbiology 48:485-
493. 
82. Olson LD, Gilbert AA. 1993. Characteristics of Mycoplasma hominis 
adhesion. J Bacteriol 175:3224-3227. 
83. Hopfe M, Deenen R, Degrandi D, Kohrer K, Henrich B. 2013. Host Cell 
Responses to Persistent Mycoplasmas - Different Stages in Infection of HeLa 
Cells with Mycoplasma hominis. PLOS ONE 8:e54219. 
84. Christiansen G. 1992. Genetic variation in natural populations, p 561-574. In 
Maniloff J, McElhaney RN, Finch LR, Baseman JB (ed), Mycoplasmas 
Molecular biology and pathogenesis. American Society for Microbiology, 
Wasington DC. 
85. Rossier O, Starkenburg SR, Cianciotto NP. 2004. Legionella pneumophila 
type II protein secretion promotes virulence in the A/J mouse model of 
Legionnaires' disease pneumonia. Infect Immun 72:310-321. 
86. Olson LD, Renshaw CA, Shane SW, Barile MF. 1991. Successive synovial 
Mycoplasma hominis isolates exhibit apparent antigenic variation. Infect 
Immun 59:3327-3329. 
87. Ladefoged SA, Birkelund S, Hauge S, Brock B, Jensen LT, Christiansen 
G. 1995. A 135-kilodalton surface antigen of Mycoplasma hominis PG21 
contains multiple directly repeates sequenes. Infection and immunity 63:212-
223. 
88. Christiansen G, Mathiesen SL, Nyvold C, Birkelund S. 1994. Analysis of a 
Mycoplasma hominis membrane protein, P120. FEMS Microbiol Lett 
121:121-127. 
89. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleischmann 
RD, Bult CJ, Kerlavage AR, Sutton G, Kelley JM, Fritchman RD, 
Weidman JF, Small KV, Sandusky M, Fuhrmann J, Nguyen D, Utterback 
TR, Saudek DM, Phillips CA, Merrick JM, Tomb JF, Dougherty BA, Bott 
KF, Hu PC, Lucier TS, Peterson SN, Smith HO, Hutchison CA, 3rd, 
Venter JC. 1995. The minimal gene complement of Mycoplasma genitalium. 
Science 270:397-403. 
90. Christiansen G, Ladefoged S, Hange S, Birkelund S, Anderson H. 1990. 
Use of monoclonal antibodies for detection of gene and antigen variation in 
Mycoplasma hominis. Zbl Bakt Suppl 20:535-545. 
91. Zhang Q, Wise KS. 1997. Localized reversible frameshift mutation in an 
adhesin gene confers a phase-variable adherence phenotype in mycoplasma. 
Mol Microbiol 25:859-869. 
92. Zhang Q, Wise KS. 1996. Molecular basis of size and antigenic variation of 
a Mycoplasma hominis adhesin encoded by divergent vaa genes. Infection and 
immunity 64:2737-2744. 
93. Belland RJ, Morrison SG, Carlson JH, Hogan DM. 1997. Promoter strength 
influences phase variation of neisserial opa genes. Mol Microbiol 23:123-135. 
94. Zimmerman CU, Rosengarten R, Spergser J. 2011. Ureaplasma antigenic 
variation beyond MBA phase variation: DNA inversions generating chimeric 
structures and switching in expression of the MBA N-terminal paralogue 
UU172. Mol Microbiol 79:663-676. 
95. Zimmerman CU, Stiedl T, Rosengarten R, Spergser J. 2009. Alternate 
phase variation in expression of two major surface membrane proteins (MBA 
278 
 
References 
 
and UU376) of Ureaplasma parvum serovar 3. FEMS Microbiol Lett 292:187-
193. 
96. Henrich B, Lang K, Kitzerow A, MacKenzie C, Hadding U. 1998. 
Truncation as a novel form of variation of the p50 gene in Mycoplasma 
hominis. Microbiology 144:2979-2985. 
97. Boesen T, Emmersen J, Jensen LT, Ladefoged SA, Thorsen P, Birkelund 
S, Christiansen G. 1998. The Mycoplasma hominis vaa gene displays a 
mosaic gene structure. Mol Microbiol 29:97-110. 
98. Kong Y, Ma JH, Warren K, Tsang RS, Low DE, Jamieson FB, Alexander 
DC, Hao W. 2013. Homologous recombination drives both sequence diversity 
and gene content variation in Neisseria meningitidis. Genome Biol Evol 
5:1611-1627. 
99. Boesen T, Fedosova NU, Kjeldgaard M, Birkelund S, Christiansen G. 
2001. Molecular design of Mycoplasma hominis Vaa adhesin. Protein Science 
10:2577-2586. 
100. Tashiro M, Tejero R, Zimmerman DE, Celda B, Nilsson B, Montelione 
GT. 1997. High-resolution solution NMR structure of the Z domain of 
Staphylococcal protein A. Journal of Molecular Biology 272:573-590. 
101. Zheng D, Aramini JM, Montelione GT. 2004. Validation of helical tilt 
angles in the solution NMR structure of the Z domain of Staphylococcal 
protein A by combined analysis of residual dipolar coupling and NOE data. 
Protein Sci 13:549-554. 
102. Henrich B, Hopfe M, Kitzerow A, Hadding U. 1999. The adherence-
associated lipoprotein P100, encoded by an opp operon structure, functions as 
the oligopeptide-binding domain OppA of a putative oligopeptide transport 
system in Mycoplasma hominis. J Bacteriol 181:4873-4878. 
103. Steinberg F, Konerding MA, Sander A, Streffer C. 1991. Vascularization, 
proliferation and necrosis in untreated human primary tumours and untreated 
human xenografts. Int J Radiat Biol 60:161-168. 
104. Filippini A, Taffs RE, Agui T, Sitkovsky MV. 1990. Ecto-ATPase activity 
in cytolytic T-lymphocytes. Protection from the cytolytic effects of 
extracellular ATP. J Biol Chem 265:334-340. 
105. Hopfe M, Henrich B. 2004. OppA, the substrate-binding subunit of the 
oligopeptide permease, is the major Ecto-ATPase of Mycoplasma hominis. J 
Bacteriol 186:1021-1928. 
106. Hopfe M, Henrich B. 2008. OppA, the ecto-ATPase of Mycoplasma hominis 
induces ATP release and cell death in HeLa cells. BMC microbiology 8:55. 
107. Hopfe M, Dahlmanns T, Henrich B. 2011. In Mycoplasma hominis the 
OppA-mediated cytoadhesion depends on its ATPase activity. BMC 
Microbiology 11. 
108. Canoz O, Belenli O, Patiroglu TE. 2002. General features of gastric 
carcinomas and comparison of HSP70 and NK cell immunoreactivity with 
prognostic factors. Pathol Oncol Res 8:262-269. 
109. Scott K, Manunta M, Germain C, Smith P, Jones M, Mitchell P, Dessi D, 
Branigan Bamford K, Lechler RI, Fiori PL, Foster GR, Lombardi G. 
2005. Qualitatively distinct patterns of cytokines are released by human 
dendritic cells in response to different pathogens. Immunology 116:245-254. 
110. Waites KB, Balish MF, Atkinson TP. 2008. New insights into the 
pathogenesis and detection of Mycoplasma pneumoniae infections. Future 
microbiology 3:635-648. 
279 
 
References 
 
111. Sillis M. 1990. The limitations of IgM assays in the serological diagnosis of 
Mycoplasma pneumoniae infections. Journal of medical microbiology 33:253-
258. 
112. Dumke R, Strubel A, Cyncynatus C, Nuyttens H, Herrmann R, Luck C, 
Jacobs E. 2012. Optimized serodiagnosis of Mycoplasma pneumoniae 
infections. Diagn Microbiol Infect Dis 73:200-203. 
113. Thacker WL, Talkington DF. 2000. Analysis of Complement Fixation and 
Commercial Enzyme Immunoassays for Detection of Antibodies to 
Mycoplasma pneumoniae in Human Serum. Clinical and Diagnostic 
Laboratory Immunology 7:778-780. 
114. Busson L, Van den Wijngaert S, Dahma H, Decolvenaer M, Di Cesare L, 
Martin A, Vasseur L, Vandenberg O. 2013. Evaluation of 10 serological 
assays for diagnosing Mycoplasma pneumoniae infection. Diagn Microbiol 
Infect Dis 76:133-137. 
115. Baczynska A, Friis Svenstrup H, Fedder J, Birkelund S, Christiansen G. 
2005. The use of enzyme-linked immunosorbent assay for detection of 
Mycoplasma hominis antibodies in infertile women serum samples. Hum 
Reprod 20:1277-1285. 
116. Bernet C, Garret M, de Barbeyrac B, Bebear C, Bonnet J. 1989. Detection 
of Mycoplasma pneumoniae by using the polymerase chain reaction. J Clin 
Microbiol 27:2492-2496. 
117. Jensen JS, Sondergard-Andersen J, Uldum SA, Lind K. 1989. Detection of 
Mycoplasma pneumoniae in simulated clinical samples by polymerase chain 
reaction. Brief report. APMIS 97:1046-1048. 
118. Razin S. 1994. DNA probes and PCR in diagnosis of mycoplasma infections. 
Mol Cell Probes 8:497-511. 
119. Ursi D, Dirven K, Loens K, Ieven M, Goossens H. 2003. Detection of 
Mycoplasma pneumoniae in respiratory samples by real-time PCR using an 
inhibition control. J Microbiol Methods 55:149-153. 
120. Michelow IC, Olsen K, Lozano J, Duffy LB, McCracken GH, Hardy RD. 
2004. Diagnostic utility and clinical significance of naso- and oropharyngeal 
samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection 
in children with community-acquired pneumonia. J Clin Microbiol 42:3339-
3341. 
121. Miyashita N, Saito A, Kohno S, Yamaguchi K, Watanabe A, Oda H, 
Kazuyama Y, Matsushima T, Group CAPS. 2004. Multiplex PCR for the 
simultaneous detection of Chlamydia pneumoniae, Mycoplasma pneumoniae 
and Legionella pneumophila in community-acquired pneumonia. Respir Med 
98:542-550. 
122. Nour M, Trabelsi A, Maatouk N, Hammami M. 2005. Amplification of P1 
and 16S rRNA genes by nested PCR for detection of Mycoplasma pneumoniae 
in paediatric patients. Pathol Biol (Paris) 53:9-14. 
123. Mygind T, Birkelund S, Christiansen G. 1998. DNA sequencing reveals 
limited heterogeneity in the 16S rRNA gene from the rrnB operon among five 
Mycoplasma hominis isolates. Int J Syst Bacteriol 48 Pt 3:1067-1071. 
124. Baczynska A, Svenstrup HF, Fedder J, Birkelund S, Christiansen G. 2004. 
Development of real-time PCR for detection of Mycoplasma hominis. BMC 
microbiology 4:35. 
125. Ferandon C, Peuchant O, Janis C, Benard A, Renaudin H, Pereyre S, 
Bebear C. 2011. Development of a real-time PCR targeting the yidC gene for 
280 
 
References 
 
the detection of Mycoplasma hominis and comparison with quantitative 
culture. Clin Microbiol Infect 17:155-159. 
126. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. 2008. Molecular 
quantification of Gardnerella vaginalis and Atopobium vaginae loads to 
predict bacterial vaginosis. Clin Infect Dis 47:33-43. 
127. Bebear C, Pereyre S, Bebear CM. 2006. Mycoplasma spp. Principles and 
Practice of Clinical Bacteriology, ed 2 ed. John Wiley & Sons Ltd., Hoboken, 
NJ. 
128. Cousin-Allery A, Charron A, de Barbeyrac B, Fremy G, Skov Jensen J, 
Renaudin H, Bebear C. 2000. Molecular typing of Mycoplasma pneumoniae 
strains by PCR-based methods and pulsed-field gel electrophoresis. 
Application to French and Danish isolates. Epidemiol Infect 124:103-111. 
129. Dorigo-Zetsma JW, Dankert J, Zaat SA. 2000. Genotyping of Mycoplasma 
pneumoniae clinical isolates reveals eight P1 subtypes within two genomic 
groups. J Clin Microbiol 38:965-970. 
130. Dumke R, Jacobs E. 2011. Culture-independent multi-locus variable-number 
tandem-repeat analysis (MLVA) of Mycoplasma pneumoniae. J Microbiol 
Methods 86:393-396. 
131. Dumke R, Catrein I, Pirkil E, Herrmann R, Jacobs E. 2003. Subtyping of 
Mycoplasma pneumoniae isolates based on extended genome sequencing and 
on expression profiles. Int J Med Microbiol 292:513-525. 
132. Degrange S, Cazanave C, Charron A, Renaudin H, Bebear C, Bebear CM. 
2009. Development of multiple-locus variable-number tandem-repeat analysis 
for molecular typing of Mycoplasma pneumoniae. J Clin Microbiol 47:914-
923. 
133. Ferandon C, Peuchant O, Renaudin H, Bebear C. 2013. Diversity of 
Mycoplasma hominis clinical isolates from Bordeaux, France, as assessed by 
multiple-locus variable-number tandem repeat analysis. BMC Microbiol 
13:120. 
134. Chalker VJ, Stocki T, Mentasti M, Fleming D, Harrison TG. 2011. 
Increased incidence of Mycoplasma pneumoniae infection in England and 
Wales in 2010: multilocus variable number tandem repeat analysis typing and 
macrolide susceptibility. Euro Surveillance 16. 
135. Boesen T, Emmersen J, Baczynska A, Birkelund S, Christiansen G. 2004. 
The vaa locus of Mycoplasma hominis contains a divergent genetic islet 
encoding a putative membrane protein. BMC microbiology 4:37. 
136. Mardassi BB, Ayari H, Bejaoui-Khiari A, Mlik B, Moalla I, Amouna F. 
2007. Genetic variability of the P120' surface protein gene of Mycoplasma 
hominis isolates recovered from Tunisian patients with uro-genital and 
infertility disorders. BMC infectious diseases 7:142. 
137. Mygind T, Birkelund S, Christiansen G. 2000. Characterization of the 
variability of a 75-kDa membrane protein in Mycoplasma hominis. FEMS 
Microbiol Lett 190:167-176. 
138. Foy HM. 1993. Infections caused by Mycoplasma pneumoniae and possible 
carrier state in different populations of patients. Clinical Infectious Diseases 
17:S37-46. 
139. Korppi M, Heiskanen-Kosma T, Kleemola M. 2004. Incidence of 
community-acquired pneumonia in children caused by Mycoplasma 
pneumoniae: Serological results of a prospective, population-based study in 
primary health care. Respirology 9:109-114. 
281 
 
References 
 
140. Cherry JD, Welliver RC. 1976. Mycoplasma pneumoniae infections of adults 
and children. The Western Journal of Medicine 125:47-55. 
141. Shields MD, Bush A, Everard ML, McKenzie S, Primhak R, British 
Thoracic Society Cough Guideline G. 2008. BTS guidelines: 
Recommendations for the assessment and management of cough in children. 
Thorax 63 Suppl 3:iii1-iii15. 
142. van Gageldonk-Lafeber AB, Heijnen ML, Bartelds AI, Peters MF, van 
der Plas SM, Wilbrink B. 2005. A case-control study of acute respiratory 
tract infection in general practice patients in The Netherlands. Clin Infect Dis 
41:490-497. 
143. Wang K, Chalker V, Bermingham A, Harrison T, Mant D, Harnden A. 
2011. Mycoplasma pneumoniae and respiratory virus infections in children 
with persistent cough in England: a retrospective analysis. Pediatr Infect Dis J 
30:1047-1051. 
144. Hammerschlag MR. 2001. Mycoplasma pneumoniae infections. Curr Opin 
Infect Dis 14:181-186. 
145. Harnden A, Perera R, Brueggemann AB, Mayon-White R, Crook DW, 
Thomson A, Mant D. 2007. Respiratory infections for which general 
practitioners consider prescribing an antibiotic: a prospective study. Arch Dis 
Child 92:594-597. 
146. Chalker VJ, Stocki T, Mentasti M, Fleming D, Sadler C, Ellis J, 
Bermingham A, Harrison TG. 2011. Mycoplasma pneumoniae infection in 
primary care investigated by real-time PCR in England and Wales. Eur J Clin 
Microbiol Infect Dis 30:915-921. 
147. Sutherland ER, Brandorff JM, Martin RJ. 2004. Atypical bacterial 
pneumonia and asthma risk. J Asthma 41:863-868. 
148. Nisar N, Guleria R, Kumar S, Chand Chawla T, Ranjan Biswas N. 2007. 
Mycoplasma pneumoniae and its role in asthma. Postgraduate medical journal 
83:100-104. 
149. Esposito S, Droghetti R, Bosis S, Claut L, Marchisio P, Principi N. 2002. 
Cytokine secretion in children with acute Mycoplasma pneumoniae infection 
and wheeze. Pediatr Pulmonol 34:122-127. 
150. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. 2001. A link 
between chronic asthma and chronic infection. J Allergy Clin Immunol 
107:595-601. 
151. Cassell GH, Cole BM. 1981. Mycoplasmas as agents of human diseases. The 
New England Journal of Medicine 304:80-89. 
152. Bar Meir E, Amital H, Levy Y, Kneller A, Bar-Dayan Y, Shoenfeld Y. 
2000. Mycoplasma-pneumoniae-induced thrombotic thrombocytopenic 
purpura. Acta Haematol 103:112-115. 
153. Kasahara I, Otsubo Y, Yanase T, Oshima H, Ichimaru H, Nakamura M. 
1985. Isolation and characterisation of Mycoplasma pneumoniae from 
cerebrospinal fluid of a patient with pneumonia and menigoencephalitis. The 
Journal of Infectious Diseases 152:823-825. 
154. Koletsky RJ, Weinstein AJ. 1980. Fulminant Mycoplasma pneumoniae 
infection. Report of a fatal case, and a review of the literature. Am Rev Respir 
Dis 122:491-496. 
155. Narita M, Matsuzono Y, Itakura O, Togashi T, Kikuta H. 1996. Survey of 
mycoplasma bacteremia detected in children by polymerase chain reaction. 
Clinical Infectious Diseases 23. 
282 
 
References 
 
156. Said MH, Layani MP, Colon S, Faraj G, Glastre C, Cochat P. 1999. 
Mycoplasma pneumoniae-associated nephritis in children. Pediatr Nephrol 
13:39-44. 
157. Bebear C, Robertson JA. 1996. Determination of minimal inhibitory 
concentration. In Tully JG, Razin S (ed), Molecular and diagnostic procedures 
in mycoplasmology volume II. American Press, New Yrok. 
158. Christie LJ, Honarmand S, Talkington DF, Gavali SS, Preas C, Pan CY, 
Yagi S, Glaser CA. 2007. Pediatric encephalitis: what is the role of 
Mycoplasma pneumoniae? Pediatrics 120:305-313. 
159. Bitnun A, Ford-Jones EL, Petric M, MacGregor D, Heurter H, Nelson S, 
Johnson G, Richardson S. 2001. Acute childhood encephalitis and 
Mycoplasma pneumoniae. Clin Infect Dis 32:1674-1684. 
160. Bitnun A, Ford-Jones E, Blaser S, Richardson S. 2003. Mycoplasma 
pneumoniae ecephalitis. Semin Pediatr Infect Dis 14:96-107. 
161. Narita M, Tanaka H, Togashi T, Abe S. 2005. Cytokines involved in CNS 
manifestations caused by Mycoplasma pneumoniae. Pediatr Neurol 33:105-
109. 
162. Ang CW, Tio-Gillen AP, Groen J, Herbrink P, Jacobs BC, Van 
Koningsveld R, Osterhaus ADME, Van der Meche FGA, van Doorn PA. 
2002. Cross-reactive anti-galactocerebroside antibodies and Mycoplasma 
pneumoniae infections in Guillain-Barre syndrome. Journal of 
Neuroimmunology 130:179-183. 
163. Stamm B, Moschopulos M, Hungerbuehler H, Guarner J, Genrich GL, 
Zaki SR. 2008. Neuroinvasion by Mycoplasma pneumoniae in acute 
disseminated encephalomyelitis. Emerging Infectious Diseases 14:641-643. 
164. Cherry JD. 1993. Anemia and mucocutanenous lesions due to Mycoplasma 
pneumoniae infections. Clinical Infectious Diseases 17 S47-51. 
165. Levine DP, Lerner AM. 1978. The clinical spectrum of Mycoplasma 
pneumoniae infections. Med Clin North Am 62:961-978. 
166. Macfarlane J. 1980. Mycoplasma pneumoniae infection, antibiotics and 
exanthema. Infection 8:119-120. 
167. Stutman HR. 1987. Stevens-Johnson syndrome and Mycoplasma 
pneumoniae: evidence for cutaneous infection. J Pediatr 111:845-847. 
168. Han Z, Burnham CA, Clohisy J, Babcock H. 2011. Mycoplasma 
pneumoniae periprosthetic joint infection identified by 16S ribosomal RNA 
gene amplification and sequencing: a case report. J Bone Joint Surg Am 
93:e103. 
169. Azumagawa K, Kambara Y, Murata T, Tamai H. 2008. Four cases of 
arthritis associated with Mycoplasma pneumoniae infection. Pediatr Int 
50:511-513. 
170. Davis CP, Cochran S, Lisse J, Buck G, DiNuzzo AR, Weber T, Reinarz 
JA. 1988. Isolation of Mycoplasma pneumoniae from synovial fluid samples 
in a patient with pneumonia and polyarthritis. Arch Intern Med 148:969-970. 
171. Dionisio D, Valassina M, Uberti M, Fabbri C, Parri F, Saffi EG. 2001. 
Mycoplasma pneumoniae non-pulmonary infection presenting with 
pharyngitis, polyarthritis and localized exanthem. Scand J Infect Dis 33:782-
783. 
172. Khoury T, Abu Rmeileh A, Kornspan JD, Abel R, Mizrahi M, Nir-Paz R. 
2015. Mycoplasma pneumoniae Pneumonia Associated With 
283 
 
References 
 
Methemoglobinemia and Anemia: An Overlooked Association? Open Forum 
Infect Dis 2:ofv022. 
173. Gu L, Chen X, Li H, Qu J, Miao M, Zhou F, Zhu Y, Wang X, Wang C, 
Liu Y, Li W, Cao B. 2014. A case of lethal hemolytic anemia associated with 
severe pneumonia caused by Mycoplasma pneumoniae. Chin Med J (Engl) 
127:3839. 
174. Mardh P-A. 1983. Mycoplasma hominis - a neglected human pathogen. 
European Journal of Clinical Microbiology and Infectious Diseases 2:303-308. 
175. Hay P. 2005. Bacterial vaginosis. Medicine 33:58-61. 
176. Rappelli P, Carta F, Delogu G, Addis MF, Dessi D, Cappuccinelli P, Fiori 
PL. 2001. Mycoplasma hominis and Trichomonas vaginalis symbiosis: 
multiplicity of infection and transmissibility of M. hominis to human cells. 
Arch Microbiol 175:70-74. 
177. Dessi D, Delogu G, Emonte E, Catania MR, Fiori PL, Rappelli P. 2005. 
Long-term survival and intracellular replication of Mycoplasma hominis in 
Trichomonas vaginalis cells: potential role of the protozoon in transmitting 
bacterial infection. Infect Immun 73:1180-1186. 
178. Yarlett N, Martinez MP, Moharrami MA, Tachezy J. 1996. The 
contribution of the arginine dihydrolase pathway to energy metabolism by 
Trichomonas vaginalis. Mol Biochem Parasitol 78:117-125. 
179. Morada M, Manzur M, Lam B, Tan C, Tachezy J, Rappelli P, Dessi D, 
Fiori PL, Yarlett N. 2010. Arginine metabolism in Trichomonas vaginalis 
infected with Mycoplasma hominis. Microbiology 156:3734-3743. 
180. Dessi D, Rappelli P, Diaz N, Cappuccinelli P, Fiori PL. 2006. Mycoplasma 
hominis and Trichomonas vaginalis: a unique case of symbiotic relationship 
between two obligate human parasites. Front Biosci 11:2028-2034. 
181. Fiori PL, Diaz N, Cocco AR, Rappelli P, Dessi D. 2013. Association of 
Trichomonas vaginalis with its symbiont Mycoplasma hominis synergistically 
upregulates the in vitro proinflammatory response of human monocytes. Sex 
Transm Infect 89:449-454. 
182. Keane FEA, Thomas BJ, Whitaker L, Renton A, Taylor-Robinson D. 
1997. An association between non-gonococcal urethritis and bacterial 
vaginosis and the implications for patients and their sexual partners. 
Genitourninary Medicine 73:373-377. 
183. Platt R, Warren JW, Edelin KC, Lin J-SL, Rosner B, McCormack WM. 
1980. Infection with Mycoplasma hominis in postpartem fever. The Lancet 
2:1217-1221. 
184. Novy MJ, Duffy L, Axthelm MK, Sadowsky DW, Witkin SS, Gravett MG, 
Cassell GH, Waites KB. 2009. Ureaplasma parvum or Mycoplasma hominis 
as sole pathogens cause chorioamnionitis, preterm delivery, and fetal 
pneumonia in rhesus macaques. Reprod Sci 16:56-70. 
185. Meyer RD, Clough W. 1993. Extragenital Mycoplasma hominis Infections in 
Adults: Emphasis on Immunosuppression. Clinical Infectious Diseases 
17:S243-S249. 
186. Lee EH, Winter HL, van Dijl JM, Metzemaekers JD, Arends JP. 2012. 
Diagnosis and antimicrobial therapy of Mycoplasma hominis meningitis in 
adults. Int J Med Microbiol 302:289-292. 
187. Phuah CL, Javid B, Aliyu SH, Lever AM. 2007. A case of Mycoplasma 
hominis septic arthritis postpartum. J Infect 55:e135-137. 
284 
 
References 
 
188. Luttrell LM, Kanj SS, Corey GR, Lins RE, Spinner RJ, Mallon WJ, 
Sexton DJ. 1994. Mycoplasma hominis septic arthritis: two case reports and 
review. Clin Infect Dis 19:1067-1070. 
189. Noska A, Nasr R, Williams DN. 2012. Closed trauma, Mycoplasma hominis 
osteomyelitis, and the elusive diagnosis of Good's syndrome. BMJ Case Rep 
2012. 
190. Mian AN, Farney AC, Mendley SR. 2005. Mycoplasma hominis septic 
arthritis in a pediatric renal transplant recipient: case report and review of the 
literature. Am J Transplant 5:183-188. 
191. Lyon GM, Alspaugh JA. 1997. Mycoplasma hominis Pneumonia 
Complicating Bilateral Lung Transplantation. Chest 112:1428-1432. 
192. Burdge DR, Reid GD, Reeve CE, Robertson JA, Stemke GW, Bowie WR. 
1988. Septic arthritis due to dual infection with Mycoplasma hominis and 
Ureaplasma urealyticum. J Rheumatol 15:366-368. 
193. Garcia-Porrua C, Blanco FJ, Hernandez A, Atanes A, Galdo F, Moure R, 
Alonso A. 1997. Septic arthritis by Mycoplasma hominis: a case report and 
review of the medical literature. Ann Rheum Dis 56:699-700. 
194. van der Bijl AE, Kamper AM, de Fijter JW, Paul LC. 2000. Mycoplasma 
hominis peritonitis after renal transplantation. Nephron 86:541-542. 
195. Mitsani D, Nguyen MH, Silveira FP, Bermudez C, Toyoda Y, Pasculle 
AW, Clancy CJ. 2010. Mycoplasma hominis pericarditis in a lung transplant 
recipient: review of the literature about an uncommon but important 
cardiothoracic pathogen. Transpl Infect Dis 12:146-150. 
196. Hopkins P. 2001. A cluster of mycoplasma hominis infection in heart-lung 
transplantation. J Heart Lung Transplant 20:223-224. 
197. Hopkins PM, Winlaw DS, Chhajed PN, Harkness JL, Horton MD, Keogh 
AM, Malouf MA, Glanville AR. 2002. Mycoplasma hominis infection in 
heart and lung transplantation. J Heart Lung Transplant 21:1225-1229. 
198. Horiuchi K, Matsumoto T, Ohno Y, Kasuga E, Negishi T, Yaguchi T, 
Sugano M, Honda T. 2014. Intra-abdominal Mycoplasma hominis infection 
in a liver transplant recipient: a case report. Jpn J Infect Dis 67:232-233. 
199. Losada I, Canle D, Moure R, Villanueva R, Bueno J, Sanchez-Galindo A, 
Ramil C, Gomez M. 2004. Mycoplasma hominis infection after liver 
transplantation in a child. Transplantation 77:1624-1625. 
200. Marini H, Merle V, Frebourg N, Godier S, Bastit D, Benadiba L, Menguy 
E, Quesney M, Plissonnier D, Czernichow P. 2008. Mycoplasma hominis 
wound infection after a vascular allograft. J Infect 57:272-274. 
201. Whitson WJ, Ball PA, Lollis SS, Balkman JD, Bauer DF. 2014. 
Postoperative Mycoplasma hominis infections after neurosurgical 
intervention. J Neurosurg Pediatr 14:212-218. 
202. Flouzat-Lachaniette CH, Guidon J, Allain J, Poignard A. 2013. An 
uncommon case of Mycoplasma hominis infection after total disc replacement. 
Eur Spine J 22 Suppl 3:S394-398. 
203. McCarthy KL, Looke DF. 2008. Successful treatment of post-neurosurgical 
intracranial Mycoplasma hominis infection using gatifloxacin. J Infect 57:344-
346. 
204. Watson L, Pang YM, Mitchell S, Dodgson A. 2008. Mycoplasma hominis 
Meningitis in a 24 Week Premature Neonate: Case Report and Short Literature 
Review. J Pediatr Pharmacol Ther 13:251-254. 
285 
 
References 
 
205. Hata A, Honda Y, Asada K, Sasaki Y, Kenri T, Hata D. 2008. Mycoplasma 
hominis meningitis in a neonate: case report and review. J Infect 57:338-343. 
206. Rao RP, Ghanayem NS, Kaufman BA, Kehl KS, Gregg DC, Chusid MJ. 
2002. Mycoplasma hominis and Ureaplasma species brain abscess in a 
neonate. Pediatr Infect Dis J 21:1083-1085. 
207. Chong JS, Tseung SY, Lam HS, Chu WC, Ip M, Wong HT, Zhu CX, Ng 
PC. 2009. Successful treatment of multiple subdural empyemata caused by 
Mycoplasma hominis in a newborn. Neonatology 95:179-182. 
208. Jones DM, Tobin B. 1968. Neonatal eye infections due to Mycoplasma 
hominis. Br Med J 3:467-468. 
209. Powell DA, Miller K, Clyde WA, Jr. 1979. Submandibular adenitis in a 
newborn caused by Mycoplasma hominis. Pediatrics 63:798-799. 
210. Jones DM. 1967. Mycoplasma hominis in Abortion. British Medical Journal 
1:338-340. 
211. Alonso-Vega C, Wauters N, Vermeylen D, Muller MF, Serruys E. 1997. A 
Fatal Case of Mycoplasma hominis Meningoencephalitis in a Full-Term 
Newborn. Journal of clinical microbiology 35:286-287. 
212. Wealthall SR. 1975. Mycoplasma meningitis in infants with spina bifida. Dev 
Med Child Neurol Suppl:117-122. 
213. Jacobs E. 2012. Mycoplasma pneumoniae: now in the focus of clinicians and 
epidemiologists. Euro Surveill 17. 
214. Chalker VJ, Stocki T, Litt D, Bermingham A, Watson J, Fleming D, 
Harrison TG. 2012. Increased detection of Mycoplasma pneumoniae 
infection in children in England and Wales, October 2011 to January 2012. 
Euro Surveillance 17. 
215. Clyde WA, Jr. 1979. Mycoplasma pneumoniae infections of man. In Tully 
JG, Whitcomb RF (ed), The mycoplasmas II Human and animal mycoplasmas, 
vol Volume II. Academic Press, New York. 
216. Nguipdop Djomo P. 2009. Contribution to understanding the dynamics of 
Mycoplasma pneumoniae infections in England and WalesUniversity of 
London, London. 
217. Ghosh K, Clements GB. 1992. Surveillance of Mycoplasma pneumoniae 
infections in Scotland 1986-1991. J Infect 25:221-227. 
218. Gadsby NJ, Reynolds AJ, McMenamin J, Gunson RN, McDonagh S, 
Molyneaux PJ, Yirrell DL, Templeton KE. 2012. Increased reports of 
Mycoplasma pneumoniae from laboratories in Scotland in 2010 and 2011 - 
impact of the epidemic in infants. Euro Surveill 17. 
219. Gunson RN, Bennett S, Maclean A, Carman WF. 2008. Using multiplex 
real time PCR in order to streamline a routine diagnostic service. J Clin Virol 
43:372-375. 
220. Brown RJ, Nguidop-Djomo P, Zhao H, Stanford E, Spiller OB, Chalker 
VJ. 2016. Mycoplasma pneumoniae epidemiology in England and Wales: a 
national perspective. Frontiers in Microbiology 7. 
221. Chalker V, Pereyre S, Dumke R, Winchell J, Khosla P, Sun H, Yan C, 
Vink C, Bebear C, ESGMI. 2015. International Mycoplasma pneumoniae 
typing study: the interpretation of Mycoplasma pneumoniae multilocus 
variable-number tandem-repeat analysis. New Microbes and New Microbes 
doi:10.1016/j.nmni.2015.05.005. 
222. Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R, Shintani M, Sasaki 
Y, Yayoshi M. 1996. Epidemiological study of Mycoplasma pneumoniae 
286 
 
References 
 
infections in japan based on PCR-restriction fragment length polymorphism of 
the P1 cytadhesin gene. J Clin Microbiol 34:447-449. 
223. Chalker VJ, Wood A, Stocki T, Curtis C. 2012. Mycoplasma pneumoniae 
in a patient with severe transverse myelitis, abstr IOM 2012, Toulouse, France,  
224. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. 1995. 
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric 
community-acquired pneumonia: comparative efficacy and safety of 
clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 14:471-
477. 
225. Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, 
Lina B. 1999. Incidence of upper respiratory tract Mycoplasma pneumoniae 
infections among outpatients in Rhone-Alpes, France, during five successive 
winter periods. Journal of Clinical Microbiology 37:1721-1726. 
226. Marston BJ, Plouffe JF, File TM, Jr., Hackman BA, Salstrom SJ, Lipman 
HB, Kolczak MS, Breiman RF. 1997. Incidence of community-acquired 
pneumonia requiring hospitalization. Results of a population-based active 
surveillance Study in Ohio. The Community-Based Pneumonia Incidence 
Study Group. Arch Intern Med 157:1709-1718. 
227. Lind K, Benzon MW, Jensen JS, Clyde WA, Jr. 1997. A 
seroepidemiological study of Mycoplasma pneumoniae infections in Denmark 
over the 50-year period 1946-1995. Eur J Epidemiol 13:581-586. 
228. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, Meng F, Zhu L, Lv M, Yin Y, 
Zhang J. 2013. Surveillance of macrolide-resistant Mycoplasma pneumoniae 
in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother 57:1521-
1523. 
229. Nir-Paz R, Abutbul A, Moses AE, Block C, Hidalgo-Grass C. 2012. 
Ongoing epidemic of Mycoplasma pneumoniae infection in Jerusalem, Israel, 
2010 to 2012. Euro Surveill 17. 
230. Waites KB, Crouse DT, Cassell GH. 1993. Systemic neonatal infection due 
to Ureaplasma urealyticum. Clin Infect Dis 17 Suppl 1:S131-135. 
231. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, 
Kaplan SL, Mace SE, McCracken GH, Jr., Moore MR, St Peter SD, 
Stockwell JA, Swanson JT, Pediatric Infectious Diseases S, the Infectious 
Diseases Society of A. 2011. The management of community-acquired 
pneumonia in infants and children older than 3 months of age: clinical practice 
guidelines by the Pediatric Infectious Diseases Society and the Infectious 
Diseases Society of America. Clin Infect Dis 53:e25-76. 
232. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson 
A, British Thoracic Society Standards of Care C. 2011. British Thoracic 
Society guidelines for the management of community acquired pneumonia in 
children: update 2011. Thorax 66 Suppl 2:ii1-23. 
233. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, 
Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead 
MA, Pneumonia Guidelines Committee of the BTSSoCC. 2009. BTS 
guidelines for the management of community acquired pneumonia in adults: 
update 2009. Thorax 64 Suppl 3:iii1-55. 
234. Waites K, Lysnyansky I, Bebear C. 2014. Emerging antimicrobial resistance 
in mycoplasmas of humans and animals, p 289-322. In Browning G, Citti C 
(ed), Mollicutes: molecular biology and pathogenesis. Caister Academic Press, 
Norfolf, UK. 
287 
 
References 
 
235. Waites KB, Duffy LB, Bebear CM, Matlow A, Talkington DF, Kenny GE, 
Totten PA, Bade DJ, Zheng X, Davidson MK, Shortridge VD, Watts JL, 
Brown SD. 2012. Standardized Methods and Quality Control Limits for Agar 
and Broth Microdilution Susceptibility Testing of Mycoplasma pneumoniae, 
Mycoplasma hominis, and Ureaplasma urealyticum. Journal of clinical 
microbiology 50:3542-3547. 
236. Bebear C, Pereyre S, Peuchant O. 2011. Mycoplasma pneumoniae: 
susceptibility and resistance to antibiotics. Future Microbiol 6:423-431. 
237. Roberts M. 1992. Antibiotic resistance, p 513-524. In Maniloff J, McElhaney 
RN, Finch LR, Baseman JB (ed), Mycoplasmas: Molecular Biology and 
Pathogenesis. American Society for Microbiology, Washington DC. 
238. Bebear C. 2010. Mycoplasma, ureaplasma, p 519-529. In Courvalin P, 
Leclercq R, Rice L (ed), Antibiogram. ESKA Publishing, ASM Press, 
Portland, USA. 
239. Bebear C, Kempf I. 2005. Antimicrobial therapy and antimicrobial resistance, 
p 535-568. In Blanchard A, Browning G (ed), Mycoplasmas: Pathogenesis, 
Molecular Biology, and Emerging Strategies for Control. Horizon Bioscience, 
Wymondham, UK. 
240. Bebear CM, Renaudin H, Bryskier A, Bebear C. 2000. Comparative 
activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial 
agents against human mycoplasmas. Antimicrob Agents Chemother 44:1980-
1982. 
241. Kenny GE, Cartwright FD. 2001. Susceptibilities of Mycoplasma hominis, 
M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, 
dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, 
quinupristin-dalfopristin, and telithromycin compared to their susceptibilities 
to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents 
Chemother 45:2604-2608. 
242. Pereyre S, Gonzalez P, De Barbeyrac B, Darnige A, Renaudin H, Charron 
A, Raherison S, Bebear C, Bebear CM. 2002. Mutations in 23S rRNA 
account for intrinsic resistance to macrolides in Mycoplasma hominis and 
Mycoplasma fermentans and for acquired resistance to macrolides in M. 
hominis. Antimicrob Agents Chemother 46:3142-3150. 
243. Waites KB, Crabb DM, Duffy LB. 2003. In vitro activities of ABT-773 and 
other antimicrobials against human mycoplasmas. Antimicrob Agents 
Chemother 47:39-42. 
244. Raherison S, Gonzalez P, Renaudin H, Charron A, Bebear C, Bebear CM. 
2002. Evidence of active efflux in resistance to ciprofloxacin and to ethidium 
bromide by Mycoplasma hominis. Antimicrob Agents Chemother 46:672-679. 
245. Bebear CM, Pereyre S. 2005. Mechanisms of drug resistance in Mycoplasma 
pneumoniae. Curr Drug Targets Infect Disord 5:263-271. 
246. Rocha EP, Blanchard A. 2002. Genomic repeats, genome plasticity and the 
dynamics of Mycoplasma evolution. Nucleic Acids Res 30:2031-2042. 
247. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High 
frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung 
infection. Science 288:1251-1254. 
248. Jacobs MR, Johnson CE. 2003. Macrolide resistance: an increasing concern 
for treatment failure in children. Pediatr Infect Dis J 22:S131-138. 
288 
 
References 
 
249. Ban N, Nissen P, Hansen J, Moore PB, Steitz TA. 2000. The complete 
atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 
289:905-920. 
250. Douthwaite S, Hansen LH, Mauvais P. 2000. Macrolide-ketolide inhibition 
of MLS-resistant ribosomes is improved by alternative drug interaction with 
domain II of 23S rRNA. Mol Microbiol 36:183-193. 
251. Nissen P, Hansen J, Ban N, Moore PB, Steitz TA. 2000. The structural basis 
of ribosome activity in peptide bond synthesis. Science 289:920-930. 
252. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, 
Yonath A, Franceschi F. 2001. Structural basis for the interaction of 
antibiotics with the peptidyl transferase centre in eubacteria. Nature 413:814-
821. 
253. Vester B, Douthwaite S. 2001. Macrolide resistance conferred by base 
substitutions in 23S rRNA. Antimicrob Agents Chemother 45:1-12. 
254. Bradshaw CS, Jensen JS, Tabrizi SN, Read TR, Garland SM, Hopkins 
CA, Moss LM, Fairley CK. 2006. Azithromycin failure in Mycoplasma 
genitalium urethritis. Emerg Infect Dis 12:1149-1152. 
255. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. 2008. 
Azithromycin treatment failure in Mycoplasma genitalium-positive patients 
with nongonococcal urethritis is associated with induced macrolide resistance. 
Clin Infect Dis 47:1546-1553. 
256. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, 
Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, 
Sasaki T. 2004. Characterization and molecular analysis of macrolide-
resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. 
Antimicrob Agents Chemother 48:4624-4630. 
257. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, 
Sasaki Y, Arakawa Y, Sasaki T. 2001. Characteristics of macrolide-resistant 
Mycoplasma pneumoniae strains isolated from patients and induced with 
erythromycin in vitro. Microbiol Immunol 45:617-620. 
258. Lucier TS, Heitzman K, Liu SK, Hu PC. 1995. Transition mutations in the 
23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. 
Antimicrob Agents Chemother 39:2770-2773. 
259. Pereyre S, Guyot C, Renaudin H, Charron A, Bebear C, Bebear CM. 
2004. In vitro selection and characterization of resistance to macrolides and 
related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents 
Chemother 48:460-465. 
260. Critchley IA, Jones ME, Heinze PD, Hubbard D, Engler HD, Evangelista 
AT, Thornsberry C, Karlowsky JA, Sahm DF. 2002. In vitro activity of 
levofloxacin against contemporary clinical isolates of Legionella 
pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from 
North America and Europe. Clin Microbiol Infect 8:214-221. 
261. Niitu Y, Hasegawa S, Suetake T, Kubota H, Komatsu S, Horikawa M. 
1970. Resistance of Mycoplasma pneumoniae to erythromycin and other 
antibiotics. J Pediatr 76:438-443. 
262. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. 2007. First 
report of macrolide-resistant strains and description of a novel nucleotide 
sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical 
strains isolated in France over 12 years. J Clin Microbiol 45:3534-3539. 
289 
 
References 
 
263. Stopler T, Gerichter CB, Branski D. 1980. Antibiotic-resistant mutants of 
Mycoplasma pneumoniae. Isr J Med Sci 16:169-173. 
264. Bebear C. 2012. Editorial Commentary: Infections Due to Macrolide-
Resistant Mycoplasma pneumoniae: Now What? Clinical infectious diseases : 
an official publication of the Infectious Diseases Society of America 55:1650-
1651. 
265. Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear 
CM, Pereyre S. 2009. Increased macrolide resistance of Mycoplasma 
pneumoniae in France directly detected in clinical specimens by real-time PCR 
and melting curve analysis. J Antimicrob Chemother 64:52-58. 
266. Dumke R, Schnee C, Pletz MW, Rupp J, Jacobs E, Sachse K, Rohde G, 
Capnetz Study G. 2015. Mycoplasma pneumoniae and Chlamydia spp. 
infection in community-acquired pneumonia, Germany, 2011-2012. Emerg 
Infect Dis 21:426-434. 
267. Meyer Sauteur PM, Bleisch B, Voit A, Maurer FP, Relly C, Berger C, 
Nadal D, Bloemberg GV. 2014. Survey of macrolide-resistant Mycoplasma 
pneumoniae in children with community-acquired pneumonia in Switzerland. 
Swiss Med Wkly 144:w14041. 
268. Nilsson AC, Jensen JS, Bjorkman P, Persson K. 2014. Development of 
macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients 
treated with macrolides. Scand J Infect Dis 46:315-319. 
269. Principi N, Esposito S. 2013. Macrolide-resistant Mycoplasma pneumoniae: 
its role in respiratory infection. J Antimicrob Chemother 68:506-511. 
270. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M. 2009. Antimicrobial 
susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of 
macrolide-resistant strains from Shanghai, China. Antimicrob Agents 
Chemother 53:2160-2162. 
271. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, 
Zhang YY, Wang H, Wang C. 2010. High prevalence of macrolide resistance 
in Mycoplasma pneumoniae isolates from adult and adolescent patients with 
respiratory tract infection in China. Clin Infect Dis 51:189-194. 
272. Morozumi M, Takahashi T, Ubukata K. 2010. Macrolide-resistant 
Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of 
community-acquired pneumonia. J Infect Chemother 16:78-86. 
273. Chalker VJ, Stoki T, Mentasti M, Harnden A, Wang K, Harrison TG. 
2012. Macrolide resistant Mycoplasma pneumoniae in England and Wales: 
Abstract P724, abstr European Congress of Clinical Microbiology and 
Infections Diseases, Clin Microbiol Infect,  
274. Ferguson GD, Gadsby NJ, Henderson SS, Hardie A, Kalima P, Morris 
AC, Hill AT, Cunningham S, Templeton KE. 2013. Clinical outcomes and 
macrolide resistance in Mycoplasma pneumoniae infection in Scotland, UK. J 
Med Microbiol 62:1876-1882. 
275. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. 2009. 
Emerging macrolide resistance in Mycoplasma pneumoniae in children: 
detection and characterization of resistant isolates. Pediatr Infect Dis J 28:693-
696. 
276. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ. 2015. Detection 
of macrolide resistant Mycoplasma pneumoniae in England, September 2014 
to September 2015. Euro Surveill 20:pii=30078. 
290 
 
References 
 
277. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, 
Valzano A, Esposito S. 2011. Macrolide-resistant Mycoplasma pneumoniae 
in paediatric pneumonia. Eur Respir J 37:1522-1524. 
278. Pioletti M, Schlunzen F, Harms J, Zarivach R, Gluhmann M, Avila H, 
Bashan A, Bartels H, Auerbach T, Jacobi C, Hartsch T, Yonath A, 
Franceschi F. 2001. Crystal structures of complexes of the small ribosomal 
subunit with tetracycline, edeine and IF3. EMBO J 20:1829-1839. 
279. Blanchard A, Crabb DM, Dybvig K, Duffy LB, Cassell GH. 1992. Rapid 
detection of tetM in Mycoplasma hominis and Ureaplasma urealyticum by 
PCR: tetM confers resistance to tetracycline but not necessarily to 
doxycycline. FEMS Microbiol Lett 74:277-281. 
280. Roberts MC, Kenny GE. 1986. Dissemination of the tetM tetracycline 
resistance determinant to Ureaplasma urealyticum. Antimicrob Agents 
Chemother 29:350-352. 
281. Roberts MC, Koutsky LA, Holmes KK, LeBlanc DJ, Kenny GE. 1985. 
Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM 
sequences. Antimicrob Agents Chemother 28:141-143. 
282. American Thoracic S, Infectious Diseases Society of A. 2005. Guidelines 
for the management of adults with hospital-acquired, ventilator-associated, and 
healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388-416. 
283. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, 
Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, Torres 
A, Whitney CG, Infectious Diseases Society of A, American Thoracic S. 
2007. Infectious Diseases Society of America/American Thoracic Society 
consensus guidelines on the management of community-acquired pneumonia 
in adults. Clin Infect Dis 44 Suppl 2:S27-72. 
284. MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. 2005. Antimicrobial 
drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 11:380-
384. 
285. Hooper DC. 2000. Mechanisms of action and resistance of older and newer 
fluoroquinolones. Clin Infect Dis 31 Suppl 2:S24-28. 
286. Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, Ratet 
N, Lecoq C, Goniot A, Bisch D, Crouzet J. 1996. Differential behaviors of 
Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. 
Antimicrob Agents Chemother 40:2714-2720. 
287. Hooper DC. 2003. Mechanisms and Spectrum of Activity and Resistance, p 
41-67. In Hooper DC, Rubinstein E (ed), Quinolone antimicrobial agents. 
ASM Press, Washington D.C. 
288. Hooper DC. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist 
Updat 2:38-55. 
289. Gruson D, Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM. 
2005. In vitro development of resistance to six and four fluoroquinolones in 
Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob 
Agents Chemother 49:1190-1193. 
290. Yi J, Yoon BH, Kim EC. 2005. Detection and biovar discrimination of 
Ureaplasma urealyticum by real-time PCR. Mol Cell Probes 19:255-260. 
291. Murphy NM, McLauchlin J, Ohai C, Grant KA. 2007. Construction and 
evaluation of a microbiological positive process internal control for PCR-
based examination of food samples for Listeria monocytogenes and 
Salmonella enterica. Int J Food Microbiol 120:110-119. 
291 
 
References 
 
292. Dumke R, Luck PC, Noppen C, Schaefer C, von Baum H, Marre R, Jacobs 
E. 2006. Culture-independent molecular subtyping of Mycoplasma 
pneumoniae in clinical samples. Journal of clinical microbiology 44:2567-
2570. 
293. Zhao F, Cao B, Li J, Song S, Tao X, Yin Y, He L, Zhang J. 2011. Sequence 
analysis of the p1 adhesin gene of Mycoplasma pneumoniae in clinical isolates 
collected in Beijing in 2008 to 2009. J Clin Microbiol 49:3000-3003. 
294. Saitou N, Nei M. 1987. The neighbour-joining method: A new method for 
reconstructing phylogenetic trees. Molecular Biology and Evolution 4:406-
425. 
295. Kimura M. 1980. A simple method for estimating evolutionary rate of base 
substitutions through comparative studies of nucleotide sequences. Journal of 
Molecular Evolution 16:111-120. 
296. Jukes TH, Cantor CR. 1969. Evolution of protein molecules, p 21-132. In 
Munro HN (ed), Mammalian Protein Metabolism. Academic Press, New York. 
297. Nei M, Kumar S. 2000. Molecular Evolution and Phylogenetics. Oxford 
University Press, New York. 
298. Felsenstein J. 1985. Confidence limits on phylogenies: An approach using the 
bootstrap. Evolution 39:783-791. 
299. Beeton ML, Chalker VJ, Maxwell NC, Kotecha S, Spiller OB. 2009. 
Concurrent titration and determination of antibiotic resistance in ureaplasma 
species with identification of novel point mutations in genes associated with 
resistance. Antimicrob Agents Chemother 53:2020-2027. 
300. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for 
Illumina sequence data. Bioinformatics 30:2114-2120. 
301. Nurk S, Bankevich A, Antipov D, Gurevich A, Korobeynikov A, Lapidus 
A, Prlibelsky A, Pyshkin A, Sirotkin A, Sirotkin S, Stepanauskas R, 
McLean J, Lasken R, Clingenpeel SR, Woyke T, Tesler G, Alekseyev MA, 
Pevzner PA. 2013. Assembling Genomes and Mini-metagenomes from 
Highly Chimeric Reads. Research in Computational Molecular Biology 
7821:158-170. 
302. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, 
Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin 
AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A 
New Genome Assembly Algorithm and Its Applications to Single-Cell 
Sequencing. Journal of Computational Biology 19:455-477. 
303. Johnson LS, Eddy SR, Portugaly E. 2010. Hidden Markov model speed 
heuristic and iterative HMM search procedure. BMC Bioinformatics 11:431. 
304. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, 
Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell 
TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler 
D, Daly MJ. 2011. A framework for variation discovery and genotyping using 
next-generation DNA sequencing data. Nat Genet 43:491-498. 
305. Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with 
reduced time and space complexity. BMC Bioinformatics 5:113. 
306. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy 
and high throughput. Nucleic Acids Res 32:1792-1797. 
307. Hsu LY, Harris SR, Chlebowicz MA, Lindsay JA, Koh TH, Krishnan P, 
Tan TY, Hon PY, Grubb WB, Bentley SD, Parkhill J, Peacock SJ, Holden 
292 
 
References 
 
MT. 2015. Evolutionary dynamics of methicillin-resistant Staphylococcus 
aureus within a healthcare system. Genome Biol 16:81. 
308. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, 
Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of 
recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids 
Res 43:e15. 
309. Agresti A, Coull BA. 1998. Approximate is better than "exact" for interval 
estimation of binomial proportions. The American Statistician 52:119-126. 
310. Waites KB, Schelonka RL, Xiao L, Grigsby PL, Novy MJ. 2009. 
Congenital and opportunistic infections: Ureaplasma species and Mycoplasma 
hominis. Semin Fetal Neonatal Med 14:190-199. 
311. Gdoura R, Kchaou W, Chaari C, Znazen A, Keskes L, Rebai T, Hammami 
A. 2007. Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis 
and Mycoplasma genitalium infections and semen quality of infertile men. 
BMC Infect Dis 7:129. 
312. Phillips LE, Faro S, Pokorny SF, Whiteman PA, Goodrich KH, Turner 
RM. 1987. Postcesarean wound infection by Mycoplasma hominis in a patient 
with persistent postpartum fever. Diagnositic Microbiology and Infectious 
Disease 7:193-197. 
313. Tully JG, Smith LG. 1968. Postpartum Septicemia with Mycoplasma 
hominis. JAMA 204:827-828. 
314. Aguilera-Arreola MG, Gonzalez-Cardel AM, Tenorio AM, Curiel-
Quesada E, Castro-Escarpulli G. 2014. Highly specific and efficient primers 
for in-house multiplex PCR detection of Chlamydia trachomatis, Neisseria 
gonorrhoeae, Mycoplasma hominis and Ureaplasma urealyticum. BMC Res 
Notes 7:433. 
315. Mygind T, Zeuthen Sogaard I, Melkova R, Boesen T, Birkelund S, 
Christiansen G. 2000. Cloning, sequencing and variability analysis of the gap 
gene from Mycoplasma hominis. FEMS Microbiol Lett 183:15-21. 
316. Payne MS, Tabone T, Kemp MW, Keelan JA, Spiller OB, Newnham JP. 
2014. High-resolution melt PCR analysis for genotyping of Ureaplasma 
parvum isolates directly from clinical samples. J Clin Microbiol 52:599-606. 
317. Burd EM. 2010. Validation of laboratory-developed molecular assays for 
infectious diseases. Clin Microbiol Rev 23:550-576. 
318. Saunders N, Zambon M, Sharp I, Siddiqui R, Bermingham A, Ellis J, 
Vipond B, Sails A, Moran-Gilad J, Marsh P, Guiver M, Division HPAMS. 
2013. Guidance on the development and validation of diagnostic tests that 
depend on nucleic acid amplification and detection. J Clin Virol 56:260-270. 
319. Carlsen KH, Jensen JS. 2010. Mycoplasma genitalium PCR: does freezing 
of specimens affect sensitivity? J Clin Microbiol 48:3624-3627. 
320. Teng LJ, Zheng X, Glass JI, Watson HL, Tsai J, Cassell GH. 1994. 
Ureaplasma urealyticum biovar specificity and diversity are encoded in 
multiple-banded antigen gene. J Clin Microbiol 32:1464-1469. 
321. Microbiology ASo. 2001. Cumitech 34, Laboratory diagnosis of mycoplasmal 
infections. ASM Press, Washington DC. 
322. Blanchard A, Yanez A, Dybvig K, Watson HL, Griffiths G, Cassell GH. 
1993. Evaluation of intraspecies genetic variation within the 16S rRNA gene 
of Mycoplasma hominis and detection by polymerase chain reaction. J Clin 
Microbiol 31:1358-1361. 
293 
 
References 
 
323. Dussurget O, Roulland-Dussoix D. 1994. Rapid, sensitive PCR-based 
detection of mycoplasmas in simulated samples of animal sera. Appl Environ 
Microbiol 60:953-959. 
324. Grau O, Kovacic R, Griffais R, Launay V, Montagnier L. 1994. 
Development of PCR-based assays for the detection of two human mollicute 
species, Mycoplasma penetrans and M. hominis. Mol Cell Probes 8:139-147. 
325. Wang H, Kong F, Jelfs P, James G, Gilbert GL. 2004. Simultaneous 
detection and identification of common cell culture contaminant and 
pathogenic mollicutes strains by reverse line blot hybridization. Appl Environ 
Microbiol 70:1483-1486. 
326. Yoshida T, Maeda S, Deguchi T, Miyazawa T, Ishiko H. 2003. Rapid 
detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma 
parvum, and Ureaplasma urealyticum organisms in genitourinary samples by 
PCR-microtiter plate hybridization assay. J Clin Microbiol 41:1850-1855. 
327. Zariffard MR, Saifuddin M, Sha BE, Spear GT. 2002. Detection of 
bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, 
Gardnerella vaginalis and Mycoplasma hominis. FEMS Immunol Med 
Microbiol 34:277-281. 
328. Touati A, Benard A, Hassen AB, Bebear CM, Pereyre S. 2009. Evaluation 
of five commercial real-time PCR assays for detection of Mycoplasma 
pneumoniae in respiratory tract specimens. J Clin Microbiol 47:2269-2271. 
329. Ladefoged SA, Christiansen G. 1992. Physical and Genetic Mapping of the 
Genomes of Five Mycoplasma hominis Strains by Pulse-Field Gel 
Electrophoresis. Journal of bacteriology 174:2199-2207. 
330. Cheah FC, Anderson TP, Darlow BA, Murdoch DR. 2005. Comparison of 
the Mycoplasma Duo test with PCR for detection of ureaplasma species in 
endotracheal aspirates from premature infants. J Clin Microbiol 43:509-510. 
331. Evans GE, Anderson TP, Seaward LM, Murdoch DR. 2007. Evaluation of 
the Mycoplasma Duo kit for the detection of Mycoplasma hominis and 
Ureaplasma urealyticum from urogenital and placental specimens. Br J 
Biomed Sci 64:66-69. 
332. Yoon BH, Romero R, Kim M, Kim EC, Kim T, Park JS, Jun JK. 2000. 
Clinical implications of detection of Ureaplasma urealyticum in the amniotic 
cavity with the polymerase chain reaction. Am J Obstet Gynecol 183:1130-
1137. 
333. Yoon BH, Romero R, Lim JH, Shim SS, Hong JS, Shim JY, Jun JK. 2003. 
The clinical significance of detecting Ureaplasma urealyticum by the 
polymerase chain reaction in the amniotic fluid of patients with preterm labor. 
Am J Obstet Gynecol 189:919-924. 
334. Gerber S, Vial Y, Hohlfeld P, Witkin SS. 2003. Detection of Ureaplasma 
urealyticum in second-trimester amniotic fluid by polymerase chain reaction 
correlates with subsequent preterm labor and delivery. J Infect Dis 187:518-
521. 
335. Svenstrup HF, Jensen JS, Bjornelius E, Lidbrink P, Birkelund S, 
Christiansen G. 2005. Development of a quantitative real-time PCR assay for 
detection of Mycoplasma genitalium. J Clin Microbiol 43:3121-3128. 
336. Abele-Horn M, Wolff C, Dressel P, Zimmermann A, Vahlensieck W, Pfaff 
F, Ruckdeschel G. 1996. Polymerase chain reaction versus culture for the 
detection of Ureaplasma urealyticum and Mycoplasma hominis in the 
294 
 
References 
 
urogenital tract of adults and the respiratory tract of newborns. European 
Journal of Clinical Microbiology and Infectious Diseases 15:595-598. 
337. Luki N, Lebel P, Boucher M, Doray B, Turgeon J, Brousseau R. 1998. 
Comparison of polymerase chain reaction assay with culture for detection of 
genital mycoplasmas in perinatal infections. Eur J Clin Microbiol Infect Dis 
17:255-263. 
338. Stellrecht KA, Woron AM, Mishrik NG, Venezia RA. 2004. Comparison of 
multiplex PCR assay with culture for detection of genital mycoplasmas. J Clin 
Microbiol 42:1528-1533. 
339. Teng K, Li M, Yu W, Li H, Shen D, Liu D. 1994. Comparison of PCR with 
culture for detection of Ureaplasma urealyticum in clinical samples from 
patients with urogenital infections. J Clin Microbiol 32:2232-2234. 
340. Jensen JS, Hansen HT, Lind K. 1996. Isolation of Mycoplasma genitalium 
strains from the male urethra. J Clin Microbiol 34:286-291. 
341. Petrikkos GL, Hadjisoteriou M, Daikos GL. 2007. PCR versus culture in 
the detection of vaginal Ureaplasma urealyticum and Mycoplasma hominis. 
Int J Gynaecol Obstet 97:202-203. 
342. Quinn PA, Shewchuk AB, Shuber J, Lie KI, Ryan E, Sheu M, Chipman 
ML. 1983. Serologic evidence of ureaplasma urealyticum infection in women 
with spontaneous pregnancy loss. Am J Obstet Gynecol 145:245-250. 
343. Abele-Horn M, Wolff C, Dressel P, Pfaff F, Zimmermann A. 1997. 
Association of Ureaplasma urealyticum biovars with clinical outcome for 
neonates, obstetric patients, and gynecological patients with pelvic 
inflammatory disease. J Clin Microbiol 35:1199-1202. 
344. Horowitz S, Mazor M, Romero R, Horowitz J, Glezerman M. 1995. 
Infection of the amniotic cavity with Ureaplasma urealyticum in the 
midtrimester of pregnancy. J Reprod Med 40:375-379. 
345. Naessens A, Foulon W, Breynaert J, Lauwers S. 1988. Serotypes of 
Ureaplasma urealyticum isolated from normal pregnant women and patients 
with pregnancy complications. J Clin Microbiol 26:319-322. 
346. Wiley CA, Quinn PA. 1984. Enzyme-linked immunosorbent assay for 
detection of specific antibodies to Ureaplasma urealyticum serotypes. J Clin 
Microbiol 19:421-426. 
347. Cassell GH, Waites KB, Watson HL, Crouse DT, Harasawa R. 1993. 
Ureaplasma urealyticum intrauterine infection: role in prematurity and disease 
in newborns. Clin Microbiol Rev 6:69-87. 
348. Kim M, Kim G, Romero R, Shim SS, Kim EC, Yoon BH. 2003. Biovar 
diversity of Ureaplasma urealyticum in amniotic fluid: distribution, 
intrauterine inflammatory response and pregnancy outcomes. J Perinat Med 
31:146-152. 
349. Zheng X, Watson HL, Waites KB, Cassell GH. 1992. Serotype diversity and 
antigen variation among invasive isolates of Ureaplasma urealyticum from 
neonates. Infect Immun 60:3472-3474. 
350. Robertson JA, Honore LH, Stemke GW. 1986. Serotypes of Ureaplasma 
urealyticum in spontaneous abortion. Pediatr Infect Dis 5:S270-272. 
351. Stemke GW, Robertson JA. 1985. Problems associated with serotyping 
strains of Ureaplasma urealyticum. Diagn Microbiol Infect Dis 3:311-320. 
352. Payne MS, Goss KC, Connett GJ, Legg JP, Bruce KD, Chalker V. 2012. 
A quantitative analysis of Ureaplasma urealyticum and Ureaplasma parvum 
295 
 
References 
 
compared with host immune response in preterm neonates at risk of developing 
bronchopulmonary dysplasia. J Clin Microbiol 50:909-914. 
353. Malaguti N, Bahls LD, Uchimura NS, Gimenes F, Consolaro ME. 2015. 
Sensitive Detection of Thirteen Bacterial Vaginosis-Associated Agents Using 
Multiplex Polymerase Chain Reaction. Biomed Res Int 2015:645853. 
354. Cao B, Wang S, Tian Z, Hu P, Feng L, Wang L. 2015. DNA Microarray 
Characterization of Pathogens Associated with Sexually Transmitted Diseases. 
PLoS One 10:e0133927. 
355. Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT. 2005. 
Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal 
Ed 90:F220-224. 
356. Nasution TA, Cheong SF, Lim CT, Leong EW, Ngeow YF. 2007. Multiplex 
PCR for the detection of urogenital pathogens in mothers and newborns. 
Malays J Pathol 29:19-24. 
357. Kim Y, Kim J, Lee KA. 2015. Analytical Performance of Multiplex Real-
Time PCR for Six Sexually Transmitted Pathogens. Clin Lab 61:1749-1754. 
358. Cox C, Saxena N, Watt AP, Gannon C, McKenna JP, Fairley DJ, Sweet 
D, Shields MD, Cosby SL, Coyle PV. 2016. The common vaginal commensal 
bacterium Ureaplasma parvum is associated with chorioamnionitis in extreme 
preterm labour. J Matern Fetal Neonatal Med 
doi:10.3109/14767058.2016.1140734:1-15. 
359. Blanchard A, Hentschel J, Duffy L, Baldus K, Cassell GH. 1993. Detection 
of Ureaplasma urealyticum by polymerase chain reaction in the urogenital tract 
of adults, in amniotic fluid, and in the respiratory tract of newborns. Clin Infect 
Dis 17 Suppl 1:S148-153. 
360. Vancutsem E, Soetens O, Breugelmans M, Foulon W, Naessens A. 2011. 
Modified real-time PCR for detecting, differentiating, and quantifying 
Ureaplasma urealyticum and Ureaplasma parvum. J Mol Diagn 13:206-212. 
361. Cao X, Wang Y, Hu X, Qing H, Wang H. 2007. Real-time TaqMan 
polymerase chain reaction assays for quantitative detection and differentiation 
of Ureaplasma urealyticum and Ureaplasma parvum. Diagn Microbiol Infect 
Dis 57:373-378. 
362. Sogaard IZ, Boesen T, Mygind T, Melkova R, Birkelund S, Christiansen 
G, Schierup MH. 2002. Recombination in Mycoplasma hominis. Infect Genet 
Evol 1:277-285. 
363. Sendzik T, Balbier S, Hofmann M, Steimer M, Carman WF, Buch S, 
Kneweler K. 2013. Evaluation of the Fast-track Diagnositics Real time 
multiplex PCR for simultaneous detection of Neisseria gonorrhoeae, 
Chlamydia trachomatis, Mycoplasma genitalium, Trachomonas vaginalis, 
Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum., 
abstr ASM, Denver, Colorado,  
364. Couldwell DL, Gidding HF, Freedman EV, McKechnie ML, Biggs K, 
Sintchenko V, Gilbert GL. 2010. Ureaplasma urealyticum is significantly 
associated with non-gonococcal urethritis in heterosexual Sydney men. Int J 
STD AIDS 21:337-341. 
365. Sobouti B, Fallah S, Mobayen M, Noorbakhsh S, Ghavami Y. 2014. 
Colonization of Mycoplasma hominis and Ureaplasma urealyticum in 
pregnant women and their transmission to offspring. Iran J Microbiol 6:219-
224. 
296 
 
References 
 
366. Sweeney EL, Kallapur SG, Gisslen T, Lambers DS, Chougnet CA, 
Stephenson SA, Jobe AH, Knox CL. 2015. Placental Infection With 
Ureaplasma species Is Associated With Histologic Chorioamnionitis and 
Adverse Outcomes in Moderately Preterm and Late-Preterm Infants. J Infect 
Dis doi:10.1093/infdis/jiv587. 
367. Morioka I, Fujibayashi H, Enoki E, Yokoyama N, Yokozaki H, Matsuo 
M. 2010. Congenital pneumonia with sepsis caused by intrauterine infection 
of Ureaplasma parvum in a term newborn: a first case report. J Perinatol 
30:359-362. 
368. Bharat A, Cunningham SA, Scott Budinger GR, Kreisel D, DeWet CJ, 
Gelman AE, Waites K, Crabb D, Xiao L, Bhorade S, Ambalavanan N, 
Dilling DF, Lowery EM, Astor T, Hachem R, Krupnick AS, DeCamp MM, 
Ison MG, Patel R. 2015. Disseminated Ureaplasma infection as a cause of 
fatal hyperammonemia in humans. Sci Transl Med 7:284re283. 
369. Glaser K, Wohlleben M, Speer CP. 2015. An 8-month history of meningitis 
in an extremely low birth weight infant? - Long-lasting Infection with 
Ureaplasma parvum. Z Geburtshilfe Neonatol 219:52-56. 
370. Kasper DC, Mechtler TP, Bohm J, Petricevic L, Gleiss A, Spergser J, Witt 
A, Herkner KR, Berger A. 2011. In utero exposure to Ureaplasma spp. is 
associated with increased rate of bronchopulmonary dysplasia and 
intraventricular hemorrhage in preterm infants. J Perinat Med 39:331-336. 
371. Okogbule-Wonodi A, Gross G, Sun C, Agthe A, Xiap L, Waites KB, 
Viscardi R. 2011. Nectrotizing enterocolitis is associated with ureaplasma 
colonizatin in preterm infants. Pediatric Research 69:442-447. 
372. Viscardi RM, Hasday JD. 2009. Role of Ureaplasma species in neonatal 
chronic lung disease: epidemiologic and experimental evidence. Pediatr Res 
65:84R-90R. 
373. Lode HM. 2009. Clinical impact of antibiotic-resistant Gram-positive 
pathogens. Clin Microbiol Infect 15:212-217. 
374. Waites K, D.J. B, Bebear C, Brown SD, Davidson MK, Duffy L, Kenny G, 
Matlow A, Shortridge D, Talkington DF, Totten PA, Watts JL, Zheng X. 
2011. M43-A: Methods for antimicrobial susceptibility testing for human 
Mycoplasmas; approved guideline. Clinical and Laboratory Standards Institute 
31. 
375. Beeton ML, Chalker VJ, Jones LC, Maxwell NC, Spiller OB. 2015. 
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from 
Neonates in England and Wales between 2007 and 2013. Antimicrob Agents 
Chemother 60:52-56. 
376. Beeton ML, Maxwell NC, Davies PL, Nuttall D, McGreal E, Chakraborty 
M, Spiller OB, Kotecha S. 2011. Role of pulmonary infection in the 
development of chronic lung disease of prematurity. Eur Respir J 37:1424-
1430. 
377. Wolfs TG, Kallapur SG, Knox CL, Thuijls G, Nitsos I, Polglase GR, 
Collins JJ, Kroon E, Spierings J, Shroyer NF, Newnham JP, Jobe AH, 
Kramer BW. 2013. Antenatal ureaplasma infection impairs development of 
the fetal ovine gut in an IL-1-dependent manner. Mucosal Immunol 6:547-556. 
378. Romero R, Shamma F, Avila C, Jimenez C, Callahan R, Nores J, Mazor 
M, Brekus CA, Hobbins JC. 1990. Infection and labor. VI. Prevalence, 
microbiology, and clinical significance of intraamniotic infection in twin 
gestations with preterm labor. Am J Obstet Gynecol 163:757-761. 
297 
 
References 
 
379. Mazor M, Hershkovitz R, Ghezzi F, Maymon E, Horowitz S, Leiberman 
JR. 1996. Intraamniotic infection in patients with preterm labor and twin 
pregnancies. Acta Obstet Gynecol Scand 75:624-627. 
380. Phung DT, Blickstein I, Goldman RD, Machin GA, LoSasso RD, Keith 
LG. 2002. The Northwestern Twin Chorionicity Study: I. Discordant 
inflammatory findings that are related to chorionicity in presenting versus 
nonpresenting twins. Am J Obstet Gynecol 186:1041-1045. 
381. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA. 2011. 
Toll-like receptor 2 mediates fatal immunopathology in mice during treatment 
of secondary pneumococcal pneumonia following influenza. J Infect Dis 
204:1358-1366. 
382. Ghoneim HE, McCullers JA. 2014. Adjunctive corticosteroid therapy 
improves lung immunopathology and survival during severe secondary 
pneumococcal pneumonia in mice. J Infect Dis 209:1459-1468. 
383. Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids--
new mechanisms for old drugs. N Engl J Med 353:1711-1723. 
384. Barnes PJ. 2006. How corticosteroids control inflammation: Quintiles Prize 
Lecture 2005. Br J Pharmacol 148:245-254. 
385. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, 
van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters 
JC, Bos WJ, Biesma DH. 2011. Dexamethasone and length of hospital stay 
in patients with community-acquired pneumonia: a randomised, double-blind, 
placebo-controlled trial. Lancet 377:2023-2030. 
386. Shafiq M, Mansoor MS, Khan AA, Sohail MR, Murad MH. 2013. 
Adjuvant steroid therapy in community-acquired pneumonia: a systematic 
review and meta-analysis. J Hosp Med 8:68-75. 
387. Nie W, Zhang Y, Cheng J, Xiu Q. 2012. Corticosteroids in the treatment of 
community-acquired pneumonia in adults: a meta-analysis. PLoS One 
7:e47926. 
388. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. 
2010. Efficacy of corticosteroids in community-acquired pneumonia: a 
randomized double-blinded clinical trial. Am J Respir Crit Care Med 181:975-
982. 
389. Ranzani OT, Ferrer M, Esperatti M, Giunta V, Bassi GL, Carvalho CR, 
Torres A. 2012. Association between systemic corticosteroids and outcomes 
of intensive care unit-acquired pneumonia. Crit Care Med 40:2552-2561. 
390. Polverino E, Cilloniz C, Dambrava P, Gabarrus A, Ferrer M, Agusti C, 
Prina E, Montull B, Menendez R, Niederman MS, Torres A. 2013. 
Systemic corticosteroids for community-acquired pneumonia: reasons for use 
and lack of benefit on outcome. Respirology 18:263-271. 
391. Skornik WA, Dressler DP. 1974. The effects of short-term steroid therapy on 
lung bacterial clearance and survival in rats. Ann Surg 179:415-421. 
392. Hicks CW, Sweeney DA, Danner RL, Eichacker PQ, Suffredini AF, Feng 
J, Sun J, Moriyama B, Wesley R, Behrend EN, Solomon SB, Natanson C. 
2012. Beneficial effects of stress-dose corticosteroid therapy in canines depend 
on the severity of staphylococcal pneumonia. Intensive Care Med 38:2063-
2071. 
393. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz 
K, Gomez AM, Esposito S, Principi N, Hardy RD. 2008. The impact of 
298 
 
References 
 
steroids given with macrolide therapy on experimental Mycoplasma 
pneumoniae respiratory infection. J Infect Dis 198:1180-1188. 
394. Pereyre S, Metifiot M, Cazanave C, Renaudin H, Charron A, Bebear C, 
Bebear CM. 2007. Characterisation of in vitro-selected mutants of 
Ureaplasma parvum resistant to macrolides and related antibiotics. Int J 
Antimicrob Agents 29:207-211. 
395. Zalewska-Kaszubska J, Gorska D. 2001. Anti-inflammatory capabilities of 
macrolides. Pharmacol Res 44:451-454. 
396. Theron AJ, Feldman C, Anderson R. 2000. Investigation of the anti-
inflammatory and membrane-stabilizing potential of spiramycin in vitro. J 
Antimicrob Chemother 46:269-271. 
397. Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y. 
2000. Effects of clarithromycin on cultured human nasal epithelial cells and 
fibroblasts. Laryngoscope 110:126-131. 
398. Ozdemir R, Erdeve O, Dizdar EA, Oguz SS, Uras N, Saygan S, Karabulut 
E, Dilmen U. 2011. Clarithromycin in preventing bronchopulmonary 
dysplasia in Ureaplasma urealyticum-positive preterm infants. Pediatrics 
128:e1496-1501. 
399. Cultrera R, Seraceni S, Germani R, Contini C. 2006. Molecular evidence 
of Ureaplasma urealyticum and Ureaplasma parvum colonization in preterm 
infants during respiratory distress syndrome. BMC Infect Dis 6:166. 
400. Jao RL. 1967. Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in 
vitro. Am J Med Sci 253:639-650. 
401. Eszik I, Lantos I, Onder K, Somogyvari F, Burian K, Endresz V, Virok 
DP. 2016. High dynamic range detection of Chlamydia trachomatis growth by 
direct quantitative PCR of the infected cells. J Microbiol Methods 120:15-22. 
402. Goy G, Greub G. 2009. Antibiotic susceptibility of Waddlia chondrophila in 
Acanthamoeba castellanii amoebae. Antimicrob Agents Chemother 53:2663-
2666. 
403. Degrange S, Renaudin H, Charron A, Bebear C, Bebear CM. 2008. 
Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: 
prevalence in Bordeaux, France, from 1999 to 2002 and description of two 
tet(M)-positive isolates of M. hominis susceptible to tetracyclines. Antimicrob 
Agents Chemother 52:742-744. 
404. Diaz L, Cabrera LE, Fernandez T, Ibanez I, Torres Y, Obregon Y, Rivero 
Y. 2013. Frequency and antimicrobial sensitivity of Ureaplasma urealyticum 
and Mycoplasma hominis in patients with vaginal discharge. MEDICC Rev 
15:45-47. 
405. Koh E, Kim S, Kim I, Maeng KY, Lee SA. 2009. Antimicrobial 
susceptibilities of Ureaplasma urealyticum and Mycoplasma hominis in 
pregnant women. Korean Journal of Clinical Microbiology 12. 
406. Krausse R, Schubert S. 2010. In-vitro activities of tetracyclines, macrolides, 
fluoroquinolones and clindamycin against Mycoplasma hominis and 
Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect 
16:1649-1655. 
407. Azizmohammadi S, Azizmohammadi S. 2015. Antimicrobial Susceptibility 
Patterns of Ureaplasma urealyticum and Mycoplasma hominis Isolated From 
Pregnant Women. Iran Red Crescent Med J 17:e17211. 
299 
 
References 
 
408. Su YA, He P, Clewell DB. 1992. Characterization of the tet(M) determinant 
of Tn916: evidence for regulation by transcription attenuation. Antimicrob 
Agents Chemother 36:769-778. 
409. Enne VI, Delsol AA, Roe JM, Bennett PM. 2006. Evidence of antibiotic 
resistance gene silencing in Escherichia coli. Antimicrob Agents Chemother 
50:3003-3010. 
410. Saez A, Monteagudo I, Minambres E, Ots E, Rodriguez-Borregan JC, 
Garcia C. 2003. Pneumonia due to Mycoplasma hominis in a healthy adult. 
Scand J Infect Dis 35:282-284. 
411. Wylam ME, Kennedy CC, Hernandez NM, Peters SG, Maleszewski JJ, 
Cassivi SD, Scott JP. 2013. Fatal hyperammonaemia caused by Mycoplasma 
hominis. Lancet 382:1956. 
412. Jensen LT, Thorsen P, Moller B, Birkelund S, Christiansen G. 1998. 
Antigenic and genomic homogeneity of successive Mycoplasma hominis 
isolates. Journal of Medical Microbiology 47:659-666. 
413. Busch U, Nitschko H, Pfaff F, Henrich B, Heesemann J, Abele-Horn M. 
2000. Molecular comparison of Mycoplasma hominis strains isolated from 
colonized women and women with various urogenital infections. Zentralbl 
Bakteriol 289:879-888. 
414. Kokotovic B, Friis NF, Jensen JS, Ahrens P. 1999. Amplified-fragment 
length polymorphism fingerprinting of Mycoplasma species. J Clin Microbiol 
37:3300-3307. 
415. Soroka AE, Momynaliev KT, Taraskina AM, Savicheva AM, Govorun 
VM. 2001. Genetic heterogeneity of Mycoplasma hominis clinical isolates 
detected during observation of patients with recurrent urogenital inflammation. 
Bulletin of Experimental Biology and Medicine 132:663-665. 
416. Cazanave C, Charron A, Renaudin H, Bebear C. 2012. Method comparison 
for molecular typing of French and Tunisian Mycoplasma genitalium-positive 
specimens. J Med Microbiol 61:500-506. 
417. McAuliffe L, Ayling RD, Nicholas RA. 2007. Identification and 
characterization of variable-number tandem-repeat markers for the molecular 
epidemiological analysis of Mycoplasma mycoides subspecies mycoides SC. 
FEMS Microbiol Lett 276:181-188. 
418. Pinho L, Thompson G, Rosenbusch R, Carvalheira J. 2012. Genotyping of 
Mycoplasma bovis isolates using multiple-locus variable-number tandem-
repeat analysis. J Microbiol Methods 88:377-385. 
419. Vranckx K, Maes D, Calus D, Villarreal I, Pasmans F, Haesebrouck F. 
2011. Multiple-locus variable-number tandem-repeat analysis is a suitable tool 
for differentiation of Mycoplasma hyopneumoniae strains without cultivation. 
J Clin Microbiol 49:2020-2023. 
420. Sulyok KM, Kreizinger Z, Fekete L, Janosi S, Schweitzer N, Turcsanyi I, 
Makrai L, Erdelyi K, Gyuranecz M. 2014. Phylogeny of Mycoplasma bovis 
isolates from Hungary based on multi locus sequence typing and multiple-
locus variable-number tandem repeat analysis. BMC Vet Res 10:108. 
421. McAuliffe L, Gosney F, Hlusek M, de Garnica ML, Spergser J, Kargl M, 
Rosengarten R, Ayling RD, Nicholas RA, Ellis RJ. 2011. Multilocus 
sequence typing of Mycoplasma agalactiae. J Med Microbiol 60:803-811. 
422. Tocqueville V, Ferre S, Nguyen NH, Kempf I, Marois-Crehan C. 2014. 
Multilocus sequence typing of Mycoplasma hyorhinis strains identified by a 
real-time TaqMan PCR assay. J Clin Microbiol 52:1664-1671. 
300 
 
References 
 
423. Mayor D, Jores J, Korczak BM, Kuhnert P. 2008. Multilocus sequence 
typing (MLST) of Mycoplasma hyopneumoniae: a diverse pathogen with 
limited clonality. Vet Microbiol 127:63-72. 
424. Brown RJ, Holden MT, Spiller OB, Chalker VJ. 2015. Development of a 
Multilocus Sequence Typing Scheme for Molecular Typing of Mycoplasma 
pneumoniae. J Clin Microbiol 53:3195-3203. 
425. Barile MF, Grabowski MW, Stephens EB, O'Brien SJ, Simonson JM, 
Izumikawa K, Chandler DK, Taylor-Robinson D, Tully JG. 1983. 
Mycoplasma hominis- tissue cell interactions: a review with new observations 
on phenotypic and genotypic properties. Sex Transm Dis 10:345-354. 
426. Zhang J, Kong Y, Feng Y, Huang J, Song T, Ruan Z, Song J, Jiang Y, Yu 
Y, Xie X. 2014. Development of a multilocus sequence typing scheme for 
Ureaplasma. Eur J Clin Microbiol Infect Dis 33:537-544. 
427. Grattard F, Soleihac B, De Barbeyrac B, Bebear C, Seffert P, Pozzetto B. 
1995. Epidemiologic and molecular investigations of genital mycoplasmas 
from women and neonates at delivery. Pediatr Infect Dis J 14:853-858. 
428. Bebear CM, Bove JM, Bebear C, Renaudin J. 1997. Characterization of 
Mycoplasma hominis mutations involved in resistance to fluoroquinolones. 
Antimicrob Agents Chemother 41:269-273. 
429. Dumke R, Von Baum H, Luck PC, Jacobs E. 2010. Subtypes and variants 
of Mycoplasma pneumoniae: local and temporal changes in Germany 2003-
2006 and absence of a correlation between the genotype in the respiratory tract 
and the occurrence of genotype-specific antibodies in the sera of infected 
patients. Epidemiol Infect 138:1829-1837. 
430. Jolley KA, Maiden MC. 2010. BIGSdb: Scalable analysis of bacterial 
genome variation at the population level. BMC Bioinformatics 11:595. 
431. Manso-Silvan L, Dupuy V, Lysnyansky I, Ozdemir U, Thiaucourt F. 2012. 
Phylogeny and molecular typing of Mycoplasma agalactiae and Mycoplasma 
bovis by multilocus sequencing. Vet Microbiol 161:104-112. 
432. Rosales RS, Churchward CP, Schnee C, Sachse K, Lysnyansky I, Catania 
S, Iob L, Ayling RD, Nicholas RA. 2015. Global multilocus sequence typing 
analysis of Mycoplasma bovis isolates reveals two main population clusters. J 
Clin Microbiol 53:789-794. 
433. Dandekar T, Huynen M, Regula JT, Ueberle B, Zimmermann CU, 
Andrade MA, Doerks T, Sanchez-Pulido L, Snel B, Suyama M, Yuan YP, 
Herrmann R, Bork P. 2000. Re-annotating the Mycoplasma pneumoniae 
genome sequence: adding value, function and reading frames. Nucleic Acids 
Res 28:3278-3288. 
434. Krishnakumar R, Assad-Garcia N, Benders GA, Phan Q, Montague MG, 
Glass JI. 2010. Targeted chromosomal knockouts in Mycoplasma 
pneumoniae. Appl Environ Microbiol 76:5297-5299. 
435. Kenri T, Ohya H, Horino A, Shibayama K. 2012. Identification of 
Mycoplasma pneumoniae type 2b variant strains in Japan. J Med Microbiol 
61:1633-1635. 
436. Kenri T, Horino A, Matsui M, Sasaki Y, Suzuki S, Narita M, Ohya H, 
Okazaki N, Shibayama K. 2012. Complete genome sequence of Mycoplasma 
pneumoniae type 2a strain 309, isolated in Japan. Journal of bacteriology 
194:1253-1254. 
437. Dos Vultos T, Mestre O, Rauzier J, Golec M, Rastogi N, Rasolofo V, 
Tonjum T, Sola C, Matic I, Gicquel B. 2008. Evolution and diversity of 
301 
 
References 
 
clonal bacteria: the paradigm of Mycobacterium tuberculosis. PLoS One 
3:e1538. 
438. Woese CR. 1987. Bacterial evolution. Microbiol Rev 51:221-271. 
439. Diaz MH, Benitez AJ, Winchell JM. 2015. Investigations of Mycoplasma 
pneumoniae infections in the United States: trends in molecular typing and 
macrolide resistance from 2006 to 2013. J Clin Microbiol 53:124-130. 
440. Zhou Z, Li X, Chen X, Luo F, Pan C, Zheng X, Tan F. 2015. Macrolide-
resistant Mycoplasma pneumoniae in adults in Zhejiang, China. Antimicrob 
Agents Chemother 59:1048-1051. 
441. Chen FQ, Yang YZ, Yu LL, Bi CB. 2015. Prevalence of Mycoplasma 
pneumoniae: a cause for community-acquired infection among pediatric 
populaztion. Niger J Clin Pract 18:354-358. 
442. Klement E, Talkington DF, Wasserzug O, Kayouf R, Davidovitch N, 
Dumke R, Bar-Zeev Y, Ron M, Boxman J, Lanier Thacker W, Wolf D, 
Lazarovich T, Shemer-Avni Y, Glikman D, Jacobs E, Grotto I, Block C, 
Nir-Paz R. 2006. Identification of risk factors for infection in an outbreak of 
Mycoplasma pneumoniae respiratory tract disease. Clin Infect Dis 43:1239-
1245. 
443. Touati A, Blouin Y, Sirand-Pugnet P, Renaudin H, Oishi T, Vergnaud G, 
Bebear C, Pereyre S. 2015. Molecular epidemiology of Mycoplasma 
pneumoniae: genotyping using single nucleotide polymorphisms and 
SNaPshot technology. J Clin Microbiol doi:10.1128/JCM.01156-15. 
444. Pereyre S, Charron A, Hidalgo-Grass C, Touati A, Moses AE, Nir-Paz R, 
Bebear C. 2012. The spread of Mycoplasma pneumoniae is polyclonal in both 
an endemic setting in France and in an epidemic setting in Israel. PLoS One 
7:e38585. 
445. Nilsson AC, Bjorkman P, Welinder-Olsson C, Widell A, Persson K. 2010. 
Clinical severity of Mycoplasma pneumoniae (MP) infection is associated with 
bacterial load in oropharyngeal secretions but not with MP genotype. BMC 
Infect Dis 10:39. 
446. Jain M, Fiddes IT, Miga KH, Olsen HE, Paten B, Akeson M. 2015. 
Improved data analysis for the MinION nanopore sequencer. Nat Methods 
12:351-356. 
447. Ling CL, Oravcova K, Beattie TF, Creer DD, Dilworth P, Fulton NL, 
Hardie A, Munro M, Pond M, Templeton K, Webster D, Workman S, 
McHugh TD, Gillespie SH. 2014. Tools for detection of Mycoplasma 
amphoriforme: a primary respiratory pathogen? J Clin Microbiol 52:1177-
1181. 
448. Versage JL, Severin DD, Chu MC, Petersen JM. 2003. Development of a 
multitarget real-time TaqMan PCR assay for enhanced detection of Francisella 
tularensis in complex specimens. J Clin Microbiol 41:5492-5499. 
449. Thurman KA, Walter ND, Schwartz SB, Mitchell SL, Dillon MT, 
Baughman AL, Deutscher M, Fulton JP, Tongren JE, Hicks LA, Winchell 
JM. 2009. Comparison of laboratory diagnostic procedures for detection of 
Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 48:1244-
1249. 
450. Diaz MH, Winchell J. 2016. The evolution of advanced molecular diagnostics 
for the detection and characterisation of Mycoplasma pneumoniae. Frontiers 
in Microbiology 7:232. 
302 
 
References 
 
451. Chua KB, Ngeow YF, Ng KB, Chye JK, Lim CT. 1998. Ureaplasma 
urealyticum and Mycoplasma hominis isolation from cervical secretions of 
pregnant women and nasopharyngeal secretions of their babies at delivery. 
Singapore Med J 39:300-302. 
452. Izraeli S, Samra Z, Sirota L, Merlob P, Davidson S. 1991. Genital 
mycoplasmas in preterm infants: prevalence and clinical significance. Eur J 
Pediatr 150:804-807. 
453. Embree J. 1988. Mycoplasma hominis in maternal and fetal infections. Ann 
N Y Acad Sci 549:56-64. 
454. Capoccia R, Greub G, Baud D. 2013. Ureaplasma urealyticum, Mycoplasma 
hominis and adverse pregnancy outcomes. Curr Opin Infect Dis 26:231-240. 
455. McDonald HM, Brocklehurst P, Gordon A. 2007. Antibiotics for treating 
bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 
doi:10.1002/14651858.CD000262.pub3:CD000262. 
456. Morency AM, Bujold E. 2007. The effect of second-trimester antibiotic 
therapy on the rate of preterm birth. J Obstet Gynaecol Can 29:35-44. 
457. Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. 
2008. Antenatal lower genital tract infection screening and treatment programs 
for preventing preterm delivery. Cochrane Database Syst Rev 
doi:10.1002/14651858.CD006178.pub2:CD006178. 
458. Huang FK, Chen HL, Yang PH, Lin HC. 2015. Bird's Eye View of a 
Neonatologist: Clinical Approach to Emergency Neonatal Infection. Pediatr 
Neonatol doi:10.1016/j.pedneo.2015.06.004. 
459. Neu J. 2015. Preterm infant nutrition, gut bacteria, and necrotizing 
enterocolitis. Curr Opin Clin Nutr Metab Care 18:285-288. 
460. Berdon WE. 1964. Necrotizing enterocolitis in the premature infant. 
Radiology 83. 
461. Foy HM, Grayston JT, Kenny GE, Alexander ER, McMahan R. 1966. 
Epidemiology of Mycoplasma pneumoniae infection in families. JAMA 
197:859-866. 
462. File TM, Jr., Tan JS, Plouffe JF. 1998. The role of atypical pathogens: 
Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella 
pneumophila in respiratory infection. Infect Dis Clin North Am 12:569-592, 
vii. 
463. Walter ND, Grant GB, Bandy U, Alexander NE, Winchell JM, Jordan 
HT, Sejvar JJ, Hicks LA, Gifford DR, Alexander NT, Thurman KA, 
Schwartz SB, Dennehy PH, Khetsuriani N, Fields BS, Dillon MT, Erdman 
DD, Whitney CG, Moore MR. 2008. Community outbreak of Mycoplasma 
pneumoniae infection: school-based cluster of neurologic disease associated 
with household transmission of respiratory illness. J Infect Dis 198:1365-1374. 
464. Waites KB, Atkinson TP. 2009. The role of Mycoplasma in upper respiratory 
infections. Curr Infect Dis Rep 11:198-206. 
465. Winchell J. 2013. Mycoplasma pneumoniae - A national public health 
perspective. Curr Pediatr Rev 9:324-333. 
466. Rasmussen JN, Voldstedlund M, Anderson RL. 2010. Increased incidence 
of Mycoplasma pneumoniae infections detected by laboratory-based 
surveillance in Denmark 2010. Euro Surveill 15. 
467. Linde A, Ternhag A, Torner A. 2012. Antibiotic prescriptions and 
laboratory-confirmed cases of Mycoplasma pneumoniae during the epidemic 
in Sweden in 2011. Euro Surveill 17. 
303 
 
References 
 
468. Blystad H, Anestad G, Vestrheim DF. 2012. Increased incidence of 
Mycoplasma pneumoniae infection in Norway 2011. Euro Surveill 17. 
469. Polkowska A, Harjunpaa A, Toikkanen S. 2012. Increased incidence of 
Mycoplasma pneumoniae pneumonia infection in Finland, 2010-2011. Euro 
Surveill 17. 
470. Kim EK, Youn YS, Rhim JW. 2015. Epidemiological comparison of three 
Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 
years. Korean Journal of Paediatrics 58:172-177. 
471. Ito I, Ishida T, Osawa M. 2001. Culturally verified Mycoplasma pneumoniae 
in Japan: a long-term observation from 1979-99. Epidemiology and Infection 
127:365-367. 
472. Omori R, Nakata Y, Tessmer HL, Suzuki S, Shibayama K. 2015. The 
determinant of periodicity in Mycoplasma pneumoniae incidence: an insight 
from amthematical modelling. Scientific Reports 5:14473. 
473. Lenglet A, Herrador Z, Magicrakos AP. 2012. Surveillance status and recent 
data for Mycoplasma pneumoniae infections in the Eurpean Union and 
European economic area, January 2012. Euro Surveill 17. 
474. Bebear C. 2012. Editorial commentary: infections due to macrolide-resistant 
Mycoplasma pneumoniae: now what? Clin Infect Dis 55:1650-1651. 
475. Singh A, Goering RV, Simjee S, Foley SL, Zervos MJ. 2006. Application 
of molecular techniques to the study of hospital infection. Clin Microbiol Rev 
19:512-530. 
476. Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, Gallo V, 
Ramsay M, Sonnenberg P, Maccannell D, Charlett A, Egger M, Green J, 
Vineis P, Abubakar I. 2014. Strengthening the Reporting of Molecular 
Epidemiology for Infectious Diseases (STROME-ID): an extension of the 
STROBE statement. Lancet Infect Dis 14:341-352. 
477. Blanc DS. 2004. The use of molecular typing for epidemiological surveillance 
and investigation of endemic nosocomial infections. Infect Genet Evol 4:193-
197. 
478. Ranjbar R, Karami A, Farshad S, Giammanco GM, Mammina C. 2014. 
Typing methods used in the molecular epidemiology of microbial pathogens: 
a how-to guide. New Microbiol 37:1-15. 
479. Ho PL, Law PY, Chan BW, Wong CW, To KK, Chiu SS, Cheng VC, Yam 
WC. 2015. Emergence of Macrolide-Resistant Mycoplasma pneumoniae in 
Hong Kong Is Linked to Increasing Macrolide Resistance in Multilocus 
Variable-Number Tandem-Repeat Analysis Type 4-5-7-2. J Clin Microbiol 
53:3560-3564. 
480. Zoll J, Rahamat-Langendoen J, Ahout I, de Jonge MI, Jans J, Huijnen 
MA, Ferwerda G, Warris A, Melchers WJ. 2015. Direct multiplexed whole 
genome sequencing of respiratory tract samples reveals full viral genomic 
information. J Clin Virol 66:6-11. 
481. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan 
JZ, Depledge DP, Nikolayevskyy V, Broda A, Stone MJ, Christiansen MT, 
Williams R, McAndrew MB, Tutill H, Brown J, Melzer M, Rosmarin C, 
McHugh TD, Shorten RJ, Drobniewski F, Speight G, Breuer J. 2015. 
Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates 
Directly from Clinical Samples. J Clin Microbiol 53:2230-2237. 
482. Pallen MJ. 2014. Diagnostic metagenomics: potential applications to 
bacterial, viral and parasitic infections. Parasitology 141:1856-1862. 
304 
 
References 
 
483. Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A, 
Waller A, Mende DR, Kultima JR, Martin J, Kota K, Sunyaev SR, 
Weinstock GM, Bork P. 2013. Genomic variation landscape of the human 
gut microbiome. Nature 493:45-50. 
484. Briese T, Palacios G, Kokoris M, Jabado O, Liu Z, Renwick N, Kapoor V, 
Casas I, Pozo F, Limberger R, Perez-Brena P, Ju J, Lipkin WI. 2005. 
Diagnostic system for rapid and sensitive differential detection of pathogens. 
Emerg Infect Dis 11:310-313. 
485. Dominguez SR, Briese T, Palacios G, Hui J, Villari J, Kapoor V, Tokarz 
R, Glode MP, Anderson MS, Robinson CC, Holmes KV, Lipkin WI. 2008. 
Multiplex MassTag-PCR for respiratory pathogens in pediatric 
nasopharyngeal washes negative by conventional diagnostic testing shows a 
high prevalence of viruses belonging to a newly recognized rhinovirus clade. 
J Clin Virol 43:219-222. 
486. Pabbaraju K, Tokaryk KL, Wong S, Fox JD. 2008. Comparison of the 
Luminex xTAG respiratory viral panel with in-house nucleic acid 
amplification tests for diagnosis of respiratory virus infections. J Clin 
Microbiol 46:3056-3062. 
487. Reijans M, Dingemans G, Klaassen CH, Meis JF, Keijdener J, Mulders B, 
Eadie K, van Leeuwen W, van Belkum A, Horrevorts AM, Simons G. 
2008. RespiFinder: a new multiparameter test to differentially identify fifteen 
respiratory viruses. J Clin Microbiol 46:1232-1240. 
488. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, 
Schrag SJ, Taylor TH, Jr., Beall BW, Breiman RF, Feikin DR, Njenga 
MK, Mayer LW, Oberste MS, Tondella ML, Winchell JM, Lindstrom SL, 
Erdman DD, Fields BS. 2011. Application of TaqMan low-density arrays for 
simultaneous detection of multiple respiratory pathogens. J Clin Microbiol 
49:2175-2182. 
489. Diaz MH, Waller JL, Napoliello RA, Islam MS, Wolff BJ, Burken DJ, 
Holden RL, Srinivasan V, Arvay M, McGee L, Oberste MS, Whitney CG, 
Schrag SJ, Winchell JM, Saha SK. 2013. Optimization of Multiple Pathogen 
Detection Using the TaqMan Array Card: Application for a Population-Based 
Study of Neonatal Infection. PLoS One 8:e66183. 
490. Calcutt MJ, Foecking MF. 2015. Complete Genome Sequence of 
Mycoplasma hominis Strain Sprott (ATCC 33131), Isolated from a Patient 
with Nongonococcal Urethritis. Genome Announc 3. 
 
 
305 
 
Publications 
 
Publication list 
Brown RJ, Chalker VJ, Spiller OB. 2014. Mycoplasma hominis Variable Adherence-
Associated Antigen: A Major Adhesin and Highly Variable Surface Membrane 
Protein. Advances in Microbiology 4:736-746. 
Brown RJ, Holden MT, Spiller OB, Chalker VJ. 2015. Development of a Multilocus 
Sequence Typing Scheme for Molecular Typing of Mycoplasma pneumoniae. Journal 
of Clinical Microbiology 53:3195-3203. 
Brown RJ, Spiller OC, Chalker VJ. 2015. Molecular typing of Mycoplasma 
pneumoniae: where do we stand? Future Microbiology 10:1793-1795. 
Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ. 2015. Detection of macrolide 
resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. 
Eurosurveillance 20. 
Brown RJ, Nguipdop-Djomo P, Zhao H, Stanford E, Spiller OB, Chalker VJ. 2016. 
Mycoplasma pneumoniae Epidemiology in England and Wales: A National 
Perspecitive.  Frontiers in Microbiology 7:157. 
 
306 
 
Publications 
 
307 
 
Publications 
 
308 
 
Publications 
 
309 
 
Publications 
 
310 
 
Publications 
 
311 
 
Publications 
 
312 
 
Publications 
 
313 
 
Publications 
 
314 
 
Publications 
 
315 
 
Publications 
 
316 
 
Publications 
 
 
  
317 
 
Publications 
 
318 
 
Publications 
 
319 
 
Publications 
 
320 
 
Publications 
 
321 
 
Publications 
 
322 
 
Publications 
 
323 
 
Publications 
 
324 
 
Publications 
 
325 
 
Publications 
 
 
  
326 
 
Publications 
 
327 
 
Publications 
 
328 
 
Publications 
 
 
  
329 
 
Publications 
 
330 
 
Publications 
 
331 
 
Publications 
 
 
332 
 
Publications 
 
333 
 
Publications 
 
334 
 
Publications 
 
335 
 
Publications 
 
336 
 
Publications 
 
337 
 
Publications 
 
338 
 
Publications 
 
 
339 
 
Publications 
 
 
  
340 
 
Publications 
 
Conference abstracts 
European Mycoplasma Meeting: “Mycoplasmas – a practical approach”.  June 
2013 Dubrovnik, Croatia 
The Bactericidal Activity of Normal Human Serum against 21 Clinical Isolates 
of Mycoplasma pneumoniae. 
*Rebecca J. Brown1, O. Brad Spiller1, Victoria J. Chalker2 
1Department of Child Health, Institute of Molecular and Experimental Medicine, School of Medicine, 
Cardiff University, CF14 4XN 
2Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ 
Poster presentation 
Mycoplasma pneumoniae is a common cause of upper and lower respiratory tract 
infections and may be responsible for up to 15-20% of community-acquired 
pneumonias. However, as a consequence of Mycoplasma pneumoniae infection, 
extrapulmonary complications may occur (e.g. encephalitis), related to 
immunopsuppression or direct spread of infection. Understanding of the host immune 
response to Mycoplasma pneumoniae infection has advanced over the recent years 
although little is known about the role of serum killing and serum resistance to 
Mycoplasma pneumoniae infection.  The ability of normal human serum to kill 
bacteria, via the complement system, plays an important role in the host immune 
defence against infection. The complement system is activated via three pathways and 
is directly able to kill many microorganisms. 
We have screened for complement killing of 21 Mycoplasma pneumoniae clinical 
isolates by normal human serum. Seropositive and seronegative normal human serums 
for Mycoplasma pneumoniae were identified and the presence of specific antibodies 
was confirmed by Western blot and Lineblot analysis. The serum killing assay was 
performed by incubating clinical isolates in 50% NHS (or heat-inactivated control 
serum) at 37°C for one hour. Complement specific killing was measured as the fold 
decrease in survival relative to the matched heat-inactivated control serum.  
Our initial findings indicate varying susceptibility of the Mycoplasma pneumoniae 
clinical isolates to seropositive serum killing. Five isolates were particularly 
susceptible, with less than 0.1% survival, including one with survival of approximately 
0.001%. One particularly resistant strain has been identified with greater than 10% 
survival. Further investigation is on-going to determine the pathway of complement 
activation that is responsible for the highly susceptible isolates. A comparison of the 
inherent killing ability of seropositive and seronegative normal human serum against 
these Mycoplasma pneumoniae clinical isolates is being made. 
The initial results and future plans for the research will be presented. 
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MiTREG South West and South Wales Annual Meeting.  October 2014 Cardiff, 
UK 
Examination of the genetic diversity of Mycoplasma hominis reveals high levels 
of variation in comparison to Mycoplasma pneumoniae. 
Rebecca J. Brown, Victoria J. Chalker and O. Brad Spiller 
Oral presentation 
Mycoplasma hominis is an opportunistic, urogenital pathogen that can cause serious 
diseases such as meningitis and septic arthritis. In comparison, Mycoplasma 
pneumoniae is a respiratory pathogen that is a common cause of pneumonia. A multi-
locus sequence typing (MLST) scheme for M. hominis, based on the sequence of eight 
housekeeping genes, revealed high levels of genetic diversity in this pathogen. A 
discriminatory ability of 0.9 STs per isolate was resolved and phylogenetic analysis 
confirmed a high level of intra-species diversity. In comparison, a MLST scheme for 
M. pneumoniae resulted in a discriminatory ability of 0.26 STs per isolate. The 
stability of the M. hominis STs were investigated by re-sequencing eight strains after 
short-term passage; only two of the isolates had conserved STs. The high genetic 
variability of M. hominis observed indicates that M. hominis is well adapted to evolve, 
potentially aiding immune system evasion and rapid development of antibiotic 
resistance-mediating mutations.  
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Public Health England PhD Student’s Day and Annual UKRO visit.  March 2015 
Chilton, UK 
Genetic diversity of Mycoplasma pneumoniae and Mycoplasma hominis: 
consequences for epidemiological studies. 
Rebecca J. Brown, Victoria J. Chalker and O. Brad Spiller 
Oral presentation 
Mycoplasma hominis and Mycoplasma pneumoniae are urogenital and respiratory 
pathogens, respectively. Within a human population it is important to determine 
pathogen epidemiology and transmission; methodologies have been developed to type 
organisms into discriminate strains, usually based on genetic diversity. Genetic 
diversity was examined for M.hominis and M.pneumoniae by developing two novel 
multi-locus sequence typing (MLST) schemes. This successfully discriminated 
between strains of M.pneumoniae, comparable to current genetic typing methods. 
However, for M. hominis high levels of genetic diversity and poor genetic fidelity were 
found, indicating that current conventional genetic typing methodologies for 
M.hominis have little value for epidemiology and transmission studies. However, 
results indicate that M.hominis is well adapted to evolve, potentially aiding immune 
system evasion and antibiotic resistance. 
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25th European Congress of Clinical Microbiology and Infectious Diseases.  April 
2015 Copenhagen, Denmark 
Development of a multi-locus typing scheme for Mycoplasma pneumoniae 
 
Rebecca J. Brown1,2, Vicki J. Chalker2, O. Brad Spiller1 
1Cardiff University, Cardiff, UK 
2Public Health England, London, UK 
 
Poster presentation 
 
Objectives 
Mycoplasma pneumoniae is a respiratory pathogen that is a common cause of 
pneumonia and may cause other serious extra-pulmonary infections such as 
encephalitis. The pathogen is found in all age groups, with higher prevalence in 
children aged 5-14 years. The objective of this work was to study the genetic diversity 
of this pathogen using a multi-locus typing (MLST) scheme in comparison to 
previously established multiple-locus variable-number tandem-repeat (VNTR) 
analysis (MLVA) and P1-typing methodologies. 
Methods 
An MLST scheme was developed based on the sequence of eight housekeeping genes 
(ppa, pgm, gyrB, gmk, glyA, atpA, arcC and adk) and applied to 36 M. pneumoniae 
clinical isolates and the two type strains, M129 and FH. DNA was extracted from 
isolates and PCR reactions were performed for each individual locus. PCR amplicons 
were sequenced and allelic types were assigned arbitrary numbers for each locus based 
on nucleotide differences. Combination of the eight alleles determined an isolate’s 
allelic profile and each unique allelic profile was designated a unique sequence type 
(ST).  
Results 
A total of ten STs were resolved for the 38 M. pneumoniae isolates tested. The 
discriminatory ability of this MLST scheme for M. pneumoniae is 0.26, with ST2 the 
predominating ST. Examination of the Hunter-Gaston diversity index indicated 
moderate diversity between the sequence types (DI: 0.779; 95% CI: 0.692-0.866) with 
the greatest diversity shown in pgm (DI: 0.637; 95% CI: 0.570-0.703) and the lowest 
diversity in arcC (DI: 0.105; 95% CI: 0.000-0.235). Phylogenetic analysis of 
concatenated sequences of the eight loci for the ten STs using both maximum-
likelihood and neighbour-joining methods resulted in two genetically distinct clusters; 
the first containing ST1, ST3, ST5 and ST9, and the second containing ST2, ST4, ST6, 
ST7, ST8 and ST10. The grouping of M. pneumoniae isolates using this MLST scheme 
had higher discriminatory power than VNTR-MLVA and was not comparable to P1-
type. 
Conclusion 
MLST is generally considered an intermediate scale typing method and in this case 
was found to be discriminatory among the M. pneumoniae isolates tested. This 
molecular typing approach provides an alternative method to type M. pneumoniae 
isolates, allowing further characterisation of clinical isolates and epidemiological 
analysis, in combination with already established typing methods. 
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33rd Annual Meeting of the European Society for Paediatric Infectious Diseases.  
May 2015 Leipzig, Germany 
Detection of Mycoplasma hominis, Ureaplasma parvum and Ureaplasma 
urealyticum in sequential, neonate clinical samples using a novel multiplex assay. 
Rebecca J. Brown1,2, Sarah Phillips1, Nicola Maxwell3, O. Brad Spiller2 and Victoria 
J. Chalker1 
1Vaccine Preventable Bacteria Reference Unit, Public Health England, 
61 Colindale Ave, NW9 5HT London, U.K  
2Cardiff University, School of Medicine, Department of Child Health, 5th floor 
University Hospital of Wales, Cardiff, CF14 4XN, UK  
3Consultant Neonatologist, Derriford Hospital, Plymouth, PL6 8DH, UK 
 
Poster presentation 
 
Background and aims 
Mycoplasma hominis and Ureaplasma species are associated with infections in 
neonates (pneumonia, bacteremia, meningitis, abscesses and chronic lung disease). 
This study established a quantitative real-time PCR to simultaneously detect M. 
hominis, U. urealyticum and U. parvum in neonate clinical specimens to improve 
current clinical diagnostic services.  
Methods 
The multiplex assay developed included two gene targets; yidC gene of M. hominis, 
ureaseB gene of Ureaplasma species with species-specific probes and control. 
Specificity and sensitivity were determined. Endo-tracheal secretions were tested from 
53 intubated, preterm neonates (anonymised; Plymouth) and 6 intubated, preterm 
neonates treated with clarithromycin (clinical diagnosis samples; Cardiff). 
Results 
The assay was 100% specific and had positive predictive values of 81.82% and 
82.86% and negative predictive values of 98.11% and 92% for U. urealyticum and U. 
parvum, respectively, when compared to culture. A total of 238 clinical samples were 
tested of which 6 were positive for M. hominis, 23 were positive for U. urealyticum 
and 52 were positive for U. parvum. Four mixed infections were identified. Treatment 
with clarithromycin cleared U. parvum infection by 48 hours post-treatment in 4 out 
of the 6 neonates however 2 neonates tested PCR positive for U. parvum at 48 hours 
and 72 hours post-treatment, respectively. 
Conclusions 
In conclusion, we developed a specific, sensitive and reproducible real-time PCR to 
detect M. hominis, U. ureaplasma and U. parvum in oral clinical samples. This PCR 
assay was used to successfully diagnose infections in neonatal samples and monitor 
infection levels over the period of intubation.    
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European Mycoplasma Meeting: “Progress in Human and Animal 
Mycoplasmology”.  June 2015 Istanbul, Turkey 
Detection of Mycoplasma hominis, Ureaplasma parvum and Ureaplasma 
urealyticum in neonate clinical samples: comparison between a novel multiplex 
assay and existing clinical practices. 
*R.J. Brown1,2, S. Phillips1,O. B. Spiller2 and V.J. Chalker1 
1Vaccine Preventable Bacteria Reference Unit, Public Health England, 61 Colindale Ave, NW9 5HT 
London, U.K  
2Cardiff University, School of Medicine, Department of Child Health, 5th floor University Hospital of 
Wales, Cardiff, CF14 4XN, UK  
Oral presentation 
Background  
Mycoplasma hominis and Ureaplasma species are associated with infections in 
neonates including: pneumonia, bacteremia, meningitis, abscesses and chronic lung 
disease.  
Objectives 
This study compared three methods (two multiplex assays and culture) for the 
detection of M. hominis, U. urealyticum and U. parvum in neonate clinical specimens 
to improve current clinical diagnostic services.  
Methods 
A panel of neonatal clinical samples (clinical diagnosis samples; 2014; Public Health 
England) were tested for Ureaplasma species and M. hominis using the current in-
house multiplex assay, a novel multiplex assay and traditional culture methods. The 
novel multiplex assay developed included two gene targets; yidC gene of M. hominis, 
ureaseB gene of Ureaplasma species with species-specific probes and control. This 
assay was able to quantify bacterial load using a positive control plasmid containing 
one copy of each gene target for M. hominis, U. urealyticum and U. parvum. 
Results 
M. hominis, U. urealyticum and U. parvum were detected by all three diagnostic 
methods. The novel multiplex assay was more sensitive and detected more positive 
results than the current in-house multiplex assay. Using this novel assay, additional 
M. hominis, and mixed infections with U. urealyticum and U. parvum positive clinical 
samples were identified. 
Conclusions 
The novel multiplex assay is more specific and sensitive for the detection of M. 
hominis and Ureaplasma species in oral clinical samples than the current in-house 
assay. The use of a molecular assay has advantages over culture as it is able to 
distinguish between Ureaplasma species and is able to quantify bacterial load, 
allowing for more informed treatment of infections by clinicians.  
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